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Between 1998 and 2008, GP recorded anxiety symptoms increased, but recorded anxiety disorders 
decreased. No data are available for recent years. Little is known about trends in prescriptions for 
anxiety, or the views of individuals with anxiety and those who treat it. This thesis aimed to 
understand the identification, diagnosis and management of anxiety in UK primary care.  
Methods 
Qualitative interviews with 15 GPs, 20 patients, and 9 therapists, explored practitioners’ and 
patients’ views on the identification, diagnosis and management of anxiety.  
Two quantitative studies used Clinical Practice Research Datalink data (n=2,569,153 adults registered 
with UK practices between 2003-2018). Incidence rates and 95% confidence intervals were 
calculated for: (1) recorded anxiety symptoms and diagnoses; (2) anxiolytic prescriptions.  
Results 
Interview findings indicated that having an anxiety disorder diagnosed, and considered as a separate 
condition to depression, helped patients understand their symptoms and the treatment needed. 
However, GPs were reluctant to give a diagnosis, and did not distinguish between the two 
conditions. GPs held the view that patients prefer to take medication, whereas patients did not view 
medication as a positive choice. GPs and therapists commented on a recent rise in anxiety in young 
adults.  
The incidence of anxiety symptoms rose from 6.2 to 14.7/1000 person years at risk (PYAR) from 
2003-2018. Between 2003-2008, the incidence of anxiety diagnoses fell from 13.2 to 
10.1/1000PYAR; markedly increasing between 2014-2018 to 15.3/1000PYAR.  
Between 2003-2008, the incidence of antidepressant prescriptions decreased from 10.2 to 
7.4/1000PYAR; rising to 11.7/1000PYAR in 2018. Incidence of prescriptions of beta-blockers 
increased over the study, whereas incident benzodiazepine prescriptions decreased.  
Incidence of anxiety symptoms and diagnosis, and of prescriptions of each drug class, rose 
particularly in young adults in recent years.  
Conclusion 
Recent increases in anxiety and anxiolytic prescriptions may reflect increased presentation to 
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Chapter 1 Introduction 
1.1 Thesis overview  
This thesis focuses on the management of anxiety disorders in United Kingdom (UK) primary care. 
The body of work presented is comprised of three studies: (1) a qualitative study exploring 
practitioners’ and patients’ views and experiences of the identification, diagnosis and management 
of anxiety; (2) a quantitative study examining trends in the recording of anxiety diagnoses and 
symptoms in UK primary care; and (3) a second quantitative study examining trends in the 
prescribing for anxiety in UK primary care.   
The thesis is structured as follows. Anxiety is introduced in a general context in this chapter (Chapter 
1), in terms of how it is defined, the epidemiology and pressure it places on the NHS, the impact of 
anxiety on the individual, and recommended treatments for anxiety in UK primary care. At the end 
of this chapter, the main areas of interest and the studies reported in this thesis are introduced. 
In Chapter 2, existing qualitative and quantitative evidence is reviewed and summarised with a focus 
on identification, diagnosis, and management. This is followed by a short summary of the literature, 
and the aims and objectives of this thesis. Following this, the qualitative methods, results and 
discussion are presented in Chapter 3, followed by the methods, results and discussion for the 
quantitative studies in Chapters 4 and 5. In Chapters 4 and 5, data from the qualitative study are 
presented alongside quantitative results to aid interpretation of the trends observed. Finally, 
Chapter 6 provides an overall discussion of both the quantitative and qualitative results, reflections 
on the strengths and limitations of the thesis, and details implications of the findings and potential 
future work. 
 
1.2 What is anxiety? 
The term anxiety can refer to a broad range of constructs. It can be used to describe the sensations 
people might feel prior to an anxiety-provoking situation, such as a job interview or public-speaking, 
which might be considered a relatively normal anticipatory response (Gonzalez-Bono et al., 2002). It 
can also be used to describe a personality trait, and indeed there are several measures that have 
been developed to quantify individual differences of anxiety as a trait (Spielberger & Reheiser, 
2003). It may also be used to refer to anxiety disorders, that is, symptoms of anxiety that are 





The term anxiety disorders is used to describe a group of mental disorders that can cause severe 
distress, or significant fear or worry, that does not go away, or can get worse over time (Antony & 
Stein, 2008). The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) details anxiety 
disorders that broadly fall into categories of social phobia (or social anxiety disorder), panic disorder, 
generalised anxiety disorder (GAD), and specific phobias such as agoraphobia (American Psychiatric 
Association., 2013). Obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD) 
are not considered anxiety disorders in the DSM-5, and research focused on anxiety does not tend to 
include these conditions (Walters et al., 2012; John et al., 2016). In addition to the DSM-5 disorders, 
the International Classification of Diseases (ICD-10) also includes mixed anxiety and depressive 
disorder (MADD), whereby patients exhibit co-morbid symptoms of anxiety and depression that 
cause impairment or disability, but are below the clinical threshold (World Health Organisation, 
1992). Psychological symptoms of anxiety include a feeling of ‘dread’ or of being on ‘edge’, 
restlessness, irritability, and difficulty concentrating (Tuma & Maser, 2019). Anxiety can also induce 
physical symptoms, such as heart palpitations, excessive sweating, shortness of breath, trembling or 
shaking, or a sense of dizziness (Tuma & Maser, 2019). Furthermore, those with panic disorder will 
experience panic attacks that can occur either regularly or at any time, and this can often be for no 
apparent reason (Tuma & Maser, 2019).  
Anxiety disorders are frequently associated with other psychiatric morbidities such as major 
depressive disorder (MDD) (Martin-Merino et al., 2010). Due to the extensive symptom overlap, and 
the fact the two are frequently co-morbid, this can make accurate identification of anxiety difficult 
(Ronalds et al., 1997). In clinical practice, a diagnosis of MADD may be given to patients that present 
with co-morbid symptoms, even if the symptoms of both the anxiety and the depression are above 
clinical threshold. Patients with MADD have a poorer prognosis than those with either anxiety or 
depression alone (Roy-Byrne et al., 2008). In addition, their symptoms are more likely to be 
treatment resistant, and they will experience greater disability (Roy-Byrne et al., 2008). Together, 
anxiety disorders, depressive disorders, and mixed anxiety and depressive disorder, have been 
termed common mental disorders (CMD). Due to their collective increasing prevalence in the UK, 
reducing CMD is now a major public health challenge (Davies, 2014). 
 
1.3 Historical context of anxiety 
For much of the past century, the most common mental health condition was anxiety, termed a 
‘nervous breakdown’ or ‘neurosis’ (Swindle Jr et al., 2000). It was thought of as a “problem of the 





In contrast, depression was considered much less common. Depression was associated with patients 
who were experiencing vegetative or psychotic symptoms, and these patients were more likely to be 
hospitalised (Shorter, 2008). However, in many countries, by the 1970s, health insurance was 
increasingly being used to pay for treatment, and providers stipulated that that they would only pay 
for treatment if it was for a specific disorder, rather than a “problem of living” (Horwitz, 2010). 
Around the same time, attitudes within psychiatry transitioned from advocating the psychodynamic 
domain, to the biological (Kolb et al., 2000). Proponents of the biological approach argued that it 
would ensure the discipline was reliable and scientific, and research into the biological 
underpinnings of depression gave momentum to this paradigm shift (Bunney & Davis, 1965). 
Therefore, when the third edition of the DSM was published in 1980, it divided anxiety into multiple 
sub-types (such as the newly termed GAD, and panic disorder), on the basis that they had different 
biological responses to medication (Crocq, 2017). In contrast, MDD become the only major 
nonpsychotic category among the affective disorders (Horwitz, 2010).  
Alongside this, there was a backlash from the public and the media against benzodiazepines, the 
main anxiolytic medication that had been traditionally used for anxiety (Gabe, 1990). Whilst the 
growth in prescriptions of anxiety medications declined, prescriptions for antidepressants 
substantially increased, driven by pharmaceutical marketing targeting the treatment of depression 
(Healy, 1997). Thus, toward the end of the 20th century, there was shift from anxiety toward 
depression, with diagnosis rates for depression growing at a much faster rate than those for anxiety 
(Horwitz, 2010). It has been suggested that problems previously considered as ‘anxiety’, were 
instead labelled as ‘depression’, and it is the latter that now dominates mental health research and 
clinical treatment (Horwitz & Wakefield, 2007).  
 
1.4 Epidemiology of anxiety and impact on the NHS 
Globally, anxiety disorders are ranked as the sixth leading cause of non-fatal health loss when 
considering years lived with disability (YLD) (World Health Organisation, 2017). Within the European 
Union (EU), roughly 38% of people experience a mental health condition each year, of which anxiety 
is the most common disorder (14%) (Wittchen et al., 2002). In the UK, anxiety disorders represented 
3.5% of total YLD in 2015 (World Health Organisation, 2017), with the proportion of young adults 
with GAD increasing from 3.6% in 2007 to 6.3% in 2014 (Stansfeld et al., 2016). Within UK general 
practice, the prevalence and incidence of anxiety disorders is high (prevalence: 7.2%, incidence: 9.7 
per 1000 person-years) (Martin-Merino et al., 2010). In reality, these figures are likely to be higher in 
the general population as many individuals do not seek professional help for their symptoms 





practitioner (GP), rather than a private therapist (van Rijswijk et al., 2009). As the prevalence of 
anxiety is increasing, so too is the demand on National Health Service (NHS) primary care services for 
the care of those with anxiety (Lépine, 2002). GAD in particular is thought to be a key factor in the 
high utilisation of primary care services (Hoffman et al., 2008). 
Historically, the main first-line pharmacological treatment for anxiety was benzodiazepines. 
However, in more recent years concerns around toxicity and dependency have led to a move away 
from prescribing benzodiazepines, to selective serotonin re-uptake inhibitors (SSRIs) (Lader et al., 
2009). There has also been increasing demand from the public for non-drug treatments. This has led 
to substantial investment in the Increasing Access to Psychological Therapies (IAPT) programme. Set 
up around 2007/2008, IAPT is a national primary care initiative developed to increase access to, and 
availability of, talking therapies. IAPT was designed to reduce the economic impact of mental health 
related long-term sickness through improving access to talking therapies. Before the service was set 
up, there was evidence to suggest that anxiety and depression had led to a reduction in England’s 
national income of about £80 million each year (a 4% reduction), through a combination of 
unemployment, sick days, welfare benefits and reduced productivity (OECD, 2014). In addition, the 
service costs for the NHS treatment of anxiety were around £1.2 billion in 2007, and this was 
estimated to increase to £2 billion by 2026 (McCrone et al., 2008).  
Between 2007 and 2019, the provision of  IAPT services is thought to have cost the NHS about £1 
billion (Marks, 2018). However, it is argued that the IAPT programme saves costs when set against 
the expenses of welfare payments and physical healthcare (Layard & Clark, 2015). In 2018/2019, 
there were 1.6 million referrals to the service, roughly an 11% increase in the number of referrals 
compared with previous years (Baker, 2020). Despite the increasing number of referrals, the wait 
time between referral and the first date of an intervention has decreased from 23 days in 2016/17 to 
20 days in 2018/19 (Baker, 2020). Yet for some patients the waiting time is still considered too long, 
with just over 10% of patients waiting longer than six weeks for therapy in 2018/19 (Atkinson, 2014; 
Baker, 2020). Therefore, GPs remain the primary point of ongoing clinical care and support for these 
patients.  
1.5 Impact of anxiety 
For patients experiencing anxiety, the severity of the symptoms can range from mild to severe, and 
symptoms can have a significant impact on their quality of life. An association between anxiety and 
impairment in social functioning and physical problems is often reported (Goldberg & Huxley, 1992), 
and this can be highly distressing for individuals and those around them. It can also lead to 





patients may be reluctant to seek help for many reasons, including viewing antidepressants as 
addictive, believing treatment options are stigmatising, or seeing practical and economic barriers to 
psychological therapy (Prins et al., 2008). In patients who do not seek help, but who view themselves 
as needing clinical care, untreated anxiety can lead to greater symptom severity at follow-up (van 
Beljouw et al., 2010). Furthermore, if untreated, patients with co-morbid symptoms of anxiety and 
depression have outcomes comparable with those of conditions such as diabetes or heart disease, 
experiencing a significant reduction in physical, social and emotional functioning (Schonfeld et al., 
1997). Even when receiving treatment, patients with comorbid depression and anxiety have a worse 
trajectory than individuals being treated for anxiety or depression alone (Penninx et al., 2011).  
 
1.6 Treatments for anxiety 
Current National Institute for Health and Care Excellence (NICE) guidelines for the treatment of 
anxiety and depression are similar, in that they advocate a stepped care model (NICE, 2009, 2011b). 
Treatment recommendations within the guidelines depend on the severity of impairment, with the 
mainstays of active treatment being antidepressant medication and/or psychological therapy. If 
patients do not respond to the initial intervention, they may be ‘stepped-up’ to the next level of 
intervention. Similarity between treatment guidelines for depression and anxiety results in 
convergence in some areas which can contribute to a lack of clarity around the distinction between 
the two disorders. As previously outlined, often patients access the recommended psychological 
interventions through local IAPT services. Patients can either self-refer or be referred by their GP, 
and are assessed independently of their GP diagnosis, and offered appropriate treatment depending 
on their symptoms (Clark, 2011). The specific stepped-care model for anxiety is discussed in detail in 
Chapter 2.  
 
1.7 Thesis interests 
As previously mentioned, there is a high prevalence and incidence of anxiety in the UK, and this is an 
increasing public health challenge. For patients with the condition, symptoms can be debilitating and 
can reduce quality of life. This can be further compounded by the fact that, sometimes, accurate 
identification and diagnosis can be difficult.  
The literature review detailed in Chapter 2 establishes that there are limited data on the views and 
experiences of individuals with anxiety, and of those who treat it. It is also not known whether the 





individuals who experience symptoms of anxiety, and individuals who receive a formal diagnosis. 
There is also little information about how patients with anxiety manage their condition, and what 
treatments GPs offer to help alleviate symptoms.  
This thesis is comprised of three studies to address these unknowns: a qualitative study exploring 
how practitioners and patients view and experience the identification, diagnosis and management of 
anxiety disorders; a quantitative study investigating trends in the recording of anxiety diagnoses and 
symptoms; and a second quantitative study examining trends in drugs prescribed for anxiety. The 






Chapter 2 Literature Review 
2.1 Chapter overview 
This chapter focuses on existing literature relating to anxiety disorders in primary care and is 
presented in three sections. The first describes how anxiety is identified and diagnosed by GPs, and 
also covers issues relating to the discussion and labelling of anxiety in primary care. Previous data on 
the incidence rates of recorded anxiety diagnoses and symptoms are also discussed. The second 
section outlines the NICE guidelines for the treatment of anxiety and focuses on the literature 
around psychological interventions, such as cognitive behavioural therapy (CBT), and provides more 
details of the IAPT programme. The third section covers pharmacological treatment, starting with an 
overview of drugs that can be prescribed for anxiety, followed by more in-depth discussion of 
antidepressants, benzodiazepines, and other drugs. In keeping with the multi-method design of this 
thesis, both the qualitative and quantitative evidence is reviewed and summarised throughout this 
chapter. Finally, the literature and the evidence gaps are briefly summarised, followed by the aims 




Preliminary searches of the literature highlighted a notable lack of qualitative research where the 
primary focus was on anxiety. Therefore, a broad search strategy was employed to identify a wide 
range of research that may be relevant to understand the views of patients and primary care 
practitioners. A range of databases were electronically searched (PsycINFO, Medline, Embase & Web 
of Science) to provide greater coverage of all potential publications. The initial search terms used are 
presented in Table 1 and were informed by the reference list of previously identified papers, and the 
Medical Subject Headings from each database. Terms were chosen to ensure all research was 
retrieved regardless of the qualitative method used, or the type of anxiety disorder. This included 
using text word searching (.tw) and method searching (.md), and combining terms using the 'or' and 
'and' functions. Searches yielded a large volume of papers (n=1,848), and a flow chart depicting the 







Table 1 Qualitative search terms 
Qualitative methodology  • (("semi-structured" or semistructured or unstructured or 
informal or "in-depth" or indepth or "face-to-face" or 
structured or guide or guides) adj3 (interview* or 
discussion* or questionnaire*)).tw. 
• (focus group* or qualitative or ethnograph* or fieldwork or 
"field work" or "key informant").tw. 
• exp qualitative research/ or qualitative study.md. 
• exp interviews/ or exp group discussion/ 
• literature review.md. or narrative review.md or qualitative 
synthesis.tw 
Mental health  Initial search 
terms (anxiety 
specific) 
• anxiety disorders/ or generalized anxiety disorder/ or 
posttraumatic stress disorder/ anxiety disorder*.tw. or 
anxiety.tw 





• mental disorders/ or mental health.tw. or common mental 
disorder*.tw. or emotional disorder*.tw. 
• depression/ or depressive disorder/ or major 
depression.tw. 
Primary care  • primary health care/ or general practitioners/ 
• family physician/ or GP.tw. or general practitioner*.tw. 
• primary care.tw. or general practice.tw or family practi*.tw. 
Topic specific  • diagnosis/ or diagnos*.tw. or categor*.tw. or label*.tw 
• view*.tw. or perspective*.tw. or attitude*.tw. 
• management/ 





Figure 1 A flowchart demonstrating the selection of qualitative papers for inclusion in the literature 
review 
 
After removing duplicates and quantitative papers, initial screening of abstracts took place. Many 
abstracts referred to anxiety as a symptom of another condition, or as part of a psychometric 
measure in the methodology, and therefore were not relevant. A substantial number of articles 
were excluded at this point. Additionally, research focused on specific populations was not included 
as it was considered outside of the remit of this thesis. This included, for example, veterans, patients 
with chronic disease, and autistic individuals. Work that had been conducted in relation to situation 
specific anxiety was also excluded (i.e., dental anxiety or performance anxiety).  
The remaining papers were read in detail, and for those that were relevant to the aims of the thesis 
(n=34), notes recorded on the populations and key findings. The majority of the literature was 
focused on patients presenting with depression, or general mental health. However, there were 
three main articles that were specific to anxiety, either on its’ own or comorbid with depression, 
that were considered most relevant. These have been summarised in Table 2, along with the key 





Additional searches were undertaken to ensure that all literature relating to depression and general 
mental health, that might also be relevant to anxiety, had been retrieved. Terms relating to these 
topics were added to the literature search and are also recorded in Table 1. No further relevant 
papers were identified as a result of this additional search.  
Table 2 Key qualitative evidence 
Authors and title Sample and method  Relevant Key themes  Key gaps  
Kadam et al (2001).  
A qualitative study of 
patients' views on 
anxiety and 
depression 
Interviews with 27 
patients from one 
practice.  
Identified as having 
anxiety and/or 





• A hostile world –
stigma, and lack of 
understanding of 
mental health 
• Searching for 
sources of help - 
worry that 
symptoms would 
be seen as trivial 
by GP, and not 
enough time to 
disclose symptoms  
• No data on how 
many patients had 
anxiety, and if 
views differ on the 
two conditions  
• No data on how 
many had a 
diagnosis, and the 
views held toward 
receiving a 
diagnosis 
• >20years ago 
Ford et al. (2016). 
"You don't 
immediately stick a 
label on them": a 
qualitative study of 
influences on general 
practitioners' 
recording of anxiety 
disorders 
Two vignettes used 
with 17 GPs from 
three general 
practices (conducted 
in 2013-2014)  
• Giving patients a 
coding ‘label’ - 
concern is it 
stigmatising 
• Time as a tool to 
delay coding  
• Concerns about 
usefulness of 
coding in general 
• Focused on how 
GPs code, but no 
data on how 
anxiety is discussed 
with patients 
• No data on causes, 
those at risk, or 
treatments for 
anxiety 
Geraghty et al. (2017). 
'You feel like your 
whole world is caving 
in': A qualitative study 




Interviews with 20 




but not diagnosed  
(interviewed in 
2013) 
• Experience of 
stress as different 
to a mental health 
condition 
• Depression 
viewed negatively  
• Anxiety described 





unclear how many 
patients had 
anxiety symptoms  




Quantitative literature  
Whilst the literature searches for qualitative papers were broad, the searches for the quantitative 





and trends in prescribing for anxiety. The same databases were used (PsycINFO, Medline, Embase & 
Web of Science), and the search terms are outlined in Table 3. As with the qualitative searches, 
search terms were informed by the reference list of previously identified papers and the Medical 
Subject Headings from each database. Again, text word searching (.tw) and method searching (.md) 
was used and combining terms using the 'or' and 'and' functions. As the literature did not comprise a 
formal systematic review, a record of the number of papers retrieved, and subsequently excluded, 
was not kept. However, all evidence retrieved that was directly related to GP recording of anxiety, 
and GP prescribing for anxiety, has been included in the literature review.  
Table 3 Quantitative search terms 
Quantitative methodology  • trends.mp. or over time.mp. or cohort Studies/ or cohort.tw 
• incidence/ or prevalence/ 
• literature review.md or systematic review.md or narrative 
review.md 
Recording of anxiety • anxiety symptoms.tw or anxiety diagnoses.tw or anxiety.tw 
• anxiety disorders/ or generalized anxiety disorder/ or 
posttraumatic stress disorder/ 
• social phobia/ or social anxiety/ or social anxiety disorder.tw. 
Medication  • Benzodiazepines/ 
• Antidepressive Agents/ or antidepressants.tw 
• Antipsychotic Agents/ or antipsychotics.tw 
• exp Anticonvulsants/ or gabapentinoids.tw 
• exp Adrenergic beta-Antagonists/ or beta-blockers.tw 
• anxiolytics.tw 
 
2.2 Identification and Diagnosis of Anxiety 
The identification of anxiety can be challenging, particularly as the symptoms of anxiety are 
frequently associated with many physical illnesses, and often occur alongside depression and other 
mental health disorders. This challenge applies to both clinical and research settings. In UK based 
research, the Clinical Interview Schedule Revised version (CIS-R) is often used to establish whether 
an individual meets criteria for a mental health disorder, such as anxiety (Lewis & Pelosi, 1990). The 
CIS-R is comprised of five diagnostic categories from the ICD-10: GAD, depressive episode, phobias 
(including social phobia), obsessive-compulsive disorder and panic disorder. If symptoms of both 
anxiety disorders and depressive episodes are present, but do not meet the criteria for any of the 
five diagnostic categories, and neither is clearly predominant, then a diagnosis of MADD may be 
used (World Health Organisation, 1992). However, the validity and clinical usefulness of MADD has 
been questioned, with some arguing that not enough is yet known about the diagnosis and its’ 





patient has subthreshold symptoms of anxiety and depression, they should be given the 
subthreshold diagnosis of those categories, for example, dysthymia (Batelaan et al., 2012). Whilst 
MADD was not included in the DSM-5, it continues to be used in UK research and clinically, and is 
frequently used for patients who present with both subthreshold and threshold symptoms of anxiety 
and depression (Möller et al., 2016).  
In contrast with research settings, specific diagnostic tools for anxiety are used infrequently by GPs 
in primary care, largely due to the constraints on consultation time. That said, evidence suggests 
they are more likely to be used if a patient is presenting with a specific sub-type of anxiety, or 
requires referral to secondary care (Olariu et al., 2015). The most frequently used tools to screen for 
symptoms of anxiety or depression in clinical practice are the General Anxiety Disorder 7 item Scale 
(GAD-7) (Spitzer et al., 2006) and the Patient Health Questionnaire 9 item scale (PHQ-9) (Kroenke et 
al., 2001). Alongside these tools, a diagnosis of an anxiety disorder is informed by discussions 
between the patient and GP, and is based on the patient’s medical history and reported symptoms 
(Ford et al., 2016). However, this can be challenging as GPs need to assess, potentially diagnose, and 
formulate a treatment plan, and do so within a consultation that is often no longer than ten 
minutes. Furthermore, distinguishing between anxiety subtypes can be a complex task regarded by 
many GPs as more appropriate for specialists (Ford et al., 2016).  
Talking about mental health symptoms to gain an accurate assessment of what is going on may be 
particularly challenging with certain groups of patients. An important factor in the identification and 
diagnosis of anxiety is communication, and previous literature reviews have found a gap in 
communication between clinicians and patients when discussing mental health, with the individual 
characteristics of both influencing the likelihood of a discussion around a diagnosis taking place  
(Milton & Mullan, 2014). This includes older patients, who may think it is ‘normal’ to be anxious or 
find it difficult to discuss their mental health (Wuthrich & Frei, 2015), and men who may perceive 
more than women that there is a stigma around disclosure of anxiety (Clement et al., 2015). 
Similarly, there can also be a language barrier with some patients, with research suggesting GPs are 
less likely to identify mental health symptoms in patients from particular ethnic groups, such as 
African Americans or Hispanics (Borowsky et al., 2000), or those that are Asian (Comino et al., 2001).  
In addition, as previously outlined, it can often be difficult to disentangle anxiety disorders and 
depression. Frequently anxiety can be labelled as depression or stress, or go unexplained for many 
years, and this makes it more difficult for patients to understand the specifics of their condition 
(Anxiety UK., 2009). This may have further implications for treatment pathways, particularly if those 





treatment approaches to depression. For example, the combination of CBT and medication may be 
beneficial for patients with depression, but patients with panic disorder who receive both 
psychological and pharmacological treatment may be more likely to relapse in the long term 
compared with those who receive only CBT (Barlow et al., 2000). Many patients report depressive 
symptoms developing as a result of their untreated anxiety, suggesting that if practitioners can 
identify and treat anxiety first, later depressive symptomology may be prevented or ameliorated 
(Anxiety UK., 2009). Furthermore, national charity data suggests the public have much less 
awareness and understanding of anxiety disorders than of depression, suggesting fewer patients 
may seek help for symptoms of anxiety (Anxiety UK., 2009). When examining the current literature 
on the diagnosis of anxiety, studies have tended to focus less on anxiety disorders, and more on 
depression, or depression that is comorbid with anxiety. However, research suggests that anxiety 
may be just as important as depression, particularly when considered alongside its’ impact on 
physical illnesses (Roy-Byrne et al., 2008).  
All of the above complexities around identifying anxiety can lead to the under-detection and under-
treatment of anxiety (Rosner, 2015). Research has estimated that around 50% of patients with 
anxiety or depression do not have their condition detected by their GP (Kroenke et al., 2007). There 
is some evidence that the use of diagnostic tools might improve detection of anxiety disorders. A 
meta-analysis of 24 studies of assisted and unassisted diagnoses of anxiety reported higher 
sensitivity (63.3%) for detecting anxiety when using diagnostic tools, compared with unassisted 
diagnoses (sensitivity: 30.5%), but with slightly lower specificity seen in assisted compared with 
unassisted (87.9% versus 91.4%) (Olariu et al., 2015). However, such studies only provide a picture of 
what happens in a single consultation. Importantly, there is evidence that GPs identify most patients 
with anxiety and depression during follow-up consultations. In a longitudinal study in UK primary 
care, only 18% (n = 16/88) of patients reporting severe symptoms did not have a diagnosis at 
subsequent consultations (Kessler et al., 2002). However, it is not known if those in whom anxiety is 
not diagnosed ever seek help for their symptoms, and the impact anxiety has on their quality of life.  
Patients may choose not to seek help because they are unaware they are experiencing symptoms of 
anxiety, or because they find it difficult to disclose emotional concerns to their GP (Parker et al., 
2020). Those that are aware they are experiencing anxiety may be concerned that they would not be 
consulting for a legitimate reason, such as a physical health problem, or that doing so would be a 
waste of GP time (Rogers, 2001; Cromme et al., 2016). Qualitative interviews with patients with 
either anxiety or depression found patients reported hiding symptoms for fear they would not be 
accepted as readily as a physical illness (Kadam et al., 2001). Patients felt their GP would see their 





psychological problems, with not enough time during consultations to discuss their mental health 
needs (Kadam et al., 2001; Barnes et al., 2019). Likewise, self-stigma or perceived stigma from family 
or friends can also contribute to a reluctance to seek help, and this has been found in studies of 
patients with anxiety and with depression (Davies, 2000; Barney et al., 2006; Clement et al., 2015). In 
addition, some patients may not consult because they do not know where to get help (Salaheddin & 
Mason, 2016).  
 
2.2.1 Discussion and labelling of anxiety within the primary care consultation 
For patients who consult their GP and have anxiety identified, evidence from the 2014 Adult 
Psychiatric Morbidity Survey (APMS) suggests there may be a difference in how patients refer to 
their diagnosis, compared with the symptoms they are experiencing (Stansfeld et al., 2016). It 
reported that whilst most people with common mental disorders state the diagnosis given to them 
by a healthcare professional is ‘depression’ or ‘panic attacks’, the most common symptoms indicated 
on the CIS-R, are those of GAD (Stansfeld et al., 2016). These discrepancies may reflect the 
terminology used by GPs to talk about mental health with patients. There may be a disparity 
between the disorder GPs identify, and the label they chose to use when discussing symptoms with 
the patient. Likewise, patients may interpret discussions around their symptoms to be those of 
depression or panic attacks, rather than seeing anxiety as a specific condition (Anxiety UK., 2009). 
Research with patients with arthritis has demonstrated that they experience consultations very 
differently to the clinicians, particularly with regard to discussions around symptoms, and this may 
contribute to misunderstandings around diagnosis (Stiggelbout et al., 2012). For example, patients 
felt it was useful and positive to have a definitive label for their ‘problems’, but only if the doctor had 
conducted enough tests, taken the time to explore other possibilities, and conveyed this process to 
the patient (Stiggelbout et al., 2012). In contrast, doctors felt it was more important to offer 
reassurance and then move on, often not going into much detail about diagnosis for milder cases, or 
giving much opportunity for shared decision-making (Stiggelbout et al., 2012).  
In the case of anxiety symptoms, previous research in the Netherlands found that GPs think patients 
prefer to be assigned a physical cause for their mental health symptoms, with GPs considering the 
treatment plan for managing distress as more important than the diagnosis itself (van Rijswijk et al., 
2009). Qualitative research with GPs and health visitors in the UK on postnatal depression (PND) 
found that GPs were reluctant to medicalise the symptoms of PND and give a diagnosis, particularly 
if they were unable to offer appropriate treatment (Chew-Graham et al., 2008). Similarly, health 





to appropriate services. This may be particularly relevant for anxiety disorders, where the wait for 
access to IAPT therapies can often be substantial, and a proportion of patients with anxiety may 
perceive medication as addictive or a less favourable option than psychotherapy (Prins et al., 2008). 
In addition, when considered in the context of IAPT interventions, the services only tend to use 
diagnostic labels as a means of measuring outcomes, focusing on patient set goals and reported 
impairment, rather than the diagnosis.  
There is limited literature on how patients perceive mental health labels, and most research on this 
topic has been conducted outside the UK. Research conducted in Zimbabwe, indicated that there is 
no direct equivalent word for anxiety, but there is a construct of mental illness termed ‘kufungisisa’, 
which means the disease of thinking too much (Patel et al., 2001). Research in India reports patients 
using ‘tension’ or ‘worry’ as a long-term label for their symptoms, rather than anxiety or depression 
(Andrew et al., 2012). It was common for patients to report seeing their GP for the physical 
symptoms of mental illness, such as palpitations or numbness, rather than using psychiatric labels 
(Andrew et al., 2012). In contrast, a Norwegian study identified students going through a process of 
accepting that, rather than just shyness, their social anxiety was a symptom of mental illness, and 
once identified it was something they recognised as a part of who they were (Hjeltnes et al., 2016). 
This gave them a “language for understanding” their symptoms, and an ability to make sense of the 
emotional distress they had experienced. Further qualitative research with patients in Australia 
found that the use of a specific and accurate label, such as ‘anxiety’ rather than ‘stress’, predicted a 
preference for help-seeking, and encouraged acceptance of treatments as being useful (Wright et 
al., 2012). It is important to consider the cultural context of these findings, particularly in the case of 
the first study, in which Indian culture demonstrates a preference for a physical rather than a 
psychiatric cause (Andrew et al., 2012).  
To date, UK studies have focused on patient views of depression or patients with threshold 
‘emotional distress’ without a diagnosis. Geraghty et al. (2017) found that patients without a 
diagnosis, but with either anxious or depressive symptoms, considered their experience different to 
how they perceived ‘actual’ depression or ‘mental illness’. They rejected the idea of having ‘actual’ 
depression and felt the term had negative connotations, preferring to use the label ‘stress’ or ‘not 
coping’. The authors did not ask patients for their views on anxiety specifically, although patients 
used the label anxiety in a more definitive way than that of depression, in that they used it to refer 
to an underlying anxiety disorder, rather than when they were discussing their responses to stressful 
situations. Similarly, another UK study found the label of depression was associated with negative 
stigma for patients, with difficulty understanding the diagnosis, and a reluctance to accept treatment 





about how useful it is to communicate psychiatric diagnoses to patients (Kelly, 2018), or indeed if 
the psychiatric construct of diagnosing a specific mental health disorder is still a valid model 
(Deacon, 2013). So far, the UK literature on patient perspectives on the value of diagnosing anxiety is 
limited.   
 
2.2.2 Trends in the Diagnosis of Anxiety  
When patients consult for anxiety, GPs record presenting symptoms or diagnoses in patients’ 
computerised medical records (de Lusignan & Chan, 2008). There is evidence to suggest that how 
GPs have recorded presentations of anxiety has changed over time. Between 1998 and 2008 GP 
recording of anxiety symptoms increased (from 3.9/1000PYAR to 5.8/1000PYAR), whereas GP 
recording of anxiety disorders decreased from 7.9/1000PYAR to 4.9/1000PYAR between 1998 and 
2008 (Walters et al., 2012). Research examining the incidence of anxiety codes combined with 
depression codes also found an increase in symptom codes, but with a stable incidence of diagnosis 
codes, between 2000 and 2009 (John et al., 2016). The fall in recorded anxiety diagnoses reported in 
the former study may be due to a reluctance by GPs to formally label patients with an anxiety 
disorder, or a preference for using broad symptom codes rather than distinguishing between the 
subtypes of anxiety (Walters et al., 2012; Swift et al., 2014). Few studies have explored GP views on 
mental health diagnostic labels in the UK that might explain these trends, and only two studies have 
explored GPs’ views specifically in relation to anxiety. One of these studies focused on childhood 
anxiety (O’Brien et al., 2017). The other found GPs were reluctant to label patients with an anxiety 
disorder in the early stages, regardless of how confident they may feel about the diagnosis (Ford et 
al., 2016). Other factors that may influence the likelihood of a GP giving a formal diagnosis may be 
their experience of managing anxiety disorders, with skills-based training shown to increase 
diagnosis rates (Naismith et al., 2001).   
There have also been differences in the recording of anxiety according to age and gender. Studies 
have found the incidence of anxiety in women to be twice that seen in men (Martin-Merino et al., 
2010; Walters et al., 2012; Stansfeld et al., 2016). Incidence has also been found to be higher in 
younger adults, with previous research using primary care data finding the incidence of anxiety 
highest in adults aged 20-29 years old (Martin-Merino et al. (2010). The 2014 APMS, which used 
population data, also found similar results in terms of age differences (Stansfeld et al., 2016). In 
addition, evidence from national survey data suggests that the incidence of anxiety in young adults 
may be increasing over time, with mental health disorders in those aged 16-24 years reported to be  





data on the incidence of anxiety in UK primary care in more recent years, both in terms of looking at 
the incidence of anxiety overall, and by age and gender.  
There have been several factors that may have affected incidence rates and may have changed how 
anxiety is being recorded by GPs. These include the introduction of the depression Quality Outcomes 
Framework (QOF) in 2006 (British Medical Association, 2006); the introduction of the IAPT service in 
2007/2008; the economic recession in 2008; and the updated NICE anxiety guidelines published in 
2011 (NICE, 2011b).   
The first of these changes, the QOF, was introduced to incentivise recording of clinical quality 
indicators. Indicators such as regular reviews were required for patients with a range of common 
health conditions, including depression, but not including anxiety. An analysis of trends in the 
recording of depression indicated that the introduction of the depression QOF in 2006 impacted 
GPs’ willingness to label patients with a diagnostic code, with an increase in the use of symptom 
codes (Kendrick et al., 2015). Although anxiety disorders are not one of the given conditions 
required to have quality indicators by the QOF, the change in practice may also apply to how GPs 
record anxiety, or there may have been a tendency to prioritise the recording of depression over 
anxiety, particularly in cases where patients presented with mixed anxiety and depression (Mitchell 
et al., 2011). Furthermore, qualitative data suggests that review type consultations now have a 
biomedical focus, that establishes a situation in which the GP is the expert and the patient’s ‘agenda’ 
is not acknowledged (Chew-Graham et al., 2013). Whilst this biomedical model may be largely 
satisfactory for physical conditions, it may be at odds with the needs of patients with mental health 
conditions, and may be a barrier to productive conversations about mental health (Chew-Graham et 
al., 2013).  
The second event that may have influenced trends in the recording of anxiety is the introduction of 
IAPT in 2007/2008. Increasing availability of talking therapy does not appear to have reduced the 
prevalence of anxiety at a population-level, as reported in the APMS (Stansfeld et al., 2016). 
However, it may have reduced the number of patients presenting to GPs if patients have self-
referred directly to IAPT services. This is discussed further in section 2.3.2. In contrast, the 2008 
economic recession may have led to an increase in recorded anxiety, as recessions have been 
associated with increased prevalence of common mental disorders (Frasquilho et al., 2016). The 
analysis of trends in the recording of depression, referenced in the previous paragraph, also found 
that after the 2008 recession, the prevalence of depression increased in men. This increase was 





Finally, the NICE guidelines for the management of GAD and panic disorder were updated in 2011. 
This update is discussed further in the following section (2.3). One of the updated recommendations 
was that the “recognition and communication of the diagnosis of GAD should occur as early as 
possible to help people understand the disorder and start effective treatment promptly” (page 7) 
(NICE, 2011b). It is possible that the inclusion of this recommendation may have encouraged GPs to 
diagnose anxiety disorders at an earlier stage than they might have previously. The updated 
guidelines may also have increased general awareness of the importance of anxiety among GPs, 
which may have led to better recognition and therefore increased diagnosis rates.  
 
2.3 Management of anxiety – stepped care and psychological therapies 
As outlined in Chapter 1, treatments for anxiety are guided by a stepped-care model, with the 
recommended intervention based on symptom severity (NICE, 2011a). The NICE stepped care model 
for GAD and panic disorder, originally published in 2004, was updated in 2011. Updated 
recommendations include the following: “recognition and communication of the diagnosis of GAD 
should occur as early as possible to help people understand the disorder and start effective treatment 
promptly”, and “do not offer an antipsychotic for the treatment of GAD in primary care” (page 7 + 
18) (NICE, 2011b). The latest stepped care model, from the guidance published in 2011, is outlined in 
Table 4, along with the model for depression for comparison. Each step of the model for anxiety and 
depression are similar. However, medication is recommended as an option at step 3 for anxiety, 
compared with the earlier recommendation at step 2 for depression, with fewer interventions for 
anxiety, compared to depression. In addition, NICE specifies that for patients who present with 
depression, with comorbid anxiety symptoms, the depression should be treated first (NICE, 2011a).  
When considered in the context of the stepped care model, the first step (step 1) for all known and 
suspected presentations of anxiety is education about the condition and the options for treatment, 
along with active monitoring of symptoms. Education may include materials such as an information 
leaflet or website that a GP or other health-care professional can signpost patients to. Often, this 
can be the first step patients make towards gaining a better understanding of their mental health, 
and has been the focus of national policy and population level campaigns (Jorm et al., 2000). The 
basis of these campaigns tends to centre on introducing the patient to stress-reduction activities, 
such as mindfulness, or increasing knowledge around mental health symptoms and management 
strategies (Gu et al., 2015). They are designed to be easy to implement, applied immediately, 
inexpensive, and hopefully accessible to more people than conventional psychological or 






Table 4 The stepped-care model from the NICE clinical guidelines for GAD/panic disorder and 
depression   
 








Identification and assessment; 
education about condition and 




monitoring and referral for 
further assessment and 
interventions 
2 Diagnosed GAD/panic 
disorder that has not 
improved after 




facilitated self-help, individual 




depressive symptoms or 
mild to moderate 
depression  
 Low-intensity psychosocial 
interventions/psychological 
interventions (e.g. Individual 
facilitated self-help, 
computerised CBT), medication 
and referral for further 
assessment and interventions 
3 GAD/panic disorder with 
inadequate response to 
step 2 or marked 
functional impairment 
High-intensity psychological 
intervention: CBT (or applied 




depressive symptoms or 
mild to moderate 
depression with 
inadequate response to 
step 2; moderate and 
severe depression.  
 Medication, high-intensity 
psychological interventions (e.g. 
CBT, behavioural activation, 
counselling), combined 
treatments, collaborative care 
and referral for further 




depression and marked 
functional impairment, 
high risk of self-
harm/risk to life  
Highly specialist treatment, 
such as complex drug and/or 
psychological treatment 
regimens; input from multi-
agency teams, crisis services, 
day hospitals or inpatient care 
Medication, high-intensity 
psychological interventions, 
electroconvulsive therapy, crisis 
service, combined treatments, 
multi-professional and inpatient 
care 






Following on from step 1, are steps 2 and 3, which refer to low and high intensity psychological 
interventions respectively. Low intensity interventions are for patients with mild to moderate 
anxiety that has not improved after identification, education and monitoring. Step 2 may include 
guided self-help, computerised CBT, or psycho-educational groups. The psycho-educational groups 
may include one-off or repeated group sessions with a therapist, with psychoeducational exercises 
(Donker et al., 2009). These sessions make take place face-to-face, or increasingly, are delivered 
online (Reins et al., 2019). High intensity interventions are intended for patients with severe anxiety, 
and those who have not responded to step 2 interventions, and include individual CBT with a high 
intensity trained therapist (Donker et al., 2009). CBT is discussed further in section 2.3.1. As outlined 
above, drug treatment is also recommended at step 3 as an option, and this is discussed in further 
detail in section 2.4. The final step (step 4) is for severe anxiety, and includes complex drug and/or 
psychological therapy, and is likely to include working with secondary care teams. Alternative 
therapies may also be used to help with the symptoms of anxiety. These include acupuncture or 
herbal remedies, exercise based activities such as yoga, or diet-based changes such as increasing 
omega-3 consumption (Ravindran & da Silva, 2013). However, these therapies are not NICE 
recommended, largely due to limited evidence supporting their effectiveness (Ravindran & da Silva, 
2013).  
 
2.3.1 Cognitive behavioural therapy (CBT) and applied relaxation 
CBT is a form of talking therapy, and is the main psychological therapy recommended by NICE for the 
treatment of anxiety (Clark, 2011). CBT is based on the idea that how people think about things 
affects how they feel and what they do. When people experience negative or unrealistic thoughts, 
they may interpret situations incorrectly, and this has a negative impact on any further action they 
take. Therefore, the therapy aims to help patients become aware of these negative thoughts and 
think about how they behave, and explores whether there may be alternative thoughts and actions 
that would be more helpful (UCL, 2020a). It is intended to be a collaborative therapy, with patients 
encouraged to take shared responsibility for the work and view the process as a ‘guided-discovery’, 
with the skills learnt enabling them to cope better with any potential future adversity (UCL, 2020a).  
There have been several meta analyses of randomised controlled trials (RCT) that suggest CBT is an 
effective therapy for treating anxiety disorders (Hofmann & Smits, 2008; Tolin, 2010). Furthermore, 
there is evidence that this benefit not only relates to the short-term period after treatment (Stewart 
et al., 2009), but is also maintained over 12 months (DiMauro et al., 2013). Notably, qualitative work 





relate to how the patient engaged with therapy. Those who saw it as a learning process were better 
able to manage their symptoms long-term, compared with those who saw it as a chance to talk 
about their problems (French et al., 2017). 
With reference to the NICE guidelines, applied relaxation is the only other recommended high 
intensity therapy for GAD. This is focused on helping the patient to learn how to relax in a way that 
enables a corresponding reduction in tension and anxiety (Hayes-Skelton et al., 2013). Applied 
relaxation may be useful for patients with ‘worry’, compared with intensive CBT which may be 
effective for patients with physical symptoms of anxiety (Dugas et al., 2009). There is some evidence 
that CBT more may be more effective than applied relaxation at maintaining improvement of GAD 
symptoms over the long-term (24 months) (Dugas et al., 2010). However, there are challenges for 
GPs to deliver CBT in primary care consultations due to the time taken to learn CBT techniques 
(Aschim et al., 2011), and the lack of time during the consultation (Wiebe & Greiver, 2005). 
 
2.3.2 Increasing Access to Psychological Therapies (IAPT)  
Whilst GPs can implement some CBT techniques, as just mentioned, they may not always have the 
time or training to do so. In addition, patients may not be able to afford talking therapies given 
through private providers.  
Although IAPT was set up to increase access to talking therapies for anyone who may need it, there 
has not been a corresponding reduction in the prevalence of anxiety and depression when examined 
at a population-level in the APMS (Stansfeld et al., 2016). In fact, as outlined previously, the APMS 
found that the prevalence of anxiety has increased since the introduction of IAPT. The increase may 
be due multiple possible causes, but may include gaps in treatment access, or the limited long-term 
effects of CBT for anxiety (Bastiampillai et al., 2019). Whilst the NICE guidelines for the treatment of 
anxiety recommend 12-15 sessions of CBT, the average number of treatment sessions received by 
patients in IAPT is much lower (average sessions for anxiety and depression in 2018/19: 6.9) (NICE, 
2011b; Baker, 2020). Furthermore, it is estimated that only 15% of patients with anxiety or 
depression received treatment through IAPT in 2016 (Kendrick, 2018; Baker, 2020). Whilst the target 
is to increase this proportion to 25% in 2020/21, that still leaves the remaining three quarters who 
will receive care through their GP, if indeed they seek help at all (Kendrick, 2018).  
Patients can self-refer to IAPT, or be referred by their GP (Clark, 2011). Some GPs may prefer to 
encourage self-referral to IAPT as they view it as an important step toward patient recovery, 





that attendance is likely to be better in those who self-refer, compared with those who have been 
referred by their GP (Davis et al., 2020). However, there are no data from IAPT practitioners as to 
whether self-referral also improves engagement with treatment. When a patient contacts the 
service, they are assessed on the severity and duration of their symptoms and, if appropriate, 
offered an intervention. This assessment is independent of any diagnosis that the GP may have 
made. It is not known if GP diagnoses tend to be consistent with the conditions identified by IAPT 
assessments, and if there is an impact on therapy when they are discordant. If a patient presents 
with co-morbid anxiety and depression, then the two conditions are treated as separate conditions. 
If patients do not have a preference for which condition to work on first, then the depression is 
treated first, which is in line with NICE guidelines (Clark, 2011). There are no data on whether 
patients have a preference for working on a particular condition first, or if IAPT practitioners think it 
is important to treat one prior to the other or both together.   
Therapists deliver low or high intensity interventions based on a standard IAPT protocol (Clark, 
2011). A considerable part of IAPT interventions are focused on normalising experiences of anxiety, 
and qualitative evidence suggests that patients find this particularly useful in group interventions 
where they meet other patients with anxiety (Newbold et al., 2013). IAPT measures the outcome of 
treatment in terms of recovery rate and reliable change in symptoms. The former is based on a 
reduction in the severity of symptoms, and the aim is to reduce symptoms to the point at which they 
would be below the clinical threshold of an anxiety disorder, whereby the patient is viewed as 
having recovered. In 2018/19, around two thirds of those finishing IAPT therapies experienced an 
improvement in symptoms, with 52.1% having moved to recovery (Clark, 2018; Baker, 2020).  
 
2.4 Management of anxiety – pharmacological therapy 
In primary care, other than psychoeducation or referral to IAPT, the main treatment option for 
anxiety is medication. The most frequently prescribed drugs are antidepressants, which include 
monoamine oxidase inhibitors (MAOIs), SSRIs, serotonin–norepinephrine reuptake inhibitors 
(SNRIs), and tricyclic antidepressants (TCAs). Whilst MAOIs and TCAs are effective in the treatment 
of anxiety, the newer antidepressants (SSRIs and SNRIs) are safer, better tolerated, and are 
recommended as first-line treatments for each of the anxiety disorders (Nash & Nutt, 2007; NICE, 
2011b; Baldwin et al., 2014). Other medications that may be prescribed as monotherapies or 
augmentation therapies include benzodiazepines, buspirone, anticonvulsants, atypical antipsychotics 
and beta-blockers (Baldwin et al., 2011; Baldwin et al., 2013; Dooley, 2015). Of the anticonvulsants, 





and panic disorder. Whilst benzodiazepines are not recommended as a routine treatment for 
anxiety, NICE guidelines state there may be some specific indications where they may be 
appropriate, such as short-term crisis management (NICE, 2011b, 2014). Data that specifically relates 
to use of these medications in the treatment of anxiety are outlined in the following sections: 
antidepressants – section 2.4.1, benzodiazepines – section 2.4.2, and other drugs (antipsychotics, 
beta-blockers, and anticonvulsants) – section 2.4.3.  
Research using a large nationally representative dataset, The Health Improvement Network (THIN), 
found that 63% of patients with an anxiety disorder were prescribed either an antidepressant, 
benzodiazepine, or antipsychotic in the first three months after being diagnosed (Martin-Merino et 
al., 2010). Of these patients, 12% were treated with an antipsychotic, 18% received a 
benzodiazepine, and 80% received an antidepressant, of which the majority (60%) were SSRIs. 
However, this study did not exclude patients with depression, and therefore some of these 
prescriptions may have been for comorbid anxiety and depression. There is also evidence to suggest 
patients with anxiety, or mixed anxiety and depression, are less frequently offered pharmacological 
therapy by their GP when compared with patients with depression (Hyde et al., 2005b). 
There may be differences in prescribing according to patients’ age and gender. For example, 
previous UK studies have shown antidepressant use to be twice as prevalent in women compared to 
men for anxiety (Martin-Merino et al., 2010), and for depression (Mars et al., 2017). The level of 
prescribing of antidepressants for any indication has also been shown to increase with age (Mars et 
al., 2017; Public Health England, 2019). A US study has shown similar trends for benzodiazepine use, 
again for all indications, regarding both gender and age (Olfson et al., 2015), with prescriptions 
thought to be inappropriately high in older adults (Van Der Hooft et al., 2008). Similarly, a Swedish 
study found that for the treatment of GAD with antidepressants, benzodiazepines, antipsychotics 
and buspirone, treatment duration tends to be longer in older adults, who are more likely to be 
receiving a combination of medications from within those drug classes (Sandelin et al., 2012). 
 
2.4.1 Antidepressants 
Although antidepressants, and in particular SSRIs, are the recommended first-line treatment for 
anxiety, there is little guidance on which SSRI to use in the first instance, and RCTs comparing 
sertraline or citalopram have found that both are effective, well tolerated drugs in the treatment of 
depression (Ekselius & Eberhard, 1997; Stahl, 2000). However, citalopram may be more effective 
than fluoxetine, particularly in the treatment of anxiety symptoms (Patris et al., 1996; Bougerol et 





cases of subthreshold and mild depression, there is some evidence that antidepressants are not 
always appropriately prescribed in this group (Baumeister, 2012). It is not known if this is also the 
case for patients with symptoms of anxiety below the diagnostic threshold.  
There is some variability in how patients respond to different types of SSRIs, and patients may switch 
between different SSRIs if symptoms do not improve, or if they experience unwanted side effects 
(Simon et al., 1996). Side effects can include weight gain, sleepiness, and reduction in sexual 
functioning (Cascade et al., 2009), and there has also been concern about the possibility of an 
increased risk of suicide in patients treated with SSRIs (Healy et al., 2003). Furthermore, the use of 
SSRIs for anxiety may initially exacerbate symptoms (Quagliato et al., 2018). Consideration of the 
risks and benefits of using these drugs is important, and qualitative evidence has shown that some 
GPs think they are over-valued, used too readily, and that the effects seen are similar to the natural 
recovery of an anxiety disorder (van Rijswijk et al., 2009). Indeed, another qualitative study found 
that GPs are cautious in their prescribing of antidepressants for depression, employing strategies of 
watchful waiting in the first instance (Hyde et al., 2005a). Furthermore, GPs have reported patients 
are reluctant to take antidepressants due to potential side effects and dependency (van Rijswijk et 
al., 2009). Patients have also reported negative views of antidepressants, seeing them as something 
foreign, chemical, or unnatural, and only viewing themselves as having properly recovered from a 
mental health disorder once they have stopped taking antidepressants (Bosman et al., 2016). 
However, the same study also reported that patients thought there was a biological cause of their 
anxiety or depression, and therefore the antidepressants were helping to fix this biological 
imbalance.  
Despite concerns from both GPs and patients about antidepressants, there has been a substantial 
increase in the prescribing of these drugs over the past two decades, with the greatest increase 
being observed for SSRIs, which account for the majority of antidepressants prescribed (Lockhart & 
Guthrie, 2011). Rates of SSRI prescriptions rose from 1.03 per 100 person-years in 1995 to 2.15 per 
100 person-years in 2001, but remained stable from then to 2012 (McCrea et al., 2016). Whilst this 
figure is for all indications, including depression, this will include prescriptions for anxiety. The 
reasons for this upward trend are not clear, but it is thought to be due to an increase in the long 
term use of antidepressants, rather than an increase in those starting the medication (Moore et al., 
2009; Mars et al., 2017). However, to date, how this increase in the long-term prescribing of 
antidepressants relates to anxiety disorders is not known. Similarly, it is unclear if the increase could 
be linked to concerns around the use of benzodiazepines and potential reduction in their use 





seen in antidepressant prescribing was due to clinical decisions to use antidepressants in instances 
where they previously might have used benzodiazepines to treat anxiety (Morrison et al., 2008).  
Trends in prescribing for anxiety may be influenced by the increased availability of psychological 
therapy through the IAPT programme. The majority of patients prefer psychological therapies to 
medication (van Schaik et al., 2004). Gyani et al (2012) found that GPs who can refer patients to IAPT 
services are less likely to offer medication to patients with severe depression. Although the authors 
did not comment on anxiety specifically, if these preferences are strong, this may have been 
expected to influence prescribing for anxiety (Sreeharan et al., 2013). However, in the three years 
following the inception of the IAPT programme, antidepressant prescribing rates (for all indications) 
increased (Sreeharan et al., 2013), which may reflect long waiting times (Atkinson, 2014). It is not 
known how prescribing of antidepressants for anxiety has changed over time.  
 
2.4.2 Benzodiazepines  
Patients with severe or acute symptoms of anxiety may be prescribed benzodiazepines on a short-
term basis to help with acute distress. This may be as a combination treatment to alleviate side 
effects of antidepressants, such as increased feelings of anxiousness or jitteriness, or as a 
monotherapy (Dunlop & Davis, 2008). They may also be prescribed as a second line treatment for 
patients who have not improved on antidepressants, or prescribed long term for those with a severe 
prognosis (Nutt, 2005). A meta-analysis comparing benzodiazepines with TCAs for the treatment of 
anxiety found that benzodiazepines had a superior adverse effect profile and greater efficacy 
compared with TCAs (Offidani et al., 2013). In addition, an RCT of lorazepam, paroxetine and placebo 
for GAD showed that, for the 115 participants who completed the study, the group who received the 
benzodiazepine had a reduction in their somatic symptoms compared with both placebo and 
paroxetine (Feltner et al., 2009).  
However, benzodiazepines are not considered to be effective in the treatment of anxiety with 
comorbid depression, and they can also cause severe side effects, such as sedation and memory 
problems (Baldwin & Polkinghorn, 2005). Additionally, patients can become dependent on 
benzodiazepines and struggle with the withdrawal of treatment, potentially experiencing rebound 
anxiety (Baldwin et al., 2011). Therefore, due to their potential for abuse, through either 
dependency or toxicity, benzodiazepines are not recommended for routine treatment or long term 
use (NICE, 2014). When prescribed, it should be on a short term basis of up to four weeks, and 
should only be at a low dose (Lader, 2015). Some have argued that the NICE guidelines should be 





evidence for their efficacy when used as a combination therapy, and the lack of evidence for other 
anxiolytics superiority in treating anxiety (Starcevic, 2014). In contrast, other authors consider the 
risk to benefit ratio as too harmful for most clinical situations, arguing that they should become a 
controlled substance to reduce potentially “dangerous prescribing” (Moore et al., 2015).  
Benzodiazepines were more often prescribed routinely in the past and were the mainstay in the 
treatment of anxiety disorders for many years (Lader, 2011). Currently there are a substantial 
number of elderly patients who have taken benzodiazepines on a long term basis (Kurko et al., 
2015). Qualitative interviews with GPs in America found that they viewed the use of 
benzodiazepines as an effective treatment for anxiety in elderly patients, and were less concerned 
about the risks of continued use for this group of patients (Cook et al., 2007b). The same authors 
also interviewed elderly patients, and reported that they were reluctant to discontinue this 
medication (Cook et al., 2007a). GPs in the UK report being cautious of initiating benzodiazepines, 
being vigilant in their monitoring when they do, and as not considering long-term prescribing as 
appropriate (Rogers et al., 2007). Nonetheless, they did not criticise GPs for initiating long-term 
benzodiazepine prescriptions in the past as it was the norm, and there was a lack of prior evidence 
about potential harm  (Rogers et al., 2007). Similarly, a Belgian study found that GPs were reluctant 
to use benzodiazepines, but did so because of the lack of alternatives that would work quickly, and 
insufficient time that they are able to spend with their patients to address psychosocial problems 
(Anthierens et al., 2007). Interestingly, there is also evidence that GP practices that prescribe 
antidepressants at a higher rate, also prescribe higher levels of benzodiazepines (Morrison et al., 
2008). 
Nevertheless, current UK practice is at odds with clinical guidelines, with prescriptions of 
benzodiazepines appearing to remain at a moderate levels, despite ongoing concerns from the 
medical community (Donoghue & Lader, 2010; Sirdifield et al., 2013). Indeed in England, between 
2008 and 2012, primary care prescribing of benzodiazepines was relatively constant, varying 
between 10.9 and 11.1 million prescriptions each year (MHRA, 2015). Evidence from Public Health 
England (PHE) suggests incidence has started to decline in recent years (Public Health England, 
2019). Of the 11 million annual benzodiazepine prescriptions, around one-third to a half of these 
prescriptions are for anxiety (Simon & Ludman, 2006; Haw & Stubbs, 2007; Bachhuber et al., 2016). 
The remaining proportion of these prescriptions are for other indications, which include controlling 
epileptic seizures, alleviating insomnia, and use in acute psychiatric settings (Riss et al., 2008; 
Riemann & Perlis, 2009; Citrome & Volavka, 2011). It is not known if the potential decreasing use of 
benzodiazepines for insomnia may be masking changing trends in the prescribing of benzodiazepines 





group of patients in the UK who are taking benzodiazepines on a long-term basis, and clearly this is a 
concern for public health (Davies et al., 2017). However, there are no data on benzodiazepine use 
specifically for anxiety, and how this may have changed over time. 
 
2.4.3 Other medications prescribed for anxiety  
SSRIs and SNRIs are specified as the first-line pharmacological therapy for GAD, usually followed by a 
change to another SSRI/SNRI, mirtazapine,  buspirone, or benzodiazepines (Baldwin et al., 2011). 
Nonetheless for these first and second-line treatments, there are significant side effects and 
remission may only occur in one-third of patients, and a third to two-thirds of the remainder may 
not experience any improvement (Huh et al., 2011). There are alternatives to these conventional 
drugs, such as antipsychotic medication, beta-blockers, or anticonvulsants. There is evidence that 
atypical antipsychotics, and in particular quetiapine, may be as effective as antidepressants in 
reducing symptoms for patients with GAD, however the tolerability of these drugs is lower due to 
the unwanted side effects (Depping et al., 2010). Furthermore, the 2011 update to the NICE 
guidelines specified that antipsychotics were no longer recommended in the treatment of GAD and 
panic disorder. Nonetheless, for all indications, antipsychotic prescriptions increased by 5.1% 
between 1998 and 2010 (Ilyas & Moncrieff, 2012). 
Beta-blockers may help control the physical symptoms of anxiety, such as palpitations, and this in 
turn may be part of a positive feedback loop that reduces anxiety. However, the evidence is sparse. 
A study published in 1987 found that the beta-blocker propranolol was more effective than placebo 
in treating the symptoms of anxiety after a two week period, but that this was not maintained over 
time (Meibach et al., 1987). In contrast, a small open-label study with 31 patients examined their use 
for GAD, and found evidence of effectiveness in the short-term (Swartz, 1998). However, there is 
inconclusive evidence for the therapeutic benefit, and a lack of RCTs in recent years (Steenen et al., 
2016; Brudkowska et al., 2018). Nevertheless, beta blockers may be useful for specific situations, 
such as performance anxiety for musicians (Patston & Loughlan, 2014). In terms of anticonvulsants, 
pregabalin, which was licensed in 2004, has been shown to lead to the most improvement in both 
physical and psychological symptoms of anxiety (Lydiard et al., 2010). When looking at prescriptions 
for all indications, there has been an increase in patients starting the drug, from 128 per 100,000 
person years to 379 per 100,000 person years between 2007 and 2017 (Montastruc et al., 2018). 
There are some concerns about the potential abuse of pregabalin, along with gabapentin, with 
increasing reports of excessively high doses and rises in dependency (Evoy et al., 2017). In 2019 both 





about what impact this might have on patients with anxiety (Torjesen, 2019). However, there are no 
data on the prescribing rates of anticonvulsants for anxiety, or that of antipsychotics or beta-
blockers.  
 
2.5 Summary and evidence gaps 
How GPs record anxiety has changed over time, with an increase in the recording of anxiety 
symptoms and a decrease in the recording of anxiety disorders between 1998 and 2008 (Walters et 
al., 2012). However, there are no data on the incidence of anxiety recorded by GPs in UK primary 
care in recent years, and there have been several events and developments that may have had an 
impact on trends in coding: the introduction of the depression QOF in 2006; the introduction of the 
IAPT service in 2007/2008; the economic recession in 2008; and the publication of the updated NICE 
anxiety guidelines in 2011.  
The earlier changes observed may relate to a possible reluctance by GPs to formally label patients 
with an anxiety disorder (Walters et al., 2012; Ford et al., 2016), or a potential reluctance by patients 
to fully disclose their extent of their symptoms to their GP (Kadam et al., 2001; Cromme et al., 2016). 
The reasons are unclear as there has been limited research exploring GP and patient perspectives on 
the identification, diagnosis and management of anxiety. Furthermore, the management of anxiety 
in primary care encompasses care from GPs, which is mainly medication focused, to psychological 
treatments, usually provided through IAPT. However, to date, IAPT therapists’ views and experiences 
of how referral and diagnosis can influence management within the service and impact on patient 
engagement with treatment, have not been explored. 
In addition, there is a wide range of anxiolytic medication that may be prescribed for the treatment 
of anxiety disorders (Baldwin et al., 2005). Antidepressants are the main recommended drug, and 
whilst it is known that there has been a substantial increase in the prescribing of antidepressants for 
depression in the past two decades (Lockhart & Guthrie, 2011), it is not known if this increase is also 
seen in prescriptions for anxiety. Likewise, other drugs such as benzodiazepines may be prescribed 
for anxiety. Whilst benzodiazepine prescriptions for all indications were stable between 2008 and 
2012 (MHRA, 2015), no data for benzodiazepine use have been published to indicate how trends 
may have changed for anxiety. This is also the case for the other drugs used in the treatment of 





2.6 Aims and objectives 
The overall aim of this thesis is to gain an understanding of how anxiety is being diagnosed and 
managed within UK primary care. This thesis details qualitative interviews held with GPs, patients 
and IAPT therapists, to explore their views and experiences of the identification, diagnosis and 
management of anxiety. It also details a quantitative study conducted to investigate trends in the 
recording of anxiety diagnoses and symptoms between 2003 and 2018 using data from the Clinical 
Practice Research Datalink Gold (CPRD), and a second quantitative study using the same dataset that 
examined trends in prescribing of drugs used to manage anxiety by GPs. Together, the results of 
these three studies provide a comprehensive insight into the management of anxiety in UK primary 
care. The specific aims and objectives of each study are outlined below. 
 
2.6.1 Practitioners’ and patients’ views on identifying, diagnosing and managing anxiety 
disorders in primary care 
The overall aim of the qualitative study conducted as part of this thesis was to understand how 
patients and practitioners view and experience the identification, diagnosis, and management of 
anxiety disorders in primary care. The specific objectives were:  
• To understand how GPs conceptualise, diagnose and discuss anxiety, and explore factors 
influencing these processes. 
• To explore patient experiences of anxiety in terms of help-seeking, diagnosis and 
management. 
• To explore IAPT therapists’ views on how diagnostic labels may influence management 
within primary care psychological services and patient engagement with treatment.  
 
2.6.2 Trends in the recording of anxiety diagnoses and symptoms in UK primary care  
The first quantitative component of this thesis aimed to investigate trends in the incident recording 
of anxiety diagnoses and symptoms in UK primary care between 2003 and 2018 using CPRD Gold 






2.6.3 Trends in the prescribing for anxiety in UK primary care 
The second quantitative study for this thesis aimed to investigate trends in prescribing for anxiety 
disorders in UK primary care between 2003 and 2018, again using CPRD Gold data, and to examine 
factors that may be associated with these trends. 
Specifically, the study objectives were: 
• To examine trends in prescribing overall and by drug class (antidepressants, 
benzodiazepines, beta-blockers, anticonvulsants, antipsychotics) between 2003 and 2018. 
• To examine potential differences in prescribing over time according to age and gender 
• To determine whether any changes in prescribing over time were due to: (i) an increase in 
the number of new patients receiving medication (incident cases); and/or (ii) changes in the 









Chapter 3 Practitioners’ and patients’ views on identifying, 
diagnosing, and managing Anxiety Disorders in Primary Care 
 
3.1 Chapter overview  
This chapter details the qualitative component of the thesis that was conducted to understand how 
patients and practitioners view and experience the identification, diagnosis and management of 
anxiety disorders in primary care. The chapter starts with an outline of the main research paradigms 
and the theoretical stance taken. It then details the methods used, and findings from the interviews 
held with patients, GPs and IAPT therapists. It ends with a discussion that summarises the results, 
reflects on the study’s strengths and weaknesses, situates the findings within the context of previous 
research, and outlines implications for potential future research. Some sections in this chapter are 
based on a journal article which is due to be submitted for publication to BJGP: GPs’ and patients’ 
views on the value of diagnosing anxiety disorders in primary care: A qualitative study (Archer et al.). 
Findings from GP and therapist interviews, relating to the recording of, and prescribing for, anxiety, 
are outlined in the subsequent chapters (Chapters 4 and 5 respectively).  
 
3.2 Methods 
3.2.1 Research paradigms and theoretical stance 
The concept of research paradigms is defined as a set of ontological and epistemological 
assumptions shared by all researchers working within that paradigm, which relate to how the 
phenomena of interest should be viewed and studied (Kuhn, 2012). Broadly speaking there are two 
main paradigms within healthcare research, which tend to be described as having opposing 
assumptions. The first is positivism, which is usually connected with quantitative methodology. It is 
based on the assumption that there is one concrete reality, which can be understood through 
objective methods to test hypotheses (Park et al., 2020). Traditional methods used within this 
paradigm aim to statistically test the relationship between exposure and outcomes variables, and 
include randomised controlled trials, systematic reviews and meta-analyses, and structured 
interviews. The other paradigm is interpretivism, which is usually associated with qualitative work. 
Interpretivism posits that reality is socially constructed, and understood through one’s own 





Sample sizes in qualitative research tend to be smaller than those seen in quantitative research, with 
the focus on richness and depth of data. Methods include in-depth interviews, focus groups, and 
ethnographic studies. Researchers may seek multiple perspectives, and practice iterative and 
emergent data collection techniques (Willis et al., 2007). There is also a third paradigm, that can be 
viewed as sitting between these two paradigms, called critical realism. Whilst it shares the tenets of 
positivism, stating that there is one true reality, it theorises that there is a difference between what 
can be observed within the world, and that reality, and argues that the latter can only be understood 
through one’s own experiences and perspective (Patomäki & Wight, 2000).  
The study described in the chapter has taken an interpretivist stance, employing qualitative methods 
of data collection and analysis to understand events and experiences from the perspective of those 
involved. How the stance taken fits within a multi-methods thesis is discussed in Chapter 6 (section 
6.3).  
 
3.2.2 Overall study design 
Having reviewed the literature on anxiety, it was evident that there is a lack of qualitative research 
that focuses solely on patients with anxiety, or on patients with depression and anxiety, where 
anxiety is the primary diagnosis. In addition, it was apparent that whilst research had explored some 
of the complexities around GP coding of anxiety, it had not explored how this might affect diagnoses 
and discussions with patients. Therefore, I designed a qualitative study that would entail conducting 
in-depth interviews with GPs and patients about their views and experiences of the identification, 
diagnosis and management of anxiety. I decided this study would also include interviews with 
therapists working within the IAPT service, as being practitioners whose role is focused on the 
psychological treatment of anxiety, they might bring a valuable perspective on how anxiety should 
be managed in primary care. 
Note that as I was the only researcher working on this study, I have referred to myself as ‘the 
researcher’ from this point forward. 
Semi-structured interviews were conducted on a one-to-one basis with participants. This method of 
data collection was viewed as the most appropriate, as semi-structured interviews allow individuals 
to explain their views and experiences in detail, and in their own terms, and to raise issues that were 
salient to them but not predicted by the researcher. They also allow the researcher to guide the 
focus of the interview and probe responses if necessary. Interviews were held with practitioners 





registered with general practices in the same region. This region includes areas of varying socio-
economic deprivation.  
The study had HRA and ethical approval from the South West Frenchay Research Ethics Committee 
(REC reference: 18/SW/0088). Local study site approvals were given by the BNSSG Clinical 
Commissioning Group (APCRC reference: 2018-021) and Avon and Wiltshire Mental Health 
Partnership NHS Trust (AWP reference: 1041AWP).  
 
3.2.3 GP interviews – recruitment, sampling and data collection 
GPs were recruited for interview through GP practices who had been informed about the study by 
the West of England Clinical Research Network (CRN). Practices were given the option of supporting 
recruitment for both GPs and patients, only GPs, or only patients. The CRN informed the researcher 
which practices were willing to support the study and in what way. The researcher then sampled 
practices from this list that varied in terms of whether they were located in relatively affluent or 
relatively deprived areas, determined by the deprivation decile recorded on the National General 
Practice Profiles website (Public Health England, 2020). Deprivation deciles were calculated from the 
2015 English Indices of Deprivation (National Statistics, 2015).  
To recruit GPs, practice managers working in the practices involved, provided their GPs with a study 
invitation letter and an information sheet. The researcher also presented the study at practice team 
meetings, to give GPs the opportunity to ask questions directly. Practice managers then emailed 
response forms completed by GPs who were interested in taking part. These forms asked GPs for 
their contact details and gender. This information, alongside knowledge of their practice, was used 
to purposively sample GPs for interview of varying gender, and who worked in practices that differed 
in terms of their deprivation decile. GPs sampled were then contacted by telephone, provided with 
more information about the study and asked if they were still willing to be interviewed. GPs were 
informed that they could be interviewed in person or by telephone. It was hoped that giving them 
this choice would encourage GPs to take part, and research suggests that well-structured telephone 
interviews can collect the same information as those conducted in person (Sturges & Hanrahan, 
2004). If the individual was willing to be interviewed, an interview time and place (if a face to face 
interview) were agreed during this telephone call.  
Informed consent was taken from GPs immediately prior to the interview, via either verbal 
telephone consent or written consent in person. Consent was also sought to audio-record the 





guide was based on the aims of the study, informed by the literature, and discussed within the 
supervisory team and with members of the study’s patient and public involvement (PPI) group 
(detailed later). It included questions about causes and symptoms of anxiety; management of 
mental health in primary care; similarities and differences between anxiety and depression; and how 
diagnoses were coded and discussed with patients.  
Data collection and data analysis proceeded in parallel, and the topic guide was slightly revised to 
incorporate questions that related to issues raised by interviewees. After each interview, GPs were 
asked to complete a brief demographic questionnaire that requested information on their gender, 
age, length of time practising as a GP, whether they were salaried or a partner, and any additional 
psychiatry or mental health qualifications. The information gathered was used during the analysis to 
reflect on whether accounts given varied depending on the GP’s gender, age and length of time 
practising; and to describe GP interviewees when disseminating findings.  
 
3.2.4 Patient interviews – recruitment, sampling and data collection 
Patients were also recruited for interview through GP practices. Again, these practices were 
informed about the study by the CRN. The researcher selected practices from the list of those who 
responded with expressions of interest to support patient recruitment, and that varied in terms of 
whether they were located in relatively affluent or relatively deprived areas, according to the 
recorded deprivation decile on the National General Practice Profiles website (Public Health England, 
2020). 
GP practices identified eligible patients through database searches and manual screening of 
retrieved records. Eligible patients were those aged 18 years or older, and having a current diagnosis 
of either anxiety disorder, MADD, or as having reported anxiety symptoms to their GP in the last 12 
months. Excluded were those who had a recent history of bipolar disorder, schizophrenia, 
personality disorder, dementia, substance (alcohol/drugs) misuse, or who the GP felt would be 
unable to complete the questionnaires.  
Eligible patients were mailed an invitation letter and information sheet about the study by their GP 
practice (Appendix - A.2). Patients interested in participating posted response forms back to the 
researcher, using stamped addressed envelopes that were enclosed with their invitation letters. 
Reminder letters were sent to patients who had not responded after two weeks.  
Patients were also recruited for interview by GPs opportunistically mentioning the study to patients 





part, GPs completed a brief ‘permission to contact’ form and gave the patient a copy of the 
invitation letter and information sheet to take away. The ‘permission to contact’ form requested 
information on the patient’s contact details and basic sociodemographic information (age, gender 
and ethnicity), and was sent back to the researcher by secure fax. GPs also completed and faxed a 
referral form confirming that the patient met the eligibility criteria. This information, alongside 
researcher knowledge of their practice, was used to purposively sample individuals of varying age, 
gender, ethnicity, who were registered with practices that differed in terms of deprivation decile. 
Having received both forms, individuals sampled were then contacted by the researcher by 
telephone to explain more about the study, and asked if they were still willing to be interviewed. 
Like GPs, patients were given a choice of being interviewed over the telephone or in person. The 
date, time and location (if a face to face interview) was then arranged.  
Immediately prior to interview, informed consent was taken either verbally by telephone or written 
in person. Consent was also sought to audio-record the interviews. During the interviews, key areas 
were discussed with each individual using a topic guide (Appendix - A.3). It was designed in parallel 
to the GP guide to ensure key areas relevant to both patients and GPs would be covered, as this 
would help comparison of GPs’ and patients’ views when analysing the data. Key areas covered by 
the patients’ guide included causes and symptoms of anxiety; help-seeking for anxiety; management 
of mental health; similarities and differences between anxiety and depression; and whether they felt 
it was important for GPs to distinguish between anxiety and depression. As data collection and data 
analysis proceeded in parallel, the topic guide was slightly revised in response to insights gained as 
the interviews progressed. After each interview, patients were asked to complete a brief 
questionnaire that gathered further socio-demographic information (age, education, employment & 
marital status) and symptoms of anxiety and depression using the GAD-7 (Spitzer et al., 2006) and 
the PHQ-9 (Kroenke et al., 2001). This information was gathered so that the researcher could explore 
during data analysis whether factors such as symptom severity appeared to affect views expressed, 
and in order that the sample interviewed could be described in detail when disseminating results.  
 
3.2.5 IAPT therapist interviews – recruitment, sampling and data collection 
All the GPs interviewed refer patients into the local IAPT service. At the time of interview, this was 
the Bristol Wellbeing Therapies (BWT) service. If the patients interviewed choose (or had chosen) to 
self-refer for NHS talking therapy treatment, this was also the service that would assess and manage 





management of anxiety, from the perspective of practitioners who have been trained in the 
psychological treatment of anxiety.  
All therapists working in the BWT service were invited to take part, and were given an invitation 
letter and information sheet by their service manager. The researcher also presented the study at 
one team meeting, to ensure therapists had the opportunity to ask questions about the study in 
person. Therapists who were interested in participating provided their contact details and current 
level of IAPT work (i.e. high or low-intensity practitioner) on a signup sheet during the team meeting 
or emailed the researcher directly. On receiving contact details for those willing to be interviewed, 
all therapists were contacted by telephone, provided with more information about the study and 
asked if they were still willing to be interviewed. As with the GPs and patients, therapists were given 
a choice of being interviewed over the telephone or in person. The date, time and location (if a face 
to face interview) was then arranged.  
Informed consent, via either verbal telephone consent or written consent in person, was taken 
immediately prior to the interview (Appendix - A.4). Consent was also sought for audio-recording the 
interview. During the interviews, key areas were discussed with each individual using a topic guide 
(Appendices - A.5). The guide was developed in parallel with the GP and patient guides, to ensure 
that areas relevant to each group of interviewees would be covered, as this would help during data 
analysis when comparing the views of GPs, patients and therapists. As with the GPs’ and patients’ 
guides, key areas covered included causes and symptoms of anxiety, and the similarities and 
differences between anxiety and depression. However, the therapists’ guide also covered the 
management of anxiety and depression within IAPT, and how diagnostic labels affect patients’ 
engagement with IAPT interventions. After the interview, therapists were asked to complete a brief 
questionnaire that requested information about their professional qualifications, length of time 
working in IAPT, and socio-demographic information (age, gender), that was then considered during 
the analysis and used to describe those interviewed.  
 
3.2.6 Data analysis 
Data collection and analysis took place in parallel, so that data collection could end when data 
saturation had been reached, i.e. no new themes were identified in the later interviews (Mason, 
2010). This was an iterative approach, whereby initial interviews informed later interviews. For 
example, insights from early interviews with GPs indicated that the sociodemographic characteristics 





this an additional four GPs were interviewed. These GPs worked in practices with a lower 
deprivation decile than the practices of those previously interviewed. Iteration also took place 
between the patient and practitioner interviews. For example, patient interviews highlighted that 
anxiety and depression were not being discussed as separate conditions. Therefore, later interviews 
with practitioners included a question on whether they highlighted the distinction between the two 
conditions with patients, even if they were coded separately.  
All interviews were audio recorded, transcribed verbatim and checked for accuracy. Following the 
steps defined by Braun and Clarke (2006), data were analysed thematically. A thematic approach 
was used to highlight the views each group held towards a specific issue, for example the value of 
managing anxiety separately from depression, and to enable comparisons to be made within and 
across the interviews to identify common themes and differences in accounts. 
Initially, each dataset was analysed separately, with the patient interviews fully analysed before the 
GP interviews, followed by analysis of the therapist interviews. For each dataset, the researcher and 
a member of the supervisory team read and re-read a subset of transcripts to identify possible 
codes, and then met to compare and discuss their coding and interpretation of the data. There was a 
‘pause’ in interviews at this point, to reflect on the preliminary data collected, and whether there 
needed to be revisions made to the topic guides. Some slight revisions were made, such as the use 
of the term ‘over-medicalised’ rather than ‘over-pathologised’. Following these discussions, a 
preliminary coding framework was developed for each interview set. The three coding frameworks 
were developed in parallel to ensure common codes were used when appropriate. Each coding 
framework was revised as new codes were identified in subsequent transcripts, with the coding 
frameworks for the other interview sets also revised, where appropriate. Transcripts that had 
previously been coded were recoded where necessary. All transcripts were electronically coded in 
NVivo 12 (QSR International, 2020), so that coding reports could be electronically generated to 
extract data relating to each code.  
Once all the data had been coded, coding reports were created. They were read and re-read to 
identify key themes and deviant cases. Using an approach based on Framework analysis (Ritchie & 
Spencer, 1994), data in these reports were summarised in tables where the rows represented each 
interviewee and the columns each code. Due to the number of codes identified, multiple tables were 
created (for each dataset). Each table collated codes broadly relating to diagnosis, causes and 
symptoms, management, or comparisons of anxiety and depression. Once data had been 
summarised in each table, the researcher wrote summary documents that detailed individual 





explanations for the accounts given. When considering possible explanations for the patients’ data, 
the researcher identified similarities and differences in accounts from individuals who varied in 
terms of their demographics, duration of symptoms, and/or experiences of depression. For the 
practitioner datasets, the researcher considered patterns and differences between the accounts 
given by practitioners who varied in terms of age, gender, and number of years practising; and for 
the GPs, the sociodemographic characteristics of their patients; and for the therapists, the level they 
were working at within IAPT. Themes and subthemes identified during the analysis, and the possible 
relationships between them, were then summarised in mind-maps to provide a visual overview. 
These mind-maps, and the researcher’s interpretation of the data, were discussed with a member of 
the supervisory team. An example of the mind-maps is provided in the Appendix - A.6. Findings from 
the three datasets were then compared to identify similarities and differences between GPs’, 
patients’, and therapists’ accounts.  
3.2.7 PPI involvement 
Four PPI contributors, who had all been referred to IAPT services, were identified during a local 
Psychological Therapies Health Integration Team (InPsyTe HIT) meeting. They were asked if they 
would be willing to support the study by one of the InPsyTe HIT directors, and all agreed. At this HIT 
meeting, ran by the InPsyTe HIT co-ordinator and directors, PPI contributors discussed and 
commented on initial ideas for the study and the research aims. One month later, contributors 
provided input into the content of the interview topic guides by email. Questions around 
differentiating between anxiety and depression were included as a result of this. Seventeen months 
later, four individuals were invited to a meeting with the researcher to comment on study findings. 
This included one individual who had attended the first meeting, and three who had been invited 
through the University of Bristol’s Centre for Academic Primary Care's (CAPC) PPI pool of 
contributors. Contributors felt the results were important, relevant, and agreed with the 






3.3 Results - overview 
The results from each dataset are presented separately below. GPs’, patients’, and therapists’ views 
have been detailed under the headings of causes and symptoms (and help-seeking for patients), 
diagnosis or labelling, management, and comparisons between depression and anxiety. These 
headings relate broadly to the aims of the GP, patient, and therapist interviews. Under each heading, 
findings have been presented to highlight similarities and differences identified between the 
accounts of each interview group. Within these different sections, there are subheadings that reflect 
the themes identified during the analysis. 
 
3.4 Results - GPs 
Between September 2018 and March 2019, fifteen GPs from six GP practices were interviewed 
(Table 5). Interviews lasted between 20 to 40 minutes (mean: 29 minutes). Four GPs were 
interviewed in their practice, and the remainder over the telephone. All the interviews were 
conducted by the researcher. Just over half of the GP interviewees were women (n = 8, 53.3%), and 
the mean age was 44.9 years (Standard deviation (SD) 7.7 years). Those interviewed had been 
consulting in general practice between 4 and 27 years. One GP reported an additional qualification in 
mental health or psychiatry.   
Table 5 Socio-demographic details of GP interviewees and their associated general practices 
Details of GPs interviewed Details of GP practices 
ID Gender Partner/Salaried Age Deprivation 
Score 1-10* 
Clinical commissioning group (CCG) 
1 Male Partner 30-39 3 Bristol 
2 Female Partner 40-49 9 South Gloucestershire  
3 Female Salaried 30-39 9 South Gloucestershire 
4 Male Partner 50+ 9 South Gloucestershire 
5 Female Partner 40-49 10 North Somerset 
6 Female Partner 50+ 3 Bristol 
7 Female Partner 40-49 10 North Somerset 
8 Male Partner 40-49 10 North Somerset 
9 Male Partner 40-49 10 North Somerset 
10 Female Salaried 40-49 4 Bristol 
11 Male Salaried 30-39 4 Bristol 
12 Male Partner 50+ 1 Bristol 
13 Female Partner 40-49 1 Bristol 
14 Male Partner 30-39 6 South Gloucestershire 
15 Female Partner 50+ 6 South Gloucestershire 
*Deprivation score for the practice patient population where 1 indicates the most deprived patient population and 






3.4.1 GPs’ views on the causes and symptoms of anxiety 
Most GPs viewed anxiety as a result of a combination of internal and external factors, and talked 
about specific ‘at risk’ groups. 
Causes of anxiety  
GPs reported that there were multiple causes of anxiety, rather than one specific cause. Most GPs 
divided causes into “nature and nurture” (GP 1), and commented that it was a combination of these 
causes that resulted in an individual developing anxiety. From the nature, or internal perspective, 
GPs talked about personality traits and inherited familial links, or genetic pre-disposition. GPs 
commented on “anxious families” (GP 6), and observed that patients refer to themselves as “born 
worriers” (GP 6).  
“I think it’s to do with just inherent personality, and how much of that is genetic and how much 
isn’t I don’t know. I suppose I think familial and a sort of inherent thing are the main causes, 
and then I think there are life issues which happen, and it’s usually when people get in trouble 
that their inherent personality goes too far.” GP 6 
From the nurture, or external perspective, GPs commented on childhood experiences, and included 
childhood upbringing, trauma, and seeing how family members may react to stresses. Additionally, 
they also commented on challenging or stressful experiences as an adult, as being a cause or a 
trigger.  
Some GPs commented on anxiety resulting as a lack of balance or control over multiple areas of a 
patient’s life. 
“It’s about balance isn’t it, and I think people start to get anxious when things in their life aren’t 
balanced in the way they need to be. That balance is unique to them and it’s about I think, you 
know, it might be the balance between work and home, it might be the balance in their 
relationship, it might be the balance of never having any time to relax and to do something for 
themselves. It might be the balance of how much control they feel they have, but usually I think 
if you’re just thinking about what causes anxiety, I think drilling down into where they’ve lost 
that balance versus control, I think helps us to look at it.” GP 5 
One GP felt anxiety was an experience that related to how patients perceive their situation, resulting 
from an interaction of their personality, circumstances, and views on life.  
“I think anxiety is a feeling which people experience, and for each individual it’s a complex 





relationship status, their perceptions of the meaning of things. I don’t think that the cause as 
such- I think I’d hesitate to use the word cause, I think it’s a, yeah, it’s an experience, and a 
perception, and interpretation of how people feel in the context of various things.” GP 4 
Some GPs commented on changes over time, with increasing levels of anxiety seen within society, 
and cited several reasons for this. Many GPs commented on how the increased reliance on using the 
internet for shopping, working, and interacting with people, had reduced people’s social and 
physical contact with others. Furthermore, GPs felt the rise in social media use was contributing to a 
skewed perception of what an ideal life should be like, resulting in pressure to achieve the 
impossible. 
Causes of anxiety and changes over time are discussed in more detail in Chapter 4.  
Groups at risk of anxiety  
GPs identified groups of patients that they thought were at risk of developing anxiety. Most GPs 
referenced young women as experiencing the “true sort of isolated anxiety” (GP 9), whereby they 
experienced generalised symptoms of anxiety, without low mood. Some GPs also felt the elderly 
population were most at risk because they were the group that might be least likely to seek help for 
symptoms of mental health, perhaps due to a reluctance to acknowledge they might need help for 
mental health problems, or due to social isolation.  
“Our older teenagers are hugely vulnerable at the moment, and some of the young adults 
actually, and I think the parents, more commonly mums, but the ones that are just trying to 
juggle too much. But we’ve got a lot of- like extreme elderly, you know, late eighties elderly 
who live on their own in a rural area with no facilities, no local services, no bus, no nothing. 
There’s even patches in this surgery area where there are no care agencies that will cover some 
of the villages, and those people get very, very- they get very stressed because, and I think that 
there is a patch of- there is a pocket of people that are very vulnerable to anxiety, and I look 
after two or three people who are desperate, who truly are anxious in that bracket who just 
will not get help. They are the generation that just don’t see it as a thing, you put up and shut 
up, and they’re really suffering and they’re just a naturally silent, hidden pocket of need really.” 
GP 5 
However, GPs also reflected that the groups they had identified as at risk, such as young women, 
were also the same groups that they were most likely to see. They commented that this might mean 





that whilst the older groups did consult quite regularly, but they did not tend to consult specifically 
about anxiety or acknowledge they might need help for anxiety.  
“Although saying that, they’re still the war generation so they don’t want to make a fuss so 
they might present in a different way, like phoning frequently for visits about other health 
issues.” GP 1 
Symptoms of anxiety 
GPs were consistent in explaining the symptoms of anxiety, and distinguished between physical and 
psychological symptoms. GPs felt the physical and psychological symptoms were intertwined, 
although they stated that some patients might find it easier to talk about symptoms of ‘stress’ rather 
than use the word ‘anxiety’.  
“Occasionally they’ll use a different word, like stressed, and then when you sort of tease things 
out a little bit, it sort of seems to be more generalised anxiety.” GP 10 
GPs reported that patients consulted for the physical symptoms frequently, and that sometimes 
patients were surprised when they explained these symptoms were due to anxiety.  
“Some people will present with physical symptoms, and so they’re looking for a sort of kind of 
physical cause for their symptoms. And then it may be that you have to work with them 
gradually to sort of, eventually, come to understand that maybe there isn’t some underlying 
physical illness that we’re going to identify and maybe this is anxiety.” GP 8 
GPs also commented that about a third of their patients presented with low mood, and that these 
patients might find it difficult to explain how they were feeling, if they did not realise they were 
experiencing anxiety (in addition to, or instead of, the low mood).  
“Some present with mood problems, but they don’t really know how to put their finger on how 
they’re feeling, and then if you sort of go through the history, it is anxiety symptoms that come 
out.” GP 13 
 
3.4.2 GPs’ experiences of diagnosing, recording, and discussing anxiety  
Within the accounts given by most of the GPs interviewed, there were themes around the threshold 






Threshold for coding and diagnosing  
As mentioned earlier, GPs talked about anxiety as a potentially learned behaviour, that could relate 
to the rise of social media and the concept of chasing the “perfect life” (GP 1). Therefore, there was a 
sense that it was not an illness that should be diagnosed by a medical practitioner, but rather it 
could be a personality trait or genetic pre-disposition. However, GPs acknowledged that they had a 
role in supporting patients’ understanding and management of their symptoms, although also 
reflected that they had little time, resources or expertise to do this. Some GPs said they were careful 
what words they used when discussing anxiety with patients, reporting a tendency to use words like 
“anxious or on edge” (GP 1) rather than ‘anxiety’, as the latter could imply they were making a 
diagnosis.    
GPs referred to anxiety as being something that everyone experiences in some way, such as prior to 
an interview or an exam. They reported that patients can have difficulty in understanding that there 
is a distinction between this type of transient anxiety, which might be better termed as ‘stress’, 
versus that which would be diagnosable at a clinical level.  
“I think that people get confused between stress and anxiety... and again where does… very 
bad stress then flip into anxiety because actually sustained stress will make you anxious in the 
end anyway, so how do you spot someone who’s switching into the next step of the problems.” 
GP 5 
GPs stated anxiety was very common in primary care, with five to ten percent of their patients 
presenting with symptoms. They emphasised that a large part of their role was about normalising 
anxiety as a human emotion, and that they had a ‘threshold’ for it becoming a clinical problem. GPs 
stated they were reluctant to code for an anxiety diagnosis when a patient first presented. This 
could be more challenging if patients presented with preconceived thoughts about having an anxiety 
disorder (or depression, or both).  
“Now everybody knows they’re depressed before they come to the doctor, they tell me they’re 
depressed but they usually don’t meet the criteria [for a disorder]. It’s quite difficult to engage 
people in that kind of conversation ‘cos they already know they meet the criteria ‘cos they’ve 
read it on the internet.” GP 4 
When GPs were referring to the threshold for coding, they explained the decision to code for an 
anxiety disorder was dependent on severity and chronicity of symptoms. Information gathering was 
essential when considering coding for an anxiety disorder, with a focus on duration and excluding 





establish this. GPs explained that discussions around mental health are complex, and fully 
understanding a patient’s situation and symptoms could take longer than the time the GP had 
available. As such, GPs encouraged follow-up appointments and continuity of care where possible, 
and would delay coding for an anxiety disorder until they had established an accurate picture of 
what was going on, following multiple appointments with the patient.  
“I think it depends whether they come back. So, yeah, (pause) yeah, so I might not code it as 
that on the first consultation but I think if it’s, you know, if it’s becoming more apparent as the 
consultations develop then I might do, so I might code it as anxiety states say on the first 
consultation, and then [it] might develop into [a] generalised anxiety type code or even chronic 
anxiety if they’d had episodes in the past.” GP 10 
The accounts about thresholds for coding, and specific codes used by GPs, are discussed in more 
detail in Chapter 4. 
Reluctance to use a diagnostic label  
GPs described themselves as generalists who did not specialise in psychiatry, and viewed this as 
another challenge for them in knowing when to code for a disorder, rather than just symptoms. As 
such, several GPs reported that they would “shy away from labelling it as generalised anxiety disorder 
without a psychiatrist back-up” (GP 1), or that it would be the role of a psychiatrist to diagnose an 
anxiety disorder.  
“I think anxiety is treated very much in primary care, it’s rare that I refer someone, but to 
actually label someone with an ICD-10 diagnosis anxiety condition, I don’t go through that 
formal thought process. We probably just generally label it as anxiety rather than actually a 
formal medical diagnosis label. We’re just not as expert at doing that as a psychiatrist.” GP 9 
Some GPs reported that they did not think they had ever given a diagnostic code themselves, and 
had only ever used them when re-activating old codes that had been previously recorded by another 
GP.  
“I don’t think I’ve actually put an anxiety disorder really as a diagnosis, I think I’ve often- it has 
often been reactivation of an old diagnosis.” GP 3 
The value and impact of labelling  
GPs commented that by the time a patient with anxiety presented to them, there was an 





to be recorded as a medical disorder. GPs reflected this could result in medicalising symptoms that 
were a normal part of life, or that anxiety was becoming over-pathologised.  
“I think we tend to make things more a disorder than we did before. They were just ‘oh she’s 
always been an anxious soul’ rather than it being a label, so I think there is a little bit of a 
tendency to do that.” GP 6 
One GP reported that he did not think it was helpful to ‘label’ anxiety at all, and found discussions 
around anxiousness and what is ‘normal’ to be a better use of consultation time.  
“I don’t think it’s helpful to see it as a pathology, which is a disease that’s treated by doctors. I 
think that happens far too much… if I have the time and the person is sort of philosophically 
minded, then I’ll try and engage them in a little sort of philosophical conversation about what’s 
normal, ‘who decides what’s normal?’” GP 4 
GPs commented that some patients want a label, and that it can help patients understand what is 
going on in terms of their mental health, and to think about treatment and how they could get better. 
They felt it could have a positive impact on patients’ management of their anxiety, with diagnosis 
tending to elicit feelings of relief or a sense of control for patients.   
“It gives them an identity they can relate to; it puts everything into perspective for them and 
they then can say I’ve got this - I think patients sometimes like the ownership of something. I 
guess maybe it’s that realisation they have got a problem, and if they’ve got a problem, they’ve 
got a diagnosis, therefore have a treatment element to it. A relief that there is actually 
something there they’ve got and maybe it’s then not their fault or something.” GP 9 
Yet, GPs also commented that sometimes their patients discouraged them from coding for anxiety, 
as they were concerned about having potentially stigmatising labels on their medical records, and 
thought there was a possibility of employers or insurers viewing it, or because they did not think that 
they had anxiety. Some GPs also reported perceptions that sometimes patients did not want or a need 
a label, they just wanted help with their symptoms.  
“I would say lots of people I talk to they don’t want a medical label; they don’t want to be given 
a diagnosis, they just want assistance with how they’re feeling.” GP 4 
GPs mentioned they did not code if they thought it would be unhelpful for the patient, or if giving a 
diagnosis might be “troublesome” (GP 6) in terms of them then needing to spend more time 





coding for anxiety was particularly unhelpful if it encouraged patients to adopt a “sick role” (GP 13), 
potentially exacerbating the situation.  
“Some people I think it makes it easier for them to assume the sick role, and to think that 
they’re not getting better… but then they lose their self-confidence about returning to work 
which then exacerbates the anxiety situation, and they kind of carry the mantle around with 
them that they suffer with anxiety.” GP 13 
“Some people respond well to having a diagnosis and a label, but others…malingering is too 
strong a word for it, but then you just wonder if they just attach all their problems to that and 
that’s not necessarily the case.” GP 7 
GPs also discussed the value of making a formal diagnosis of anxiety, in terms of the impact it would 
have on the management of the condition. GPs commented that there were long waiting times to 
access talking therapies, described secondary mental health care for anxiety as non-existent, and 
viewed the threshold for accessing psychiatric support as too high for this patient group. Therefore, 
most GPs saw little practical value in making a diagnosis. However, in contrast to this, some GPs 
reflected that recording a diagnosis of anxiety could be beneficial for patients in terms of enabling 
them to access help, or further support, outside the health care system.  
“Having a label can sometimes be a useful product that allows them to either access help, 
access benefits and maybe get some time off.” GP 12 
In addition, some GPs commented that there was a relationship between coding for an anxiety 
disorder and prescribing medication, in that they would not prescribe medication without first 
making sure the patient had a diagnostic code. This is discussed in more detail in Chapters 4 and 5. 
 
3.4.3 GPs’ experiences of treating anxiety within primary care 
GPs talked about the use of medication and psychological therapy, and about constraints on their 
time or skill, in the management of anxiety.  
Treatments for anxiety 
GPs reported different strategies in discussing treatment options, such as continued discussion in 
repeat appointments, and time for patients to consider their options. They stated decisions on 





or talking therapy. GPs said they would generally suggest a combination of talking therapy, self-help 
resources, and medication.   
“So, I normally manage it with a kind of combination of things in terms of offering sort of 
talking therapy type treatments, and considering medication if it feels appropriate. Depending 
obviously on the level of distress and their experiences before, and giving them some self-help 
resources in terms of websites and apps and all those kind of things, books, that kind of thing, if 
that seems to be their thing. So basically, largely dependent on what you think that they want 
and what their previous experiences are of previous therapies.” GP 2 
GPs commented that they would suggest patients reconsulted after a short period to see how they 
were getting on with managing the symptoms of anxiety, and at this point they might suggest 
something else, such as medication (if the patient had not already tried it). 
All GPs commented on the immense value that the IAPT service gave patients, particularly for 
signposting to other services. However, they reported whilst the threshold for accessing treatment 
was lower than that of secondary care, there was still a long wait for patients to start getting help. 
Nonetheless, many GPs said they always suggested referral to IAPT as an option, regardless of 
whether they were also suggesting medication.  
“I always tell them to [self-refer to IAPT] (laughs). I don’t ever leave it out as an option really 
and I think it’s important ‘cos- As far as I’m aware, I mean in terms of gold standard, CBT is the 
one thing if that people engage with and do it well, that’s more likely to change their anxiety 
than just taking an antidepressant.” GP 9 
Some GPs commented that they thought patients preferred medication, over trying to manage their 
anxiety in another way – “they don’t want to try and manage it themselves, they’d rather have 
tablets” (GP 3). GPs reported that some patients expected medication when they consulted, and 
wanted a quick fix rather than seeing it as a long-term management issue. However, GPs reported 
that they generally avoided rushing into prescribing medication, particularly within the first 
consultation. GPs acknowledged that “where warranted they could be a useful tool” (GP 12), but 
there were also some GPs who spoke about currently reviewing their practice, and “trying to give 
suggestions other than medication” (GP 1). They used repeat appointments to encourage patients to 
think about their options, and tried to offer medication alongside referral to talking therapies.  
One GP saw medication for anxiety as a last resort, that should only be done in conjunction with a 





“I think anybody who’s taking medication for anxiety, that should be done only because there is 
very significant, long-term, ongoing management by a multi-disciplinary team of psychologists, 
occupational therapists, and psychiatrists, who engage long-term with those patients. Because 
medication for anxiety should be a last, well I mean this is what the guidelines say to what they 
were, it should be because you’ve tried everything else.” GP 4 
GPs reported that the use of antidepressants for anxiety could sometimes confuse patients. Some 
GPs reflected that this could make it harder for patients to understand why they were being 
prescribed antidepressants, when they identified as having anxiety.  
“But often people will- when you mention the antidepressants to them they’ll say ‘oh but I 
feel quite happy, I’m not depressed’- so they clearly feel that they don’t- they don’t always 
understand it. Some of them are quite vocal about the fact that they have no- they’re not 
depressed, they’re quite happy with their life.” GP 3 
Data on prescribing for anxiety, such as GPs’ views on prescribing, are discussed in more detail in 
Chapter 5. 
Reflections on NHS primary & secondary care 
GPs reported limited availability of mental health professionals for patients in their practice. One GP 
said that they had previously had a practice counsellor, but that the funding had been stopped due 
to the introduction of IAPT talking therapies. GPs said that they felt there should more mental health 
support available, embedded within practices. 
“I think if we had an experienced mental health worker managing patients with anxiety and 
depression. I think everyone should know that if you’re not feeling mentally well you go to a 
mental health worker, not a GP ‘cos then you’ll get proper management…it would seem likely 
that they would need to be embedded in GP practices.” GP 4 
GPs commented that there were groups of patients with anxiety that were not being appropriately 
managed within primary care, in particular individuals too severe for primary care, but not severe 
enough for secondary care, and so “they just fall between the gaps” (GP 1).  
GPs reflected that for those patients, CBT might just be a “sticking plaster” (GP 6), and that those 
patients were likely to return again and again to their GP, needing more than their GPs could offer. GPs 
also reported the lack of time and training they had to manage these patients.  
“It’s giving them CBT type strategies as best we possibly can even though if you said, ‘well are 





we end up doing more or less the same for every person, but it’s because that’s what we have 
available and it’s a real, real shame.” GP 5 
“I’m finding increasingly mental health services are virtually non-existent. I see my role as the 
GP to manage the problem but I’m not the psychotherapist, I’m not the counsellor, I’ve got ten 
minutes with this patient, I can see them again and again, but once I’ve diagnosed the issue, 
we really need to be able to access appropriate resource and signpost people. I always worry 
that you say ‘there’s good evidence that CBT may help, ring them up’, and you know that the 
patient’s going to ring up and then be told that they’re not going to get anything for ages and 
what does that do to them?” GP 8 
Many GPs commented that secondary care for anxiety felt non-existent. GPs stated they hardly ever 
referred patients to secondary care if they had anxiety, unless their functioning was severely impaired. 
GPs explained that this meant their own practice threshold for referrals was very high, as they knew 
from “years of experience that we were wasting our time referring patients”. (GP 12). 
 
3.4.4 GPs’ views on the differences between anxiety and depression 
GP accounts highlighted that diagnosing anxiety can be complicated by the presence of co-morbid 
depression, and they outlined differences between two conditions in terms of presentation and 
management. 
Difference between the presentation of anxiety and depression 
GPs described depression as generating a lack of motivation, or lowered energy levels, whilst they 
thought anxiety resulted in “higher, or heightened energy” (GP 12). They reported depression as 
being a general “lowness of spirits, of things not getting better” (GP 6), whereas anxiety was centred 
around worry and overthinking. GPs also reflected on the cyclical relationship between the two 
conditions, and how they can both cause each other and co-exist.  
“With some people it’s depression, and then that causes them to be not motivated, and [they] 
don’t want to go out and [they] don’t want to see people, and then they start to get the 
physical symptoms of anxiety and worry about things. And [they] can’t rationalise what they’re 
thinking because they’re depressed, and I think there are some people who are anxious and 
feel that way, and then that lowers their mood and then they get the symptoms of depression, 





GPs also explained differences between how anxiety and depression manifest, with depression being 
the condition more likely to be presented repeatedly in practice. They commented that they did not 
know if this was because anxiety was more likely to resolve, or because patients with anxiety were 
less likely to return with it again.  
“I tend to see people with depression repeatedly coming back maybe a bit more but I don’t 
know whether that’s because the anxiety’s gone away or because maybe they don’t feel that 
it needs to be presenting repeatedly I don’t know.” GP 2 
Distinguishing between anxiety and depression 
GPs talked about anxiety and depression as having a large symptom overlap, and that it was common 
for patients to meet the criteria for both. One GP referenced the idea of “the whole Venn diagram 
thing” (GP 5), and that patients sat somewhere within that “middle grey area and you’re trying to 
unravel which is which” (GP 5).  
GPs commented that it could be difficult to distinguish between anxiety and depression during short 
consultations, and this might be reflected in the codes they use. They reported a tendency to use co-
morbid labels, or sometimes just code for ‘depression’ if the anxiety symptoms were not clearly the 
primary problem.  
“Often there’s one symptom that’s overwhelming. It can be difficult if someone’s depressed 
and having panic attacks, and I think that the majority I do put as depression, but if someone 
has predominantly anxiety then I will classify them as depression with anxiety.” GP 12 
That said, some GPs commented that depression, or low mood, was often the condition they 
diagnosed first in co-morbid patients, with the anxiety becoming more evident later. They reported 
this might be because the symptoms of depression were apparent to the patient and therefore the 
condition that they consult for. However, GPs stated that after some probing, they often also 
identified symptoms of anxiety. In contrast, GPs also described patients consulting for panic attack 
type symptoms, yet further investigation would indicate depression.  
“So if it’s someone with depression it’ll be ‘I’m just feeling really low, I’m fed up’, and then if 
you start probing there will be some [anxiety symptoms] there that you unearth, but they 
probably would come in with the depression symptoms ‘cos that’s what they’re feeling most. 
Whereas somebody who’s really panicky and anxious might come in with panic attacks, and 
actually as we were talking it becomes evident that because they’ve been battling with this for 
a long time, they’re actually quite depressed as well ‘cos it’s quite tiring just dealing with the 





Two GPs said that anxiety could lead on to depression, particularly in the case of untreated social 
anxiety, whereby anxious thoughts and strategies such as avoidance could put patients at risk of 
depression.  
When anxiety and depression were clearly co-morbid, most GPs reported that they did not discuss 
this distinction with patients. They stated they might use the term ‘mental health’ or might just 
focus symptoms in terms of the causes, such as cumulative lack of sleep or stress from work. GPs 
also commented that they did not explain the distinction between the two because the treatment 
pathway was the same for both.  
“I don’t think I do [distinguish between them]. Well not to them, if you see what I mean, 
necessarily highlighting which bit is which. No, I think I probably don’t particularly pull those 
two separately, I guess because they tend to be managed the same.” GP 2 
GPs described consultations as being patient driven, in that if patients distinguished between anxiety 
and depression, then GPs reported they did the same.  
Differences in the management of anxiety and depression 
Most GPs commented that due to the potential suicide risk, there was an increased likelihood that 
they would act promptly or actively follow-up patients with depression, in comparison with those 
who only had anxiety. For this reason, some GPs stated they thought they would be “more likely to 
prioritise depression over anxiety” (GP 11) and increased referrals to secondary care for these 
patients.  
“With depression more people would probably be referred on if they’ve got low, you know, if 
they’ve got suicidal thoughts and things, things you don’t tend to get with anxiety. So probably 
greater use of primary care liaison services I think.” GP 15 
However, two GPs reported that whilst they were aware that GPs “tend to have a generic way of 
looking at depression as being more serious than anxiety” (GP 12), they did not completely agree 
with that, and were aware that anxiety could be just as limiting for patients. They commented that 
they mitigated this by “asking the same questions of both diagnoses” (GP 12) when considering 
management of symptoms.  
“Actually, anxiety limits people’s lives more than depression, and it made me consider anxiety 
far more seriously than I had before. The idea that because we think depression is feeling sad, 
and we all know what it feels like to feel sad, that that must be the worst thing to be. And 





anxiety, it paralyses them often so their lives are limited by it because they don’t do things 
because of that anxiety, whereas the depressed people do them even if they’re not quite 
engaging.” GP 6 
In terms of treatment for anxiety and depression, most GPs commented that there was not any 
significant difference between the two conditions. They stated that depending on severity, they 
would suggest self-help or offer talking therapies, medication or secondary care referral for both. 
One GP reflected that it was strange to use the same treatments for different disorders with 
different symptoms.  
“I think the difference lies within the skillset that I don’t have, which is the psychological 
management of it. As a GP - if somebody is anxious or depressed they still get Sertraline, even 
though you’re trying to treat different symptoms, which is just bizarre when you think about it. 
On the face of it you’re doing something very similar for them, but in reality they are very 
different disorders, but I think that is where it is more the psychological strategies in terms of 
how you alter the thinking, behaviours and understanding.” GP 5 
Nonetheless, GPs also said they were more likely to treat patients with SSRIs more quickly if they 
presented with depression, due to the increased risk of suicide. Some GPs also commented that they 
might be more likely to use a higher dose of SSRIs for anxiety, and said they would not use 
benzodiazepines or propranolol for ‘pure’ depression. Data relating to specific drugs used, and the 
threshold for prescribing, are discussed in more detail in Chapter 5.  
 
3.5 Results – patients 
Twenty patients were interviewed (Table 6) between October 2018 and March 2019. They were 
recruited through four GP practices. Six patients were interviewed at their GP practice, ten in their 
own home, and the remainder over the telephone. The interviews lasted between 15 to 70 minutes 
(mean: 34 minutes). Half of the interviewees were women (n = 10, 50%), and the mean age was 54 
years (SD 19.7 years). As per the inclusion criteria, all patients had either symptoms of anxiety or a 
diagnosis of an anxiety disorder. Nine patients had a GAD-7 score of 10 or more. Just over half the 






Table 6 Socio-demographic details of patient interviewees 
 
All Patients 
n = 20 
Age: mean (SD) in years 54 (19.7) 
Female: n (%) 10 (50.0) 
White British: n (%) 19 (95.0) 
  
Highest educational qualification: n (%) 
 
A levels/advanced diploma/degree  13 (65.0) 
GCSE, standard grade, O-level or equivalent 4 (20.0) 
No formal qualifications 3 (15.0) 
  
Marital status: n (%) 
 
Married/living as married 12 (60.0) 
Single 5 (25.0) 
Divorced 3 (15.0) 
  
 
Employment status: n (%) 
 
Paid employment 12 (60.0) 
Retired 6 (30.0) 
Unemployed due to ill health 2 (10.0) 
  
Practice deprivation decile: n (%) 
 
3rd most deprived decile 4 (20.0) 
4th most deprived decile 6 (30.0) 
9th least deprived decile  5 (25.0) 
10th least deprived decile 5 (25.0) 
 
GAD-7 score: median [IQR]* 6.5 [5, 12] 
PHQ-9 score: median [IQR]*  5 [2, 11.5] 
*Interquartile range  
 
 
3.5.1 Patients’ views and experiences of causes, symptoms and help-seeking 
Causes of anxiety  
Patients generally reported being unable to identify a specific cause of their anxiety, and their 
accounts suggested there were multiple causes that had cumulatively led to their symptoms. 
Patients of working age speculated that they had been under increasing amounts of stress, either 
due to education, work, or their personal lives (e.g. divorce, supporting family, financial issues). 
Three patients stated that the first time they experienced anxiety was after a panic attack, but they 





those of retirement age, commented that they thought there might be some element of anxiety as 
being an inherited trait, or that it was related to their upbringing.  
Symptoms of anxiety 
Patients reported physical and psychological symptoms of anxiety as being entwined, and for some 
patients, this combination was incredibly debilitating, with one leading to the other. 
“I think it’s more of a physical thing. I’ve been suffering with nerve problems within my breast 
armpit area since September, and I believe that that is from my anxiety. When I phoned 111 to 
ask advice they said to go to A&E as they were worried that it was a blood clot. It turned out it 
wasn’t but I do think a lot of all this has stemmed from anxiety, nerves, you know, all that kind 
of thing, so when you’re then worried about your own health, you just feel like you’re on this 
treadmill.” Patient 16 
Common physical symptoms reported were palpitations, trembling hands, nausea, and chest pains. 
Such symptoms could elicit panic attacks. Psychological symptoms included a feeling of disconnect 
or being on edge, rumination over past events, or worry about the future, and a general sense of 
being “worked up” (Patient 2). Some patients also reported worrying about the anxiety itself, in 
terms of what other people would think, i.e. they were anxious about having symptoms that could 
be observed by others.  
“I start to get very hot and sweaty, I get palpitations, what I’m being anxious about is the only 
thing I can focus on. I don’t really socialise very much; I get very anxious in social- well social 
areas. Paranoia is a little bit of my symptoms as well, so I was quite- became quite paranoid 
that everybody knew what was wrong and everything.” Patient 9 
Despite only one patient reporting a specific diagnosis for social anxiety, many patients commented 
that they struggled with social situations with other people, where they were “not very good at 
mixing with people” (Patient 4). They speculated that this might be because they were anxious about 
what others might think, unsure how social situations would go, or that they did not have control 
over what might happen.  
There was also a sense that patients found anxiety physically exhausting, and that after situations 
that elicited symptoms or prolonged periods of anxiety, patients needed time to recover and rest.  
“I just lock myself in my house and I don’t go out, and I just shut all the curtains and can’t be 





though my heart is going to come out- I’m awake all-night thinking, and sleeping all day.” 
Patient 7 
Help-seeking 
Patients’ accounts indicated that they might not seek medical help because they were not aware 
they were experiencing symptoms of anxiety, or at a threshold that would require medical help, or 
because they were reluctant to discuss their symptoms with others. Some patients assumed their 
symptoms were related to their physical health, or because they were “run down” (Patient 12). This 
was commonly reported in relation to chest pains or palpitations. There were also some patients, 
usually male, who reported not knowing what anxiety was.  
“The paramedics had tried to convince me that I needed to go, and I was like no I’m just 
rundown, I don’t think I fully appreciated what anxiety was.” Patient 12 
Patients reflected on the role society has had in perpetuating a lack of awareness of anxiety. They felt 
that there could be a lack of understanding in differentiating between what might be termed as 
normal anxiety, such as that experienced prior to a job interview, and anxiety at a level requiring 
treatment. Patients said the use of the same word for two different situations was unhelpful, and 
reported how this contributed to a perception that anxiety was “common” (Patient 2) and therefore 
not something to seek help for.  
“It’s because it’s so common that people just choose to ignore it [anxiety].” Patient 2 
Some patients commented that they had normalised their symptoms of anxiety, viewing them as a 
being a part of who they were. For many years they felt they could “handle it” (Patient 16), or that the 
symptoms would eventually go away. As such, for these patients it took reaching a crisis point to 
trigger a consultation with their GP. Family members or close friends were frequently reported as 
encouraging or arranging the initial GP appointment. These crisis points were described by patients as 
“breakdowns” (Patient 7) and a time when symptoms had become “unbearable” (Patient 19) and they 
were no longer able to cope.  
“Feeling so unwell and so out of control, I kind of experienced symptoms over the year and 
they sort of come and go, and I’ve never sought help…I think perhaps this year the level of it 
made me speak to my GP and maybe do something about it.” Patient 13 
Self-stigma and perceived stigma of what others would think also contributed to a reluctance to 
consult. Some patients reported a sense of failure or embarrassment in having to ask for help, whilst 





“Even in your own family you wouldn’t mention anything, they would think of it as a stigma, 
madness… ooh no you mustn’t tell anybody.” Patient 3 
Patients also delayed seeking help if they thought their employers or insurance companies would have 
to be informed. Language such “nutcase” (Patient 10) or “crazies” (Patient 12) were used to describe 
how others might view them, with derogatory terms preventing help-seeking for fear of being given 
such labels.  
Reluctance to discuss anxiety with a GP   
Prior to consulting, patients were concerned about how their GP would react to them, predicting that 
they might not understand or take them seriously. Some felt they would not be believed, and they had 
to reach a “low point” (Patient 2) for the GP to “recognise that there was a problem” (Patient 2). They 
reported feeling anxious about having to call to book an appointment, and found it difficult to talk 
about symptoms over the telephone.  
During the consultation, patients were worried about talking about anxiety, and how to build rapport 
with the GP whilst doing this. This was further intensified by a lack of continuity of care with a specific 
GP, with patients finding it hard to disclose symptoms of anxiety to GPs they had no prior relationship 
with. Past experiences with GPs also intensified this discomfort, with previous negative interactions 
contributing to reluctance to make an appointment with the practice.  
“When I rang up this last sort of episode, I was very anxious about doing so because I do feel 
it’s a bit of a weakness to admit it… I do sometimes find that some of my GPs think I’m a bit 
of a hysterical woman. I haven’t always been listened to.” Patient 9 
Patients also reported that they did not want to bother their GP. They felt their symptoms were not 
serious enough to take up their time, and that they might take too long or ask questions that the GP 
viewed as not important. For some patients this meant they did not ask about everything they had 
wanted to discuss, and often avoided arranging follow-up appointments.  
“It sort of feels a bit like sometimes I’m wasting the GP’s time if I just sit there and say ‘I’m on 
these tablets and do I need to keep taking them?’, and they say ‘yeah’, it feels a bit pointless 
really but- yeah. It is something I would like to talk to them about really.” Patient 13 
There were some patients who did not want to talk about their anxiety, even though they knew they 
had symptoms. When they did consult with their GP, it was in relation to a physical health condition.  
“I didn’t really trouble my doctor with it, but it came out through other symptoms. I tend to get 





that it was depression and anxiety so I suppose, I mean I’d said it was the doctor that 
suggested that these other medical things might be anxiety and depression related, but I mean, 
I went to the doctors knowing I was depressed and anxious.” Patient 4 
For many patients, GPs had explained anxiety was experienced by everyone, and that it was normal 
to have some level of anxiety. Patients stated they recognised that most people experienced anxiety 
to some extent, and that anxiety could be helpful in some situations. However, particularly those 
who had long-term anxiety, went on to draw comparisons between the level of anxiety that they 
experienced, versus that which other people experience.  
“I felt like everyone experiences anxiety and I don’t know why mine feels particularly bad or 
why my symptoms are particularly bad.” Patient 2 
 
3.5.2 Patients’ experiences of diagnosis and the value of diagnosis  
Most patient accounts suggested that there was a value in receiving a diagnosis of anxiety, however, 
the way in which this was communicated to them was important.   
The value and impact of labelling  
When patients received a diagnosis of anxiety, and it fitted with the causes, symptoms, and impact it 
was having on their life, they found it helped them to accept and understand their condition. 
Patients reported a sense of “relief” (Patient 6) that they now had a “label” (Patient 9) for how they 
had been feeling, and that they were not “mad, they were ill” (Patient 5). Some patients experienced 
receiving a label as profoundly moving, as it provided clarity and helped them to engage with 
treatment. Such comments were mainly made by patients who were more educated and had 
experienced a longer duration of symptoms. 
“[The diagnosis] helped accept that I’m ill, that you can’t always just keep yourself busy and 
ignore [it] and it’ll go away, and everything will be fine. So, it is quite helpful just to hear 
somebody medical telling me that. Almost gave me permission to acknowledge that I, you 
know, just how anxious I am.” Patient 20 
“I remember looking at that diagnosis and tears coming down my face. It helped me to have 
a title and go ‘this is what I’m working with and here’s what I’m going to do to try and get 
better’.” Patient 12 
Receiving a diagnosis of anxiety was also important for patients in terms of facilitating better 





know that it was “something I could try to control” (Patient 13). Patients reported that it helped 
them to think about their treatment options and led to readiness to engage with those options.   
“Once the diagnosis was official, I suppose I tried a bit harder to find an answer, to find a 
way of helping myself.” Patient 4 
“I had a much better understanding of what was going on and it gave me the mental ability 
to deal with it, and say well, well why are we doing this?” Patient 11 
In addition, for those patients that did not fully understand anxiety, once a diagnosis had been 
made, it was important for the GP to take the time to explain the diagnosis.   
“I did struggle a bit at first to wonder what it was all about, but I mean Dr S was here at the 
time, she was very good, [she] did help me along the way a lot [in understanding anxiety].”  
Patient 15 
Whilst patients reported value in receiving a diagnosis, two patients commented that it was “good to 
have a diagnosis” (Patient 10) but it left them “in limbo” (Patient 10) as it was not followed up by the 
GP, apart from being offered antidepressants, which they did not want.  
The label of ‘anxiety’ was difficult for some patients. They explained that this was in part due to how 
anxiety is viewed by society. Some of them suggested that this might be because most people think 
they have experienced anxiety in some way, and therefore do not understand how debilitating it can 
be. For some, this meant they choose not to share their anxiety diagnosis with other people.  
“There’s less understanding with anxiety. I think when you [tell] somebody you’re anxious they 
see it as ‘yeah I get anxious too’, I don’t think people understand that when we mean we’re 
anxious to this level, it’s totally consuming. So I don’t say I have anxiety because it requires a lot 
more explanation and understanding, I just say I have mental health issues.” Patient 9 
Lack of clarity around the diagnosis  
Patients’ accounts suggested they did not understand how GPs determine, record and communicate 
diagnoses. Comments were made about the disparity between what might be discussed during a 
consultation, and what might be written on fit notes (medical sickness certificates), or what is 
discussed during psychological therapy sessions. Patients reflected that this was not particularly 
helpful, and that particular phrases, such as ‘anxiety states’ were too medical, and did not provide 





“I’m not sure if he did make a diagnosis in a very clear sense…I was wondering ‘what’s he 
putting on the fit note’, and he put anxiety states which is a really weird expression. So, I 
don’t know whether I’m diagnosed with an anxiety condition, or what that means.” Patient 1 
Other patients had depression recorded as a formal diagnosis, but felt they understood their 
diagnosis better when the GP referred to it as “anxiety leading into depression” (Patient 19). When 
patients were unclear about whether they had a diagnosis of an anxiety disorder, or felt the 
diagnosis did not fit with their experience, they were less able to understand their symptoms. For 
patients who had not had a diagnosis communicated to them by a GP, but had described severe 
anxiety symptoms during a consultation with their GP, uncertainty remained about whether they 
had experienced anxiety.  
“I don’t think anybody’s ever told me ‘Mr (name), you have anxiety’, as clear as that. It’s 
always been ‘mm, well maybe you do, but…’.” Patient 5 
 
3.5.3 Patients’ experiences of the treatment in primary care 
Most patients talked about their experiences of medication, but accounts differed in terms of how 
positively they viewed managing their symptoms pharmacologically. They also spoke about talking 
therapies but reported a lack of availability. 
Management with GP support 
Many patients reported that the first time they consulted about anxiety, the GP’s initial response 
was positive. Most patients commented that GPs were “very good, kind and understanding” (Patient 
1), that they were “super lovely, responsive” (Patient 8) and “weren’t dismissed in any way” (Patient 
5). However, some patients reflected that GPs had not always responded in this way, and in the past 
had been unhelpful or not listened.  
Patients reported that initially, their GP explained treatment options in terms of medication and 
talking therapies, and then suggested a return appointment to give the patient time to consider their 
options. Many patients found this very helpful, and it gave them ownership over the direction of 
their treatment. However, two patients stated they found this unhelpful, and wanted their GP to be 
more directive.  
“She signed me off work for a couple of weeks which was her advice. She explained the options 
in terms of SSRIs or the counselling route. I didn’t feel, you know, I was just running on empty at 





anything along those lines at the time, so that was definitely- I don’t think I can do that at this 
time. And so I went away without any real treatment and she basically sent me away to think 
about it which, looking back, I don’t think that was necessarily the best thing.” Patient 12 
For the ongoing management of anxiety, some patients stated they had some GPs who they would 
intentionally avoid as they knew they did not have an “open ear and were understanding” (Patient 16). 
Patients reported trying to arrange appointments with GPs who were easy to talk to, and commented 
that continuity of care was very important as it was easier to talk about the anxiety without having to 
build rapport first.  
“That initial going and talking about it is really difficult, it gets easier because for me, you 
know, if I build a rapport with somebody then I find it much easier to talk to them and through 
one, two, three, four, five sort of times that I’ve gone to the doctor about something like this, 
I’ve only seen- I’ve seen four doctors, so four out of five times, but it’s sort of establishing that 
rapport again - sometimes you just want to check in, you know, and just- ‘so this is what 
happened, this is what I did, this is what I’m taking, what do you think about that?’, and it 
might be ‘yep all sounds fine, carry on as you are’” Patient 20 
Treatments for anxiety 
There was a sense that some patients did not view taking medication for anxiety as a positive choice, 
that they “would prefer to do things naturally than with medicines, and not numbing it” (Patient 1). 
Some patients commented that they were “against taking medication” (Patient 3), or that “it didn’t 
appeal [because of] the lack of control I’d have” (Patient 8). Others were concerned about the long-
term effects.  
“I don’t think anybody really knows the very long-term effects of taking this stuff, because 
they’re relatively new aren’t they, and I don’t think anyone knows what happens if you take 
these antidepressants for thirty or forty years.” Patient 4 
For patients taking medication for anxiety, there were mixed feelings about how patients and GPs 
discussed staying on treatment long-term. Some patients expressed a preference for coming off 
antidepressants, or beta-blockers, but had been persuaded by their GP to stay on them.  
“I said about stopping them [beta-blockers] and she said ‘oh well not yet because it’s not just 
going to go away’.” Patient 13 
Other patients had concluded that they would need to continue taking their medication, but wanted 





“I’m still kind of feeling I would like to get off medication (laughs), but I’ve come to the 
conclusion that maybe I’m going to have to stay on. So I want the GP to tell me that that is 
necessary, it’s not dangerous, that it would be advisable.” Patient 3 
A third group of patients reported a conflict between what they wanted, which was to continue 
taking medication, versus their GP suggesting they should be stopping their tablets.  
“[The] GP was almost contributing to the fact that it was bad to take this tablet, which wasn’t 
helpful. I’d go to my GP, they’d give me this tablet, [I] took it for a year and that’s it, he felt that 
I was cured. I have still had problems with my GP wanting to get me off them, and I’ve tried, 
but generally within a few months of reducing them down I’m back and having to put them up 
again.” Patient 9 
For patients who had been referred to talking therapies, most patients reported they had been put 
off by the long waiting time to be seen initially. They commented that “I needed something that 
would help me now instead of twelve weeks’ time” (Patient 2). Some patients were able to pay for 
private therapy or access therapy though work. Patients that had accessed NHS talking therapies 
reported that they were “both interesting and useful” (Patient 5), but that it then stopped once they 
were no longer “ill enough” (Patient 5).  
Patients who had completed a course of CBT found it invaluable. The course had helped them “to 
realise that it’s not curable, but it can be managed” (Patient 9), and gave them “a toolkit” (Patient 8) 
to manage their symptoms.  
“CBT, absolutely brilliant. Well, when I came out from seeing the doctor, I mean I’m not a 
modern person, but I went ‘yes!’  Somebody at long last understood what was happening and 
had some solutions in place. I recognised, I’m quite a sensible person really, I recognised there’s 
no cure for anxiety, but it can be handled and that’s my attitude really.” Patient 10 
Patients reported a variety of self-care strategies, some related to physical activity such as yoga or 
cycling, whilst others were tasks used to distract their thinking, such as arts and crafts.  
Reflections on NHS primary & secondary care 
Patients reflected that ten-minute consultations were not long enough to discuss the management 
of mental health conditions. They also mentioned they would have liked more availability in terms of 
talking therapy, perhaps in the form of “practice psychotherapists, because there must be more 
people suffering” (Patient 10). Patients commented that they did not want to be taking up their GPs 





“I would have liked a little bit more support on the talking side of it. I mean, I wasn’t very good 
at it and I was a bit cynical about it, but I would have liked a bit more of that I think because 
I’ve been to the doctors, two or three times, saying that ‘I really don’t want to carry on taking 
antidepressants forever, what else can I do?’, and I haven’t got very far with that, if I’m honest 
with you.” Patient 4 
Patients also commented that they had expected and wanted one-to-one, or small group work, but 
had been offered large group work or guided self-help. Some patients reflected that although they 
had been able to access one-to-one therapy through their workplace occupational therapy instead, 
this was not an option for everyone.  
“I think there needs to be better resources for it, so things like the talking therapies, that needs 
to be sorted out. I mean I was really lucky that I work for (trust) and they have a really good 
occupational health team, but there’s a lot of people I know who don’t have access to that, and 
they don’t get the help that they need. So I think something definitely needs to be sorted about 
that, maybe looking into why it’s such a problem.” Patient 9 
One patient expressed concerns that urgent help was only available to those who were able to 
finance it themselves, and reflected that if it had not been available, the symptoms of anxiety may 
have been too much for her to continue living.  
“I know if I had been in a different situation and did not have the money for private counselling 
I think- If I had to wait a few months for therapy I’m not sure, to put it bluntly, if I would have 
been here anymore and (pause) yeah, that worries me.” Patient 8 
Two patients went on further to reflect that there had been a lack of investment in anxiety as a 
medical condition or illness, in terms of understanding the causes, developing treatment to manage 
it, and providing resources for patients to access therapy. Patients commented on the availability of 
diabetes nurses in general practice but no mental health nurses. 
 
3.5.4 Patients’ views on the difference between anxiety and depression 
Patients’ accounts suggested that there are differences between anxiety and depression, and that it 
was important that they were considered as separate, distinct, conditions.  
How it feels to experience anxiety and depression 
Patients with experience of depression reported feeling “low” (Patient 2, F18-25) or having an 





(Patient 20), or being “worthless, suicidal” (Patient 3). This was in contrast to anxiety, which was 
described as having too many thoughts. Patients also commented on the conflict between the two 
conditions in terms of symptoms.  
“Anxiety for me is a fear of not achieving things, letting people down, it tends to result in me 
being very, very active. Whereas when you get a bad bout of depression it kind of tries to drag 
you the other way, so you don’t feel like doing anything, you don’t feel like being bothered or 
whatever. So, for me there is a real conflict there and there is a real battle, so I’ve got this drive 
to get things done ‘cos I’m worried that I haven’t. I mean it’s clearly different, and the anxiety 
never goes away.” Patient 4 
Most patients (n=15) also reported clear differences between the two in terms of impact. They 
reported that whilst the depression made them less engaged or less interested in life, anxiety 
prevented them from engaging in anything at all, and was potentially more debilitating on a daily 
basis. There was a sense that anxiety was the ‘ever-present’ condition, with depression tending to 
be more short-lived, although still devastating to deal with. This was important in terms of 
management, as several patients commented on seeing a flare-up of anxiety symptoms as a warning 
sign for preventing the onset of depression. 
“Anxiety is quite bad to be fair. The anxiety is going out in public, when I’m trying to breathe 
and my heart hurts and I’m watching people looking at me. The depression you can just cry to 
yourself and then you go on.” Patient 7 
Considering anxiety and depression as separate, distinct conditions 
These differences meant patients felt it important that GPs diagnosed and considered anxiety 
separately from depression. However, patients who had not received a clear diagnosis of anxiety, 
commented that anxiety was not usually viewed as a medical condition in its own right. It was 
important that equal consideration was given to the management of the symptoms of both anxiety 
and depression and “treated more separately instead of linked together” (Patient 2). When this did 
not occur, conversations with their GP around medication were unproductive, with one condition 
not recognised, and/or not treated.  
“I don’t think anxiety was quite as well diagnosed… I had depression and when I look back 
actually no, I had some anxiety, the anxiety wasn’t treated as it wasn’t treated as a separate 
thing.” Patient 12 
Moreover, for these patients, anxiety was frequently reported to be a cause, or a pre-cursor to 





“Anxiety comes first. Anxieties give me panic, makes me scared, afraid. I get palpitations, 
sweaty and hot, where I have unreasonable thoughts and obsess over things, become a little 
bit paranoid. Whereas depression is what comes afterward. I think I can separate them quite 
[well], ‘cos I know one’s going to follow the other. But what I have been trying to do is once I 
know the anxiety is there, is manage that better, so I don’t get to the depression.”  Patient 9 
For four patients, there was a lack of clarity between what anxiety and depression were when 
thinking about them as separate constructs. They had not asked their GP about the distinction, and 
were unclear if the medication they were receiving was meant to help the symptoms of one or both 
conditions.  
Three patients were unsure about whether it was important that anxiety and depression were 
considered separately by the GP. They reflected on the differences in the causes and in how the 
symptoms of each condition made them feel, but were undecided if that meant there was a need to 
for them to be discussed separately within the consultation. For these patients, their GP had never 
distinguished between anxiety and depression when discussing their mental health, and they had 
always thought of them together. Most remarked that being interviewed was the first time they had 
ever given it any consideration. 
“I’ve never thought about it….I don’t know- I don’t even know whether I know the difference 
other than when I’m anxious I have a knot in my stomach, when I’m depressed I’m very flat and 
grumpy, you know, I don’t want to go to the party, I don’t want to go out, don’t make me do 
that, I don’t care.” Patient 20 
How anxiety and depression are viewed within society 
Nearly all patients reported that within society, there is less awareness and understanding of anxiety 
compared with depression. Patients commented that “anxiety is talked about more, but it is less 
understood” (Patient 8). Whilst the stigma of depression was viewed as decreasing, patients did not 
think this was happening for anxiety. Several patients referred to “celebrities” (Patient 4) helping to 
break down stigma around mental health and depression, but that this was not happening for 
anxiety as a separate condition. 
“There’s much less of a stigma attached to depression now and that’s fantastic. I’m not sure 
that anxiety is quite the same. No, it’s not, definitely. People tend to discuss depression on 
social media quite a lot now, and are much more open about it. So there’s celebrities that are 
coming out and they have this, that, and the other form of depression, but you don’t ever hear 





talking about anxiety as the cause of depression, nothing like that. So no, I don’t think it’s quite 
the same. I don’t think there’s quite the level of understanding.” Patient 4 
Patients also reflected on the use of language around anxiety and depression, and there was a sense 
that they felt the word ‘depression’ was viewed by other people as more serious than the word 
‘anxiety’, perhaps because anxiety has become so common within everyday conversations.  
“You can be anxious before you go out to take part in a play, or you can be anxious before you 
make a speech, but then once you’ve done it, that’s like the butterflies and it’s not the same as 
anxiety, it’s not the same as- we have anxiety and feeling anxious, it’s so different from 
everyday life, anxiousness. It’s unfortunate that we use the same words but that’s what we 
have don’t we?” Patient 3 
 
3.6 Results - Therapists  
Nine therapists were interviewed (Table 7) between October 2018 and February 2019. Five of the 
interviews were held face to face at the BWT service, and the rest were held by telephone. The 
interviews lasted between 25 to 45 minutes (mean: 34 minutes). Two thirds of the therapists 
interviewed were women (n = 6, 66.6%), and the mean age was 32.8 years (SD 8.7 years). Those 
interviewed had been working in IAPT between less than six months and up to 10 years. Most of the 
therapists described their professional background as having a psychology degree (n = 4, 44.4%) or 
being a CBT therapist (n = 3, 33.3%).  
Table 7 Characteristics and professional background of therapist interviewees 
 All Therapists 
(n = 9) 
Age: mean (SD) in years 32.8 (8.7) 
Female: n (%) 6 (66.7) 
  
Professional Background: n (%)  
Counsellor/counselling psychology 1 (11.1) 
CBT therapist 3 (33.3) 
Other: psychology degree 4 (44.4) 
Other: support worker 1 (11.1) 
  
Years qualified: mean (SD) 3.3 (3.3) 
  
Years working in IAPT: mean (SD) 5.2 (3.6) 
  
BABCP accredited: n (%) 3 (33.3) 
  





3.6.1 Therapists’ views on the causes and symptoms of anxiety 
Most therapists viewed anxiety as a result of a combination of internal and external factors, and 
talked about specific ‘at risk’ groups. 
Causes of anxiety  
When talking about causes of anxiety, therapists reported that they felt it was “ingrained” (Therapist 
7) in some people, and that patients talked about always being “worriers” (Therapist 7). They 
explained this made it difficult for patients to identify the age of onset, as anxiety was something 
they felt they had always experienced. However, therapists commented that they tried to help 
patients understand anxiety was something that could be treated, and was not necessarily a fixed 
part of who they were.  
“People quite often will say ‘I’m a worrier’, and almost laugh it off because it’s I guess [it’s] 
known maybe in our culture. But [they] might not necessarily realise how much worrying can 
affect us, and how much actually that might be an anxiety thing, not so much a personality 
characteristic.” Therapist 4 
They also commented on the links with “parental anxiety, upbringing, and expectations on young 
people in modern society” (Therapist 1), with genetic predispositions enhancing vulnerability to 
environmental factors. Therapists also reported that stressful life events could be a trigger, such as 
changes or trauma, and that this was usually the point at which patients came into the service.  
“It could be work [that led to the anxiety], it could be work stress or any related financial 
things, it could be break ups and- It can be because of early childhood experiences that may 
have been traumatic or difficult for the person to manage. Relationships could be anxiety, 
failures, people suffer from severe anxiety because they cannot cope with the pressure and the 
lack of time and the lack of quality of life.” Therapist 6 
Groups at risk of anxiety 
When asked about who they thought might be more at risk of developing anxiety, all therapists 
reported they felt younger people were now under more pressure, and this pressure had led to an 
increase in anxious symptoms in this group.  
“There is so much pressure at the moment put on young people in terms of performance, in 
terms of university, with fees increasing, perfection. I think there’s actually research that’s just 





becoming a lot more stressed and anxious, so I’ve definitely noticed that with young people.” 
Therapist 1 
The theme on the increase in anxiety seen in younger patients is discussed in further detail in 
Chapter 4.  
Therapists also commented that they had seen an increase in younger men presenting to the 
service, however they reflected that they thought this might be due to a potential decrease in stigma 
around male mental health, rather than an increase in males being at risk.  
Symptoms of anxiety 
Each therapist described the symptoms of anxiety in a similar way. Each therapist made a distinction 
between the physical sensations of anxiety (e.g. palpitations, shortness of breath) and psychological 
symptoms (e.g. restlessness, feelings of dread), but explained that they were closely linked. In 
addition, the three high intensity therapists interviewed commented that anxiety was an inability to 
“handle uncertainty” (Therapist 3). They reflected that it was not clear if that was a cause or a 
symptom of anxiety, but that it meant patients were constantly worrying or thinking about 
something, until they were able to achieve “certainty” (Therapist 3).  
When asked if there was a difference between anxiety and an anxiety disorder, therapists stated 
that both were at opposite ends on a continuum of severity. Therapists commented that anxiety 
might be the type of sensation that most people experience “before a presentation at work, that 
kind of day to day language, and accepted as day to day problem without having a mental health 
disorder” (Therapist 8). They explained that the point at which it would become a disorder, would be 
when symptoms were severe enough to impact on their ability to function, and when patients 
presented with the elements of the sub-types of anxiety, such as agoraphobia. 
“There are a smaller group of people that do suffer with anxiety, to perhaps a clinical level, and 
that’s when it steps into the anxiety disorder territory…. so essentially anxiety might be the low 
end of the spectrum, and anxiety disorder might be the high end of the spectrum, in terms of 
mild versus severe.” Therapist 3 
 
3.6.2 Therapists’ experiences of how labels are used within the IAPT service 
Therapists talked about the use of labels within the service. They said that although labels (such as 
depression, anxiety, and the subtypes of anxiety) were widely used within IAPT, and their use a 






Therapists said, when initially presenting in IAPT, patients often used words such as ‘worry’ and 
‘anxiety’ to explain how they had been feeling or, if they were more familiar with medical 
terminology, they might use phrases like “I suffer from social anxiety, or from health anxiety” 
(Therapist 6). One therapist (Therapist 7) reflected that the language used by their patients had 
changed. When she had first started working in IAPT about five years ago, patients had tended to 
use words such as ‘stress’ or ‘depression’. This same therapist went on to say that she thought this 
might be because the young adults who were now coming through the IAPT service, were more 
comfortable with the term ‘anxiety’ compared with older patients.  
“I feel younger people definitely are more comfortable using the word anxiety, so I think they 
would very much, you know, ‘I’m feeling anxious’ and I feel like that happens a lot less with 
older people. With older people it’s ‘I’m feeling stressed’ even though it would be similar 
presentations, but it’s almost like the language is different. I don’t know if that’s something to 
do with what the perception of an anxious person is, and especially if it’s somebody who’s quite 
high functioning, highly functioning and anxious, you know, they’re like well ‘no ‘cos I’m 
working every day and I’m going out and, you know, I do everything I need to do so therefore 
I’m not anxious and I must just be stressed’” Therapist 7 
Therapists reported that they were also careful in the language they used with patients, and might use 
terms such as ‘panic’ instead of ‘panic disorder’, or ‘social anxiety’ instead of ‘social anxiety disorder’. 
They commented that they felt by doing this, they were able to build better relationships with their 
patients, as it kept an element of normality to the discussion, without feeling like they were specifically 
categorising them. They also stated that, where possible, they would mirror the language used by 
patients.  
“I tend to just try and use a language that they use rather than put it in my own language, to 
try and help people understand it in their own way and their terminology, rather than them 
potentially- or confuse them or worry about it.” Therapist 5 
Value and impact of labelling 
Therapists reported that they referred to anxiety, or an anxiety disorder, as a label rather than a 
diagnostic term. Therapists stated that they might introduce the sub-types of anxiety, such as panic 
disorder, or PTSD, but that they were clear with patients they were not formally ‘diagnosing’, but 
rather explaining that the symptoms they were experiencing were indicative of that condition. In 





diagnose is either a psychiatrist or psychologist, and that’s with a long assessment. I just don’t think I 
have the ability to do that and I wouldn’t really want to do that, which I think is unethical” (Therapist 
5). However, therapists also explained that “IAPT likes its disorders, it likes to quantify things” 
(Therapist 5), and that this was because “they [the disorder] help to specify or categorise the different 
treatments and the different pathways” (Therapist 6). As such, therapists commented that they had 
to be “really specific with a provisional [label]” (Therapist 1) and that it was part of their role to share 
that label with the patient based on the assessment they had done. Therapists explained that they 
thought this was positive, as most patients found this very helpful, as it normalised their experience.  
“I think most people feel kind of reassured in some way that what they’re experiencing is 
something that’s identifiable and can be understood. It’s helpful sometimes to focus on one 
particular type of anxiety, and say to people ‘you’re experiencing this’, so it could be excessive 
worry, generalised anxiety, things like this. People, yeah, often kind of like to know when 
they’re feeling anxious, what it is that’s going on for them.” Therapist 2 
Yet, for some patients, therapists commented that labels could be unhelpful. They said patients might 
be reluctant to hear the label because it was a surprise for them, or because they had not heard of that 
type of anxiety before. Therapists also reported that sometimes patients took on the label in a way 
that could prevent them from trying to get better, i.e. they saw it as a part of who they were, rather 
than something that could be treated.  
“I know that sometimes people will take labels and run with them, and then it will be ‘I am this 
for the foreseeable future’, rather than ‘I’ve had an episode of this, I’ve been treated’. I think 
some labels get used incorrectly by patients so that kind of sense of patients saying ‘I’m a bit 
OCD’ or things like that, kind of mislabelling and misdiagnosing themselves as well. There 
sometimes can be the wording of ‘my depression’, ‘my anxiety’, which can feel very ingrained 
in somebody - and that can be hard to shift.” Therapist 7 
Furthermore, labels could cause issues when patients presented to the service after being referred by 
their GP. Therapists reported that patients usually had not been given a specific diagnosis already by 
their GP, except perhaps “mixed anxiety and depression, or clear diagnoses like OCD” (Therapist 1). 
However, in situations where a GP had given a diagnosis, if the diagnosis did not fit with the label that 
the IAPT service had identified, therapists stated this could be challenging when working with a 
patient. It can “hold a lot of power for some people” (Therapist 5), in that they “hold on” (Therapist 5) 





“If they’ve been given kind of a diagnosis by the GP that then we don’t necessarily agree on, 
then that’s when it can present difficulties, because sometimes the patient will obviously have 
been given some kind of label, go away and have their own kind of thoughts and ideas based 
on what they’ve researched as to what might be helpful for them. Whereas we might have a 
kind of competing idea on what might be helpful, and then you’ve got that kind of conflict 
there around what we think and what their GP thinks, and what might necessarily be the right 
kind of treatment for them and the right evidence base. And that’s when it can prove a bit 
tricky.” Therapist 9 
 
3.6.3 Therapists’ experiences of treating anxiety within IAPT 
GP referral versus self-referral to IAPT 
When discussing GP referrals into the IAPT service, therapists reported that they no longer received 
many patients through this route. Instead, they stated that most patients called up the service 
themselves, having been advised to do so by their GP or having heard about the service in another 
way. Therapists commented that they thought this was positive, as it gave patients a sense of 
“empowerment”’ (Therapist 14), and they were more likely to be motivated to change, and have 
“more manageable expectations and clearer goals” (Therapist 6). However, therapists also reported 
that self-referral suggested by a GP could be an issue if the GP did not have the time to explain how 
the service worked, or what therapy was about.  
“Sometimes they have no clue what the therapy is about. The GPs won’t have the time to 
explain, and say ‘call this service, they are treating anxiety’, but there are very specific ideas for 
entering the service and getting the treatment, because we cannot accommodate complex 
cases. And people may have physical conditions or long-term conditions, and co-morbid 
[mental health] that may be [related to] anxiety…and they come saying that the main problem 
is a physical one but we are not specialised to do that.” Therapist 6 
Therapists commented that this could make the management of anxiety challenging, as these 
patients might need longer to understand the process of how therapy would work. In some cases, 
therapists reported that these patients would be too complex for the service to help, particularly if 







Treatments for anxiety 
When first starting work with a patient, therapists reported that normalising symptoms was a very 
important initial phase, alongside explaining that there are ways to deal with anxiety.  
“I guess try and normalise it [anxiety], starting off just that we all experience this, it’s normal. I 
guess try and find a little bit more about it in terms of where it’s coming from and how it’s 
impacting them, and the degree of the impact. But I guess first of all I guess responding to that 
in terms of normalising it first and foremost because actually… [when they are] quite distressed 
and going through these things, you know, it’s just actually [important to] normalise that for 
them [and it] can help a little bit.” Therapist 5 
Most interventions for anxiety were delivered at low-intensity (step 2 in IAPT services), such as 
guided self-help, psychoeducational groups, or computerised CBT. All therapists emphasised the 
importance of psychoeducation, and helping patients to understand their anxiety to enable them to 
get better. They stated that if patients were able to be aware of the symptoms, the links between 
the physical and psychological symptoms, and what may be making them worse, then they would be 
in a better position to understand what they could do to improve them. Therapists talked about how 
they helped patients to learn how to “break the cycle of anxiety” (Therapist 6) by focusing on 
behaviour and thoughts.  
“You’ll go through [the] ABC cycle kind of thing, and you’ll start asking them to make links 
between the physical symptoms, the avoidance, the safety behaviours, the thoughts, and try 
and start to make links with that. I suppose that’s where the difficulty can come about, if 
people can’t see the connection between how the thoughts are impacting on the behaviours, 
‘cos we look a little bit at the physical in terms of relaxation and psycho-ed around it, but we’re 
mostly focussing on the behaviour and thoughts. That can be a bit of a challenge if they’re not 
seeing how that’s interplaying, and how that kind of vicious cycle is being maintained.” 
Therapist 7 
Reflections on NHS primary & secondary care 
When discussing the management of anxiety at step 2, therapists reflected that whilst they thought 
this was an appropriate level for short-term treatment, they did not think it was adequate in terms 
of the long-term effectiveness.  
“People will come back. We get people who have had lots of past episodes with us. They have 





what we offer. We are quite focussed on CBT, what about the future and how do we maintain 
that and not have a relapse - so it doesn’t address a lot of that.” Therapist 6 
In addition, some therapists reported that there was a lack of evidence-based treatment for patients 
who did not fit clearly into IAPT protocol categories, such as generalised anxiety disorder or panic 
disorder. Therapists suggested patients who had multiple types of sub-threshold anxiety, or a mix of 
anxiety subtypes, might therefore not receive an intervention that would work for them.  
“People do present that don’t fit the protocol of one specific anxiety disorder, but they do have 
fairly debilitating anxiety, and I suppose it is that kind of smesh board of just trying a few 
different half techniques that is lacking in the evidence base. Actually, how difficult that might 
be for clients, ‘cos then I suppose they’re getting almost a lucky dip. They might get it where it 
works really well and they manage to find the right combination for them, but equally they 
could leave the service with not having had any IAPT specific treatment and become quite 
demoralised to the entire thing.” Therapist 7 
Nonetheless, therapists also emphasised that the ability to be flexible with the interventions they can 
offer patients was a large strength of the IAPT service.  
When asked to reflect on the management of anxiety by GPs, therapists reported that they thought 
GPs were too busy to be able to manage anxiety, but that was the role of the IAPT service.  
“I don’t think GPs have the time to manage anxiety. I think if someone’s had anxiety, by the 
time they’ve said something they’ve normally had it for a long time, and it takes some time to 
explain it, and I sort of feel like GPs are under too much pressure to actually work through it 
with them. I think it’s a big relief to GPs to say ‘just phone this number’, and I think that that 
can just sometimes be as helpful for us to do the work rather than them to do it, ‘cos they’ve 
got a million other things to do, so I think that that’s probably pretty positive support for GPs to 
say ‘these are the people to go to, they’ll explain everything.’” Therapist 8 
However, therapists also commented that they would like to see GPs working closer with the service, 
with more of a multi-disciplinary relationship, particularly when patients were on medication such as 
benzodiazepines long-term.  
“Whilst we’re engaging in treatment, it doesn’t feel like the GP has much of a role at all, apart 
from to kind of respond to any medication management needs, or to be there if any kind of risk 
management concerns come up. But apart from that…it doesn’t feel like there’s that kind of 
multi-disciplinary relationship there. Which certainly for some patients where they do have 





for them to kind of play a part in that treatment plan, as well to help facilitate the recovery.” 
Therapist 9 
Therapists reported that they felt early education was key to preventing anxiety becoming an issue 
for patients. Some therapists stated that they thought this should be provided in schools from an 
early age, whilst others felt universities or employers should fill this gap. 
“Prevention can be a really helpful technique, so getting people to really understand those 
symptoms, and to know what they mean. And [to] look after their wellbeing quite well early on 
can have [a] really good preventative function [in terms of] developing an anxiety disorder. So 
rolling out educational courses in schools, universities, employers, etcetera, I think [that] is 
probably the way forward.” Therapist 1 
 
3.6.4 Therapists’ views on the differences between anxiety and depression 
Therapists said there was a difference between the presentation of anxiety and depression, and that 
they treated the two conditions separately.  
Difference between the presentation of anxiety and depression 
Some therapists commented that they generally found depression to be focused on rumination 
about the past and “going over certain things that had already happened” (Therapist 1), and anxiety 
related to worries about the future, such as “what’s going to happen or if I’m going to succeed” 
(Therapist 6). Other therapists stated that this distinction was not as clear-cut, and that depression 
could be experienced as a lack of desire to do things in the future, and anxiety could be a 
combination of past rumination that translated into future worries.  
“Depression is lack of desire to do anything in terms of the future, getting on, going out, doing 
things and making plans. Whereas anxiety can be a combination of thinking about the past and 
ruminating over things that have happened in the past, but that feeds into worry about the 
future as well.” Therapist 3 
Therapists commented that often anxiety appeared to occur before the depression, and that it might be 
part of what was maintaining the depression for the patient. Therapists reported that not all patients 
had insight into this, and that they would spend time talking to patients about timelines so that patients 





“Often it is clear with somebody experiencing anxiety it leads to depression, so I kind of ask 
about the timeframe, about what came first basically and ‘what do you think underlies the 
other?’ If you’re going to focus on anxiety you have to be quite clear that that is the thing that’s 
maintained depression for people and it is underlying depression, so we try to check that out 
with people and whether they have insight to do that as well, as much as I can.” Therapist 2 
Some therapists commented that they thought anxiety had “more of an impact” (Therapist 7) on 
patients, as it felt like the more constant condition, in comparison with depression which might come 
and go. They also reported that patients talked about the symptoms of anxiety having the greatest 
impact, and therefore some patients indicate a preference to work on these over the symptoms 
associated with their depression.  
“I: Generally speaking, is there a preference for which they choose to work on?  
T: The anxiety because it’s the most disturbing, like in day-to-day spaces. They find the anxiety 
symptoms more disturbing because it impacts a lot on the body and the sensations and the 
functioning and the sleep and the appetite. So depression comes- it’s usually- people who 
address the anxiety and find the coping strategies to manage those symptoms, they then have 
an improvement in their depression too because they are more- they can cope better.” 
Therapist 6 
In terms of the frequency that therapists saw patients, where anxiety was the primary problem, 
estimates ranged from “50% if not higher” (Therapist 4) to “75%, to 90-100% some weeks” (Therapist 
3). Most therapists reported that they “probably see anxiety more than depression” (Therapist 5).  
Distinguishing between anxiety and depression 
Some therapists commented that part of their role was helping patients understand the difference 
between anxiety and depression, and they used tools such as the PHQ-9 and GAD-7 to do this, along 
with “using diagrams and help unpick it” (Therapist 7). They reported that they “separate them for a 
reason to try and make treatment clearer and more effective for people” (Therapist 2). 
“There might be some bits that overlap but it will still kind of help to unpick it because, as the 
assessor and therapist, that’s what we should be doing.” Therapist 7 
However, some therapists reported that if “they [the patient] are describing both [conditions] as quite 
intense, then we don’t try to distinguish them” (Therapist 6) when talking to the patient in the 





feel like I want to put them in a box” (Therapist 6). However, therapists stated that they have to 
categorise patients for the purposes of the electronic record in IAPT.  
Differences in management of anxiety and depression 
All the therapists stated that anxiety and depression are treated separately within IAPT. As such, 
regardless of whether the patient was aware of the distinction between the two, therapists reported 
that, as part of the IAPT process, co-morbid patients were asked which condition they would like to 
work on first. This could be challenging for patients to hear that they had to prioritise whichever one 
was worse, or having the most impact. If patients were unable to decide, the therapists stated that 
they followed NICE guidelines, which recommended treating depression first.  
“It can be quite a difficult thing to hear ‘well actually you have to prioritise which one is worse.’  
Quite a difficult experience for the patient and quite often they don’t really know, so that’s 
what our role is, to give them a bit more to help them to understand a little bit more about the 
anxiety and depression, so that they can make that decision.” Therapist 1 
Therapists reported that it was more challenging to work with patients with co-morbid depression 
and anxiety, as “one could be a barrier to receiving treatment for the other” (Therapist 1). For 
example, symptoms of depression such as lack of motivation or energy could prevent engagement 
with CBT for anxiety, but they stated this could also happen in reverse, with anxiety symptoms such 
as worry or avoidance being an issue when treating depression.  
“Patients might say ‘I tried to do that, but I couldn’t do it because I felt really low’. So you start to 
work on that but the anxiety then prevents them from doing that so, yeah, it does make things 
more difficult, but for most of the clients we see are co-morbid in reality.” Therapist 5 
Although therapists stated that the assessment process was the same for both conditions, they 
outlined how the interventions to manage each condition differed. Whilst interventions for anxiety 
were focused on psychoeducation or exposure therapy, for depression it tended to focus on 
behavioural activation, or talking therapy.  
“For anxiety disorders we only offer cognitive behavioural therapy, whereas for depression 
people can either access cognitive behavioural therapy or counselling, and that’s just according 







3.7.1 Summary of findings 
This study focused on understanding how patients and practitioners view and experience the 
identification, diagnosis and management of anxiety disorders in primary care. There was some 
tension between the views of each group in terms of the key themes. The key findings from each 
group of interviewees in relation to these themes are summarised in Table 8, and discussed below.  
Table 8 Findings from each interview group on key themes 
 
Key themes  GPs Patients Therapists 
The value of a 
diagnosis   
Reluctant to diagnose an 
anxiety disorder for several 
reasons: they did not have 
enough information; they 
thought it could be 
unhelpful or stigmatising; or 
because it would be the role 
of the psychiatrist to make a 
formal diagnosis. There was 
recognition that some 
patients may find a 
diagnosis helpful, but they 
had limited time to discuss 
labels with patients.  
Valued having a 
diagnosis. It led to 
acceptance of anxiety as 
a medical condition and 
helped them to think 
about how they were 
going to get better and 
the treatment they 
needed. Patients 
wanted GPs to be able 
to take the time to 
explain their diagnosis.  
An emphasis on labelling 
symptoms by category or 
subtype in IAPT. However, 
they do not diagnose 
anxiety in the formal sense. 
Recognition a label could 





GPs felt there was a close 
relationship between 
anxiety and depression, and 
thought that depression was 
more likely to be identified 
first. However, they did not 
tend to distinguish between 
the two conditions when 
discussing mental health 
with patients. 
Patients felt that anxiety 
was a potential cause of 
their depression, and 
that it could have 
greater impact on their 
daily lives. It was 
therefore important 
that anxiety and 
depression were 
considered as distinct 
disorders.  
Therapists identified 
anxiety as a potential cause 
of depression. They tend to 
distinguish between the 
two conditions when 
working with patients, as 
this enables better 
understanding of mental 





GPs held the view that 
patients had a preference 
for taking medication, 
rather than ‘self-help’. This 
was compounded by the 
considerable wait times to 
access therapy through the 
IAPT service.  
Most did not view 
taking medication as a 
positive choice, and 
were reluctant to do so. 
However, the 
considerable wait times 
for therapy meant they 
felt they had limited 
alternative options.  
Patients who self-referred 
into IAPT (compared to GP 
referral) were described as 
more motivated to change. 
Although therapists 
recognised the competing 
demands on GPs’ time, 
they wanted GPs to work 





GPs and therapists identified young adults as being at risk of anxiety, and GPs also recognised that 
elderly patients were at risk. Therapists did not mention the latter, perhaps because this patient 
population does not self-refer to IAPT services, and are less readily referred by GPs than those of a 
younger age (Pettit et al., 2017). Over-65s comprise only 7% of referrals to IAPT (Age UK, 2020). 
Patients mentioned that they were reluctant to seek help from their GP because they were 
concerned about wasting GP time and that symptoms were not severe enough.   
GPs were reluctant to diagnose an anxiety disorder early on because they felt they did not have 
enough information initially to make a diagnosis, or because they thought it could be unhelpful or 
potentially stigmatising for the patient. Some GPs also felt it would be the role of the psychiatrist to 
make a formal diagnosis. Therapists were clear that whilst that there is an emphasis on labelling 
symptoms by category, or subtype, the IAPT system does not encourage them to formally diagnose 
anxiety. However, there was recognition from both GPs and therapists that some patients wanted a 
label, or that it could be helpful. Patients’ accounts supported this, as they indicated they valued 
having a diagnosis, and that it led to acceptance of anxiety as a medical condition and helped them 
to think about how they were going to get better and engage with treatment. For many, this was 
important in their progress towards recovery. Patients also wanted GPs to be able to take the time 
to explain their diagnosis, yet GPs commented on the limited time that they could give to patients. 
However, GPs encouraged the use of follow-up appointments to mitigate this, and this also provided 
the continuity of care that patients viewed as important. In contrast, whilst IAPT therapists are able 
to give more time to discuss labels, they are not able to provide long-term continuity of care (on 
average, patients receive only 6.9 sessions (Baker, 2020)). This may be particularly pertinent for 
chronic recurrent conditions, such as GAD.  
In terms of treatment, some GPs thought that patients had a preference for medication. However, 
most patients did not view taking medication as a positive choice, and were averse to doing so. 
Patient reflections that there has not been enough investment in anxiety drew parallels with the GP 
data, whereby GPs described limited availability of those trained in mental health, and secondary 
care as being non-existent for this group of patients. Both GPs and patients also noted the 
considerable wait times for IAPT therapy. Therapists recognised that patients who self-referred into 
IAPT (as opposed to being referred by their GP) were often more motivated to change, and although 
they recognised the competing demands on GPs’ time, they wanted GPs to work closer with the 
service and adopt a more multi-disciplinary approach.  
Patients and therapists spoke about anxiety as being a potential cause of depression, and that it 





relationship between anxiety and depression, most GPs reported depression as being the condition 
they were more likely to identify first. On the whole, therapists reported that they distinguished 
between the two conditions when working with patients, as this enabled patients to better 
understand their mental health. It also led to more effective and appropriate treatment. Patients 
reiterated the importance of considering anxiety and depression as distinct disorders, and explained 
that when this did not happen, the anxiety was not recognised or treated. However, for the most 
part, GPs did not tend to distinguish between anxiety and depression when discussing mental health 
with patients.  
 
3.7.2 Strengths and limitations 
The use of in-depth interviews allowed interviewees to raise issues that were salient to them. 
Conducting data collection and analysis in parallel enabled early insights to inform later interviews, 
and to establish when data saturation had been reached. The option of telephone interviews may 
have encouraged individuals to take part in the study (Sturges & Hanrahan, 2004). In addition, 
designing the topic guides for each set of interviews in parallel, and conducting interviews with the 
three different groups of participants in parallel, ensured key areas were covered with GPs, patients 
and therapists, and allowed insights from each to inform the focus of the other interviews, aiding 
later triangulation of GPs’, patients’ and therapists’ views during analysis .  
Purposively sampling participants helped toward achieving maximum variation in each group, in 
terms of, for example, age and gender. We cannot assume, however, that the views expressed will 
be representative of other patients and practitioners. The research was all based in Bristol and the 
surrounding area. Only one male under the age of thirty-five was interviewed. Our difficulty in 
recruiting male patients might be because young men are often uncomfortable, or unwilling, to talk 
about their mental health (Lynch et al., 2018). In addition, only one patient was interviewed was 
from an ethnic minority. Ethnic minorities are frequently under-represented in research (Redwood & 
Gill, 2013), and in this study, the practices that responded with expressions of interest to support 
recruitment did not have large ethnic minority populations.  
We recruited patients through GP practices who already had an anxiety symptom or diagnosis code 
in their recent medical history. Consequently, this study does not capture the views and experiences 
of those who have not yet sought help for anxiety. All interviewees volunteered to be interviewed, 
and therefore, those who took part were probably patients or practitioners who viewed themselves 
as having particular knowledge and experiences of anxiety. The study invitation clearly stated the 





identified as having anxiety were more likely to take part, and they may have more severe 
symptoms, or have different views on the importance of diagnosis. Likewise, although only one GP 
reported an additional qualification in psychiatry, it is possible that GPs interviewed may have had 
more of an interest in mental health than those who did not respond to the study invitation. In 
addition, all the therapists interviewed worked within the BWT service. Recruitment of therapists 
from other talking therapies services was considered, particularly as IAPT services differ across the 
UK in terms of organisation and therapies provided. However, BWT was the service available to the 
GPs and patients interviewed. Also, time was limited and within this service there were therapists 
who differed in terms of their age, gender, qualifications, level of training, and length of time 
working in IAPT. It therefore provided the sample needed to achieve the aim of these interviews, i.e. 
to gain insight into the management of anxiety from the perspective of practitioners trained in 
psychological treatment. 
 
3.7.3 Comparison with existing literature  
Previous studies have also found that patients are concerned that GPs would view consultations 
about mental health problems as wasting their time (Rogers, 2001; Cromme et al., 2016), and find it 
difficult to disclose emotional concerns to GPs (Parker et al., 2020). As mentioned by GPs and 
patients in our study, time constraints can also make it difficult to discuss anxiety (Barnes et al. 
(2019). Patients emphasized that continuity of care is important to the disclosure and management 
of anxiety, and can help to facilitate a collaborative relationship whereby the GP is offering advice 
and facilitating decision making. Again, this is supported by the work of others (Buszewicz et al., 
2006) . Having a collaborative relationship between the GP and patient is beneficial, and increasing 
patient education around their mental health empowers them to have more awareness and input 
into decisions around their treatment options (Saver et al., 2007). As patients in this study stated, 
having an understanding of mental health problems is important, and the consultation with the GP 
can be central for this (Parker et al., 2020). However, whilst research by Cape et al. (2010) indicated 
that coming to an understanding of mental health problems is primarily patient led, this study has 
found that consultations can also be driven by GP discussions around normalisation, diagnosis, and 
management.  
GPs have been shown to normalise symptoms of depression to avoid over-medicalisation (Chew-
Graham et al., 2002), as they have here in relation to anxiety, and there has been an ongoing debate 
about how useful it is to communicate psychiatric diagnoses to patients (Kelly, 2018). GPs have 





reluctant to use medical labels for women with symptoms indicating postnatal depression, due to a 
lack of resources available for referring women (Chew-Graham et al., 2008). However, patients in 
this study emphasised that, if appropriate, receiving a diagnosis was important, particularly in terms 
of helping them accept their illness and engage with treatment. Thomas et al. (2019) have recently 
found that self-referral to IAPT is viewed by GPs as an important step toward patient recovery, and 
data from therapists in this study suggests self-referral led to empowerment and proactivity of 
patients.  
Although depression and anxiety are often co-morbid, previous studies have not compared patients’ 
and practitioners’ views on anxiety and depression directly. This study specifically focused on the 
importance of such a distinction and highlighted that patients want them to be considered 
separately, despite this not always happening in general practice. Patients in this study reported 
experiencing anxiety as having more of an impact on their daily lives than depression, and existing 
evidence shows that over time, patients with anxiety have a longer, more chronic course than those 
with depression (Penninx et al., 2011). Indeed, this study highlighted that IAPT therapists treat the 
two conditions separately, in line with NICE guidelines (Clark, 2011).  
 
3.7.4 Implications and future work  
There is a reluctance to seek help for anxiety, and we need to understand why this is. Future 
research could explore the views and experiences of patients who have not yet sought help for the 
symptoms of anxiety.  
GPs and IAPT therapists need to be aware that some patients may find being given a diagnosis of 
anxiety helpful, and that doing so can create an opportunity to educate patients about this specific 
condition. In addition, patients want anxiety and depression to be considered separately as distinct 
disorders, because of the greater impact of anxiety on their daily lives, and because it can be a 
precursor to depression. Currently, GPs do not generally distinguish between them.  
Finally, there is a contrast between GPs’ views that patients prefer to take medication, whereas 
patients often do not view medication as a positive choice and are averse to taking it. There is a 
need for GPs to explore patients’ views on taking medication, and to reiterate that it is not an 





Awareness of these issues – of patients wanting a diagnosis, of considering anxiety and depression 
separately, and concerns around taking medication – and more discussion around these, may lead to 












Chapter 4 Trends in the recording of anxiety diagnoses and 
symptoms in UK primary care 
4.1 Chapter overview   
This chapter details one of the two quantitative components of this thesis. The focus is on 
investigating trends in the incident recording of anxiety diagnoses and symptoms in UK primary care 
between 2003 and 2018, and to examine potential differences in trends according to age and 
gender. Whilst predominately detailing quantitative findings, the chapter also presents data 
gathered during the qualitative interviews with GPs and therapists that give insight into the rationale 
underpinning their coding decisions, providing detailed insight and indicating possible reasons for 
the trends observed in the quantitative findings. 
The chapter starts with a brief overview of how GPs record clinical events in primary care, and of a 
dataset that captures this – CPRD Gold. This is followed by details of the quantitative methods and a 
description of the purpose of the qualitative data in this chapter, and how it relates to this study. 
Quantitative results are then presented in terms of describing trends in the recording of anxiety over 
time, with additional data presented according to gender, age, and diagnostic sub-type. Each section 
presents trends in coding of any anxiety code (either a diagnostic code or a symptom code), trends 
in diagnostic codes, and trends in symptom codes. In-depth findings from the qualitative interviews 
with GPs and therapists that relate specifically to trends in coding of anxiety are also presented. The 
chapter finishes with a discussion of both the quantitative and qualitative results, reflections on the 
strengths and limitations of the study, and situates the findings within the context of previous 
research and implications for future work.  
 
4.2 Methods  
4.2.1 Use of electronic health records for epidemiological research  
Within the UK, anxiety is commonly managed by GPs in primary care. It is estimated that over 98% of 
the UK population are registered with a GP practice (Herrett et al., 2015). When GPs diagnose 
anxiety, or indeed any other condition, they record these consultations in patients’ computerised 
medical records (de Lusignan & Chan, 2008). When each of these patients’ electronic medical 
records are anonymised and combined into a substantial dataset, they enable large observational 
research, providing researchers with a highly detailed database and longitudinal follow-up data 





One of these databases providing such secondary data is the CPRD Gold (Walley & Mantgani, 1997), 
and this was the source of the quantitative primary care data used in this study. Other primary care 
databases include THIN (Bourke et al., 2004) and QResearch (Hippisley-Cox et al., 2004). One of the 
main distinctions between these databases is the source of the data in terms of the practice 
management software used by practices, with EMIS software most commonly used in the UK 
(Kontopantelis et al., 2013; EMIS Health, 2020). CPRD Gold data is derived from electronic records of 
practices using Vision practice management software (In Practice Systems LTD, 2020), with practices 
using EMIS software (EMIS Health, 2020) contributing data to CPRD’s separate Arum database in 
recent years. In contrast, THIN data originates solely from practices using Vision (In Practice Systems 
LTD, 2020), whilst QResearch is comprised of data from practices just using EMIS software (EMIS 
Health, 2020). QResearch is the least utilised out of these three primary care databases, possibly due 
to the higher data quality seen in Vision based datasets (de Lusignan et al., 2015). Of the remaining 
two databases, CPRD Gold and THIN, there is around a 60% overlap between contributing practices 
(Carbonari et al., 2015). However, THIN has less practices and represents a slightly smaller 
proportion of the UK population compared with Gold (in 2015 THIN covered 6%; in 2017 CPRD Gold 
covered 8% (Kontopantelis et al., 2018)). 
The population comprised within the CPRD Gold database is considered to be representative of the 
wider UK population with regard to gender and age, although there is some under-representation of 
practices situated within the inner-London area, and fewer smaller practices than that seen at a 
national level (Walley & Mantgani, 1997). Although the database has undergone several name-
changes since its’ inception, data has been recorded for CPRD since 1987 (Walley & Mantgani, 1997).  
As stated above, all practices that have signed up to contribute to CPRD Gold use Vision practice 
management software (In Practice Systems LTD, 2020). For each registered patient, the record 
contains information such as registration dates, demographic details, consultation dates, tests, 
prescriptions, referrals, and clinical details. Practices use a comprehensive coding thesaurus of 
clinical terms to record presenting symptoms or diagnoses and, at the time of conducting this 
research, practices sampled used the READ code system (de Lusignan, 2005). GPs are also able to 
record additional information as ‘free-text’, but these are not shared with researchers as standard, 
due to the possibility of identifiable data being included. Provided the patient has not opted out of 
data sharing, practices provide these anonymised records to the CPRD Gold database on a monthly 
basis.  
CPRD conduct quality checks on the data at both patient and practice level (Herrett et al., 2015). The 





status, validity of age and gender, and the number of recorded events in the patient’s record. For 
practices, being classified as ‘up-to-standard’ (UTS) is dependent on the number of recorded deaths, 
and continuity of recording. The UTS date is calculated from the point at which the practice meets 
the qualifying criteria for these measures. At the point of data extraction for this study in July 2019, 
there were 17,269,826 acceptable patients, of which 2,852,166 were currently registered at 337 
contributing practices. Despite having a very large dataset, with ‘acceptability’ and UTS data quality 
checks, interpretation of the data from these patients should still be considered carefully. As with 
any secondary data analysis, further steps should be taken by the researcher to assess potential 
issues in data completeness and accuracy.  
CPRD provide the data to researchers in a combination of data files, ordered by the type of 
information they contain, such as prescriptions in the ‘therapy’ files, or READ codes in the ‘clinical’ 
files. Data dictionaries are also supplied to decode ‘medcodes’ and ‘prodcodes’ used in the files, 
which relate to READ codes and medication respectively. The analytic approach taken for this study 
is outlined in the following section.  
 
4.2.2 Study protocol  
The protocol for this study was approved by the CPRD’s Independent Scientific Advisory Committee 
(ISAC) prior to undertaking data analysis.  
Design and study population 
This study examined trends in the incident recording of anxiety diagnoses and symptoms in UK 
primary care between 2003 and 2018. The study used a retrospective cohort design. The sample 
included patients aged 18 years or over, registered at a CPRD Gold practice between 1st January 
2003 and 31st December 2018. Patient records had to be classified as ‘acceptable’ by CPRD, and 
from a practice that was considered UTS for at least one year prior to date of entry into the study 
(1st January 2003). In addition, patients had to be registered with practices that had contributed 
data for the whole of the specified study period, that is, between 1st January 2003 and 31st 
December 2018.   
Data preparation 
Data management and analysis was conducted using Stata version 15.1 (StataCorp LLC, 2020). 
Using the criteria outlined previously, data were extracted from the CPRD Gold database by a 





of the following: practice details, patient details, consultations, immunisations, staff, clinical, 
therapy, referrals and tests. An individual patient identifier, unique to each patient, is used to link 
data across each data file. These files were imported into Stata and saved as Stata data files. 
Initially, each data file containing ‘medcodes’ (i.e. those with clinical data containing recorded 
anxiety codes) was merged with the patient and practice files using the patient identifier. Each data 
file was then cleaned by removing patients with missing or inaccurate data. This included patients 
whose recorded transfer out date (the date the patient left the practice) or date of death was before 
the current registration date; those whose registration date was after the end date of the study (31st 
December 2018); and those who turned 18 years of age after: (i) the end date of the study, (ii) their 
transfer out date; or (iii) their date of death. Patients who were missing data on gender (n=5) were 
removed. Duplicate rows of data were dropped where the row had the same patient identifier and, 
for those with an anxiety code, the same patient identifier, ‘medcode’ (i.e. READ code) and recorded 
read code date.  
In addition, patients who had a recorded anxiety code, but missing data on the date of the code, or 
whose anxiety code was recorded after the recorded date of death or transfer out date, were 
retained within the study population, but that code was not included in the analysis.   
Codes for Anxiety 
Those with a recorded diagnosis of an anxiety disorder and/or recorded symptoms of anxiety were 
identified using the READ codes outlined in the Appendix - A.7.  
This READ code list was compiled from codes in the NHS UK READ Codes Clinical Terms (Version 3, 
April 2018) under the category of anxiety, and cross-checked with code lists from previous 
epidemiological research on recording of anxiety (Walters et al., 2012; John et al., 2016). In keeping 
with other studies focusing on anxiety, codes for phobias, obsessive compulsive disorders, and post-
traumatic stress disorder were excluded (Walters et al., 2012; John et al., 2016).  
Incident use of codes in each calendar year was examined in terms of: (i) those with a new episode 
defined by any anxiety code (symptom or diagnosis code); (ii) those with a new episode defined by a 
diagnosis code; and (iii) those with a new episode defined by a symptom code. A new episode was 
defined as a recorded symptom or diagnosis of anxiety in that year, with no prior recorded code of 
that category recorded in the previous twelve months. Patients may have had more than one 
episode within the study period, provided that there was a minimum of twelve months between 
episodes. For patients that entered the study in 2003, information on codes used in the year (2002) 





episode is in line with previous epidemiological research on anxiety (Walters et al., 2012), and is 
appropriate given that anxiety can be a chronic condition, and hence patients may be more likely to 
be presenting repeatedly. Patients had to have been registered with CPRD Gold for one year before 
the first recorded anxiety code, to ensure high quality assessment of incident cases. 
Calculating person-years at risk 
The CPRD Gold database provides researchers with longitudinal data on individuals, enabling the 
examination of trends over time in the general population. Each patient has a varying duration of 
follow-up, with the follow-up time commencing when they join the study. A patient’s follow-up time 
ends at the end of the study, or earlier if they: (i) die; (ii) transfer out of a CPRD Gold contributing 
practice; or (iii) experience the event of interest – in this instance – an incident anxiety code. When 
measured in years, follow-up time is referred to as person-years-at-risk (PYAR).  
PYAR was used as the denominator in this study, with patients entering the study on either: (i) 1st 
January 2003 or (ii) the last date of their current registration. Patients stopped contributing PYAR on 
the earliest of: (i) their transfer out date; (ii) date of death; (iii) end of the study, 31st December 
2018; or (iv) date of the incident anxiety code.  
In order to preserve patient anonymity, CPRD only provide year of birth. Patients that were 
identified as under 18 years of age, on the calculated date of entry, had their entry year amended to 
the year they turned 18 within the study period. Any anxiety codes recorded prior to this date were 
not included in the analysis.  
Statistical analyses 
The following analyses were conducted defining a new episode of anxiety as: (i) any anxiety code – 
either a diagnosis or symptom code; (ii) a diagnosis code; and (iii) a symptom code.  
To investigate trends in the incidence of recorded anxiety codes over time, the incidence of recorded 
anxiety was calculated for each year of the study period. Annual incidence rates were calculated by 
dividing the annual number of incident cases by the total PYAR for each year, and are presented per 
1000 PYAR. Estimates of 95% confidence intervals (95%CI) for these rates were calculated based on 
the Poisson distribution which is used when describing the number of events occurring over a period 
of time. Data were plotted on a graph to examine changes over time for all incident cases of anxiety, 
and then separately for diagnosis and symptoms. Data were also stratified by gender and age. Age 





Poisson regression was used to estimate incidence rate ratios (IRR) that compare incidence rates 
between years, age-bands, and gender. Univariable poisson regression models were used to 
examine the association between year of recording, age, gender, and incidence of anxiety 
symptoms/diagnoses. IRRs and 95%CIs are reported. Multivariable poisson regression models that 
included year, age and gender were used to examine the independent effects of such factors. 
Sensitivity analyses were conducted to account for any clustering within practices within the 
multivariable model using the ‘vce (cluster)’ command in Stata, which stipulates that the standard 
errors “allow for intragroup correlation” (StataCorp LLC, 2020).  
In addition, an interaction between age and year was included in the multivariable poisson 
regression model in order to examine whether trends in recording of anxiety over time varied 
according to age. This was formally tested using a likelihood-ratio test that compared models with 
and without the interaction term. An interaction between gender and year was also examined using 
the same approach in order to examine whether the trends in the recording of anxiety differed by 
gender. 
Changes in trends over time were examined using joinpoint regression using Joinpoint Trend 
Analysis Software version 4.7.0.0 (National Cancer Institute, 2020), which is available for download 
from the National Cancer Institute Surveillance Research Program website 
(https://surveillance.cancer.gov/joinpoint/). It is designed to take time-trend data, and fit a joinpoint 
model with the minimum number of joinpoints allowed by the data thus identifying points at which 
there is a change in the linear slope of the trend.  
In the first instance, the software models the minimum number of joinpoints (i.e. zero joinpoints, 
which would be a straight line). It then models (using the permutation test with a specified alpha 
level of p=0.05) whether adding an additional joinpoint would provide a better fit to the data. It 
continues to test this up to the maximum number of joinpoints specified by the user (up to two for 
this analysis, based on the recommended maximum number of joinpoints for the number of 
datapoints within the study). Through this process, the model identifies the best fitting model for 
the data and hence the years (with 95%CI) at which changes in trends occurred. The best fitting 
model for: (i) any anxiety code; (ii) diagnosis codes; and (iii) symptom codes were presented 
graphically. In addition, the annual percentage change (APC) for each of the identified trends based 
on the slope of each line ‘segment’ between joinpoints was also calculated.  
Finally, in order to better understand the use of the wide range of diagnosis codes used by GPs in the 
study, additional analyses were undertaken. Diagnosis codes were grouped based on the ICD-10 





with non-specific anxiety codes (termed NSA), mixed anxiety and depression codes (termed MADD), 
or codes relating to panic attacks or disorders (termed Panic). These groups are in line with previous 
epidemiological research on anxiety (Walters et al., 2012). Annual incidence rates were calculated 
for each diagnostic group as described earlier and are presented per 1000 PYAR. Estimates of 95% 
confidence intervals (95%CI) for these rates were calculated based on the Poisson distribution. Data 
were plotted on a graph to examine changes over time for all incident cases for each diagnostic 
group.  
 
4.2.3 Qualitative data 
During the qualitative interviews held with 15 GPs and nine therapists that were detailed in Chapter 
3, interviewees talked about trends in patients presenting with anxiety, the codes they use, and 
differences between coding of anxiety symptoms and coding for an anxiety disorder. These data are 
presented within this chapter to provide insight into possible reasons for the trends observed in the 
quantitative analysis. 
 
4.3 Results  
4.3.1 Descriptive statistics  
Sample characteristics  
The final dataset included 176 practices at which a total of 2,569,153 eligible patients were 
registered across the 16-year period (2003-2018). The median number of eligible patients registered 
per practice was 12,642 [IQR: 9,188 to 18,425]. There were 17,554,704.06 person-years of follow-up 
(PYFU) (median follow-up 4.9 years [IQR: 1.8 to 12.0 years]). There was a total of 264,127 incident 
anxiety codes (any anxiety code - either diagnosis or symptom) recorded over the duration of the 
study.  
When focusing on either diagnosis codes or symptom codes, there were 216,126 recorded new 
episodes of anxiety diagnoses with 18,135,058.53 PYFU, and 197,217 new episodes of anxiety 
symptoms with 18,312,128.32 PYFU, over the duration of the study.  
GP use of anxiety codes 
A large number of READ codes – in terms of both diagnosis and symptoms – were used by GPs 





Table 9 Frequency of Read codes used by GPs to record anxiety diagnoses – all diagnosis codes and 






























 Code or code group Total 
Freq. % 
Diagnosis codes anxiety states 93,989 43.5 
anxiety with depression 61,831 28.6 
panic attack 22,668 10.5 
anxiety state NOS 7,301 3.4 
panic disorder 5,740 2.7 
[X] mixed anxiety and depressive disorder 3,735 1.7 
generalised anxiety disorder 3,482   1.6 
chronic anxiety 3,125 1.5 
anxiety state unspecified 3,095   1.4 
agoraphobia with panic attacks 1,879 0.9 
[X] anxiety disorder, unspecified 1,549 0.7 
[X] mild anxiety depression 1,091 0.5 
[X] anxiety NOS 991 0.5 
[X] other anxiety disorders 984   0.5 
[X] generalised anxiety disorders 928 0.4 
recurrent anxiety   703 0.3 
[X] agoraphobia 630 0.3 
[X] panic attack   528 0.2 
[X] panic disorder (episodic paroxysmal 
anxiety] 
430 0.2 
[X] social phobias   410 0.2 
social phobic disorders 226 0.1 
[X] persistent anxiety depression 204 0.1 
agoraphobia without mention of panic attack 153 0.1 
[X] anxiety state 140   0.1 
[X] anxiety neurosis 135 0.1 
[X] panic state 83 0.0 
[X] panic disorder with agoraphobia 49 0.0 
[X] other mixed anxiety disorders   29 0.0 
[X] other specified anxiety disorders 12 0.0 
[X] agoraphobia without history of panic 
disorder 
  3 0.0 
[X] social neurosis    3 0.0 
Total 216,126 100 
 
Diagnosis codes - 
sub-type group 
Non-specific anxiety (NSA) 112,898 52.2 
Mixed anxiety and depression (MADD) 66,861 30.9 
Panic attack or disorder (PANIC) 29,449 13.6 
Other anxiety codes 6,918 3.2 





Many of these READ codes are neither usefully descriptive or discriminant between different 
disorders, or variants of anxiety. To better understand the use of these codes,  one of the most 
widely used classification systems of psychiatric disorder, the ICD-10 classification system was used 
to group the diagnosis codes used by GPs (World Health Organisation, 1992). These were grouped 
according to whether they related to non-specific anxiety codes (termed NSA), mixed anxiety and 
depression codes (termed MADD), or codes relating to panic attacks or disorders (termed Panic). 
These grouped counts are presented in Table 9 (diagnosis codes) and Table 10 (symptom codes).  
The most frequently used diagnostic codes were ‘anxiety states’ (43.5%), ‘anxiety with depression’ 
(28.6%) and ‘panic attack’ (10.5%), totalling 178,488 out of 216,126 (82.6%) of anxiety diagnosis 
episodes (Table 9). ICD-10 diagnostic codes were used less frequently, with ‘generalised anxiety 
disorder’ and ‘mixed anxiety and depressive disorder’ each representing less than 2% 
(n=3,482/216,126); n=3,735/216,126) of diagnostic codes. When the diagnostic codes were grouped, 
codes relating to NSA accounted for more than half of diagnosis codes used by GPs, with a further 
31% attributed to the category of MADD (Table 9).  
When recording anxiety symptoms, GPs mostly used three codes: ‘anxiousness symptom’, 
‘anxiousness’ and ‘worried’ (Table 10). These three codes were used in the vast majority (n=192,243; 
97.5%) of anxiety symptom episodes (Table 10). 















Symptom codes Total 
Freq. % 
anxiousness symptom 104,278 52.9 
anxiousness 69,775 35.4 
worried 18,220 9.2 
anxious 2,532 1.3 
nerves 958 0.5 
O/E - anxious   923 0.5 
tension - nervous 448 0.2 
O/E panic attack 64 0.0 
nervous - nervousness 19 0.0 





4.3.2 Trends in coding over time 
Incidence rates for GP recorded anxiety – any anxiety code, diagnosis codes and symptom codes – 
are presented in Figure 2 and Table 11. The incidence of any anxiety code rose from 17.8/1000PYAR 
in 2003 to 28.5/1000PYAR in 2018. Between 2003-2008, the incidence of anxiety diagnoses fell from 
13.2/1000PYAR to 10.1/1000PYAR; after which the incidence of anxiety diagnoses remained fairly 
constant, before increasing in later years (Table 11 and Figure 2). The incidence of anxiety symptoms 
more than doubled over the entire study period rising from 6.2/1000PYAR in 2003 to 14.7/1000PYAR 
in 2018 (Table 11 and Figure 2).  
 
Figure 2 Trends in the incidence of GP recorded anxiety (any code, diagnosis, and symptom codes) 





Table 11 Incidence rates for GP recorded anxiety – any anxiety code, anxiety diagnoses and anxiety symptoms – between 2003 and 2018 














Year 2003 19653 1104840 17.8 (17.5-18.0) 14560 1107325 13.2 (12.9-13.4) 6905 1111271 6.2 (6.1-6.4) 
2004 20174 1101094 18.3 (18.1-18.6) 13957 1108836 12.6 (12.4-12.8) 8295 1118817 7.4 (7.3-7.6) 
2005 20139 1090525 18.5 (18.2-18.7) 13476 1103323 12.2 (12.0-12.4) 8668 1117151 7.8 (7.6-7.9) 
2006 19969 1089605 18.3 (18.1-18.6) 12808 1107044 11.6 (11.4-11.8) 9301 1123201 8.3 (8.1-8.5) 
2007 20165 1087647 18.5 (18.3-18.8) 12172 1109495 11.0 (10.8-11.2) 10215 1126579 9.1 (8.9-9.2) 
2008 20009 1091521 18.3 (18.1-18.6) 11324 1117947 10.1 (9.9-10.3) 10884 1134517 9.6 (9.4-9.8) 
2009 21323 1089956 19.6 (19.3-19.8) 12036 1120938 10.7 (10.6-10.9) 11525 1136496 10.1 (1.0-10.3) 
2010 21006 1091637 19.2 (19.0-19.5) 11582 1126857 10.3 (10.1-10.5) 11723 1141488 10.3 (10.1-10.5) 
2011 21808 1091322 20.0 (19.7-20.3) 11685 1130669 10.3 (10.2-10.5) 12465 1143857 11.0 (10.7-11.1) 
2012 23114 1096434 21.1 (20.8-21.3) 12318 1140092 10.8 (10.6-11.0) 13372 1151609 11.6 (11.4-11.8) 
2013 23645 1096102 21.6 (21.3-21.9) 12456 1143493 10.9 (10.7-11.1) 13846 1153634 12.0 (11.8-12.2) 
2014 24320 1099656 22.1 (21.8-22.4) 12910 1150993 11.2 (11.0-11.4) 14250 1159472 12.3 (12.1-12.5) 
2015 26088 1103179 23.7 (23.4-23.9) 13907 1158402 12.0 (11.8-12.2) 15137 1165447 13.0 (12.8-13.2) 
2016 28952 1107757 26.1 (25.8-26.4) 16137 1167097 13.8 (13.6-14.0) 16305 1173397 14.0 (13.7-14.1) 
2017 30252 1106657 27.3 (27.0-27.7) 16835 1169467 14.4 (14.2-14.6) 17031 1175674 14.5 (14.3-14.7) 





Changes in trends over time were examined formally using joinpoint regression. The best fitting model for any anxiety codes included one joinpoint at 2011 
(95% CI 2009 - 2014), after which there was a substantial increase in the incidence of recorded anxiety codes (Figure 3). 
 
 





For diagnosis codes, the best fitting joinpoint model included two join points: one in 2008 (95% CI 2006-2011), after which the recorded incidence of 
anxiety diagnoses remained fairly constant, and one in 2013 (95% CI 2011-2016), after which there was a substantial increase in recorded incidence of 
anxiety diagnoses (Figure 4).  





For symptom codes, the best fitting join point model had one join point at 2007 (95% CI 2005-2009), after which recorded incidence of symptom codes 
continued to increase, but at a slower rate compared with earlier years (Figure 5). 





Incidence rate ratios (IRRs) for year, gender and age group for any anxiety code, anxiety diagnosis, 
and anxiety symptoms are shown in Table 12, Table 13, and Table 14. After adjusting for age and 
gender, the IRR for any anxiety code was 1.65 (95% CI 1.63-1.68) when comparing 2018 with 2003 
(Table 12). For symptom codes only, after adjusting for age and gender, incidence more than 
doubled (IRR 2.41 (95% CI 2.34-2.48)) when comparing 2018 with 2003 (Table 14). 
Recorded incidence of anxiety in women was nearly twice that of men (Table 12, Table 13, and Table 
14). This was consistent across any anxiety code, anxiety diagnoses and anxiety symptoms (adjusted 
IRR: women compared with men: any anxiety code IRR 2.13 (95% CI 2.11-2.14); diagnosis codes IRR 
2.07 (95% CI 2.05-2.09); symptom codes IRR 2.12 (95% CI 2.10-2.14)) (Table 12, Table 13, and Table 
14).   
Recorded incidence of anxiety (any anxiety code) decreased with age, with the incidence for those 
aged 85+ years being just over half (IRR: 0.58 (95%CI: 0.57-0.60)) that of the youngest age group 
(<25 years) (Table 12). A similar pattern was found for recorded incidence for anxiety diagnoses 
(Table 13), with the incidence for those aged 85+ years being approximately half (IRR: 0.48 (95%CI: 
0.46-0.50)) that of those aged under 25 years, and for anxiety symptoms (Table 14), with a 30% 
reduction in the incidence of anxiety for the oldest age group compared with the youngest age 
group (IRR: 0.67 (95% CI 0.65-0.69)).  
Sensitivity analyses were conducted to examine the potential impact of clustering within GP 
practices on findings. Whilst confidence intervals were wider, findings were consistent with the 
results that did not allow for clustering for any anxiety code, diagnosis codes, and symptom codes 


















Variable  Any anxiety code 
Univariable 
IRR 
(95%CI) P value Multivariable 
IRR* 
(95%CI) P value 
Year 2003 1.00  <0.001 1.00  <0.001 
2004 1.03 (1.01-1.05) 1.03 (1.01-1.05) 
2005 1.04 (1.02-1.06) 1.04 (1.02-1.07) 
2006 1.03 (1.01-1.05) 1.04 (1.02-1.06) 
2007 1.04 (1.02-1.06) 1.05 (1.03-1.07) 
2008 1.03 (1.01-1.05) 1.04 (1.02-1.06) 
2009 1.10 (1.08-1.12) 1.12 (1.09-1.14) 
2010 1.08 (1.06-1.10) 1.10 (1.08-1.12) 
2011 1.12 (1.10-1.15) 1.14 (1.12-1.17) 
2012 1.19 (1.16-1.21) 1.21 (1.18-1.23) 
2013 1.21 (1.19-1.24) 1.24 (1.21-1.26) 
2014 1.24 (1.22-1.27) 1.27 (1.25-1.30) 
2015 1.33 (1.31-1.35) 1.36 (1.34-1.39) 
2016 1.47 (1.44-1.50) 1.51 (1.48-1.54) 
2017 1.54 (1.51-1.56) 1.58 (1.55-1.61) 
2018 1.60 (1.58-1.63) 1.65 (1.63-1.68) 
Gender Male 1.00  <0.001 1.00  <0.001 




18-24 1.00  <0.001 1.00  <0.001 
25-34 1.09 (1.08-1.10) 1.08 (1.07-1.10) 
35-44 1.03 (1.02-1.05) 1.05 (1.04-1.06) 
44-54 0.97 (0.96-0.98) 0.97 (0.96-0.98) 
55-64 0.84 (0.83-0.85) 0.84 (0.83-0.85) 
65-74 0.74 (0.73-0.75) 0.72 (0.71-0.73) 
75-84 0.77 (0.76-0.79) 0.73 (0.72-0.74) 
85+ 0.67 (0.65-0.68) 0.58 (0.57-0.60) 




















(95%CI) P value 
Year 2003 1.00  <0.001 1.00  <0.001 
2004 0.96 (0.94-0.98) 0.96 (0.94-0.98) 
2005 0.93 (0.91-0.95) 0.93 (0.91-0.96) 
2006 0.88 (0.86-0.90) 0.89 (0.87-0.91) 
2007 0.83 (0.81-0.85) 0.84 (0.82-0.86) 
2008 0.77 (0.75-0.79) 0.78 (0.76-0.80) 
2009 0.82 (0.80-0.84) 0.83 (0.81-0.85) 
2010 0.78 (0.76-0.80) 0.79 (0.77-0.81) 
2011 0.79 (0.77-0.81) 0.80 (0.78-0.82) 
2012 0.82 (0.80-0.84) 0.84 (0.82-0.86) 
2013 0.83 (0.81-0.85) 0.84 (0.82-0.86) 
2014 0.85 (0.83-0.87) 0.87 (0.85-0.89) 
2015 0.91 (0.89-0.93) 0.93 (0.91-0.96) 
2016 1.05 (1.03-1.08) 1.08 (1.05-1.10) 
2017 1.09 (1.07-1.12) 1.12 (1.10-1.15) 
2018 1.16 (1.14-1.19) 1.20 (1.17-1.22) 
Gender Male 1.00  <0.001 1.00  <0.001 




18-24 1.00  <0.001 1.00  <0.001 
25-34 1.09 (1.07-1.11) 1.08 (1.06-1.10) 
35-44 1.06 (1.04-1.07) 1.06 (1.04-1.08) 
44-54 0.96 (0.94-0.97) 0.96 (0.94-0.97) 
55-64 0.81 (0.79-0.82) 0.80 (0.79-0.81) 
65-74 0.65 (0.64-0.67) 0.64 (0.62-0.65) 
75-84 0.66 (0.64-0.67) 0.62 (0.61-0.63) 
85+ 0.54 (0.53-0.56) 0.48 (0.46-0.50) 



















(95%CI) P value 
Year 2003 1.00  <0.001 1.00  <0.001 
2004 1.19 (1.16-1.23) 1.20 (1.16-1.23) 
2005 1.25 (1.21-1.29) 1.25 (1.21-1.29) 
2006 1.33 (1.29-1.37) 1.34 (1.30-1.38) 
2007 1.46 (1.42-1.50) 1.47 (1.43-1.52) 
2008 1.54 (1.50-1.59) 1.56 (1.51-1.60) 
2009 1.63 (1.58-1.68) 1.65 (1.60-1.70) 
2010 1.65 (1.60-1.70) 1.67 (1.62-1.72) 
2011 1.75 (1.70-1.81) 1.77 (1.72-1.83) 
2012 1.87 (1.82-1.92) 1.89 (1.84-1.95) 
2013 1.93 (1.88-1.99) 1.96 (1.90-2.01) 
2014 1.98 (1.92-2.04) 2.01 (1.95-2.07) 
2015 2.09 (2.03-2.15) 2.12 (2.06-2.19) 
2016 2.24 (2.17-2.30) 2.28 (2.21-2.34) 
2017 2.33 (2.27-2.40) 2.38 (2.31-2.44) 
2018 2.36 (2.29-2.43) 2.41 (2.34-2.48) 
Gender Male 1.00  <0.001 1.00  <0.001 




18-24 1.00  <0.001 1.00  <0.001 
25-34 1.08 (1.06-1.10) 1.07 (1.05-1.09) 
35-44 0.98 (0.96-0.99) 1.00 (0.98-1.01) 
44-54 0.94 (0.92-0.95) 0.93 (0.91-0.95) 
55-64 0.84 (0.82-0.85) 0.83 (0.82-0.85) 
65-74 0.81 (0.79-0.83) 0.78 (0.77-0.80) 
75-84 0.88 (0.86-0.90) 0.83 (0.82-0.85) 
85+ 0.77 (0.75-0.80) 0.67 (0.65-0.69) 





4.3.3 Trends in coding over time by gender and age 
As highlighted above, the recorded incidence of anxiety was more common in women but the 
overall pattern of trends over time (in any anxiety code, diagnoses and symptoms) were similar for 
males and females (Figure 6, Figure 7 and Figure 8). The incidence rates for men and women (for any 
anxiety code, diagnoses and symptoms) are provided in the Appendix A.9 - Table 32 and A.10 - Table 
33.  
In order to formally test whether incidence varied over time according to gender, the multivariable 
Poisson regression model was repeated including an interaction between year and gender. There 
was no evidence of an interaction by gender for any anxiety code (p value for interaction = 0.38). 
However, there was evidence of an interaction between year and gender for diagnosis codes 
(p<0.001). Visual inspection of the graph presenting the incidence of GP recorded anxiety (diagnosis 
codes) (Figure 7) suggested that these interaction effects may be driven by differences in the 
incidence of recorded diagnoses in later years, however, the differences were small and may not be 
meaningful and should therefore be interpreted with caution. In addition, there was weak evidence 
of interaction between year and gender for symptom codes (p=0.053), but again this should be 
interpreted with caution.  
 
 







Figure 7 Incidence of GP recorded anxiety (diagnosis codes) per 1000 PYAR by gender 





Incidence rates were stratified by age and are presented in Figure 9, Figure 10 and Figure 11 for any 
anxiety code, diagnosis and symptoms respectively, with the underlying data presented in the 
Appendix A.11 - Table 34. Recorded incidence increased substantially in the younger age groups in 
later years of the study. In order to formally test whether incidence varied over time according to 
age, the multivariable Poisson regression model was repeated including an interaction between year 
and age. There was strong evidence of an interaction between year and age for all models (any 
anxiety code: p value for interaction <0.001; diagnosis codes: p<0.001; symptom codes: p<0.001).  
There was a marked increase in the recorded incidence of anxiety diagnosis between 2013 and 2018 
in the two youngest age bands, increasing from 11.8/1000PYAR to 24.4/1000PYAR for the under 25s 
and from 13.1/1000PYAR to 22.7/1000PYAR for those aged 25-34 years. Incidence of anxiety 
diagnosis fell over time in the oldest age groups, decreasing from 10.5/1000PYAR in 2003 to 
8.1/1000PYAR in 2018 for those aged 75-84 years and from 8.4/1000PYAR in 2003 to 6.1/1000PYAR 
in 2018 for those aged over 85 years (Figure 10).  
There was a marked increase in the recorded incidence of anxiety symptoms over the duration of 
the study for the two youngest age bands, increasing from 4.6/1000PYAR to 22.2/1000PYAR for the 
under 25s and from 5.7/1000PYAR to 21.2/1000PYAR for those aged 25-34 years. In contrast, whilst 
the incidence of anxiety symptoms increased over the first half of the study period for the oldest age 
groups (65-74 years; 75-84 years and 85+ years), incidence then decreased in the second half of the 













Figure 10 Incidence of GP recorded anxiety (diagnosis codes) per 1000 PYAR, by age 





4.3.4 Trends in coding over time of diagnosis subtypes  
Trends over time in the diagnosis subtype groups of NSA, MADD and Panic were also examined 
(Figure 12 and Table 15). Between 2003-2008, the recorded incidence of generalised anxiety codes 
(NSA) fell from 7.0 to 5.3/1000PYAR; increasing over subsequent years to 8.2/1000PYAR in 2018 
(Table 15). The incidence of mixed anxiety and depression codes (MADD) gradually decreased from 
4.8/1000PYAR in 2003 to 2.9/1000PYAR in 2011; and then increased to 6.2/1000PYAR in 2018 (Table 
15). The recorded incidence of panic attack and disorder codes (Panic) gradually declined over the 












Figure 12 Trends in the incidence of GP recorded anxiety (any diagnosis code, generalised anxiety 






Table 15 Incidence rates for GP recorded diagnosis codes - generalised anxiety (NSA), mixed anxiety and depression (MADD), and panic attack/disorder 
(Panic) - between 2003 and 2018 














Year 2003 7735 1110795 7.0 (6.8-7.1) 5345 1111906 4.8 (4.7-5.0) 2713 1113259 2.4 (2.4-2.5) 
2004 7366 1118504 6.6 (6.4-6.7) 4914 1121800 4.4 (4.3-4.5) 2821 1125367 2.5 (2.4-2.6) 
2005 7175 1117956 6.4 (6.3-6.9) 4676 1123313 4.2 (4.0-4.3) 2708 1128498 2.4 (2.3-2.5) 
2006 6915 1125687 6.1 (6.0-6.3) 4209 1132822 3.7 (3.6-3.8) 2626 1139307 2.3 (2.2-2.4) 
2007 6449 1131423 5.7 (5.6-5.8) 4015 1140100 3.5 (3.4-3.6) 2473 1147528 2.2 (2.1-2.2) 
2008 6078 1142584 5.3 (5.1-5.5) 3547 1152729 3.1 (3.0-3.2) 2280 1160912 2.0 (1.9-2.1) 
2009 6712 1147923 5.9 (5.7-6.0) 3548 1159565 3.1 (3.0-3.2) 2407 1168332 2.1 (2.0-2.1) 
2010 6392 1156026 5.5 (5.4-5.7) 3586 1169326 3.1 (3.0-3.2) 2132 1178626 1.8 (1.7-1.9) 
2011 6763 1161722 5.8 (5.7-6.0) 3450 1176368 2.9 (2.8-3.0) 1980 1186411 1.7 (1.6-1.7) 
2012 6966 1173032 5.9 (5.8-6.1) 3780 1189160 3.2 (3.1-3.3) 2126 1199951 1.8 (1.7-1.9) 
2013 7540 1177990 6.4 (6.3-6.6) 3671 1195544 3.1 (3.0-3.2) 1876 1207214 1.6 (1.5-1.6) 
2014 7899 1186763 6.7 (6.5-6.8) 3930 1206211 3.3 (3.2-3.4) 1803 1218763 1.5 (1.4-1.6) 
2015 8374 1195608 7.0 (6.9-7.2) 4652 1216622 3.8 (3.7-3.9) 1550 1230583 1.3 (1.2-1.3) 
2016 9558 1206451 7.9 (7.8-8.1) 6021 1228668 4.9 (4.8-5.0) 1502 1245057 1.2 (1.2-1.3) 
2017 9884 1211024 8.2 (8.0-8.3) 6587 1234188 5.3 (5.2-5.5) 1431 1253591 1.1 (1.1-1.2) 





4.3.5 Qualitative data 
As outlined earlier in section 4.2.3, findings were identified during analysis of the qualitative 
interviews with practitioners (GPs and therapists) that provided some insight into possible reasons 
for the trends seen in GP coding of anxiety. These findings were briefly mentioned in the previous 
chapter (Chapter 3) and are expanded upon below.  
GP and therapist data – recent increases in anxiety  
GPs said that they thought the number of patients presenting in primary care with anxiety had 
increased over time, and this had also increased their own awareness of anxiety and its’ importance. 
GPs commented that there were multiple factors that could cause this increase in anxiety, but that 
some of the more recent contributors that could explain the rise related to increased use of the 
internet. They explained the reliance on using the internet for shopping, working, and interacting 
with people, meant people were physically more isolated from others and lacked ‘real-life’ social 
support.  
“Increasingly people are becoming more isolated because they’re not having to go out. They 
can do more online so they’re actually- it’s making people worse ‘cos they’re not having to go 
out to interact with people as much, and the less people then go out, that can cause anxiety 
about going out and doing things.”  GP 15 
In addition, GPs stated that social media had led to a skewed perception of what an ideal life should 
be like, resulting in pressure to achieve the impossible. GPs commented that it was now much easier 
to make comparisons with other peoples’ lives, and to want the “perfect life” (GP 1) being presented 
by others on social media.  
“I don’t know whether it’s social media or this sort of perception that everyone should have this 
perfect life, perfect looks, perfect body, perfect house, perfect holidays, which is everywhere. 
And the reality of life is that not everyone has…everything all the time and I think it’s the 
expectation that ‘I should have this and I don’t, why don’t I have it’, and I think that’s what’s 
feeding a bit of an anxiety boom.” GP 1 
“There just seems to be an awful lot more pressure on individuals, or perceived pressure, I think 
to either perform or to do things, or people’s perception of what they need to achieve has been 
altered…I know that there seems to be recent articles about the correlation between the 





In particular, GPs reported that they had seen a recent increase in younger patients with anxiety, i.e. 
patients aged “18 to 25” (GP 11), and this had been most notable in the past five years.  
“I’ve been a GP for 20 years and the prevalence and incidence of anxiety seems to be on the 
increase, especially maybe in the last five years, especially in younger people but also I think 
a rise in everyone that I see, all ages I mean, but mainly in the younger people.” GP 12 
They explained that they thought this was in part driven by social media, and by current pressure on 
young people - pressure to do well at school or university exams, pressure from peers, and pressure 
to secure and sustain employment.  
“I think young people coming up have a lot more anxiety than we realise. There seems to be 
such pressure on them now in terms of exam performance, social performance, work 
performance and just- I feel it’s certainly becoming more common in younger people.” GP 7 
GPs also commented that this could be compounded by online gaming, whereby, if children have 
grown up gaming, or are spending lots of time gaming as young adults, then they are living in a world 
that does not provide them with social or physical interaction. This could lead to anxiety around having 
to go out or having contact with others.  
“…like online gaming, I think all of that has a massive impact…and I think that’s one of the 
reasons that there seems to be an increase is that there’s much more- the sort of virtual world 
is not the same as the real world and I think that children and young adults are living in a 
virtual world and losing social and physical contact and it makes them anxious about going out 
and [having] social contact.” GP 13 
Finally, GPs also stated that they felt in recent years there had been more recognition of anxiety as a 
problem by the public. Reduction in stigma, and increased awareness of anxiety in the media and by 
celebrities, meant that patients were now more likely to consult and seek help for anxiety.  
“I think there’s probably greater recognition from the public of their symptoms, less stigma and 
[more likely to] seek help about it.” GP 1 
They explained that this meant patients often knew they ‘had’ anxiety and would “specifically raise 
the question themselves” (GP 4), and therefore there was potentially an expectation that the GP 
‘had’ to give their symptoms a medical label of anxiety.  
“By the time it gets to us we’re probably over-pathologising it, because we’re seeing it so we’re 
kind of feeling we have to do something about it, and it’s quite difficult just to say that’s 






“I think it’s a tough thing to say but I almost think that because of how the people come and 
see the doctor, you’re tempted to medicalise it rather than- well hopefully we try and normalise 
it, but I do feel it’s probably getting more medicalised.”  GP 11 
Similarly, therapists also reported an increase in younger patients seeking therapy, mainly “teens to 
25 or 27” (therapist 6), and cited similar causes to the GPs, such as social media and pressure to do 
well. They elaborated on the latter cause, in terms of the pressure placed on young people to do 
well, by society and by their parents, that can lead worry or anxious thought patterns.  
“Generally with GADs it probably has to do quite a lot with the fact that in modern society the 
expectations toward younger people grow, so that creates a lot more anxiety in terms of their 
performance as well which can then translate in unhelpful worry.” Therapist 1 
“There is lot of focus because it’s the society we live in at the moment that [is] very intense, and 
the expectations from parents, and media.” Therapist 6 
Therapists explained that, for university students, there was an additional pressure to do well due 
the significant fees that they were paying. Therapists commented on the culture at university, that 
there was an expectation that everyone was working hard, and students felt they could not 
understand why there were struggling, when others were not. This could be compounded by being 
away from home and family for this first time and having to take care of themselves in a potentially 
isolating situation.  
“For the last few years, [there] is definitely an increase of anxiety with young people and I 
think…there is so much pressure at the moment put on young people in terms of performance, 
in terms of university, with university fees increasing as well, perfection, and I think all of those 
factors will contribute to people becoming a lot more stressed and anxious so I’ve definitely 
noticed that with young people.” Therapist 1 
“I guess with students, you know, moving home first time, [a] lot of anxieties come out, that 
can trigger a lot of different things or suicidal behaviour, pressures of university and looking 
after themselves.” Therapist 2 
Therapists talked about an increase in awareness “in the media about mental health and anxiety” 
(Therapist 2), with mental health days and groups on social media helping to normalise anxiety for the 
younger generation. They stated this was helping to reduce stigma and encourage young people to 
access IAPT services. Some therapists reflected that rather than there being more people experiencing 





“Our society I think is definitely talking about anxiety more, and therefore capturing people 
more who have anxiety disorders, but I personally don’t think we’re medicalising it more than is 
necessary.” Therapist 9. 
GP data - coding choice and influences 
Trends in the recording of anxiety over time might also vary due to changes in GPs coding decisions. 
GPs commented they that used codes such as “anxiety states” (GP 9) rather than ICD-10 codes as 
they felt it would be the role of a psychiatrist to give a formal diagnosis, or because they felt “anxiety 
state” (GP 4) was generic enough to cover a general sense of anxiety, rather than codes such as 
“stress at work” (GP 4) which would be linked to a specific event or circumstance.  
When GPs were asked about which codes they were most likely to use, most GPs referred to non-
diagnostic symptom codes. “Anxiousness” (GP 11) was frequently cited as the more commonly used 
code for early presentation of anxiety symptoms. ‘Mixed anxiety and depression’ or ‘anxiety with 
depression’ was commonly used when patients presented with co-morbid symptoms, ‘anxiety state’, 
‘anxiety states’ or ‘anxiety not otherwise specified’ for when anxiety presented on its’ own, and 
“panic if it seems panic” (GP 15). GPs talked about progressing to other diagnostic codes during 
follow-up consultations, giving examples such as “generalised anxiety… or…chronic anxiety” (GP 10). 
 
“I think it depends whether they come back. So, yeah, (pause) yeah, so I might not code it as 
that on the first consultation but I think if it’s, you know, if it’s becoming more apparent as the 
consultations develop then I might do, so I might code it as anxiety states say on the first 
consultation and then might develop into generalised anxiety type code or even a chronic 
anxiety if they’d had episodes in the past.” GP 10 
Furthermore, when talking about anxiety and depression presenting co-morbidly, GPs reported a 
tendency to code for both conditions “under the umbrella of depression” (GP 11). 
“It can be difficult if someone’s depressed and having panic attacks, and I think that the 
majority I do put them as depression, but if someone has predominantly anxiety then I will 
classify them often as depression with anxiety.” GP 12 
When asked about influences on the specific codes GPs might choose to use, some GPs mentioned 
the QOF as influencing the decision to code for a symptom rather than a disorder. Although they 
referred to depression rather than anxiety, there was a sense that the QOF had led to GPs being 





“So I think QOF has actually skewed what we do because QOF says if you label someone with 
this you must review them, you know, if you use a drug you must do that and - I think that has 
skewed actual prevalence rates of things because now we might write low mood not 
depression, because actually if we write depression they chastise us if we haven’t done so much 
within so number of weeks, so I think these things do change what we do. So I tend to be rather 
cautious about labels.” GP 6  
GPs reported that they tried to be consistent in the codes used, so if the patient had previously had 
an anxiety code recorded then they would reactivate it, or change all previous codes to be the same 
as the code they were about to use. GPs also said they avoided coding in free text, so that codes 
were easier to search for and were more meaningful within the coding hierarchy for that practice.  
“If somebody’s used an anxiety code previously we try and match up the same code or change 
all of them…so we’d always try and encourage our team to use that because they’re easier to 
search for, they’re more meaningful in the coding structure and hierarchy. It’s just about 
making sure the record is as accurate as possible, and also technically correct, because if you 
haven’t put it on in a correct way it might as well not exist. If you free text stuff it might as well 
not exist.”  GP 5 
However, some GPs also talked about using codes interchangeably, with a tendency to select 
whichever anxiety code presented first on the drop-down list – “whatever comes up first, ‘that’s a 
code for anxiety, that’ll do” (GP 2). They added that there were certain codes used by each practice, 
and the more those codes were used, the more likely they were to appear toward the top of the list, 
although this did not mean coding would necessarily be more consistent between GPs within the 
practice.  
“What the systems often do is they have this sort of velocity coding stuff so that if as a practice 
you tend to use certain codes more often they will sort of appear towards the top of the list, 
but I think with things, if you looked at the coding of anxiety in practices I suspect it’s pretty 
varied just because there’s loads of different potential codes that one can pick.” GP 8 
GP data – threshold for coding symptom versus diagnosis 
As mentioned above and in the previous chapter (section 3.4.2), GPs were reluctant to label patients 
with a diagnostic anxiety code. This may explain the quantitative finding of a decrease in the 
incidence of recorded anxiety diagnoses between 2003-2008. GPs said had concerns around giving 
patients potentially stigmatising labels, thinking they might be unhelpful for the patients, or that it 





symptoms were consistently reported by GPs as the two factors that they would use to determine 
whether they would code for an anxiety disorder, rather than using a symptom code. GPs talked 
about duration as being particularly important, with some GPs suggesting delaying coding for a 
disorder until a certain time period had passed, depending on the impact of symptoms. 
“So persistent symptoms for…six weeks, a month, it depends on how functioning they are, so if 
they’re still managing to work then I probably would delay the diagnosis longer. If they’re 
completely not functioning then I would probably diagnose a bit sooner than that, so four to six 
weeks.” GP 1 
“Duration is one thing, no response to various things they might have tried themselves, how it’s 
affecting their life, there seems to be no precipitating factors so everything else seems to be 
ok…that sort of history of ongoing things in the past throughout their lives.” GP 15 
Similarly, GPs said they would be looking for previous episodes of anxiety, whereby recurrent 
episodes had persistently occurred over a long period of time.  
“So I might use anxiety as a single episode that may have a clear sort of factor that’s transient 
in their life, or when it gets resolved, where…I guess more in a chronic or long-standing one 
that’s when I’ll consider changing it to anxiety disorder where they have a chronic or relapsing 
sort of form of anxiety, like long-standing.” GP 11 
In addition, some GPs commented that there was association between coding for an anxiety 
disorder and prescribing medication, in that if they were prescribing medication, such as 
benzodiazepines or SSRIs, then it was likely that the patient would have had a recorded diagnostic 
code (patients do not need to be diagnosed to be given a prescription). One GP explained that if a 
patient presented with anxiety, and they were prescribing drug treatment, then they would also 
make sure a diagnostic code was recorded for that patient. That is, if a patient had reached a 
threshold for being prescribed medication, then they would have also reached the threshold for an 
anxiety diagnosis, rather than an anxiety symptom.  
“If I was prescribing purely an SSRI for anxiety without depression, I would certainly make a 






4.4 Discussion   
4.4.1 Summary of findings 
The recorded incidence of anxiety symptoms increased over the 16 years of the study (2003-2018). 
In contrast, the recorded incidence of anxiety diagnoses decreased over the first 5 years of the study 
period (2003-2008), before markedly increasing between 2013 and 2018. When subdivided by 
diagnostic category, non-specific anxiety codes (NSA) and mixed anxiety and depression (MADD) 
showed a similar trend. However, the recorded incidence of panic attack or disorder (Panic) 
gradually declined across the entire 16-year time period.  
Recorded incidence in women was nearly twice that of men – in terms of any anxiety code, diagnosis 
codes, and symptom codes. There was some evidence of a difference between the incidence of 
anxiety diagnosis codes in women compared with men in later years of the study, although the 
differences were small and should be interpreted with caution.  
There was evidence of an interaction between year and age. Recorded incidence – of any code, 
diagnosis and symptoms – increased substantially in the later years of the study in the younger age 
groups (under 25s and 25-34 year olds). There was also an increase in recorded incidence in recent 
years for 35-44 years and 45-54 year olds, although it was less marked. Whereas the recorded 
incidence for the older age groups (65-74 years, 75-84 years and 85+ years) declined in later years. 
Generic anxiety codes such as ‘anxiety states’ were recorded much more frequently than ICD-10 
codes, such as ‘generalised anxiety disorder’. Interview data from GPs indicated that this was 
because they viewed it as the role of a psychiatrist to give a formal ICD-10 diagnosis. Interviews also 
indicated that GPs prefer to use symptom codes to diagnostic codes, and that they use these codes 
in a systematic way. Symptom codes were used if the anxiety was acute and less severe, and 
diagnostic codes were used if the anxiety was chronic and more severe. This may explain the 
increase in recorded incidence of anxiety symptoms during the study period, and the decrease in the 
recorded incidence of anxiety diagnoses over the first five years of the study. It therefore may reflect 
changes in GP recording, rather than a true change in incidence. However, GPs and therapists also 
commented on a rise in the presentation of anxiety in recent years, and suggested a greater 
awareness of anxiety in society and amongst GPs, could be a possible reason for this. A rise in the 
number of patients presenting with anxiety may explain the increase in reported incidence of 
diagnostic codes in the later period of the study. Furthermore, GPs and therapists both identified an 
increase in anxiety in younger patients, and this is consistent with the increase in recorded incidence 
– of both diagnosis and symptoms – found for the youngest age groups (<25 years and 25-34-year 





years could be a potential reason for this, along with rising use of the internet and social media 
within society. 
 
4.4.2 Strengths and limitations 
The use of data from the CPRD Gold database enabled analysis of trends in a large sample size of 
more than 250,000 patients, which can be considered representative of the UK population. It also 
permitted analysis of trends in incident codes by age and gender and presents data over a long 
period of 16 years. An extensive code list was used, compiled from the national UK READ code 
clinical terms, and cross-checked with code lists from previous epidemiological research on 
recording of anxiety (Walters et al., 2012). It is therefore likely to capture all READ codes that GPs 
may use for anxiety, and prior research has validated such diagnoses recorded by GPs in primary 
care research databases (Martin-Merino et al., 2010). Using a wide range of codes also enabled 
analysis of trends in the incidence of any anxiety code, along with trends in the incidence of anxiety 
diagnoses, and of anxiety symptoms. In addition, grouping anxiety diagnoses into diagnostic sub-
types allowed better understanding of the use of these codes in terms of one of the most widely 
used classification systems of psychiatric disorder, the ICD-10. Using a multi-methods approach in 
this study also aided understanding of trends seen. The interviews suggested possible reasons for 
the trends observed, and potential explanations for the changes in recorded incidence seen over 
time. 
In terms of the limitations of the study, the sample is restricted to patients who have received an 
anxiety symptom or diagnosis READ code. It is likely that there are those with anxiety who have had 
a discussion with their GP about their symptoms, and even been prescribed anxiolytic medication, 
but have not had it coded within their record. Similarly, those whose anxiety is not detected, or 
where GPs have not coded it separately from depression or physical health conditions, will also not 
be included in this study. Likewise, it does not capture patients who may have anxiety symptoms, or 
a diagnosis, recorded in free-text on their electronic medical record, but no formal READ code. It is 
not possible to know what proportion of patients this might apply to, as free-text is not available for 
the purposes of research due to the possibility of identifiable data being included. Hence, the 
reported figures may be an underestimate, and if how GPs use the free-text recording has differed 
over time, then this may have biased the trends seen. In addition, this study is only capturing trends 
for those who consult for anxiety. As not all will seek help for their symptoms, these data will 





the results of the study are generalisable to anxiety presenting in other countries or other health 
care systems.  
Only practices who provided data to CPRD Gold across the whole study period (2003-2018) were 
included in the analysis, in order to allow greater confidence in interpreting trends over time. If all 
practices that contributed data for part of the study period had been included, it would have made 
interpretation of trends over time more difficult, as it would not have been possible to know 
whether any differences were, at least in part, due to the differences in the practices contributing 
data over time. Whilst it is possible that there may be differences between practices with complete 
or partial data over the study period, no data were available on age, gender or coding for practices 
with partial data in order to look at this in detail. No information was available on why some 
practices stopped contributing to CPRD Gold. One possible explanation was that it may be related to 
a switch in the practice software being used (CPRD Gold only included practices using Vision 
software (In Practice Systems LTD, 2020)). EMIS software (EMIS Health, 2020) provides a greater 
opportunity to use free-text recording (compared to Vision systems) and therefore there may be 
differences in the coding of symptoms or diagnoses between practices with complete or partial 
data that may impact on the estimates obtained. However, it is difficult to quantify this, 
and previous research using a different CPRD dataset did not find any differences in age, gender, or 
use of diagnostic codes when comparing complete and partial data from contributing practices 
(Moore et al., 2009). 
With regard to the qualitative interviews, topic guides were developed with the quantitative work in 
mind, and therefore specifically designed to collect data that would enable identification of possible 
reasons for the trends observed. For example, they included questions on: the causes of anxiety; 
who was most at risk of anxiety; and what specific READ codes GPs used and why. Interviews were 
analysed prior to analysis of the CPRD Gold data, and therefore not influenced by knowledge of the 
quantitative findings. Practitioners were purposively sampled who varied in terms of age, gender, 
deprivation decile of their practice (if a GP), and length of time working in primary care. Whilst those 
interviewed did not necessarily work at practices that had contributed to the quantitative dataset, 
the qualitative data demonstrated themes that were consistent with the trends seen. As outlined in 
Chapter 3 (section 3.7.2), the use of in-depth interviews allowed adequate time for disclosure of 
views, and conducting data collection and analysis in parallel enabled early insights to inform later 
interviews and to establish when data saturation had been reached. However, as previously 
highlighted, the GPs and therapists who took part were self-selecting, and it is possible that those 





4.4.3 Comparison with previous studies 
Compared with depression, there has been less epidemiological research on anxiety alone, although 
one study looked at the incidence of anxiety in primary care between 1998 and 2008 (Walters et al., 
2012). However, there are no data on the incidence of anxiety in recent years, and there have been 
several changes that may have had an impact on trends in coding during this time: the introduction 
of the depression QOF in 2006 (British Medical Association, 2006); the introduction of the IAPT 
service in 2007/2008; the economic recession in 2008; and the NICE anxiety guidelines in 2011 (NICE, 
2011b).  
The introduction of the 2006 QOF provided financial incentives for practices that recorded certain 
qualifying READ codes and met practice performance indicators (Mitchell et al., 2011). Whilst there 
is not a QOF for anxiety disorders, there is a QOF for depression (British Medical Association, 2006). 
Previous research has found changes in how GPs recorded depression after its introduction, with 
increasing use of symptom codes (Kendrick et al., 2015). However, the present study did not find a 
corresponding increase in anxiety symptom codes around the time of the introduction of the QOF, 
rather finding a reduction in the rate of increase in incidence seen after 2007. It is possible that this 
reduction in the rate of increase may reflect increasing presentation to IAPT services (introduced in 
2007/08), rather than to GPs. However, this is unlikely as any changes in incidence resulting from the 
introduction of IAPT would have been expected to have been seen over a prolonged period. In terms 
of the economic recession, it is feasible that this had an impact on incidence rates, as recorded 
diagnosis codes levelled off between 2008 to 2013, after a previously sharp decline. Previous studies 
have also found reversals in previously declining rates of suicide, and increases in rates of 
depression, after the recession (Coope et al., 2014; Frasquilho et al., 2016). Finally, the updated NICE 
anxiety guidelines in 2011, with their recommendation for earlier diagnosis, may have increased 
awareness of anxiety among GPs (NICE, 2011b). Indeed, this study found an increase seen in the 
incidence rate of any anxiety code – symptoms or diagnosis – after 2011. 
Results from this study are consistent with that of Walters et al. (2012), in that recorded incidence of 
anxiety symptoms increased over time. When comparing incidence rates for the overlapping years, 
Walters et al. (2012) found symptom rates rose from 3.9 in 2003 to 5.8/1000PYAR in 2008, 
compared with the higher rates of 6.2 to 9.6/1000PYAR seen in this study. The higher incidence rates 
seen in the present study may be due to the additional symptom codes included in the READ code 
list, which account for 11% of the total symptom codes recorded by GPs (‘worried’, ‘anxious’, ‘on 
exam - anxious’, and ‘on exam - panic attack’). Likewise, a recorded decrease in the incidence of 





al. (2012) study (4.9/1000PYAR in 2008) is also consistent with the decline seen in NSA codes in this 
study (5.3/1000PYAR in 2008). Similarly, there was a trend of reduced incidence of panic disorder 
and mixed anxiety and depression during the same overlapping period in the two studies, although 
rates in this study were slightly higher. Between 2003 and 2008, mixed anxiety and depression was 
3.9 to 2.2/1000PYAR in the study by Walters et al. (2012), compared with 4.8 to 3.1/1000PYAR in 
this study. Whilst the present study included one additional mixed anxiety and depression code in 
the READ code list (‘persistent anxiety depression’), this only accounted for a small percentage of 
the total codes used for this diagnostic sub-type. However, there is only a 60% overlap in the 
practices providing data to both CPRD Gold and THIN databases, and therefore it is possible that the 
higher rates seen in the present study are due to the differences in the populations seen by 
contributing practices (Carbonari et al., 2015). Importantly, the findings from Walters et al. (2012) 
only present trends in recording of anxiety up to 2008. Whilst the present study reports the 
continued increase of incident anxiety symptoms, it also highlights a contrasting increase in incident 
anxiety diagnoses since the end of 2008, and most notably in the most recent five years.  
Using primary care data recorded in the Swansea Secure Anonymised Information Linkage (SAIL) 
Databank, another study reported an increase in symptom codes for anxiety, depression and MADD 
between 2000 and 2009, but a stable incidence of diagnosis codes over this period (John et al., 
2016). However, this study did not present data for anxiety separately (John et al., 2016). 
Furthermore, as previously discussed, analysis of trends in the recording of depression indicate the 
introduction of the depression QOF in 2006 impacted GP willingness to label patients with a 
diagnostic code, with an increase in the use of symptom codes seen (Kendrick et al., 2015). Whilst 
Kendrick et al. (2015) only looked at depression, qualitative data from interviews with GPs about 
coding for anxiety supports this finding (Ford et al., 2016). That is, that GPs are reluctant to code for 
an anxiety disorder in the first instance, and prefer to use symptom codes where possible, as 
evidenced in the qualitative interviews in this study. However, this does not explain why the present 
study found an increase in diagnostic codes in more recent years. Literature suggests that increasing 
mental health promotion may be leading to increased awareness and reduced stigma (Stuart, 2016), 
and therefore, it is possible that a reduction in stigmatising views may be increasing help-seeking 
behaviour in the general public (Schnyder et al., 2017), along with greater awareness among GPs of 
the importance of diagnosing anxiety. A recent study used data from the nationally representative 
Attitudes to Mental Illness Survey, published annually between 2012 and 2016 (Henderson et al., 
2017). The study found that the national anti-stigma campaign, ‘Time To Change’ (TTC), had led to 





disclosure of mental health. This may help to explain the rise in anxiety diagnoses seen in the last 
five years of the present study, along with the continued rise of anxiety symptoms.  
The finding of an increased incidence of anxiety in women is consistent with previous research in 
primary care, whereby diagnoses of anxiety, or anxiety symptoms, are twice as high in women when 
compared with men (Martin-Merino et al., 2010; Walters et al., 2012). Surveys of the general 
population have also identified a higher prevalence of anxiety in women compared with men 
(Stansfeld et al., 2016). A critical review of research conducted within the community across the EU 
found an increased prevalence in women of all ages, with diagnoses of anxiety disorders in women 
over double that seen in men (Wittchen & Jacobi, 2005).  
Using primary care data recorded in THIN between 2002 and 2004, an earlier study found that the 
incidence of any anxiety code was highest in adults aged 20-29 years old (Martin-Merino et al. 
(2010). However, the study did not distinguish between codes for anxiety disorders and codes for 
anxiety symptoms, and included a broader range of READ codes describing anxiety, such as phobias. 
The present study has extended these findings by using CPRD Gold data for a 16-year period and 
found that, in recent years, there has been an increase in the recorded incidence of anxiety – both 
diagnoses and symptoms – particularly for young adults (aged<35 years). This pattern reflects 
observations from population data.  
Using data from the 2014 APMS, Stansfeld et al (2016) found that women aged 16-24 years old were 
three times more likely to have symptoms of common mental disorders than men in the same age 
band. In addition, the proportion of adults aged 16-24 years old with NSA increased from 3.6% to 
6.3% from 2007 to 2014, whilst prevalence decreased for those aged over 75 years old, which aligns 
with the findings from this study. National survey data, focused specifically on prevalence in young 
people, has also identified that those aged 16-24 years were nearly ten times more likely to state 
that they had a mental health condition in 2014, compared with 1995 (Pitchforth et al., 2019). The 
authors speculate that this increase may be due to decreased stigma, and an increased awareness 
and willingness to discuss mental health, as outlined in other studies above (Henderson et al., 2017; 
Schnyder et al., 2017). One of the authors also suggests that an increase in pressure, the effects of 
social media and cyber-bullying, and ‘generational inequality’, may be contributing to the rise 
(Hargreaves, 2018). In the qualitative interviews for the present study, GPs and therapists suggested 
the recent increase in anxiety seen in younger adults, may be due to increased social media and 
internet use, and increasing pressure on this group. These findings are also mirrored by studies with 
adolescents, which have found increased social media use is associated with higher levels of anxiety 





social media combined with decreased stigma around mental health, with a corresponding greater 
awareness, may explain the increase in recorded anxiety – of any anxiety code, diagnosis codes, and 
symptoms codes – in recent years in younger adults.  
 
4.4.4 Implications and future work  
There was a decrease in the incidence of recorded anxiety diagnoses between 2003 and 2008, but 
the incidence of anxiety diagnoses increased in recent years (2013-2018). In contrast, there was an 
increase in the incidence of recorded anxiety symptoms over the 16-years of the study (2003-2018). 
The increase in recorded incidence of both diagnosis and symptom codes in later years of the study 
was substantial for younger adults. The earlier decline in recording of anxiety diagnoses may have 
been due to GP preference for using symptom codes rather than codes for an anxiety disorder. 
However, the recent rise in incidence of both recorded anxiety diagnoses and symptoms may reflect 
increased awareness of anxiety in both patients and GPs, and hence increased presentation in 
primary care. GPs and therapists both reported a rise in the incidence of anxiety amongst young 
adults and suggested that factors such as social media use, or an increase in pressure on young 
people may be contributing to this.  
There is a clear need for future research to focus on the rise in anxiety seen in young adults in recent 
years and to understand why this is happening. Whilst this study reports GP and therapist 
perspectives, data on the views of patients are limited, particularly those under thirty-five years of 
age in which increasing incidence of anxiety was most notable. Future research could seek to 
interview young adults to understand these trends, and this would be critical in the development of 
potential interventions for young adults with anxiety, and the wider population. Additionally, a 
longitudinal study that focuses on the use of social media and the internet may help to explain if 








Chapter 5 Trends in the prescribing for anxiety in UK primary care 
5.1 Chapter overview   
This chapter details the second of the two quantitative components of this thesis, and presents 
qualitative data from the GP interviews that give insight into the rationale underpinning their 
prescribing behaviour, providing detailed insight and indicating possible reasons for the trends 
observed in the quantitative findings. The focus is on examining trends in medication prescribed for 
anxiety in UK primary care between 2003 and 2018.  
The specific objectives of this quantitative component were to:  
• Examine trends in prescribing overall and by drug class (antidepressants, benzodiazepines, 
beta-blockers, antipsychotics, anticonvulsants) between 2003 and 2018.  
• Examine potential differences in prescribing over time according to age and gender. 
• Determine whether any changes in prescribing over time were due to: (i) an increase in the 
number of new patients receiving medication (incident cases); and/or (ii) changes in the 
duration of treatment over the study period.  
The chapter starts with an outline of the quantitative methods. This is followed by a description of 
the purpose of the qualitative data in this chapter, and how it relates to this study. The quantitative 
results are then presented. Firstly, brief descriptive statistics summarising the sample characteristics, 
then data on the prevalence and incidence of prescriptions for anxiety over the study period. This is 
followed by data on the duration of incident prescriptions, incidence of combination therapies, and 
doses of incident antidepressant medication. Each section presents overall trends in any anxiolytic 
medication, and trends in each drug class, alongside each other. In-depth findings from the 
qualitative interviews with GPs are then presented that relate specifically to prescribing for anxiety. 
The chapter finishes with a discussion of both the quantitative and qualitative results, reflections on 
the strengths and limitations of the study, and situates the findings within the context of previous 








5.2 Methods  
5.2.1 Study protocol 
Data source 
This study used the CPRD Gold, which, as summarised in the previous chapter (section 4.2.1), is a 
large observational database providing anonymised primary care data. The study protocol for the 
analysis was set out in advance and was approved by the CPRD ISAC. 
As previously outlined, CPRD conduct quality checks on the data at both patient and practice level 
(Herrett et al., 2015), termed ‘acceptability’ and UTS respectively. As with the trends in coding for 
anxiety study, at the point of data extraction for this study (July 2019), there were 17,269,826 
acceptable patients, of which 2,852,166 were currently registered at 337 contributing practices.  
Design and study population 
The study used a retrospective cohort design. The sample included patients aged 18 or over in CPRD 
Gold who had a prescription for an anxiolytic between 1st January 2003 and 31st December 2018. 
Patient records had to be classified as ‘acceptable’ by CPRD, and from a practice that was considered 
UTS for at least one year prior to date of entry into the study (1st January 2003). In addition, patients 
had to be registered with practices that had contributed data for the whole of the specified study 
period, that is, between 1st January 2003 and 31st December 2018.   
Data preparation 
Data management and analysis was conducted using Stata version 15.1 (StataCorp LLC, 2020).  
The dataset that was used for the trends in coding for anxiety study, which was extracted from the 
CPRD Gold database by a member of the CPRD team on the 22nd July 2019, was also used for this 
study.  
Initially, each data file was cleaned as outlined in the previous chapter (section 4.2.2). This included 
removing duplicated rows, and removing patients with missing or inaccurate data, such as those 
who had a recorded transfer out date or death date that was before the current registration date. 
Patients with missing data on gender (n=5) were also removed. For full details refer to Chapter 4 
(section 4.2.2). 
Codes for Anxiolytics  
Analyses focussed on all prescriptions of any anxiolytic medication according to the appropriate 





This list of drugs was compiled based on the British Association for Psychopharmacology’s (BAP) 
recommendations for pharmacological treatment for anxiety disorders (Baldwin et al., 2014) and the 
NICE guidelines (NICE, 2011b), and was also informed by GP interviews (sections 3.4 and 5.3.11 ). In 
addition, prescriptions were also examined by drug class: antidepressants; benzodiazepines; 
anticonvulsants (pregabalin and gabapentin only); atypical antipsychotics; and beta-blockers 
(propranolol only). Further analyses focussed on SSRIs and ‘other antidepressant’ prescriptions only.  
Routine data does not link prescribing with symptoms or diagnoses. Therefore, in order to link the 
prescribing event with an anxiety code, in line with the protocol, the prescription for the anxiolytic 
medication had to have occurred within the 3 months prior to an anxiety READ symptom or 
diagnosis code date, or within the 6 months afterward. This aligns with timeframes used in similar 
studies (Moore et al., 2009). Anxiety codes were defined according to the READ codes outlined in 
the Appendix - A.7, and were comprised of symptom or diagnosis codes. These were the same codes 
as those used for the trends in coding for anxiety study reported in the previous chapter (section 
4.2.2). 
Originally, the protocol defined the study population as those who had a recorded anxiety code, in 
addition to the criteria listed under the study population sub-heading. However, once analysis 
commenced, it became apparent that the coding of anxiety and the prescribing of an anxiolytic were 
closely linked. That is, over half of the study population had a prescription on the same date as a 
recorded anxiety code, and therefore did not contribute any person-years-at-risk (median PYAR: 0 
[IQR: 0, 0.41]). Therefore, a minor protocol amendment was approved by the CPRD ISAC  in order to 
define those ‘at risk’ of receiving a prescription for anxiety as individuals aged 18 or over who were 
in CPRD Gold during the study period as described earlier.   
Any anxiolytic prescription that commenced on the same date as another anxiolytic prescription was 
defined as combination therapy. For the analysis focusing on the incidence of anxiolytic 
prescriptions, patients had to have been registered with CPRD Gold for one year before the first 
recorded anxiolytic prescription to ensure high quality assessment of incident cases. 
Calculating person-years at risk 
Person-years at risk (PYAR) was used as the denominator, with patients entering the study on the 
last date of either their current registration date or the 1st January 2003. Patients stopped 
contributing PYAR on the earliest date of either their transfer out date; date of death; 31st December 
2018; or date of their anxiolytic prescription. To preserve patient anonymity, CPRD only provide year 





their entry year amended to the year they turned 18 within the study period. Any anxiolytic 
prescriptions recorded prior to this date were not included in the analysis. Age was categorised into 
eight age-bands (<25, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+ years).  
Statistical analyses 
The following analyses were conducted firstly for any anxiolytic (any of the drugs listed earlier) and 
also for each drug class: (2) any antidepressant;  (3) SSRIs & ‘other’ antidepressants; (4) 
benzodiazepines; (5) beta-blockers (propranolol); (6) antipsychotics; (7) anticonvulsants (pregabalin 
or gabapentin). 
Trends in the prevalence of prescriptions for anxiety 
To investigate trends in the prevalence of prescriptions, users of the products investigated were 
defined in each calendar year as patients who had received at least one prescription of that drug in 
that year. Period prevalence was calculated by dividing the number of cases by the total PYAR for 
each calendar year and are presented per 1000 PYAR. Estimates of 95% confidence intervals (95%CI) 
were calculated based on the Poisson distribution. Data were plotted on a graph to examine changes 
over time for all prescriptions of any anxiolytic, and then separately for each of the above drug 
classes. Data were also stratified by age and gender.  
Univariable poisson regression models were used to examine the association between year of 
recording, age, gender and prevalence of the drug(s) of interest. Prevalence rate ratios (PRRs) and 
95%CIs are reported. Multivariable poisson regression models that included year, age and gender 
were used to examine the independent effects of such factors. A sensitivity analysis was conducted 
to account for any clustering by practices within the multivariable model.  
In addition, an interaction between age and year was included in the multivariable poisson 
regression model in order to examine whether trends in prescribing of anxiolytics varied according 
to age. This was formally tested using a likelihood-ratio test that compared models with and without 
the interaction term. An interaction between gender and year was also examined using the same 
approach in order to examine whether the trends in the prescribing of anxiolytics differed by gender.  
Changes in trends over time were examined using joinpoint regression, using Joinpoint Trend 
Analysis Software (National Cancer Institute, 2020). The method tested for points in time where 
there was a noticeable change in trends. Models differing by one join point were compared to 
determine the model with the best fit to the data. A fuller explanation of joinpoint regression was 





A sensitivity analysis was conducted to consider anxiolytic medication prescribed within either the 
one month prior to the READ symptom or diagnosis code, or one month afterward. In addition, a 
sensitivity analysis was conducted to exclude patients prescribed low doses of amitriptyline in the 
analysis looking at any anxiolytic and all antidepressants.  
Trends in the incidence of prescriptions for anxiety 
To investigate trends in incident prescriptions, first time users of the products investigated were 
defined in each calendar year as patients who had received at least one prescription of that drug in 
that year, but had no prior prescriptions of that same drug during the study period, or in the one 
year before the study start date (i.e., 1st January 2002 for patients entering the study on 1st January 
2003). A time frame of one year prior to date of entry was selected to allow for high quality 
assessment of incident cases at baseline.  
Annual incidence rates were calculated by dividing the number of incident cases by the total PYAR 
for each year. They are presented per 1000 PYAR. Estimates of 95% confidence intervals (95%CI) for 
these rates were calculated based on the Poisson distribution. Data were plotted on a graph to 
examine changes over time for all incident prescriptions of any anxiolytic, and then separately for 
each of the above drug classes. Data were also stratified by age and gender. 
As with the analysis investigating trends in prevalence, univariable poisson regression models were 
used to examine the association between year of recording, age, gender and incidence of the 
prescribing event of interest. Multivariable poisson regression models that included year, age and 
gender were used to examine the independent effects of such factors. A sensitivity analysis was 
conducted to account for any clustering by practices within the multivariable model.  
Again, as with the prevalence analysis, an interaction between age and year, and gender and year, 
was included in the multivariable poisson regression model in order to examine whether trends in 
prescribing of anxiolytics varied according to age or gender. Changes in trends over time were also 
examined using joinpoint regression.  
Sensitivity analyses were again conducted to consider anxiolytic medication prescribed one month 
either side of the READ anxiety code, and, in the analysis looking at any anxiolytic and all 
antidepressants, excluding patients prescribed low doses of amitriptyline.  
Trends in prescriptions of combination therapy 
For reporting incident combination therapies, an anxiolytic prescription that commenced on the 





conducted for: (1) any anxiolytic – any combination; (2) SSRI/‘other’ antidepressant and a 
benzodiazepine; (3) SSRI/‘other’ antidepressant and a beta-blocker (propranolol). NICE and BAP 
guidelines recommend a combination of an SSRI or SNRI with a benzodiazepine in certain clinical 
situations (NICE, 2011b; Baldwin et al., 2014).  
Annual incidence rates were calculated by dividing the number of incident cases by the total PYAR 
for each year and are presented per 1000 PYAR. Estimates of 95% confidence intervals (95%CI) for 
these rates were calculated. Data were plotted on a graph to examine changes over time for all 
incident prescriptions of any anxiolytic, and then separately for each of the above drug class 
combinations. A sensitivity analysis was conducted to consider a later prescription for an anxiolytic 
medication issued within 4 weeks of the original prescription as a combination treatment. Where 
combination prescriptions were recorded across two years (i.e. December and January), the count 
was allocated to the year of the first prescription date. 
Trends in treatment duration 
To determine whether any changes in prescribing over time were due to changes in the duration of 
treatment over the study period, the duration of prescribed treatment was calculated for each 
incident anxiolytic prescription. The following analyses were conducted for each drug class: (1) any 
antidepressant;  (2) SSRIs & ‘other’ antidepressant; (3) benzodiazepines; (4) beta-blockers 
(propranolol); (5) antipsychotics; and (6) anticonvulsants (pregabalin or gabapentin).  
For each incident anxiolytic prescription, duration was derived by dividing the quantity of drug 
prescribed by the daily dose. If no dosage instructions were entered, then the median of the 
substance specific prescription duration of the same drug from the complete study cohort was used. 
Previous studies examining prescribing trends have used a similar approach (Moore et al., 2009; 
Mars et al., 2017). Depending on drug class, there were between 12 to 168 patients with incomplete 
dosage instructions. A prescription occurring within ≤12 months of the previous prescription ending 
(based on the prescribed dosing regimen) was considered part of the same treatment episode. 
Patients not prescribed medication for a period of >12 months were considered as having ended 
treatment, and any further prescriptions were regarded as part of a new treatment episode. 
Duration was subdivided into categories (<15 days, 16-30 days, 31-60 days, 61-180 days, 181 – 365 
days, 366+ days). The proportion of each duration category was plotted by year to examine whether 
there have been changes in long-term prescribing over time.   





Patterns of dosing for antidepressant prescriptions were calculated for prescriptions in the ‘all 
antidepressant’ drug class based on the expectation that there may be higher doses of 
antidepressants used in the treatment of anxiety (compared with prescribing for depression) 
(Cassano et al., 2002). There were 148 patients with missing dosage information, and a further 187 
with daily dose values of zero. For these patients, the median dose for the substance specific 
prescription of the same drug from the complete study cohort was used. Median [IQR] doses were 
then tabulated for each individual antidepressant drug.  
 
5.2.2 Qualitative data 
During the interviews held with 15 GPs, which were detailed in Chapter 3, interviewees talked about 
when they might prescribe for anxiety, and their views and experiences of specific drugs they 
prescribe. These data are presented in this chapter to provide detailed insight into GPs’ prescribing 
behaviour and thereby, possible reasons for some of the quantitative findings.   
 
5.3 Results  
5.3.1 Descriptive statistics  
Sample characteristics  
The final dataset included 176 practices at which a total of 2,569,153 eligible patients were 
registered across the 16-year period (2003-2018). The median number of eligible patients registered 
per practice was 12,642 [IQR: 9,188 to 18,425]. When looking at prescriptions for any anxiolytic, 
9.8% (n=250,925) of eligible patients were prescribed an anxiolytic within the three months prior, or 
the six months after, an anxiety READ code.  
There were 546,154 anxiolytic prescribing events recorded for the duration of the study (Table 16), 
in 250,925 patients, with 17,684,056.1 PYFU (median follow-up: 5.0 years [IQR: 1.7 to 12.3 years]).  
Focusing on drug class, there were 449,499 antidepressant prescribing events recorded over the 
duration of the study (18,067,571.1 PYFU). When TCAs and MAOIs were excluded, there were 
407,229 SSRI & ‘other antidepressant’ (e.g. SNRIs such as venlafaxine) prescribing events recorded 
over the duration of the study (18,065,985.6 PYFU). There were 210,743 benzodiazepine prescribing 
events (18,469,794.8 PYFU), 100,146 beta-blocker (propranolol) prescribing events (18,834,179.4 





prescriptions (19,108,786.2 PYFU). Across each drug class of interest, a greater proportion of 
patients were prescribed an anxiolytic on the same date as, or after, an anxiety READ code, than 
they were prior to the READ code (Table 16). This was most notable for atypical antipsychotics and 
anticonvulsants, where only 22.7% and 23.9% of prescribing events were prescribed prior to an 
anxiety code.   
Table 16 Number of prescribing events during the study – for any anxiolytic and by drug class  




 3 months prior to 
anxiety code* 
Same date as, or 6 
months after, anxiety 
code* 
Freq. Freq. % Freq. % 
Any anxiolytic 546,154∞ 199,357 36.5 346,797 63.5 
All antidepressants 449,499 147,548 32.8 301,951 67.2 
SSRI & ‘other’ antidepressants 407,229 136,899 33.6 270,330 66.4 
Benzodiazepines 210,743 92,050 43.7 118,693 56.3 
Beta-blockers (Propranolol) 100,146 48,570 48.5 51,576 51.5 
Atypical antipsychotics 26,587 6,029 22.7 20,558 77.3 
Anticonvulsants 28,601 6,843 23.9 21,758 76.1 
*includes codes relating to incident prescriptions and repeat prescriptions. 
∞this figure only includes one anxiolytic per year, per patient. Hence, it is not a sum of total prescribing events from 
each drug class.  
 
There were 194,049 incident anxiolytic prescribing events recorded for the duration of the study 
(Table 17), in 194,049 patients, with 17,825,522.0 PYFU (median follow-up: 5.0 years [IQR: 1.8 to 
12.5 years]).  
Focusing on drug class, there were 163,273 incident antidepressant prescribing events 
(17,956,588.96 PYFU). When TCAs and MAOIs were excluded, there were 153,674 incident SSRI & 
‘other antidepressant’ prescribing events (18,153,172.97 PYFU). There were 94,927 incident 
benzodiazepine prescribing events (18,513,252.17 PYFU), 52,421 incident beta-blocker (propranolol) 
prescribing events (18,847,530.62 PYFU), 10,358 incident antipsychotic prescribing events 
(19,113,653.14 PYFU), and 14,572 incident anticonvulsant prescribing events (19,109,588.97 PYFU). 
Again, patients were more likely to be prescribed an incident anxiolytic on the same date as, or after, 









Table 17 Number of incident prescribing events during the study – for any anxiolytic and by drug class  




 3 months prior to 
anxiety code 
Same date as, or 6 
months after, anxiety 
code 
Freq. Freq. % Freq. % 
Any anxiolytic 194,049∞ 94,153 48.5 99,896 51.5 
All antidepressants 163,273 69,544 42.6 93,729 57.4 
SSRI & ‘other’ antidepressants 153,674 66,802 43.5 86,872   56.5 
Benzodiazepines 94,927 51,491   54.2 43,436 45.8 
Beta-blockers (Propranolol) 52,421 31,026 59.2 21,395 40.8 
Atypical antipsychotics 10,358 2,593 25.0 7,765 75.0 
Anticonvulsants 14,572 3,856 26.5 10,716 73.5 
∞this figure only includes one anxiolytic per year, per patient. Hence, it is not a sum of total prescribing events from 






5.3.2 Trends in the prevalence of anxiolytic prescriptions 
Estimates of the prevalence of anxiolytic prescriptions are presented in Figure 13, with the 
underlying data on prevalence rates presented in Table 18, Table 19, and Table 20. Between 2003 
and 2008, the prevalence of any anxiolytic prescription was fairly constant at 25-26/1000PYAR, rising 
sharply to 43.6/1000PYAR in 2018 (Table 18, Figure 13). During the study period, a similar pattern 
was seen for all antidepressants, and for SSRI and ‘other’ antidepressants only (Table 18, Figure 13). 
The prevalence of prescriptions for benzodiazepines was lower but remained fairly constant over the 
duration of the study (Table 19, Figure 13). Prescriptions for beta-blockers (propranolol) showed a 
gradual increase from 3.8/1000PYAR in 2008 to 8.7/1000PYAR in 2018 (Table 19, Figure 13). 
Antipsychotics and anticonvulsants were prescribed infrequently over the duration of the study 
(Table 19 and Table 20, Figure 13).   
Figure 13 Prevalence of anxiolytic prescriptions (any anxiolytic, and by drug class) per 1000 person 
















Variable Any anxiolytic All antidepressants SSRIs and ‘other’ antidepressants 
N*  PYAR Prevalence 
(1000PYAR) 
(95%CI) N * PYAR Prevalence 
(1000PYAR) 
(95%CI) N* PYAR Prevalence 
(1000PYAR) 
(95%CI) 
Year 2003 27259 1094262 24.9 (24.6-25.2) 21714 1097927 19.8 (19.5-20.0) 21714 1097927 19.8 (19.5-20.0) 
2004 28014 1095981 25.6 (25.3-25.9) 22253 1102648 20.2 (19.9-20.5) 22253 1102648 20.2 (19.9)-20.5) 
2005 27755 1089464 25.5 (25.2-25.8) 21645 1098693 19.7 (19.4-20.0) 21645 1098693 19.7 (19.4-20.0) 
2006 28001 1091856 25.7 (25.4-26.0) 21933 1103342 19.9 (19.6-20.1) 21933 1103342 19.9 (19.6-20.1) 
2007 28571 1092352 26.2 (25.9-26.5) 22565 1105715 20.4 (20.1-20.7) 22565 1105715 20.4 (20.1-20.7) 
2008 28304 1098485 25.8 (25.5-26.1) 22373 1113529 20.1 (19.8-20.4) 22373 1113529 20.1 (19.8-20.4) 
2009 29691 1099018 27.0 (26.7-27.3) 23613 1115563 21.2 (20.9-21.4) 23613 1115563 21.2 (20.9-21.4) 
2010 30744 1102172 27.9 (27.6-28.2) 24977 1120114 22.3 (22.0-22.6) 24977 1120114 22.3 (22.0-22.6) 
2011 32136 1103020 29.1 (28.8-29.5) 26338 1122097 23.5 (23.2-23.8) 26338 1122097 23.5 (23.2-23.8) 
2012 34042 1109218 30.7 (30.4-31.0) 28117 1129367 24.9 (24.6-25.2) 28117 1129367 24.9 (24.6-25.2) 
2013 35205 1109683 31.7 (31.4-32.1) 29137 1130719 25.8 (25.5-26.1) 29137 1130719 25.8 (25.5-26.1) 
2014 36904 1113990 33.1 (32.8-33.5) 30911 1135969 27.2 (26.9-27.5) 30911 1135969 27.2 (26.9-27.5) 
2015 39873 1117944 35.7 (35.3-36.0) 33655 1140777 29.5 (29.2-29.8) 33655 1140777 29.5 (29.2-29.8) 
2016 44123 1122637 39.3 (38.9-39.7) 37667 1146445 32.9 (32.5-33.2) 37667 1146445 32.9 (32.5-33.2) 
2017 46615 1121776 41.6 (41.2-41.9) 40120 1146334 35.0 (34.7-35.3) 40120 1146334 35.0 (34.7-35.3) 
2018 48917 1122197 43.6 (43.2-44.0) 42481 1147348 37.0 (36.7-37.4) 42481 1147348 37.0 (36.7-37.4) 










Variable Benzodiazepines Beta-blockers (Propranolol) Antipsychotics 
N* PYAR Prevalence 
(1000PYAR) 
(95%CI) N* PYAR Prevalence 
(1000PYAR) 
(95%CI) N* PYAR Prevalence 
(1000PYAR) 
(95%CI) 
Year 2003 11607 1104957 10.5 (10.3-10.7) 3867 1109668 3.5 (3.4-3.6) 966 1111347 0.9 (0.8-0.9) 
2004 12155 1114743 10.9 (10.7-11.1) 4191 1124116 3.7 (3.6-3.8) 1040 1128121 0.9 (0.9-1.0) 
2005 12426 1113993 11.2 (11.0-11.4) 4197 1126933 3.7 (3.6-3.8) 1078 1133101 1.0 (0.9-1.0) 
2006 12630 1121203 11.3 (11.1-11.5) 4265 1137385 3.8 (3.6-3.9) 1133 1145482 1.0 (0.9-1.1) 
2007 12910 1126158 11.5 (11.3-11.7) 4262 1145266 3.7 (3.6-3.8) 1150 1155083 1.0 (0.9-1.1) 
2008 12617 1136325 11.1 (10.9-11.3) 4417 1158047 3.8 (3.7-3.9) 1231 1169586 1.1 (1.0-1.1) 
2009 13075 1140819 11.5 (11.8-11.7) 4838 1164696 4.2 (4.0-4.3) 1333 1177993 1.1 (1.1-1.2) 
2010 13008 1148127 11.3 (11.1-11.5) 5217 1173956 4.4 (4.3-4.6) 1499 1189143 1.3 (1.2-1.3) 
2011 13346 1153072 11.6 (11.4-11.8) 5667 1180375 4.8 (4.7-4.9) 1642 1197542 1.4 (1.3-1.4) 
2012 13592 1163783 11.7 (11.5-11.9) 6341 1192327 5.3 (5.2-5.5) 1796 1211660 1.5 (1.4-1.5) 
2013 13498 1168671 11.6 (11.4-11.8) 6962 1197801 5.8 (5.7-6.0) 1883 1219270 1.5 (1.5-1.6) 
2014 13709 1177548 11.6 (11.5-11.8) 7657 1207120 6.3 (6.2-6.5) 1964 1231060 1.6 (1.5-1.7) 
2015 13733 1186678 11.6 (11.4-11.8) 8296 1216322 6.8 (6.7-7.0) 2083 1242920 1.7 (1.6-1.8) 
2016 14442 1198091 12.1 (11.9-12.3) 9207 1227687 7.5 (7.4-7.7) 2401 1257243 1.9 (1.8-2.0) 
2017 14145 1203972 11.8 (11.6-11.9) 9995 1232947 8.1 (8.0-8.3) 2632 1265430 2.1 (2.0-2.2) 
2018 13850 1211655 11.4 (11.2-11.6) 10767 1239534 8.7 (8.5-8.9) 2756 1275138 2.2 (2.1-2.2) 





Table 20 Prevalence of prescriptions of anticonvulsants per 1000 person-years between 2003 and 
2018 
Variable Anticonvulsants 
N * PYAR Prevalence 
(1000PYAR) 
(95%CI) 
Year 2003 235 1111806 0.2 (0.2-0.2) 
2004 294 1128992 0.3 (0.2-0.3) 
2005 382 1134212 0.3 (0.3-0.4) 
2006 531 1146760 0.5 (0.4-0.5) 
2007 642 1156437 0.6 (0.5-0.6) 
2008 805 1170929 0.7 (0.6-0.7) 
2009 1101 1179208 0.9 (0.9-1.0) 
2010 1411 1190165 1.2 (1.1-1.3) 
2011 1694 1198201 1.4 (1.4-1.5) 
2012 1968 1211957 1.6 (1.6-1.7) 
2013 2315 1219106 1.9 (1.8-2.0) 
2014 2691 1230326 2.2 (2.1-2.3) 
2015 3108 1241507 2.5 (2.4-2.6) 
2016 3610 1255069 2.9 (2.8-3.0) 
2017 3888 1262534 3.1 (3.0-3.2) 
2018 3926 1271576 3.1 (3.0-3.2) 





Changes in trends over time were examined formally using join point regression. The best fitting model for any anxiolytic included two join points - one in 
2008 (95% CI 2006 - 2011), after which there was an increase in the prevalence of prescribing, and one in 2014 (95% CI 2011 - 2016), after which there was 
a substantial increase in the prevalence of anxiolytic prescriptions over the last four years of the study (Figure 14). For all antidepressants, and for the 
analysis of SSRIs and ‘other’ antidepressants, the join point model mirrored that of any anxiolytics, with two join points: one at 2008 (95% CI 2006 – 2010), 
and the second at 2014 (95% CI 2011 - 2016), with a substantial increase in the rate of prescribing over the last four years of the study period. These models 
are presented in the Appendix A.13 - Figure 60 and A.14 - Figure 61.  





For prescriptions of benzodiazepines, the best fitting model had one join point in 2005 (95% CI 2005-2016) after which there was a reduction in the rate of 
increase in prescribing and prevalence levelled off (Figure 15). 






For prescriptions of beta-blockers (propranolol), the best fitting model had one join point in 2008 (95% CI 2007-2009), after which the rate of prescribing 























The best fitting model for prescriptions of antipsychotics also had one join point, at 2007 (95% CI 2005-2010), after which the prevalence of prescribing 
increased (Figure 17). 


















The best fitting model for prescriptions of anticonvulsants (pregabalin and gabapentin) included two join points: one at 2010 (95% CI 2009-2012), when 
there was a reduction in the rate of increase in prescribing, and a second in 2016 (95% CI 2015-2016), when there was a further reduction in the rate of 
increase in prescribing (Figure 18).  






Prevalence rate ratios (PRRs) for year, gender and age group, for prescriptions of any anxiolytic, and 
for each drug (all antidepressants, SSRI & ‘other’ antidepressants, benzodiazepines, beta-blockers, 
antipsychotics, and anticonvulsants) are shown in Table 21 and Table 22, and in the Appendix A.15 - 
Table 35, A.16 - Table 36 and A.17 - Table 37.  
After adjusting for age and gender, in 2018 the prevalence of any anxiolytic, all antidepressant and 
SSRI and ‘other’ antidepressant prescriptions was nearly twice that of 2003 (adjusted PRR comparing 
2018 with 2013: any anxiolytic 1.81 (95% CI 1.78-1.83); all antidepressants 1.94 (1.90-1.97); SSRIs 
and ‘other’ antidepressants 2.19 (95% CI 2.15-2.23)) (Table 21 and Appendix A.15 - Table 35). In 
contrast, there was only a modest increase in the prevalence of prescriptions of benzodiazepines in 
2018 compared with 2003 (Table 22: adjusted PRR 1.10 (95% CI 1.07-1.12)). The adjusted PRR 
comparing prevalence in 2018 with 2003 for beta-blockers was 2.61 (95% CI 2.51-2.70), for 
antipsychotics it was 2.53 (95% CI 2.35-2.72), and for anticonvulsants it was 14.62 (95% CI 12.82-
16.68) (Table 22 and Appendix A.16 - Table 36 and A.17 - Table 37).  
Prescribing of anxiolytics in women was over twice that of men. This was consistent across any 
anxiolytic (Table 21: adjusted PRR comparing women to men: 2.23 (95% CI 2.22-2.25), and each drug 
class (all antidepressants (Table 21); SSRI & ‘other’ antidepressant (Appendix A.15 - Table 35); 
benzodiazepines (Table 22); beta-blockers (Table 22); and anticonvulsants (Appendix A.17 - Table 
37), with the exception of prescriptions of antipsychotics where the prevalence of prescribing was 
around 50% higher for women compared to men (Appendix A.16 - Table 36: PR: 1.46 (95% CI 1.42-
1.49)).  
Prescribing of any anxiolytic was less prevalent in the older age groups, with the prevalence of 
prescribing for those aged 85+ years being around 30% lower (adjusted PRR: 0.71 (95%CI 0.69-0.72)) 
than for the youngest age group (<25 years) (Table 21). Prescribing of antidepressants, SSRIs and 
‘other antidepressants’ and beta-blockers was similarly less prevalent in the older age groups (Table 
21, Table 22 and Appendix A.15  - Table 35).  
In contrast, for benzodiazepines and anticonvulsants, the prevalence of prescriptions in those aged 
25+ was two to three times that of the youngest age group (<25 years). For example, the prevalence 
of prescriptions in those aged 85+ years was around twice that of the under 25-year olds for 
benzodiazepines (Table 22: adjusted PRR: 1.91 (95% CI 1.86-1.97)), and  anticonvulsants (Appendix 
A.17  - Table 37: adjusted PPR: 2.08 (95% CI 1.89-2.30)). For antipsychotics, the prevalence of 
prescribing for those aged 25-54 years was around 40% higher than the youngest age group (<25 





For any anxiolytic, and for each drug class (all antidepressants, benzodiazepines, beta-blockers, 
antipsychotics, and anticonvulsants), sensitivity analyses were conducted to examine the potential 
impact of clustering within GP practices on findings. Whilst confidence intervals were wider, findings 
were consistent with the results that did not allow for clustering (Appendix A.18 -  Table 38 and A.19 





Table 21 Prevalence rate ratios for prescriptions of any anxiolytic, and all antidepressants  
 Any anxiolytic All antidepressants 
Variable  Univariable 
PRR 
(95%CI) P value Multivariable 
PRR* 
(95%CI) P value Univariable 
PRR 
(95%CI) P value Multivariable 
PRR* 
(95%CI) P value 
Year 2003 1.00  <0.001 1.00  <0.001 1.00  <0.001 1.00  <0.001 
2004 1.03 (1.01-1.04) 1.03 (1.01-1.05) 1.02 (1.00-1.04) 1.02 (1.00-1.04) 
2005 1.02 (1.01-1.04) 1.03 (1.01-1.05) 1.00 (0.98-1.02) 1.00 (0.98-1.02) 
2006 1.03 (1.01-1.05) 1.04 (1.02-1.06) 1.01 (0.99-1.02) 1.01 (0.99-1.03) 
2007 1.05 (1.03-1.07) 1.06 (1.04-1.08) 1.03 (1.01-1.05) 1.04 (1.02-1.06) 
2008 1.03 (1.02-1.05) 1.05 (1.03-1.06) 1.02 (1.00-1.04) 1.03 (1.01-1.05) 
2009 1.08 (1.07-1.10) 1.10 (1.08-1.12) 1.07 (1.05-1.09) 1.09 (1.07-1.11) 
2010 1.12 (1.10-1.14) 1.14 (1.12-1.16) 1.13 (1.11-1.15) 1.15 (1.12-1.17) 
2011 1.17 (1.15-1.19) 1.19 (1.17-1.21) 1.19 (1.17-1.21) 1.21 (1.19-1.23) 
2012 1.23 (1.21-1.25) 1.26 (1.24-1.28) 1.26 (1.24-1.28) 1.28 (1.26-1.31) 
2013 1.27 (1.25-1.29) 1.30 (1.28-1.32) 1.30 (1.28-1.33) 1.33 (1.31-1.35) 
2014 1.33 (1.31-1.35) 1.36 (1.34-1.38) 1.38 (1.35-1.40) 1.41 (1.38-1.43) 
2015 1.43 (1.41-1.45) 1.47 (1.45-1.49) 1.49 (1.47-1.52) 1.53 (1.50-1.56) 
2016 1.58 (1.55-1.60) 1.62 (1.60-1.65) 1.66 (1.63-1.69) 1.71 (1.68-1.74) 
2017 1.67 (1.64-1.69) 1.72 (1.69-1.74) 1.77 (1.74-1.80) 1.82 (1.79-1.85) 
2018 1.75 (1.72-1.78) 1.81 (1.78-1.83) 1.87 (1.84-1.90) 1.94 (1.90-1.97) 
Gender Male 1.00  <0.001 1.00  <0.001 1.00  <0.001 1.00  <0.001 




18-24 1.00  <0.001 1.00  <0.001 1.00  <0.001 1.00  <0.001 
25-34 1.29 (1.27-1.30) 1.28 (1.27-1.29) 1.32 (1.31-1.34) 1.31 (1.30-1.33) 
35-44 1.26 (1.24-1.27) 1.28 (1.26-1.29) 1.30 (1.29-1.32) 1.33 (1.31-1.34) 
44-54 1.19 (1.17-1.20) 1.18 (1.17-1.20) 1.22 (1.21-1.24) 1.22 (1.20-1.23) 
55-64 1.01 (1.00-1.03) 1.01 (1.00-1.02) 1.02 (1.01-1.03) 1.01 (1.00-1.03) 
65-74 0.87 (0.86-0.88) 0.84 (0.83-0.85) 0.82 (0.81-0.83) 0.79 (0.78-0.80) 
75-84 0.91 (0.90-0.92) 0.85 (0.84-0.87) 0.83 (0.82-0.85) 0.78 (0.77-0.79) 
85+ 0.82 (0.80-0.84) 0.71 (0.69-0.72) 0.73 (0.72-0.75) 0.63 (0.62-0.65) 





Table 22 Prevalence rate ratios for prescriptions of benzodiazepines, and beta-blockers 
 Benzodiazepine Beta-blockers (Propranolol) 
Variable  Univariable 
PRR 
(95%CI) P value Multivariable 
PRR* 
(95%CI) P value Univariable 
PRR 




Year 2003 1.00  <0.001 1.00  <0.001 1.00  <0.001 1.00  <0.001 
2004 1.04 (1.01-1.06) 1.04 (1.01-1.07) 1.07 (1.02-1.12) 1.07 (1.03-1.12) 
2005 1.06 (1.04-1.09) 1.07 (1.04-1.09) 1.07 (1.02-1.12) 1.07 (1.03-1.12) 
2006 1.07 (1.05-1.10) 1.08 (1.05-1.10) 1.08 (1.03-1.12) 1.08 (1.04-1.13) 
2007 1.09 (1.06-1.12) 1.10 (1.07-1.13) 1.07 (1.02-1.12) 1.08 (1.03-1.13) 
2008 1.06 (1.03-1.08) 1.06 (1.04-1.09) 1.09 (1.05-1.14) 1.11 (1.06-1.16) 
2009 1.09 (1.06-1.12) 1.10 (1.07-1.13) 1.19 (1.14-1.24) 1.21 (1.16-1.26) 
2010 1.08 (1.05-1.11) 1.09 (1.06-1.12) 1.28 (1.22-1.33) 1.30 (1.24-1.35) 
2011 1.10 (1.07-1.13) 1.11 (1.08-1.14) 1.38 (1.32-1.44) 1.40 (1.35-1.46) 
2012 1.11 (1.08-1.14) 1.12 (1.09-1.15) 1.53 (1.47-1.59) 1.56 (1.50-1.63) 
2013 1.10 (1.07-1.13) 1.11 (1.08-1.14) 1.67 (1.60-1.73) 1.71 (1.65-1.78) 
2014 1.11 (1.08-1.14) 1.12 (1.09-1.15) 1.82 (1.75-1.89) 1.87 (1.80-1.95) 
2015 1.10 (1.07-1.13) 1.11 (1.08-1.14) 1.96 (1.88-2.03) 2.02 (1.95-2.10) 
2016 1.15 (1.12-1.18) 1.16 (1.13-1.19) 2.15 (2.07-2.23) 2.23 (2.15-2.32) 
2017 1.12 (1.09-1.15) 1.13 (1.10-1.16) 2.33 (2.24-2.41) 2.42 (2.33-2.51) 
2018 1.09 (1.06-1.12) 1.10 (1.07-1.12) 2.49 (2.40-2.59) 2.61 (2.51-2.70) 
Gender Male 1.00  <0.001 1.00  <0.001 1.00  <0.001 1.00  <0.001 




18-24 1.00  <0.001 1.00  <0.001 1.00  <0.001 1.00  <0.001 
25-34 1.73 (1.70-1.77) 1.72 (1.68-1.76) 1.13 (1.11-1.16) 1.12 (1.10-1.15) 
35-44 1.98 (1.94-2.02) 1.98 (1.94-2.02) 0.98 (0.96-1.00) 1.00 (0.98-1.02) 
44-54 2.04 (2.00-2.08) 2.04 (2.00-2.08) 0.84 (0.82-0.86) 0.82 (0.81-0.84) 
55-64 1.96 (1.92-2.00) 1.95 (1.91-1.99) 0.58 (0.57-0.60) 0.57 (0.56-0.59) 
65-74 2.05 (2.01-2.10) 2.01 (1.96-2.05) 0.36 (0.35-0.38) 0.34 (0.33-0.36) 
75-84 2.32 (2.26-2.37) 2.19 (2.14-2.24) 0.25 (0.24-0.26) 0.23 (0.22-0.24) 
85+ 2.19 (2.12-2.25) 1.91 (1.86-1.97) 0.13 (0.12-0.14) 0.11 (0.10-0.12) 





5.3.3 Trends in the prevalence of anxiolytic prescriptions over time by gender and age 
As outlined above, prescribing in women was nearly twice that of men for any anxiolytic, and most  
drug classes (Figure 19 to Figure 25). Estimates of prevalence rates of anxiolytic prescriptions for 
men and women between 2003 and 2018 (for any anxiolytic, and each drug class) are provided in 
the Appendix A.19 - Table 40, A.21 - Table 41, and A.22 - Table 42, and presented graphically in 
Figure 19 to Figure 25. 
In order to formally test whether prevalence varied over time according to gender, the multivariable 
Poisson regression model was repeated including an interaction between year and gender. There 
was evidence of an interaction by gender for any anxiolytic (p value for interaction 0.02); all 
antidepressants (p=0.007); SSRIs & ‘other’ antidepressants (p=0.006); benzodiazepines (p=0.03); and 
beta-blockers (propranolol) (p=0.009). There was weak evidence of an interaction for 
anticonvulsants (p=0.07), and no evidence of an interaction for antipsychotics (p=0.44).  
Whilst visual inspection of the graphs that presented prevalence data by gender suggested that 
these interaction effects may be driven by differences in the prevalence of prescribing in later years 
of the study, inspection of the interaction parameters in the models indicated this was not always 
the case. The interaction parameters are the ratios of the rate ratios for women compared with men 
for the individual years of the study. For any anxiolytic, all antidepressants, and SSRIs & ‘other’ 
antidepressants, the interaction parameters for 2005 to 2008 were driving the interaction effect (for 
example, for any anxiolytic: Appendix A.23 - Table 43). These results need to be interpreted with 
some caution. For these years (compared with 2003), there was little temporal increase in 
prescribing for men (Appendix A.24 -  Table 44) such that the slight increase in women represented a 
large relative increase and it was this relative difference which the interaction terms were estimating 
(Appendix A.23 - Table 43 and A.24 Table 44), Similarly, for benzodiazepines, the interaction effect 
should be interpreted with caution as it was driven by a single interaction parameter (2008) (data 
not shown). For beta-blockers, the interaction parameters for 2004-2007 and 2011-2018 were 
driving the interaction effect (data not shown). Again, there was little temporal increase in 
prescribing for men between 2004 and 2007 (compared with 2003) (Appendix A.21 - Table 41) such 
that the slight increase in women represented a large relative increase in the early years that may 
not be meaningful (data not shown). The increase in prevalent prescribing of beta-blockers in 
women in later years (2011-2018) compared with men was more apparent but again should be 














Figure 20 Prevalence of all antidepressant prescriptions per 1000PYAR by 
gender 








Figure 21 Prevalence of SSRI & ‘other’ antidepressant prescription per 
1000PYAR by gender 
 

























































Estimates of the prevalence of anxiolytic prescriptions were stratified by age and are presented in 
Figure 26 to Figure 32, for any anxiolytic and by drug class, with the underlying data on incidence 
rates by age presented in the Appendix A.25 - Table 45, A.26 - Table 46 and A.27 - Table 47. 
Prevalence increased substantially in the younger age groups in the later years of the study, across 
all drug classes. In order to formally test whether incidence varied over time according to age, the 
multivariable Poisson regression model was repeated including an interaction between year and age. 
There was strong evidence of an interaction by age in all models (any anxiolytic: p value for 
interaction <0.001; all antidepressants: p<0.001; SSRIs & ‘other’ antidepressants: p<0.001; 
benzodiazepines: p<0.001; beta-blockers (propranolol): p<0.001; antipsychotics: p<0.001; 
anticonvulsants: p<0.001).  
There were similar trends seen across any anxiolytic, all antidepressants, SSRIs & ‘other’ 
antidepressants, and beta-blockers (propranolol), with a marked increase in the prevalence of 
prescribing in the three youngest age groups (<25, 25-34, 35-44 years) particularly in later years 
(Appendix A.25 - Table 45 and A.26 - Table 46; Figure 26, Figure 27, Figure 28, and Figure 30). For 
any anxiolytic, the prevalence of prescriptions rose from 17.2/1000PYAR in 2003 to 59.1/1000PYAR 
in 2018 for those aged under 25 years, compared with a more gradual increase from 25.4/1000PYAR 
in 2003 to 33.7/1000PYAR in 2018 for 55-64 year olds (Appendix A.25 - Table 45, Figure 26). In 
contrast, for the older age groups (65-74, 75-84 and 85+ years), the prevalence of prescriptions was 
fairly constant across the 16-year period (Appendix A.25 - Table 45, Figure 26). 
A similar trend was also seen for antipsychotics, with an increase in prescribing over time in the 
younger age bands, most notable in those aged 25-34 years - with  nearly a three-fold increase in 
prescribing from 0.9/1000PYAR in 2003 to 2.9/1000PYAR in 2018 (Appendix A.27 - Table 47 and 
Figure 31).  
There was an increase in the prevalence of prescriptions for anticonvulsants between 2003 and 2018 
across all age bands, but it was most notable in age groups 35-44 years (0.2/1000PYAR to 
3.9/1000PYAR), 45-54 years (0.2/1000PYAR to 4.0/1000PYAR), and 55-64 years (0.3/1000PYAR to 
3.5/1000PYAR) (Appendix A.27 - Table 47, Figure 32). 
In contrast with all other drug classes, there was a decrease in the prevalence of prescriptions for 
benzodiazepines in the four older age groups (55-64; 65-74; 75-84; 85+ years), with a fairly constant 
level of prescribing over time in those aged 44-54 (Appendix A.26 - Table 46, Figure 29). However, 
there was an increase in the prevalence of prescriptions for benzodiazepines in the youngest three 





(8.4/1000PYAR to 13.5/1000PYAR), and 35-44 years (10.5/1000PYAR to 13.6/1000PYAR) (Appendix 
A.26 - Table 46, Figure 29).   
















Figure 28 Prevalence of SSRI & ‘other’ antidepressant prescriptions per 
1000PYAR by age 
 












































5.3.4 Trends in the prevalence of anxiolytic prescriptions: sensitivity analyses 
Sensitivity analyses were conducted to examine the impact on findings when prescriptions were 
restricted to the time frame of one month either side of an anxiety READ code, or when low-dose 
amitriptyline was excluded.  
 
Restricting prescription and READ code time frame  
In the main analysis prescriptions had to have occurred in the three months prior, or the six months 
after, a recording of an anxiety READ code. The sensitivity analysis restricted the prescriptions of 
interest to those that occurred within the one month prior, or the one month after, the READ code. 
Analyses were repeated for the prevalence of prescriptions of any anxiolytic, and for the two largest 
drug classes: all antidepressants and benzodiazepines.  
Overall trends were comparable to the main analysis (Appendix A.28 - Figure 62), however, as would 
be expected, estimates of prevalence were lower.  
 
Excluding patients prescribed low-dose amitriptyline 
Prescriptions for low doses of amitriptyline (<75 mg) were excluded for the analysis looking at trends 
in the prevalence of any anxiolytic, and all antidepressants. Overall trends were comparable to the 





5.3.5 Trends in the incidence of anxiolytic prescriptions 
The number of patients starting anxiolytics (any anxiolytic and by drug class) per 1000PYAR for each 
year of the study are shown in Figure 33, with the underlying data shown in Table 23, Table 24 and 
Table 25. Between 2003 and 2008, the incidence of a prescription for an anxiolytic decreased from 
12.8/1000PYAR to 10.0/1000PYAR in 2006, after which the incidence remained fairly constant 
before rising to 13.1/1000PYAR in 2018 (Table 23, Figure 33). A similar trend was seen for all 
antidepressants, and for SSRI and ‘other’ antidepressants (Table 23, Figure 33). For benzodiazepines, 
the incidence of prescribing declined from 6.4/1000PYAR in 2003 to 4.6/1000PYAR in 2018 (Table 24, 
Figure 33). In contrast, the incidence of prescribing of beta-blockers (propranolol) rose over the 
study period (from 2.3/1000PYAR in 2003 to 4.1/1000PYAR in 2018) (Table 24, Figure 33). The 
incidence of antipsychotic prescriptions was between 0.5 to 0.7/1000PYAR across the 16 year period 
(Table 24, Figure 33). Between 2003 to 2018, the incidence of prescriptions of anticonvulsants 
slightly increased from 0.1/1000PYAR to 1.3/1000PYAR (Table 25, and Figure 33).  
 
Figure 33 Incidence of anxiolytic prescriptions (any anxiolytic and by drug class) per 1000 person 















Variable Any anxiolytic All antidepressants SSRI’s and ‘other’ antidepressants 
N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) 
Year 2003 14090 1103950 12.8 (12.6-13.0) 11305 1105492 10.2 (10.0-10.4) 9926 1106297 9.0 (8.8-9.2) 
2004 13174 1106589 11.9 (11.7-12.1) 10570 1110962 9.5 (9.3-9.7) 9392 1113145 8.4 (8.3-8.6) 
2005 11531 1099866 10.5 (10.3-10.7) 8993 1106826 8.1 (8.0-8.3) 8041 1110054 7.2 (7.1-7.4) 
2006 11045 1102031 10.0 (9.8-10.2) 8758 1111291 7.9 (7.7-8.1) 8004 1115328 7.2 (7.0-7.3) 
2007 10863 1102262 9.9 (9.7-10.0) 8768 1113456 7.9 (7.7-8.0) 8121 1118087 7.3 (7.1-7.4) 
2008 10315 1108099 9.3 (9.1-9.5) 8288 1121051 7.4 (7.2-7.6) 7672 1126154 6.8 (6.7-7.0) 
2009 10772 1108310 9.7 (9.5-9.9) 8783 1122833 7.8 (7.7-8.0) 8195 1128369 7.3 (7.1-7.4) 
2010 10661 1111207 9.6 (9.4-9.8) 8938 1127197 7.9 (7.8-8.1) 8404 1133130 7.4 (7.3-7.6) 
2011 10929 1111783 9.8 (9.7-10.0) 9263 1128978 8.2 (8.0-8.4) 8825 1135190 7.8 (7.6-7.9) 
2012 11109 1117740 9.9 (9.8-10.1) 9512 1136057 8.4 (8.2-8.5) 9055 1142511 7.9 (7.8-8.1) 
2013 11240 1117912 10.1 (9.9-10.2) 9540 1137187 8.4 (8.2-8.6) 9193 1143811 8.0 (7.9-8.2) 
2014 11833 1121964 10.6 (10.4-10.7) 10272 1142237 9.0 (8.8-9.2) 9867 1149036 8.6 (8.4-8.8) 
2015 12939 1125639 11.5 (11.3-11.7) 11262 1146843 9.8 (9.6-10.0) 10920 1153716 9.5 (9.3-9.6) 
2016 14178 1130091 12.6 (12.3-12.8) 12593 1152330 10.9 (10.7-11.1) 12227 1159319 10.6 (10.4-10.7) 
2017 14554 1128948 12.9 (12.7-13.1) 12986 1151996 11.3 (11.1-11.5) 12677 1159060 10.9 (10.8-11.1) 
2018 14816 1129131 13.1 (12.9-13.3) 13442 1152835 11.7 (11.5-11.9) 13155 1159966 11.3 (11.2-11.5) 










Variable Benzodiazepines Beta-blockers (propranolol) Antipsychotics 
N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) 
Year 2003 7102 1108130 6.4 (6.3-6.6) 2563 1110524 2.3 (2.2-2.4) 537 1111642 0.5 (0.4-0.5) 
2004 6812 1118225 6.1 (6.0-6.2) 2712 1125085 2.4 (2.3-2.5) 519 1128419 0.5 (0.4-0.5) 
2005 6365 1117369 5.7 (5.6-5.8) 2537 1127885 2.3 (2.2-2.3) 482 1133381 0.4 (0.4-0.5) 
2006 6068 1124470 5.4 (5.3-5.5) 2413 1138323 2.1 (2.0-2.2) 503 1145747 0.4 (0.4-0.5) 
2007 6065 1129297 5.4 (5.2-5.5) 2375 1146186 2.1 (2.0-2.2) 462 1155333 0.4 (0.4-0.4) 
2008 5642 1139333 5.0 (4.8-5.1) 2375 1158949 2.1 (2.0-2.1) 514 1169822 0.4 (0.4-0.5) 
2009 5929 1143711 5.2 (5.1-5.3) 2651 1165575 2.3 (2.2-2.4) 542 1178222 0.5 (0.4-0.5) 
2010 5606 1150901 4.9 (4.7-5.0) 2743 1174814 2.3 (2.3-2.4) 595 1189363 0.5 (0.5-0.5) 
2011 5672 1155708 4.9 (4.8-5.0) 2952 1181220 2.5 (2.4-2.6) 621 1197752 0.5 (0.5-0.6) 
2012 5568 1166328 4.8 (4.7-4.9) 3208 1193150 2.7 (2.6-2.8) 670 1211862 0.6 (0.5-0.6) 
2013 5493 1171102 4.7 (4.6-4.8) 3469 1198599 2.9 (2.8-3.0) 668 1219466 0.6 (0.5-0.6) 
2014 5702 1179887 4.8 (4.7-5.0) 3781 1207894 3.1 (3.0-3.2) 743 1231247 0.6 (0.6-0.7) 
2015 5673 1188918 4.8 (4.7-4.9) 4118 1217065 3.4 (3.3-3.5) 741 1243096 0.6 (0.6-0.6) 
2016 5941 1200246 5.0 (4.8-5.1) 4564 1228403 3.7 (3.6-3.8) 854 1257413 0.7 (0.6-0.7) 
2017 5750 1206016 4.8 (4.7-4.9) 4836 1233646 3.9 (3.8-4.0) 974 1265593 0.8 (0.7-0.8) 
2018 5539 1213610 4.6 (4.4-4.7) 5124 1240214 4.1 (4.0-4.3) 933 1275294 0.7 (0.7-0.8) 





Table 25 Incidence rates of prescriptions for anticonvulsants per 1000 person-years between 2003 
and 2018 
Variable Anticonvulsants 
N* PYAR Incidence 
(1000PYAR) 
(95%CI) 
Year 2003 156 1111863 0.1 (0.1-0.2) 
2004 191 1129052 0.2 (0.2-0.2) 
2005 244 1134272 0.2 (0.2-0.2) 
2006 356 1146818 0.3 (0.3-0.3) 
2007 363 1156494 0.3 (0.3-0.4) 
2008 510 1170985 0.4 (0.4-0.5) 
2009 658 1179263 0.6 (0.5-0.6) 
2010 853 1190217 0.7 (0.7-0.8) 
2011 938 1198250 0.8 (0.7-0.8) 
2012 1067 1212006 0.9 (0.8-0.9) 
2013 1220 1219152 1.0 (1.0-1.1) 
2014 1358 1230371 1.1 (1.1-1.2) 
2015 1523 1241551 1.2 (1.2-1.3) 
2016 1741 1255110 1.4 (1.3-1.5) 
2017 1723 1262573 1.4 (1.3-1.4) 
2018 1671 1271614 1.3 (1.3-1.4) 





Changes in trends over time were examined formally using join point regression. The best fitting model for prescriptions of any anxiolytic included two joint 
points: there was an initial decline in incidence rates from 2003 to the first join point at 2006 (95% CI 2005 - 2009), after which incident prescriptions 
plateaued until the second join point in 2012 (95% CI 2009 - 2015) after which there was a substantial increase in the rate of prescribing of any anxiolytic 
over the last six years of the study period (Figure 34). For all antidepressant prescriptions, and for the analysis focusing on prescriptions of SSRIs and ‘other’ 
antidepressants, again, the join point model included two join points: one at 2006 (95% CI 2005 – 2009), after which there was a gradual increase in 
incidence rates, and a second join point at 2013 (95% CI 2008 - 2016), after which there was a substantial increase in incidence rates over the last five years 
of the study period. These models are presented in the Appendix A.30 - Figure 64 and A.31 - Figure 65 . 
















For prescriptions of benzodiazepines, the best fitting joint point model had a single join point. Incidence rates decreased substantially from 2003 to the  join 
point in 2008 (95% CI 2006-2011), after which incidence rates decreased more gradually (Figure 35).  
 





For prescriptions of beta-blockers (propranolol), after an initial decline in incidence rates from the start of the study period, the best fitting join point model 
had one join point at 2008 (95% CI 2007-2009), after which incidence rates increased substantially (Figure 36). 
 





















The best fitting join point model for prescriptions of antipsychotics also had one join point. Incidence rates decreased over the first four years of the study 
to a join point in 2007 (95% CI 2005-2009), after which there was an increase in incidence rates (Figure 37). 
 





















The best fitting model for prescriptions of anticonvulsants included two join points. Incidence rates increased to the first join point in 2010 (95% CI 2009-
2011), after which incidence rates increased more slowly to the second join point in 2016 (95% CI 2015-2016). After this time there was a decrease in the 
incidence rate over the last two years of the study period (Figure 38). 







Incidence rate ratios (IRRs) for year, gender and age group for prescriptions of any anxiolytic, and for 
each class of anxiolytic (all antidepressants, SSRI & ‘other’ antidepressants, benzodiazepines, beta-
blockers, antipsychotics, and anticonvulsants) are shown in Table 26 and Table 27, and in the 
Appendix A.32 - Table 48, A.33 - Table 49 and A.34 - Table 50.  
After adjusting for age and gender, the IRR for prescriptions of any anxiolytic was 1.06 (95% CI 1.04-
1.09) when comparing 2018 with 2003 (Table 26). For all antidepressants, for the same comparison, 
the adjusted IRR was 1.18 (95% CI 1.15-1.21), for SSRIs and ‘other’ antidepressants it was 1.31 (95% 
CI 1.27-1.34), and for benzodiazepines it was 0.72 (95% CI 0.70-0.75) (Table 26, Table 27, and 
Appendix A.32 -  Table 48). The adjusted IRR for beta-blockers (propranolol) was 1.88 (95% CI 1.79-
1.97), for antipsychotics it was 1.12 (95% CI 1.38-1.71), and for anticonvulsants it was 9.35 (95% CI 
7.94-11.02) (Table 27, and Appendix A.33 - Table 49 and A.34 - Table 50).  
The incidence of anxiolytic prescriptions in women was twice that of men. This was consistent across 
any anxiolytic, and each drug class (adjusted IRR comparing women to men: any anxiolytic 2.02 (95% 
CI 2.00-2.04); all antidepressants 2.04 (95% CI 2.02-2.06); SSRI & ‘other’ antidepressant 2.02 (95% CI 
2.00-2.04); benzodiazepines 2.06 (95% CI 2.03-2.08); beta-blockers (propranolol) 2.29 (95% CI 2.24-
2.33); anticonvulsants 2.21 (95% CI 2.14-2.29), except for antipsychotics where the incidence rate of 
prescriptions was 44% higher in women compared with men (adjusted IRR: 1.44 (95% CI 1.39-1.50)) 
(Table 26 and Table 27, and Appendix A.32 - Table 48, A.33 - Table 49 and A.34 - Table 50).  
Incidence of prescriptions of any anxiolytic decreased with age, with the incidence for those aged 
85+ years being around half (Table 26: adjusted IRR: 0.49 (95%CI 0.47-0.5)) that of the youngest age 
group (18-24 years). A similar pattern of decreasing incidence of prescribing with age was seen for all 
antidepressants, SSRIs and ‘other antidepressants’ and beta-blockers (propranolol) (adjusted IRR 85+ 
years compared with 18-24 years: antidepressants 0.48 (95% CI 0.46-0.50); SSRI & ‘other’ 
antidepressant 0.44 (95% CI 0.42-0.46); and beta-blockers 0.08 (95% CI 0.07-0.09) (Table 26, Table 
27, and Appendix A.32 - Table 48). Incidence of prescriptions for antipsychotics was slightly lower in 
older individuals compared with younger individuals, although the confidence interval for the IRR for 
the oldest group included the null (Appendix A.33 - Table 49: adjusted IRR 85+years compared with 
18-24 years: 0.95 (95% CI 0.83-1.07)).  
In contrast, those aged 25 or older had between a 16% to 48% increased rate of incident 
benzodiazepine prescription compared with those aged less than 25 years (Table 27). Whereas, 
incidence of prescriptions of anticonvulsants in those aged 25 years or older was two to three times 
that of the youngest age group (Appendix A.34 - Table 50: e.g. adjusted IRR 44-54 years compared 





Sensitivity analyses were conducted to examine the potential impact of clustering within GP 
practices on findings for any anxiolytic, and for each class of anxiolytic (all antidepressants, 
benzodiazepines, beta-blockers, antipsychotics, and anticonvulsants). Whilst confidence intervals 
were wider, findings were consistent with the results that did not allow for clustering (Appendix A.35 





Table 26 incidence rate ratios for prescriptions of any anxiolytic, and all antidepressants 
 Any anxiolytic All antidepressants 














(95%CI) P value 
Year 2003 1.00  <0.001 1.00  <0.001 1.00  <0.001 1.00  <0.001 
2004 0.93 (0.91-0.96) 0.94 (0.91-0.96) 0.93 (0.91-0.96) 0.93 (0.91-0.96) 
2005 0.82 (0.80-0.84) 0.83 (0.81-0.85) 0.79 (0.77-0.82) 0.80 (0.78-0.82) 
2006 0.79 (0.77-0.81) 0.79 (0.77-0.81) 0.77 (0.75-0.79) 0.78 (0.75-0.80) 
2007 0.77 (0.75-0.79) 0.78 (0.76-0.80) 0.77 (0.75-0.79) 0.78 (0.76-0.80) 
2008 0.73 (0.71-0.75) 0.74 (0.72-0.76) 0.72 (0.70-0.74) 0.73 (0.71-0.75) 
2009 0.76 (0.74-0.78) 0.77 (0.75-0.79) 0.76 (0.74-0.79) 0.77 (0.75-0.80) 
2010 0.75 (0.73-0.77) 0.76 (0.74-0.78) 0.78 (0.75-0.80) 0.79 (0.76-0.81) 
2011 0.77 (0.75-0.79) 0.78 (0.76-0.80) 0.80 (0.78-0.82) 0.81 (0.79-0.84) 
2012 0.78 (0.76-0.80) 0.79 (0.77-0.81) 0.82 (0.80-0.84) 0.83 (0.81-0.86) 
2013 0.79 (0.77-0.81) 0.80 (0.78-0.82) 0.82 (0.80-0.84) 0.84 (0.81-0.86) 
2014 0.83 (0.81-0.85) 0.84 (0.82-0.86) 0.88 (0.86-0.90) 0.90 (0.87-0.92) 
2015 0.90 (0.88-0.92) 0.92 (0.90-0.94) 0.96 (0.94-0.99) 0.98 (0.96-1.01) 
2016 0.98 (0.96-1.01) 1.01 (0.98-1.03) 1.07 (1.04-1.10) 1.10 (1.07-1.12) 
2017 1.01 (0.99-1.03) 1.04 (1.02-1.06) 1.10 (1.07-1.13) 1.13 (1.11-1.16) 
2018 1.03 (1.00-1.05) 1.06 (1.04-1.09) 1.14 (1.11-1.17) 1.18 (1.15-1.21) 
Gender Male 1.00  <0.001 1.00  <0.001 1.00  <0.001 1.00  <0.001 




18-24 1.00  <0.001 1.00  <0.001 1.00  <0.001 1.00  <0.001 
25-34 0.95 (0.93-0.96) 0.94 (0.92-0.95) 1.00 (0.99-1.02) 0.99 (0.98-1.01) 
35-44 0.88 (0.87-0.90) 0.88 (0.87-0.90) 0.94 (0.92-0.96) 0.94 (0.93-0.96) 
44-54 0.80 (0.79-0.81) 0.80 (0.79-0.81) 0.85 (0.84-0.87) 0.85 (0.83-0.86) 
55-64 0.69 (0.68-0.70) 0.68 (0.67-0.70) 0.71 (0.70-0.73) 0.71 (0.69-0.72) 
65-74 0.59 (0.58-0.60) 0.57 (0.56-0.58) 0.59 (0.57-0.60) 0.57 (0.56-0.58) 
75-84 0.63 (0.62-0.65) 0.60 (0.58-0.61) 0.64 (0.62-0.65) 0.60 (0.59-0.62) 
85+ 0.55 (0.54-0.57) 0.49 (0.47-0.50) 0.55 (0.53-0.57) 0.48 (0.46-0.50) 





Table 27 Incidence rate ratios for prescriptions of benzodiazepines, and beta-blockers 
 Benzodiazepine Beta-blockers (propranolol) 
















Year 2003 1.00  <0.001 
 
1.00  <0.001 1.00  <0.001 1.00  <0.001 
2004 0.95 (0.92-0.98) 0.95 (0.92-0.98) 1.04 (0.99-1.10) 1.05 (0.99-1.11) 
2005 0.89 (0.86-0.92) 0.89 (0.86-0.92) 0.97 (0.92-1.03) 0.98 (0.93-1.04) 
2006 0.84 (0.81-0.87) 0.85 (0.82-0.88) 0.92 (0.87-0.97) 0.93 (0.88-0.98) 
2007 0.84 (0.81-0.87) 0.84 (0.81-0.87) 0.90 (0.85-0.95) 0.91 (0.86-0.96) 
2008 0.77 (0.75-0.80) 0.78 (0.75-0.81) 0.89 (0.84-0.94) 0.90 (0.85-0.95) 
2009 0.81 (0.78-0.84) 0.82 (0.79-0.84) 0.99 (0.93-1.04) 1.00 (0.95-1.06) 
2010 0.76 (0.73-0.79) 0.77 (0.74-0.79) 1.01 (0.96-1.07) 1.03 (0.98-1.09) 
2011 0.77 (0.74-0.79) 0.77 (0.75-0.80) 1.08 (1.03-1.14) 1.10 (1.05-1.16) 
2012 0.74 (0.72-0.77) 0.75 (0.73-0.78) 1.16 (1.11-1.23) 1.19 (1.13-1.26) 
2013 0.73 (0.71-0.76) 0.74 (0.71-0.77) 1.25 (1.19-1.32) 1.29 (1.22-1.35) 
2014 0.75 (0.73-0.78) 0.76 (0.74-0.79) 1.36 (1.29-1.43) 1.40 (1.33-1.47) 
2015 0.74 (0.72-0.77) 0.75 (0.73-0.78) 1.47 (1.40-1.54) 1.52 (1.44-1.59) 
2016 0.77 (0.75-0.80) 0.78 (0.75-0.81) 1.61 (1.53-1.69) 1.67 (1.59-1.75) 
2017 0.74 (0.72-0.77) 0.75 (0.73-0.78) 1.70 (1.62-1.78) 1.77 (1.69-1.86) 
2018 0.71 (0.69-0.74) 0.72 (0.70-0.75) 1.79 (1.71-1.88) 1.88 (1.79-1.97) 
Gender Male 1.00  <0.001 
 
1.00  <0.001 1.00  <0.001 1.00  <0.001 




18-24 1.00  <0.001 
 
1.00  <0.001 1.00  <0.001 1.00  <0.001 
25-34 1.38 (1.34-1.42) 1.37 (1.33-1.40) 0.94 (0.91-0.97) 0.93 (0.90-0.95) 
35-44 1.50 (1.45-1.54) 1.48 (1.44-1.52) 0.79 (0.76-0.81) 0.80 (0.77-0.82) 
44-54 1.44 (1.40-1.48) 1.44 (1.40-1.48) 0.64 (0.62-0.66) 0.63 (0.61-0.65) 
55-64 1.37 (1.33-1.41) 1.36 (1.32-1.40) 0.44 (0.43-0.46) 0.43 (0.42-0.45) 
65-74 1.35 (1.31-1.39) 1.33 (1.29-1.37) 0.27 (0.26-0.28) 0.25 (0.24-0.27) 
75-84 1.50 (1.45-1.55) 1.42 (1.37-1.47) 0.19 (0.18-0.20) 0.18 (0.17-0.19) 
85+ 1.31 (1.25-1.37) 1.16 (1.11-1.22) 0.10 (0.08-0.11) 0.08 (0.07-0.09) 





5.3.6 Trends in the incidence of anxiolytic prescriptions over time by gender and age 
As outlined above, incident prescribing in women was nearly twice that of men for any anxiolytic, 
and most drug classes. Incidence rates were stratified by gender and are presented in Figure 39 to 
Figure 45 for any anxiolytic and each drug class, with the underlying data on incidence rates for 
males and females presented in the Appendix A.36 - Table 53, A.38 - Table 54 and A.39 - Table 55. 
In order to formally test whether incidence varied over time according to gender, the multivariable 
Poisson regression model was repeated including an interaction between year and gender. There 
was strong evidence of an interaction by gender for any anxiolytic (p value for interaction <0.001); all 
antidepressants (p<0.001); SSRIs & ‘other’ antidepressants (p<0.001); and benzodiazepines 
(p<0.001). There was no evidence of interaction for propranolol (p= 0.40) and antipsychotics 
(p=0.53); and only weak evidence of an interaction for anticonvulsants (p= 0.11).  
In both men and women, there was a decline in incidence of prescriptions of any anxiolytic from 
2003 to 2008 after which incidence remained stable until about 2014 when it began increasing again 
(Figure 39). In the period from 2004 to 2008 there were greater absolute reductions in incidence 
(compared with 2003) for women than with men (Appendix A.36 - Table 53). Given the higher 
incidence in 2003 in women than in men, the relative differences were comparable as demonstrated 
by the interaction terms for those years which were very close to one (Appendix A.40 - Table 56). 
Between 2009 and 2013 when the incidence was relatively stable for both genders, this represented 
a greater absolute reduction in incidence (compared with 2003) as well as a greater relative 
reduction (compared with 2003) for women than with men (Appendix A.41 - Table 57). This was also 
evident from the interaction terms in the model where the evidence of interaction was strong. By 
2016, incidence was higher than in 2003 for men and the modest increases in incidence translated 
into greater relative increases than among women (Appendix A.41 - Table 57). Similar findings were 
seen in the patterns for prescriptions of all antidepressants and SSRIs and ‘other’ antidepressants for 
men and women (data not shown). However, in all analyses (any anxiolytic, all antidepressants and 
SSRIs and ‘other’ antidepressants), the differences were small and should be interpreted with 
caution.  
In contrast, in both men and women, there was a decline in incidence of benzodiazepine 
prescriptions over the duration of the study. Again, there were greater absolute reductions in 
incidence (compared with 2003) for women than with men (Appendix A.38 - Table 54). Given the 
higher incidence in 2003 in women than in men, again, the relative differences were broadly 
comparable as demonstrated by the interaction terms for those years that were close to one (data 





represented a greater absolute reduction in incidence (compared with 2003) as well as a greater 
relative reduction (compared with 2003) for women than with men. This was also evident from the 
interaction terms in the model where the evidence for an interaction was moderate (data not 
shown). Again, however, these differences were small and should be interpreted with caution.  
 



















































































Incidence rates were stratified by age and are presented in Figure 46 to Figure 51 for any anxiolytic 
and each drug class, respectively, with the underlying data on incidence rates by age presented in 
the Appendix A.42 - Table 58, A.43 - Table 59 and A.44 - Table 60. Incidence rates increased in the 
younger age groups in the later years of the study for prescriptions of any anxiolytic, all 
antidepressants, SSRIs and ‘other’ antidepressants, benzodiazepines, beta-blockers, antipsychotics, 
and anticonvulsants. In order to formally test whether incidence varied over time according to age, 
the multivariable Poisson regression model was repeated including an interaction between year and 
age. There was strong evidence of an interaction by age for all models (p value for interaction <0.001 
for any anxiolytic and for all drug groups).  
There was a marked increase in the incidence of prescribing of any anxiolytic in the two youngest 
age groups (<25 and 25-34 years) between 2013/2014 and 2018 (Appendix A.42 - Table 58, Figure 
46). The increase in incidence of prescribing for those aged 35-44 and 45-54 was more gradual over 
this period. In contrast, the incidence of prescribing of any anxiolytic remained stable or slightly 
decreased over this period for the older age groups (55+ years). A similar trend was also seen across 
all antidepressants, SSRIs & ‘other’ antidepressants, and beta-blockers (propranolol), with a marked 
increase in the prevalence of prescribing in the two youngest age groups between 2013/2014 and 
2018 (<25, 25-34 years), a more gradual increase for those aged 35-44 and 45-54 years, and 
prescribing for those aged over 55 years slightly decreasing or remaining stable (Appendix A.42 - 
Table 58, A.43 - Table 59, Figure 47, Figure 48 and Figure 49).  
A similar trend was seen for the two youngest age groups (<25 and 25-34 years) for prescriptions of 
antipsychotics, with an increase in prescribing over time. For those aged 35-44 and 45-54 years, the 
increase was more gradual. For those aged 55-64, incident prescribing over time was variable. In 
contrast, for the three oldest age groups (65+ years) incident prescriptions of antipsychotics 
decreased over the study, particularly amongst those aged 85+ years (Appendix A.44 - Table 60, 
Figure 51). However, incident prescriptions of antipsychotics for anxiety were infrequent and, as 
such, the differences between age groups must be interpreted with caution. 
For prescriptions of anticonvulsants, there was an increase in incident prescribing between 2003 and 
2018 across all age bands, with emerging differences in the rate of increase around 2014) (Appendix 
A.44 - Table 60, Figure 52). However, again incident prescriptions of anticonvulsants for anxiety were 
infrequent and differences between age groups must therefore be interpreted with caution. 
In contrast to all other drug classes, there was a decrease in the incidence of prescriptions of 





a decrease in incidence of prescribing for those aged 35-44 years, but the level of prescribing 
increased toward the second half of the study period. For the two youngest two bands (<25 and 25-
34 years), there was a fairly constant level of prescribing in the first half of the study, followed by an 
increase in incident prescribing between 2010 and 2018 (Appendix A.43 - Table 59, Figure 49). 
 
 























Figure 48 Incidence of prescriptions of SSRIs & ‘other’ antidepressants per 






























































5.3.7 Trends in the incidence of anxiolytic prescriptions: sensitivity analyses 
Sensitivity analyses were conducted to examine the impact on findings when prescriptions were 
restricted to the time frame of one month either side of an anxiety READ code, or when low-dose 
amitriptyline was excluded.  
 
Restricting prescription and READ code time frame  
As previously outlined, in the main analysis prescriptions had to have occurred in the three months 
prior, or the six months after, an anxiety READ code. The sensitivity analysis restricted the 
prescriptions of interest to those that occurred within the one month prior, or the one month after, 
the READ code. Analyses were repeated for the incidence of any anxiolytic, and the two largest drug 
classes: all antidepressants and benzodiazepines. Overall trends were comparable to the main 
analysis (Appendix A.45 - Figure 66), however, as expected, incidence rates were lower.  
 
Excluding patients prescribed low-dose amitriptyline 
Prescriptions for low doses of amitriptyline (<75 mg) were excluded for the analysis looking at trends 
in the incidence of prescriptions for any anxiolytic, and all antidepressants. The overall trends were 













5.3.8 Trends in the incidence of anxiolytic prescriptions – combination therapies 
Any anxiolytic prescription that commenced on the same date as another anxiolytic prescription was 
defined as a combination therapy. The frequency of combination therapy was examined for each 
year of the study (Table 28). Combination therapy was uncommon, comprising just 9-11% of any 
incident anxiolytic prescriptions between 2003 and 2018. NICE and BAP recommend a combination 
of an SSRI (or ‘other’ antidepressant) with a benzodiazepine in certain clinical situations (NICE, 
2011b; Baldwin et al., 2014), and this combination accounted for around 5-6% of all incident 
prescriptions for any anxiolytic (Table 28).   
Table 28 Frequency of prescriptions for any anxiolytic monotherapy, combination therapy (of any 
combination of anxiolytics), and combination therapy of SSRI & ‘other’ antidepressant with a 
benzodiazepine, between 2003 and 2018 






– any combination of 
anxiolytics 
Combination therapy – SSRI 
& ‘other’ antidepressant 
with benzodiazepine 
Freq. %* Freq. %* Freq. %* 
2003 14090 12838 91.1 1252 8.9 760 5.4 
2004 13174 11960 90.8 1214 9.2 742 5.6 
2005 11531 10441 90.5 1090 9.5 623 5.4 
2006 11045 9990 90.4 1055 9.6 629 5.7 
2007 10863 9878 90.9 985 9.1 599 5.5 
2008 10315 9371 90.8 944 9.2 550 5.3 
2009 10772 9730 90.3 1042 9.7 625 5.8 
2010 10661 9651 90.5 1010 9.5 574 5.4 
2011 10929 9833 90.0 1096 10.0 602 5.5 
2012 11109 9977 89.8 1132 10.2 559 5.0 
2013 11240 10633 89.2 1200 10.8 625 5.6 
2014 11833 10527 89.0 1306 11.0 640 5.4 
2015 12939 11501 88.9 1438 11.1 694 5.4 
2016 14178 12586 88.8 1592 11.2 722 5.1 
2017 14554 12558 88.9 1620 11.1 686 4.7 
2018 14816 13173 89.0 1643 11.0 687 4.6 
Total 194,049 174,430 89.9 19, 619 10.1 10,327 5.3 
*Percentage of total incident prescriptions for any anxiolytic 
 
Trends in the incidence rates of prescriptions for any combination therapy were consistent with the 
pattern seen in incidence rates for prescriptions of any anxiolytic, as monotherapy or combination 
therapy. Incidence declined from 1.1/1000PYAR to 0.8/1000PYAR in 2008, rising to 1.3/1000PYAR in 
2018 (Figure 53). Incidence of SSRI/’other’ antidepressant plus a benzodiazepine as combination 
therapy declined slightly over the study period, from 0.7/1000PYAR in 2003 to 0.5/1000PYAR in 2018 
(Figure 53). The underlying data on incidence rates for these two analysis groups are presented in 





In addition, whilst beta-blockers (propranolol) are not specified in the NICE or BAP guidelines, and 
the evidence for their effectiveness in the treatment of anxiety is poor (Baldwin et al., 2014), they 
were the remaining largest drug class prescribed over the study period (Table 17). Therefore, 
incidence rates were calculated for when a beta-blocker (propranolol) was prescribed with an 
SSRI/‘other’ antidepressant. The underlying incidence rates for this combination are presented in the 
Appendix A.47 - Table 61. The combination of an incident SSRI/’other’ antidepressant plus beta-
blockers (propranolol) was steady for the first half the study, and then rose from 0.1/1000PYAR in 
2010 to 0.4/1000PYAR in 2018 (Figure 53).  
A sensitivity analysis was conducted to examine the impact on findings when a later prescription for 
an anxiolytic medication, issued within 4 weeks of the original prescription, was defined as a 
combination therapy. The overall trend was similar to the main analysis for the incidence of any 
combination therapy and for the specific combination therapies (SSRI/‘other’ antidepressant plus a 
benzodiazepine, SSRI/‘other’ antidepressant plus beta-blocker) (Figure 53).  
Figure 53 Incidence of combination therapies (any anxiolytic combination, SSRI/’other’ 
antidepressant & benzodiazepine, and SSRI/’other’ antidepressant & beta-blocker) per 1000 person 








5.3.9 Trends in the duration of incident anxiolytic prescriptions 
Trends in the duration of treatment were examined for patients starting anxiolytics between 2003 
and 2018. Figure 54 to  
Figure 59 show the proportion of patients with different treatment lengths for each year of the 
study for each drug class. It should be noted that there is an apparent reduction in the proportion of 
patients who are on medication in the longest duration categories in the final year of the study. 
However, as data were extracted in July 2019, it is likely that the figures for 2018 for the longer 
duration categories are an underestimate and should be interpreted with caution.  
For all antidepressants, prescription duration remained relatively stable between 2003 and 2018 
(Figure 54). For SSRI & ‘other’ antidepressants, there was a small increase in the proportion of longer 
use (181+days) in more recent starting years, with a corresponding decrease in shorter-term use 
(<181 days) (Figure 55). In contrast, the proportion of short-term benzodiazepine prescriptions 
increased with time, with a resultant decrease in long-term use (Figure 56). For beta-blockers 
(propranolol), prescription duration remained relatively stable between 2003 and 2018 (Figure 57). 
For the remaining drug classes (antipsychotics, and anticonvulsants), proportions of short-term and 
long-term prescriptions fluctuated over time, but there was no clear trend of an increase or 





Figure 54 Changes in the proportion of patients with different treatment lengths for all 
antidepressants, between 2003 and 2018 
 
Figure 55 Changes in the proportion of patients with different treatment lengths for SSRI & ‘other’ 







Figure 56 Changes in the proportion of patients with different treatment lengths for benzodiazepines, 
between 2003 and 2018 
 
Figure 57 Changes in the proportion of patients with different treatment lengths for beta-blockers 







Figure 58 Changes in the proportion of patients with different treatment for antipsychotics, between 
2003 and 2018 
 
Figure 59 Changes in the proportion of patients with different treatment lengths for anticonvulsants, 







5.3.10 Patterns of dosing for incident antidepressant prescriptions  
Others have suggested that doses of antidepressant medication may be higher for the treatment of 
anxiety (compared with depression) (Cassano et al., 2002). In order to investigate this, the median 
dose was calculated for each incident drug substance within the antidepressant class across all years 
of the study (2003 to 2018). These data are presented in Table 29, along with the recommended 
doses for comparison.  
Citalopram (36%) was the most frequently prescribed incident antidepressant, with the median dose 
(20mg [IQR: 10, 20]) corresponding with the recommended starting dose for both anxiety and 
depression. This was followed by sertraline (17%), where the median dose (50mg [IQR: 50, 50]) was 
also within the recommended doses, however it was at the lower end of the recommended dosing 
range for both disorders. For the two other antidepressants that were frequently prescribed, no BNF 
guidance is available on the recommended daily dose for anxiety. However, in general, the doses 
prescribed were in the lower to mid range of the recommended range for depression. For example, 
for the third most frequently prescribed antidepressant - fluoxetine (16%), the median dose (20mg 
[IQR: 20, 20]) was at the lower end of the dosing range for depression. Amitriptyline was prescribed 
in 8.7% of antidepressant prescriptions, with a median dose of 15mg [IQR: 10, 25], which is lower 
than the recommended starting dose for depression. However, when prescriptions of <75mg 
amitriptyline were excluded, the median dose (100mg [IQR: 100, 150]) was well within the dosing 
range (50-150mg) for depression.  
The remainder of the most frequently prescribed substances were also within the usual starting dose 
(mirtazapine (5.8%): 15 [IQR: 15, 30];  escitalopram (4.6%): 10 [IQR: 5, 10]; paroxetine (3.0%): 20 
[IQR: 20, 20]; venlafaxine (2.9%): 75 [IQR: 75, 150]), but all at the lower end of the dosing range for 






Table 29 Median dose per drug substance for all incident antidepressant prescriptions 





dose for an adult for 
depression (mg)∞ 
Recommended 
daily dose for 
an adult for 
anxiety (mg)∞ 
Freq. % 
Citalopram  58,957 36.1 20 [10, 20] 20, up to 40  20-30, up to 40 
Sertraline  27,711 17.0 50 [50, 50] 50, up to 200 50, up to 200 
Fluoxetine  26,000 16.0 20 [20, 20] 20, up to 60 Not stated 
Amitriptyline 14,198 8.7 15 [10,25]~ 50, up to 150 Not stated 
Mirtazapine  9,480 5.8 15 [15, 30] 15-30, up to 45 Not stated 
Escitalopram  7,444 4.6 10 [5, 10] 10, up to 20 10, up to 20 
Paroxetine  4,841 3.0 20 [20, 20] 20, up to 50  10-40, up to 60 
Venlafaxine  4,736 2.9 75 [75, 150] 75-375  75-225 
Dosulepin  3,624 2.2 75 [37.5, 75] 75-150, up to 225 Not stated 
Trazodone 1,566 1.0 75 [50, 150] 150-300, up to 300  75, up to 300 
Duloxetine 1,135 0.7 60 [30, 60] 60  30-60, up to 120 
Clomipramine 909 0.6 25 [10, 50] 10-150, up to 250 Not stated 
Lofepramine  781 0.5 140 [105, 140] 140-210 Not stated 
Flupentixol  614 0.4 1 [1, 1.5] 1-2, up to 3 Not stated 
Nortriptyline 400 0.2 75 [75, 100] 75-100, up to 150 Not stated 
Imipramine  225 0.1 50 [25-75] 75, up to 150-200 Not stated 
Trimipramine  194 0.1 50 [25, 50] 50-75, up to 150-300 Not stated 
Doxepin  191 0.1 37.5 [25, 50] 25-300 Not stated 
Reboxetine 83 0.1 8 [4, 8] 4-10, up to 12 Not stated 
Moclobemide 47 <0.1 300 [300, 600] 150-600 300, up to 600 
Fluvoxamine  43 <0.1 100 [50, 100] 50-100, up to 300 Not stated 
Phenelzine  34 <0.1 15 [15, 20] 45-60, up to 90 Not stated 
Nefazodone 16 <0.1 200 [200, 400] 200, up to 300-600 Not stated 
Tranylcypromine  15 <0.1 20 [20, 30] 10-30 Not stated 
Mianserin  9 <0.1 20 [10, 45] 30-40, up to 90 Not stated 
Agomelatine 8 <0.1 37.5 [25, 50] 25, up to 50 Not stated 
Tryptophan  5 <0.1 3 [1.5, 3]^ 3, up to 6^ Not stated 
Isocarboxazid  4 <0.1 30 [25, 30] 10-60 Not stated 
Vortioxetine  2 <0.1 15 [10, 20] 10-20 Not stated 
Amoxapine  1 <0.1 300 [300, 300] 50-100, up to 600 Not stated 
Total 163,273 100    
~Amitriptyline 
<75mg excluded 
13,508 - 100 [100, 150] 50, up to 150 N/A 
*BNF recommended daily dose for an adult for anxiety (GAD, social anxiety disorder, panic disorder) or depression  
(Royal Pharmaceutical Society of Great Britain, 2020) 
∞BNF recommended doses, except for Amoxapine & Nefazodone (both discontinued in the UK), whereby 
recommended dose sourced from ‘drugs.com’ (drugs.com, 2020a, 2020b) 








5.3.11 Qualitative data 
Some of the findings detailed in Chapter 3 and based on analysis of the qualitative interviews with 
GPs, gave insight into when specific drugs might be prescribed, and therefore indicated some 
possible reasons for the trends observed in the quantitative data on prescribing for anxiety. These 
findings are expanded upon below.  
Views on prescribing antidepressants  
GPs reported antidepressants as the main medication they used to treat anxiety, which is reflected 
in the quantitative findings. They talked about being reluctant to prescribe antidepressants because 
they did not want to rush into treating anxiety with medication, and because of the potential 
increased risk of suicide in younger patients. They used follow-up appointments to delay prescribing 
where appropriate, to provide time for the patient to consider their options, and see if symptoms 
improved without the need for medication. 
“I’m trying to give other suggestions other than medications, so socially isolated people trying 
to get more either exercise or sort of group stuff, that is probably what they need rather than 
medication, but it has been quite limited what you can offer. I think it is sometimes a bit too 
easy just to prescribe and I think I would try and move away from doing that or particularly in 
younger people, with the risk of suicide and things on SSRIs, so that’s another trigger for me to 
sort of ‘I’ll see you again in a couple of weeks and let’s reassess’.”  GP 1 
GPs also commented that despite a potential reluctance to use antidepressants, they thought that 
“where warranted it can be a useful tool” (GP 12). GPs reported that this was also the case for younger 
patients, despite the previously acknowledged risk of suicide.  
 “Younger, well sort of 17, 18 year olds who’ve actually responded very well to antidepressants, 
especially if they’ve had some issues with underlying anxiety disorders like Asperger’s, syndromic 
patients who’ve got a lot of anxiety, they can be quite helpful as well.” GP 12 
There was a mix of responses given by GPs when asked about the proportion of patients with anxiety 
that were prescribed medication. Some GPs estimated it would be about 75% and suggested this might 
be because “people come to us wanting a prescription, that’s often why they come” (GP 2). However, 
other GPs thought it would only be about 25%, and that often in those cases it will be patients with co-
morbid depression.  
GPs consistently reported that patient choice was the main trigger for an antidepressant 





commented that they would be considering severity of the anxiety, and that some patients might 
need anxiolytics in the short-term to help them with symptoms, whilst they wait for a more long-
term strategy such as talking therapies.  
“I: What would trigger a prescription?  
GP: Patients’ choice probably mainly. I mean there are some people that just seem really, I’d 
say they’re struggling and that it’s becoming a functional problem more than others, and then I 
might sort of perhaps talk a little bit more about the antidepressants and how ‘they might 
allow you to cope a little bit better day to day but with the idea that they’ll help in the short-
term while you’re waiting for something long, you know, more longer term strategy to be put 
in place like through CBT’.” GP 3 
Some GPs commented on being able to prescribe higher doses of SSRIs for anxiety, compared with 
depression, although there was a sense they were conservative with their prescribing, or that 
patients responded well to lower doses, and therefore they did not use the higher doses.  
“I guess with the anxiety you do have the licence to go up to much higher doses of SSRIs than 
what you would do normally.” GP 7 
Experiences of prescribing benzodiazepines 
All the GPs reported that they would avoid prescribing benzodiazepines to patients the first time 
they consulted for anxiety. GPs gave several reasons for this: benzodiazepines were addictive, and 
“we have a real addiction problem in my population” (GP 13); that they could have unwanted side 
effects and could negatively affect an individual’s ability to drive or work; and that they were not 
long-term solution, but rather an “emergency measure” (GP 2). However, GPs acknowledged that 
benzodiazepines could be beneficial, particularly in acute crises to “get them down off the ceiling so 
that you can then begin to address things” (GP 8), in patients whose “anxiety [is] contributing with 
depression, suicidal ideation” (GP 11), or in instances where a lack of sleep was contributing to the 
anxiety state.  
“Sometimes it can be helpful in the short-term if you think that the primary problem is like 
sleep deprivation and sometimes normalising sleep will actually improve that person’s 
symptoms and often…it can be very helpful to give one to two weeks of Benzodiazepines and 
get the person back, just a way of discussing the information they provide and reviewing the 
diagnosis, see how they’re feeling, sometimes often with some, maybe a break from work for a 





Benzodiazepines were also cited as being useful as a short-term adjunctive therapy, when 
introducing an SSRI. GPs reported they did this less in the last few years, but that they “used to do it 
more, whenever I started a SSRI I’d often say ‘you might have trouble in the first two weeks, I’ll give 
you some Diazepam for those symptoms” (GP 6). 
GPs said they if they did prescribe them, either at that first consultation or during a later follow-up 
appointment, then it would be a small dose for a couple of days, and not for regular use, with the 
risks explained clearly to the patient. GPs also spoke about prior patient experiences as being a 
factor in whether they prescribed benzodiazepines. They stated that if a patient consulted for a 
second episode of anxiety, and they had found benefit beforehand in using them to manage their 
symptoms, then they might be more inclined to reissue a prescription. However, GPs also 
commented that there were several patients who were already on benzodiazepines long-term, 
despite it no longer being recognised practice, and it was “quite difficult to try and get them to stop 
taking them” (GP 3). Most GPs spoke about these patients as being patients who had come from 
other practices, and therefore they were likely to continue to prescribe benzodiazepines for these 
patients, if these patients had strong preferences to continue taking them. However, some GPs also 
acknowledged that some patients did cope with their symptoms better when taking them, and 
therefore they might not “rush” (GP 6) to get these patients off them.  
“There’s no doubt that there are some people who seem to do better with Benzos, so if people 
have had them for ever and ever, I probably wouldn’t be in a huge rush to try and get them 
off.” GP 6 
In addition, some of the GPs explained that in the past, benzodiazepines were prescribed for long-
term use. As such, GPs reported that a proportion of their current patients who were on long-term 
benzodiazepines were elderly and had been originally prescribed benzodiazepines when it was 
routine practice to do so.  
“So we’ve still got some older, some ladies in their seventies that were prescribed - I’ve got one 
here, what is she now, in her eighties, was prescribed Librium in the Seventies and that was the 
treatment.” GP 1 
There were also some instances where GPs stated they might prescribe benzodiazepines on a long-
term basis if the patient was under the care of a mental health team, or if they had been asked by 
the mental health team to prescribe “a tiny bit of Diazepam to tide [them] over, or a sleeping tablet”’ 
(GP 15). GPs clearly stated that they felt long-term medication of these drugs should only be continued 





Specific drugs used  
GPs stated that they used propranolol quite often, “for the physical kind of side of it, if it’s more 
panicky type of things” (GP 2). They said they were more likely to prescribe propranolol when a 
patient first presented with anxiety, as it was not addictive, and patients could choose whether to 
take it or not. They said that it could be useful for patients in the short-term, and that they could 
stop the progression of the physical sensations into a panic attack. 
“Sometimes, people are so anxious they can’t even concentrate to engage, so I sometimes 
use beta-blockers if it’s appropriate. Just to give them something to stop the progression of 
the anxiety into panic attacks. If you can just slow the heart rate down a little bit, sometimes 
it stops the precipitation of the physical symptoms, which often make the anxiety worse, and 
then they become anxious about panic attacks, so I use beta-blockers quite a lot.” GP 13 
GPs commented that SSRIs were the antidepressants they were most likely to use. About two thirds 
of the GPs reported starting patients with anxiety on citalopram, compared with sertraline for those 
with depression. Several GPs explained that this was because they thought citalopram was better for 
anxiety, and “it seems to have quite a good calming effect on them, gives them a sense of control so 
that they can manage their stress a little bit more easily” (GP 3). Some GPs said they preferred to 
prescribe citalopram as the tablets can be broken in half easily, and therefore they were able to start 
patients on lower doses to begin with. 
“With Citalopram ‘cos it’s quite easy, you can break them in half easily enough, is actually if 
ever I’m starting someone on something like that I always start on a small dose initially and 
then ask them to increase it after a week or two because I’ll certainly warn them that the 
anxiety element of their illness may well increase in the short-term.”  GP 8 
The remainder of the GPs reported using sertraline as the first-line treatment for anxiety, 
particularly if it was co-morbid with depression. They stated that they thought it “is slightly better 
with anxiety” (GP 7), or because with “citalopram there’s been more talk about kind of issues around 
QT intervals” (GP 8) [prolonged QT intervals can cause abnormal heart rhythms, which can lead to 
more serious issues such as cardiac arrest (Jasiak & Bostwick, 2014)]. 
There were some GPs that talked about using escitalopram or venlafaxine if the first-line SSRIs had 
not resulted in improvement. They said they might be less likely to use a sedating antidepressant, 
such as mirtazapine, in patients with anxiety, particularly when compared to those with depression. 
However, there was also sense from some GPs that they “just end up just working [their] way 





When patients had severe anxiety and had not responded well to antidepressants, some GPs reported 
prescribing pregabalin. They stated that this was the type of patient who would be referred to 
secondary care and might have other mental health comorbidities.  
“Sometimes things like pregabalin have a place in anxiety. I have some patients who have been 
really struggling with anxiety and that sort of medications helped. They tend to be people who 
are probably seeing a psychiatrist, but they may help, and sometimes they’ve got other mental 
health issues.” GP 8 
In addition, two GPs mentioned using antipsychotics for patients with very severe symptoms, who had 
not responded to an antidepressant or pregabalin.  
“I guess the only other thing is very occasionally with severe anxiety sometimes we might use 
things such as risperidone or small doses of antipsychotics to try and help manage symptoms.” GP 
12 
 
5.4 Discussion  
5.4.1 Summary of findings 
There was an increase in the prevalence of prescriptions of any anxiolytic, and antidepressants, over 
the 16 years, between 2003 and 2018. This increase in prevalence was also seen in prescriptions of 
beta-blockers (propranolol), and for antipsychotics and anticonvulsants, but at a more gradual rate. 
The prevalence of prescriptions of benzodiazepines remained fairly constant. The incidence of 
prescriptions of any anxiolytic, driven by prescribing of antidepressants, decreased between 2003 
and 2006, after which the incidence remained fairly constant, before increasing substantially 
between 2012 to 2018. There was a gradual increase in the incidence of prescriptions of beta-
blockers (propranolol), antipsychotics, and anticonvulsants between 2003 to 2018. The incidence of 
benzodiazepine prescriptions gradually declined across the entire 16-year period (2003 to 2018). The 
increases in incident prescriptions are more likely to explain the increases in prevalence, rather than 
longer treatment duration. However, for benzodiazepines, the decline in incident prescriptions, with 
a corresponding reduction in long-term use over time, may be why the prevalence of prescriptions 
remained reasonably steady from 2003 to 2018.  
Prevalence and incidence of prescriptions for anxiolytic medication in women were nearly twice that 





prescriptions were 50% higher in women. Whilst there was some statistical evidence of an 
interaction between year and gender, the effects observed were unlikely to be meaningful.  
There was evidence of an interaction between year and age. Prevalence of prescriptions of any 
anxiolytic, and each drug class, increased substantially in the later years of the study in the younger 
age groups (<25s, 25-34, and 35-44 year olds). Prevalence of prescriptions for 44-54 and 55-64 year 
olds increased more gradually, except for benzodiazepines where they declined in those aged 55-64 
years old. The other exception to this was for prescriptions of anticonvulsants, where the increase 
seen in prevalence was most notable for 35-44, 44-54 and 55-64 year olds, although numbers were 
small.  
There was a marked increase in the incidence of prescribing of any anxiolytic, and each drug class, in 
the two youngest age groups (<25s and 25-34 year olds) in recent years. Incident prescriptions for 
those aged 35-44 and 45-54 years old increased more gradually, except for benzodiazepines where 
there was a decrease in prescribing for 35-44 year olds, followed by an increase toward the second 
half of the study, and a decline seen in prescribing for those aged 45-54. Again, the other exception 
to this was for prescriptions of anticonvulsants, where the increase seen in incidence was most 
notable for 35-44, 44-54 and 55-64 year olds but again numbers were small.  
Prevalent and incident prescriptions were steady, or decreased, for any anxiolytic, and each drug 
class, for the older age groups (55-64, 65-74, 75-84, and 85 year olds). The only exception to this was 
anticonvulsants, where there was an increase in prevalence and incidence in these age groups. 
However, this may be due to co-incidental use of these drugs for other indications in older 
individuals, such as neuropathic pain (Haslam & Nurmikko, 2008). Nonetheless, both prevalent and 
incident prescriptions of anticonvulsants and antipsychotics were infrequent, and therefore 
differences between age groups must be interpreted with caution. 
Combination therapy – where more than one anxiolytic was prescribed on the same date – was 
relatively uncommon, comprising around 9-11% of any incident anxiolytic prescriptions. The 
combination of an incident prescription of an SSRI (or ‘other’ antidepressant) and a benzodiazepine, 
which is recommended in the NICE guidelines, was less frequent comprising around 5-6% of incident 
prescriptions.  
Interview data from GPs indicated that antidepressants, and in particular citalopram and sertraline, 
were the primary medications used to treat anxiety, and this is certainly consistent with the 
quantitative data. However, GP interviews did not provide insight into why a decline was seen in the 





could be related to the decrease in recorded anxiety diagnoses at the start of the study period 
reported in the previous chapter (section 4.3.2). Accounts from the GPs interviewed highlighted 
that, if a patient has a diagnosis of anxiety, they may be more likely to prescribe an anxiolytic. 
Therefore, a reduction in recorded anxiety disorders may account for the reduction in incident 
prescribing seen in the early years of the study.  
The increase seen in prescribing (of any anxiolytic, and all drug classes) in the youngest age groups 
(<25 years, 25-34-and 35-44 year olds) in the later years of the quantitative study period, is 
consistent with the GP interview data. As reported in the previous chapter (section 4.3.5), GPs 
suggested that there has been an increase in anxiety in younger patients in recent years. GPs also 
said that diagnosing an anxiety disorder and prescribing medication were linked (section 4.3.5). 
Therefore, increases in anxiety diagnoses in later years, especially in younger adults, may explain 
increases in anxiolytic prescriptions. This may also explain why prescriptions for beta-blockers 
(propranolol) have increased for younger individuals, as GPs described the drug as non-addictive and 
therefore a medication that they might prescribe more readily. In addition, the GPs’ accounts 
suggested there has been a change in practice in terms of the drugs used to treat anxiety in primary 
care, in that benzodiazepines are no longer prescribed routinely or for the long term. This could 
explain why the overall incidence of benzodiazepines decreased during the study period and the 
reduction in long-term prescribing of these drugs.  
Some GPs mentioned that they may use higher doses of SSRIs for anxiety, compared with 
depression, but this was not evidenced in the quantitative data. It is possible that this is because the 
doses examined were those of incident prescriptions, and therefore any potential increase in dosage 
for repeat prescriptions, for patients who have not improved (Strawn et al., 2018), were not 
captured in this analysis. However, the NICE (NICE, 2011b) and BAP (Baldwin et al., 2014) guidelines 
do not specify a need for higher doses of antidepressants prescribed for anxiety, compared with 
those prescribed for depression. In addition, the BNF recommended doses for anxiety do not differ 
substantially from those recommended for depression (Royal Pharmaceutical Society of Great 
Britain, 2020).  
 
5.4.2 Strengths and limitations 
The use of a large, nationally representative dataset, with a sample size of more than 250,000 
patients, enabled analysis of trends in terms of the prevalence and incidence of prescriptions of any 
anxiolytic, and by drug class. It also facilitated further analysis by age and gender, and provided 





included within the analysis, ensuring all potential prescriptions for anxiety were captured. This list 
was comprised of drugs recommended in the current NICE guidelines (NICE, 2011b), and the British 
Association for Psychopharmacology’s recommendations for pharmacological treatment for anxiety 
disorders (Baldwin et al., 2014). It is therefore likely to capture the most frequently prescribed 
medications that GPs may use for anxiety. In addition, the requirement for a prescription to have 
occurred within the defined time period of three months prior, or six months after, an anxiety READ 
code, ensures that patients who may have received an anxiolytic prescription before or after their 
anxiety has been recorded, are included within the analysis. Findings from sensitivity analyses 
restricting prescriptions to four weeks either side of the READ code were consistent with the overall 
trends seen.  
Regarding the limitations of the study, the sample is limited to patients who have a recorded anxiety 
READ code and anxiolytic prescription. There will be some patients who have been prescribed an 
anxiolytic medication, but do not have an anxiety READ code, that are not captured within this 
study. It is also restricted to medications that are prescribed in primary care, so those receiving 
anxiolytic drugs prescribed in a secondary care setting will be excluded. Such patients may differ 
from those visiting their GP for prescriptions (e.g. more chronic or severe anxiety, more co-
morbidities, more likely to be treatment resistant), meaning findings may not be generalisable to the 
wider population. However, only a very small number of individuals with anxiety are likely to be seen 
in secondary care and hence prescriptions issued in this setting would account for a very small 
proportion of the total medications prescribed for anxiety. In addition, most medium- and longer-
term prescriptions started in secondary care are shifted to primary care.  
The study focuses on medications that are prescribed by the GP, but there is no additional 
information available on dispensing, adherence to recommended treatment, or access to other 
treatments. Therefore, it is not known if patients that are prescribed these drugs are collecting their 
prescriptions, and if they are taking them on a regular basis, infrequently or not at all. Furthermore, 
whilst prescriptions must have occurred within the three months prior or the six months after an 
anxiety READ code, it is possible that some of these drugs may have been prescribed for other 
indications. For example, benzodiazepines may have been prescribed for insomnia, antipsychotics 
for psychosis, or anticonvulsants for neuropathic pain (Haslam & Nurmikko, 2008; Riemann & Perlis, 
2009; Zhang et al., 2013). Patients may have had recorded READ codes for these conditions, in 
addition to an anxiety READ code, and it could not be known with certainty which indication the 
anxiolytic medication was prescribed for. This is further compounded by the frequent co-morbidity 





of these drugs may have been prescribed for co-morbid depression, or other indications, and 
therefore the reported figures may be an overestimate. 
Finally, as previously discussed in Chapter 4 (section 4.4.2), only practices who provided data to 
CPRD Gold across the entire study period (2003-2018) were included in the analysis, in order to 
allow greater confidence in interpreting trends over time. It is possible that there may be differences 
between practices with complete or partial data over the study period, and one reason for this may 
be related to a switch in the practice software being used. Whilst it is unlikely that the practice 
choice of software would be linked to prescribing habits, it is possible that greater opportunity to 
use free-text recording may mean that there are differences in the coding of anxiety symptoms or 
diagnoses between practices with complete or partial data that may impact on the estimates 
obtained. However, it is difficult to quantify this and Moore et al. (2009) did not find differences 
when comparing complete and partial data from contributing practices in a different CPRD dataset.  
The strengths and limitations of the qualitative interviews discussed in Chapter 3 (section 3.7.2) and 
Chapter 4 (section 4.4.2) are also relevant here. 
 
5.4.3 Comparison with previous studies 
Previous research into trends in the prescribing of the anxiolytics examined in this study are limited 
to those in children (John et al., 2015), or those in adults but reported trends over a short time 
period (2002-2004) (Martin-Merino et al., 2010). Whilst there are several studies that have looked at 
trends in antidepressant prescriptions for any indication (Lockhart & Guthrie, 2011; Mars et al., 
2017), or for depression (Moore et al., 2009), there are no data on trends in prevalence or incidence 
in recent years. It is important to understand how prescribing has changed, particularly in view of 
the increasing incidence of anxiety reported in the previous chapter (section 4.3.2), and recent data 
from the general population (Stansfeld et al., 2016; Pitchforth et al., 2019). Furthermore, there have 
been several changes in recent years that may have impacted on prescribing: the introduction of the 
depression QOF in 2006; the introduction of the IAPT service in 2007; the economic recession in 
2008; and the NICE anxiety guidelines in 2011 (NICE, 2011b). Regarding the introduction of IAPT, it is 
unlikely that this impacted on prescription rates, as all drug classes, bar benzodiazepines, increased 
in incidence the year after its’ inception. Prevalence of prescriptions for most drug classes also 
increased after 2008. However, as there are limited numbers of patients with anxiety accessing 
treatment through IAPT, it is perhaps not surprising that rates of prescribing have increased, 
particularly as there are few alternative treatments (Baker, 2020). In addition, 2008 was also the 





reduction in prescribing rates from the introduction of IAPT. A previous systematic review reporting 
studies published up to 2014 found increases in mental health symptoms in the years following the 
recession, and this may be why prevalence and incidence of prescriptions increased (Frasquilho et 
al., 2016). In 2011 the NICE anxiety guidelines were updated to explicitly state – “Do not offer an 
antipsychotic for the treatment of GAD in primary care” (page 18) (NICE, 2011b). However, 
prescriptions for antipsychotics did not decline after this recommendation was introduced, with 
both prevalence and incidence rates of antipsychotic prescribing continuing to increase from 2007 to 
2018. Whilst it is possible that some of the antipsychotics in this study were prescribed for 
indications other than anxiety, this trend should still be noted as it is not in line with the clinical 
guideline.   
Previous research established that there has been a substantial increase in the prescribing of 
antidepressants in the past two decades, with the greatest increase being observed for SSRIs and 
‘other’ antidepressants, which account for the majority of antidepressants prescribed (Lockhart & 
Guthrie, 2011; Mars et al., 2017). Whilst these studies looked at antidepressant prescribing for all 
indications (Lockhart & Guthrie, 2011; Mars et al., 2017), or for depression (Moore et al., 2009), the 
results from this study are consistent with their findings, in that prevalence of prescriptions of 
antidepressants for patients with anxiety increased over the 16-year period. The earlier studies 
identified an increase in the long-term use of antidepressants, rather than an increase in those 
starting the medication (Moore et al., 2009; Lockhart & Guthrie, 2011; Mars et al., 2017). However, 
the present study did not find a similar trend, except for SSRI & ‘other’ antidepressants, but it was 
much less noticeable. This may because GPs are less likely to prescribe antidepressants for anxiety 
long-term, or because they have the option of using other anxiolytics for the treatment of anxiety.  
The same studies (Moore et al., 2009; Lockhart & Guthrie, 2011; Mars et al., 2017) also found that 
the incidence of prescriptions of antidepressants has remained relatively stable over time, although 
when Mars et al. (2017) conducted a sensitivity analysis including only those patients with 
depression, they identified a decrease between 2002 and 2005, followed by a very gradual rise to 
the end of their study period (2011). Moore et al. (2009) also revealed a drop in the same three 
years. The present study also found a decrease in incident prescriptions from the start of the study 
(2003) through to 2006, where thereafter incidence gradually rose, followed by a steeper rise from 
2012 to 2018. The reasons for this upward trend may be due to the increase in the incidence of 
patients presenting with anxiety, as reported in the GP interview data (section 4.3.5), or the 





Prior research regarding trends in the prevalence of prescribing of benzodiazepines (for all 
indications), identified that primary care prescribing was relatively constant between 2008 and 2012 
(MHRA, 2015). The findings of the present study are consistent with the earlier research, in that 
prevalence of prescribing of benzodiazepines for anxiety remained stable over the same time period, 
and extend this previous research by an additional six years, to 2018. More recent evidence suggests 
prevalence of benzodiazepine prescriptions (for any indication) has started to decline in recent 
years, between mid-2015 to mid-2018 (Public Health England, 2019). However, the present study did 
not find a clear decrease in prevalence in this same time period, but this may be because 
prescriptions were for anxiety, rather than for any indication.  
Whilst there are no published data on patients starting benzodiazepine treatment for anxiety, the 
decrease in incidence over time seen in this study is in line with clinical guidelines, and reinforced by 
the data from the GP interviews. The present study is also consistent with data from PHE, that 
suggests the number of patients starting benzodiazepine medication, for any indication, declined 
between mid-2015 to mid-2018 (Public Health England, 2019). However, whilst duration of 
benzodiazepine treatment declined over time, 20% of prescriptions in 2017 were for longer than six 
months, despite clinical guidelines recommending a maximum of four weeks treatment (NICE, 
2011b). Recent research has also shown that there are still large proportion of patients in the UK 
that are taking these drugs on a long-term basis, and that this is a concern for public health (Davies 
et al., 2017).  
The rise in the prevalence of beta-blockers (propranolol) prescriptions in this study is consistent with 
the data reported on openprescribing.net (2020), which reports prescribing trends for all indications. 
However, there are no published data on trends for beta-blockers, specific to anxiety. This may be 
due to the inconclusive evidence for the therapeutic benefit of this drug in the treatment of anxiety 
(Steenen et al., 2016; Brudkowska et al., 2018), particularly as there is no clinical guidance 
concerning when and how it should be used within the NICE guidelines, despite being licenced for 
the treatment of anxiety symptoms (Royal Pharmaceutical Society of Great Britain, 2020). However, 
a recently published report has highlighted a potential under-recognised risk of harm in the use of 
propranolol for patients with depression or anxiety, and recommends BNF and NICE guidance should 
be reviewed and updated (Healthcare Safety Investigation Branch, 2020). Therefore, knowledge that 
there is increasing use of this drug for anxiety is important.  
Regarding the remaining drug classes (antipsychotics and anticonvulsants), there has been limited 
research in trends in prescribing specific to anxiety. In previous research, between 1998 and 2010, 





Moncrieff, 2012). A similar trend was seen in this study in prescriptions for anxiety in the seven 
overlapping years, with prevalence rising from 0.9/1000PYAR in 2003, to 1.3/1000PYAR in 2010. 
Likewise, in previous research, between 2007 and 2017, the incidence of patients starting 
gabapentin treatment increased from 230 to 679 per 100 000 persons per year, and from 128 to 379 
per 100 000 persons per year for pregabalin, again for any indication (Montastruc et al., 2018), 
which is similar to the rise seen in this study.  
Previous studies have shown anxiolytic use in women to be twice that of men, for both depression 
and anxiety (Martin-Merino et al., 2010; Mars et al., 2017). Whilst this study also found the 
prevalence and incidence of prescriptions for antidepressants in women to be twice that of men, it 
also found a similar pattern for all other drug classes (with the exception of antipsychotics). This is 
consistent with data from Public Health England (2019) that reports the prevalence of 
antidepressant, benzodiazepine and anticonvulsant prescriptions in women to be at least 1.5 times 
higher than prescriptions of the same drugs for men in 2017/2018. In the present study, compared 
with all other drug classes, the prevalence and incidence of prescriptions for antipsychotics in 
women was only 50% higher than that of men. Prior research suggests prescriptions for atypical 
antipsychotics in primary care may have increased at a greater rate in men, compared with women 
(Kaye et al., 2003; Chan et al., 2006). This may reflect increased severity of illness in men who do 
consult their GP, or a greater willingness to try antipsychotic medication, particularly if men 
experience less side effects than women (Seeman, 2004).  
Previous research has shown that the level of prescribing of antidepressants, benzodiazepines, and 
anticonvulsants, for any indication, increased with age (Mars et al., 2017; Public Health England, 
2019). In contrast, the present study found that prescribing for anxiety of all drug classes increased 
most in the youngest patients, with prescriptions remaining constant or decreasing in older adults in 
all drug classes, bar anticonvulsants. This may be due to a difference in the age patients present to 
their GPs with anxiety or depression, with patients thought to be at risk for anxiety at a younger age 
(Lijster et al., 2017). The present study findings, of increased benzodiazepine prescriptions in 
younger adults, are consistent with another study that looked at prescribing specifically for anxiety 
in children (John et al., 2015). Using a primary care database, they found that between 2003 and 
2011, there was an increase in benzodiazepine prescriptions for those aged 15-18 years (John et al., 
2015). Similarly, a Swedish study using a national database also found increasing prescriptions of 
benzodiazepines for those aged 18-24 years between 2006 and 2013 (Sidorchuk et al., 2018). Whilst 






5.4.4 Implications and future work  
There was an increase in incident prescribing for anxiety in recent years in terms of all 
antidepressants, beta-blockers, antipsychotics, and anticonvulsants, and this was most notable in 
young adults. This increase in prescribing may reflect better detection of anxiety, and increasing 
acceptability of the diagnosis and of pharmacological treatment. However, some of this prescribing 
is not based on robust evidence of effectiveness, such as the use of beta-blockers, and some may 
contradict guidelines, such as the prescribing of antipsychotics. Importantly, there is limited 
evidence on the effect of taking antidepressants long-term and, as such, there may be unintended 
harm.  
Overall, there was fall in benzodiazepine prescribing over time, but a rise in use was seen in those 
under 35 years of age. In addition, in 2017, just under 50% of incident prescriptions for 
benzodiazepines were prescribed for longer than the recommended maximum of four weeks, and 
over 20% were prescribed for longer than six months. These patients are potentially at risk of 
dependency, and protracted withdrawal, and this is a public health concern. To reduce harm, it is 
important that future research focuses on understanding why patients are prescribed these drugs 
long-term and the factors influencing initiation of such treatment. This is discussed in more depth in 





Chapter 6 Discussion 
6.1 Chapter overview  
This thesis aimed to gain an understanding of how anxiety is diagnosed and managed in UK primary 
care. This final chapter discusses the key findings. Firstly, key findings across each of the three 
studies conducted are summarised, followed by a discussion of the overall strengths and weaknesses 
of the thesis. Individual strengths and limitations of the three studies have been discussed in detail 
in Chapters 3, 4, and 5, and are not repeated in this chapter. The implications of the findings and 
potential future work are outlined.   
 
6.2 Key findings 
The individual research objectives and key findings from each of the three studies are summarised in 
Table 30 and discussed below.  
Findings presented in this thesis indicate that patients might be reluctant to seek medical help for 
anxiety. As reported in Chapter 3, the reasons for this included concerns around what others would 
think, a lack of understanding among patients about what anxiety is, and a perception that anxiety is 
not a legitimate reason to consult, or take up a GP’s time. However, GPs and therapists commented 
on a rise in the number of patients presenting with anxiety in recent years, and there was a 
corresponding increase over time in the recording of any anxiety code between 2003 and 2018. GPs 
and therapists suggested that increasing internet and social media use, greater social isolation, and a 
greater awareness of anxiety in society could be a possible reason for this increase. It might also be 
that despite being reluctant to seek help for symptoms of anxiety, patients are becoming more 
willing to do so over time, potentially as a result of increasing mental health promotion and 
willingness to talk about mental health (Henderson et al., 2017; Schnyder et al., 2017). It may also 
reflect greater awareness amongst GPs of anxiety and its’ importance, and an increasing tendency 





Table 30 A brief summary of the research objectives and key findings from each study 
Study and chapter  Research objectives  Key findings  
Practitioners’ and 








To understand how patients and practitioners view 
and experience the identification, diagnosis, and 
management of anxiety. Specifically, to:  
• Understand how GPs conceptualise, diagnose and 
discuss anxiety. 
• Explore patient experiences of help-seeking, 
diagnosis and management. 
• Explore IAPT therapists’ views on how diagnostic 
labels influence management within the service and 
patient engagement with treatment. 
• Patients are reluctant to seek help, but generally find GPs to be supportive when they 
do. GPs and therapists view anxiety as arising from internal and external factors, and 
report an increase in anxiety in recent years, particularly in young adults. Social media, 
internet use, and pressure to succeed are suggested as potential causes.  
• Patients want anxiety and depression to be considered separately, and view diagnosis as 
important for acceptance/engagement with treatment. However, GPs do not generally 
distinguish between them, and tend to focus more on discussion of symptoms than the 
diagnosis itself. Therapists viewed labels as helpful for patient engagement with 
treatment, but do not formally diagnose anxiety disorders. 
• GPs view patients as preferring medication, whereas patients do not view medication as 
a positive choice and are often averse to taking it.  
Trends in the 
recording of 
anxiety diagnoses 
and symptoms in 
UK primary care, 
Chapter 4. 
• To investigate trends in the incident recording of 
anxiety diagnoses and symptoms in UK primary care 
between 2003 and 2018, and to examine potential 
differences in recording of anxiety over time 
according to age and gender. 
 
• Recorded incidence of anxiety symptoms increased over time. In contrast, recorded 
incidence of anxiety diagnoses decreased between 2003 to 2008, before markedly 
increasing between 2013 and 2018. 
• Recorded incidence of symptoms and diagnoses in women was nearly twice that of men.  
• Recorded incidence of symptoms and diagnoses increased substantially in later years in 
younger adults, whereas the recorded incidence for older adults declined in later years. 
Trends in 
prescribing for 
anxiety in UK 
primary care, 
Chapter 5. 
To investigate trends in prescribing for anxiety in UK 
primary care between 2003 and 2018, and to 
examine factors that may be associated with these 
trends. The specific objectives were to: 
• Examine trends in prescribing overall, and by drug 
class. 
• Examine potential differences in prescribing over 
time according to age and gender. 
• Determine whether any changes in prescribing over 
time are due to: (i) an increase in the number of 
new patients receiving medication; and/or (ii) 
changes in the duration of treatment over the study 
period.  
• Between 2003-2018, the prevalence of prescriptions in all drug classes increased, except 
for benzodiazepines where prevalence of prescriptions remained fairly constant. 
• Incidence of antidepressant prescriptions decreased between 2003 to 2006, and was 
then steady, before increasing substantially from 2012 to 2018. Between 2003-2018 
incident prescriptions of beta-blockers (propranolol), antipsychotics, and anticonvulsants 
gradually increased, and incident benzodiazepine prescriptions gradually declined.  
• Increases in prevalence were driven by an increase in incident prescriptions rather than 
increasing treatment duration, except for benzodiazepines where there was a reduction 
in long-term use over time.  
• Prevalence and incidence of prescriptions in women were nearly twice that of men. 
• Incidence of prescriptions increased substantially in later years in younger adults, and 
were steady or decreased in older adults. The only exception to this was for prescriptions 




Once consulting, patients want anxiety and depression to be considered as two separate conditions, 
both in terms of the diagnosis and the management of symptoms. In terms of providing insight into 
the diagnosis of anxiety disorders, patients reported that they viewed the diagnosis itself as 
important in their acceptance of having anxiety, and in being ready to engage with treatment. 
However, GPs do not necessarily distinguish between anxiety and depression, and for valid reasons 
may be reluctant to diagnose an anxiety disorder, for example, because they think it could be 
unhelpful or potentially stigmatising for the patient. GPs may also not be in a position to do so due 
to short appointments and a lack of continuity of care, both of which mean they have limited 
information on which to make a decision. Therefore, GPs tend to focus more on the management of 
the symptoms rather than the diagnosis itself. Quantitative data indicated that diagnostic codes are 
being used more in recent years (presented in Chapter 4). This increase in the number of patients 
being given diagnoses of anxiety disorders may be due to an increase in the presentations of anxiety, 
and greater awareness of anxiety among patients, as discussed above. It may also suggest a change 
in GP coding behaviour, potentially as a result of the introduction of the NICE anxiety guidelines in 
2011, which state practitioners should “identify and communicate the diagnosis of GAD as early as 
possible to help people understand the disorder and start effective treatment promptly” (page 7) 
(NICE, 2011b).  
However, whilst the incidence of recorded diagnostic codes increased in later years, GP interview 
data suggested that they are using these codes in a non-specific way. Codes such as ‘anxiety states’ 
were used to cover a general sense of anxiety, rather than making a formal diagnosis of, for 
example, generalised anxiety disorder. This may be reflective of the historical trend of referring to 
anxiety as a ‘neurosis’, or a psychosocial problem, rather than the biomedical subtypes introduced in 
the DSM-3 (Crocq, 2017). Indeed, in the interviews many GPs stated that they do not use the 
diagnostic subtypes of anxiety, viewing it as the role of a psychiatrist to make that distinction. Yet 
GPs also said that they rarely referred patients with anxiety to secondary care, due to the high 
threshold. Hence many patients do not receive a specific anxiety diagnosis. This directly contrasts 
with the views of patients, who value having a clear diagnosis, and do not find non-specific 
terminology helpful. Further, even if a GP has used a diagnostic code, this does not necessarily mean 
GPs are discussing diagnoses in depth with patients, particularly if consultation time is limited. In 
contrast, therapists have more time to discuss diagnoses with patients, and stated that a label could 
be helpful, but were clear the IAPT system does not encourage them to formally diagnose anxiety.  
GPs recognised that elderly patients were at risk of anxiety, but that they might not consult for 
mental health symptoms. Both GPs and therapists viewed young adults as being at increasing risk of 





with this, with an increased incidence of any anxiety code, symptom codes, and diagnosis codes in 
the younger age groups (presented in Chapter 4). GPs and therapists suggested recent increases may 
be due to increasing pressure on this age group, and greater social media use, with both factors also 
reported in previous research (Hargreaves, 2018; Keles et al., 2020). In the quantitative data on 
trends over time for prescriptions, there was also a substantial increase in prescriptions of any 
anxiolytic in this age group, as well as for each drug class (presented in Chapter 5). This increase in 
prescribing may therefore indicate increased presentation of anxiety in young adults, with better 
detection by GPs, and increasing acceptability of the diagnosis and of pharmacological treatment.  
In terms of the management of anxiety, GPs held the view that patients often prefer to take 
medication, whereas patients reported that they were reluctant to take medication, but felt that it 
was the only option they had  due to the long wait times for talking therapy and the perceived lack 
of other treatment options. There was evidence that the incidence of prescriptions for any anxiolytic 
is increasing and this is primarily driven by increases in antidepressant prescriptions (quantitative 
data reported in Chapter 5). This is in contrast to the rise in the prescribing of antidepressants for 
depression, which in recent years has largely been driven by longer duration of established 
prescriptions (Moore et al., 2009; Mars et al., 2017). With the exception of benzodiazepines, there 
were also increases in the incidence of prescriptions for each drug class. However, there are 
concerns within the medical community that some of this prescribing is not based on robust 
evidence of effectiveness, such as the use of beta-blockers (Steenen et al., 2016; Brudkowska et al., 
2018), and is not in line with clinical guidelines, such as the use of antipsychotics for anxiety (NICE, 
2011b). There is also limited evidence on the effect of taking antidepressants on a long-term basis, 
with GPs commenting on concerns around the possibility of an increased risk of suicide in patients 
treated with SSRIs (Healy et al., 2003). In addition, incident prescriptions of benzodiazepines 
increased in those under 35 years of age between 2003 and 2018, despite interviews with GPs 
suggesting they infrequently prescribed this medication.  
The introduction of IAPT for the psychological management of anxiety does not appear to have 
influenced rates of medication prescribing, as all drug classes, bar benzodiazepines, increased in 
incidence the year after its’ inception (2007/2008) - an increase which contrasts with patient 
preferences. GPs, patients, and therapists commented that, as discussed above, the waiting time to 
access talking therapy could be too long. However, 2008 was also the year of the economic recession 
and it is possible that the recession may have negated any potential reduction in prescribing rates. 
Indeed, incident prescriptions of both antidepressants and beta-blockers increased from 2008 





6.3 Strengths and Limitations 
The strengths and limitations of each individual study were discussed in Chapters 3, 4, and 5.   
As outlined in Chapter 3 (section 3.2.1), quantitative and qualitative methods differ in their 
underlying ontological and epistemological assumptions, usually from a positivist and interpretivist 
paradigm, respectively. If treated as distinct paradigms, this can cause complexities and confusion 
around the theoretical stance when both qualitative and quantitative methods are used within a 
research study (Bishop, 2015). McEvoy and Richards (2006) suggest adopting a critical realist 
perspective may circumvent these issues, and state that a pragmatic standpoint may also be 
acceptable. Pragmatists argue that the research methods used in a study should be those most 
appropriate to answer the research question, even if researchers have to ‘switch’ between different 
paradigms to do this (Johnson & Onwuegbuzie, 2004; Bishop, 2015). The rationale of this position is 
that neither the use of quantitative methods or of qualitative methods alone is adequate to conduct 
a comprehensive analysis (Creswell et al., 2004). Therefore, they should be used alongside each 
other in a complementary way.  
To fully understand the management of anxiety disorders in primary care, a pragmatic approach was 
taken to achieve the aims of this thesis and multiple methods used. Multi-methods research is 
defined as entailing two or more separate projects answering different research questions, with 
each project considered less dependent on the other projects than would be the case in a mixed 
methods research study (Morse & Cheek, 2014). Employing different methods in this thesis meant 
the most appropriate methods were used to address individual research objectives. Employing 
qualitative methods allowed an in-depth understanding of how anxiety is being identified, diagnosed 
and managed in primary care, from the perspective of GPs, patients, and therapists. Analysis of a 
large quantitative data set (CPRD Gold) provided insight into how trends in recorded anxiety codes 
and anxiolytic prescriptions have changed over time. As practitioners’ views on coding of anxiety and 
prescribing had been explored during the qualitative study, some of the qualitative data indicated 
possible reasons for the trends seen. Therefore, together, the methods used allowed for an 
investigation at two different levels, providing both an overview and detailed insight into the 
identification, diagnosis and management of anxiety disorders in UK primary care.  However, a 
limitation of this thesis is that patients’ and practitioners’ views on the trends observed in the 
quantitative data are not known, as the qualitative interviews were conducted prior to the CPRD 
analysis. An alternative approach to this would have been to use a mixed-methods design, rather 
than multi-methods, in which further qualitative data could have been collected after the findings of 





understand patients’ and practitioners’ views on the increase in recorded anxiety in young adults 
seen in recent years. GPs’ views toward the increase in anxiolytic prescribing could also have been 
explored, particularly that of benzodiazepines, beta-blockers, and antipsychotics. The findings 
generated from this approach would have been different to that of the current design, although 
from a pragmatic stance, may not have been feasible within the constraints of the three-year PhD.  
Within a qualitative framework and an interpretivist stance, the qualitative study aimed to 
understand anxiety through participants’ own background and experiences. Interviewing both GPs 
and therapists gave insight from two different perspectives – those that commonly manage anxiety 
in a general community setting, and those that are trained in the specific psychological management 
of anxiety. Throughout the analysis it was acknowledged that each participant’s account would be 
based on their experiences, their interpretation and understanding of those experiences, and the 
context in which each account was given. As such, there may be differences in understanding 
between, and within, practitioners and patients.  
It was also acknowledged that, within qualitative research, the researcher is part of the data 
collection process and part of the social situation they are investigating (Darawsheh et al., 2014). 
They bring their own assumptions, biases, and experiences to the data collection and analysis 
process. During this thesis, the researcher wrote field notes and reflexive analytic memos to capture 
personal thoughts on her role within this process. This included comments on participant behaviour 
during the interview, and acknowledging that the interview situation can in itself be an anxiety 
provoking situation for interviewees. Some participants may have found it difficult to disclose 
sensitive information to a researcher, whilst this may have put others more at ease. Participants may 
have also altered their responses to what they thought the researcher would expect to hear, or what 
they felt they should say. To address some of these factors, the researcher presented herself as a 
research student with an interest in anything that the participants felt was important to share, and 
spent time prior to the interviews establishing rapport. Interviewees were reassured there were no 
right or wrong answers, that it was their views the researcher wanted to hear, and that the data 
would be treated as confidential. In addition, conducting a large number of interviews by phone may 
have reduced the extent to which the researcher influenced participants’ accounts.  
In the qualitative interviews, patients indicated that they were reluctant to seek help for their 
anxiety, and some only did so after many years. As not all patients seek help for their symptoms, the 
results reported in this thesis are not capturing the views and experiences of patients who have not 
consulted their GP for anxiety. This also includes patients who may have sought help directly from an 





manage their anxiety, or if they have the condition diagnosed. On reflection, the qualitative study 
could have recruited patients for interview though other services, such as charities or support 
groups, or through the IAPT service, rather than just though GP practices. This may have provided 
additional perspectives from patients who have not yet sought help from their GP and an 
understanding of how they are managing their anxiety symptoms. However, whilst this would have 
provided those additional perspectives, this was not done as the focus of this thesis was on the 
management of anxiety within the primary care setting.  
Patients, GPs, and therapists described a significant overlap in the symptoms of anxiety and 
depression. GPs also reported a tendency to use a code for depression rather than code for anxiety if 
both were present and the latter was not clearly the primary problem. Both quantitative studies – 
the coding study and the prescribing study – would not have captured patients that had symptoms 
of anxiety but did not have a recorded anxiety code. Similarly, for both studies, it is not known how 
many patients also had a depression code as well as an anxiety code, and therefore were potentially 
prescribed anxiolytic medication for depression, rather than for anxiety. This is also applicable to 
other indications, such as insomnia, or neuropathic pain. On reflection, in the case of depression, it 
may have been useful to conduct sensitivity analyses to exclude patients that had ever received a 
depression code. However, due to the symptom overlap between anxiety and depression, and their 
frequent co-morbidity, it is likely this would have excluded a large proportion of the study 
population. Additionally, the trends seen over time during the 16 years of the quantitative studies 
may reflect other factors, rather than, or as well as, changes in incidence. This may include changes 
in how symptoms and diagnostic codes are used by GPs, perhaps as a result of the introduction of 
the NICE anxiety guidelines in 2011 (NICE, 2011b), as discussed in the previous section (section 6.2). 
It may also reflect increasing awareness and detection of anxiety by GPs, and therefore treatment 
with anxiolytic medication.  
Both quantitative studies found a clear increase in the incidence of recorded anxiety codes, and of 
anxiolytic prescriptions, in young adults (18-34 years) in recent years. During the interviews, GPs and 
therapists also talked about the increasing presentation of anxiety in younger adults. However, only 
five patients in this age group were interviewed, of which only two were under 30, and both were 
female. Therefore, we do not have multiple perspectives from which to draw insights to help us 
understand the trends seen in young adults. Whilst GPs and therapists talked about social media use 
and increasing pressure on young adults, there was limited data on these factors from the 





In addition, in both quantitative studies, an interaction between age and year, and gender and year, 
was included in all the multivariable poisson regression models in order to examine whether trends 
(in the recording of anxiety/prescribing of anxiolytics) varied according to age, and to gender. This 
was formally tested using a likelihood-ratio test that compared models with and without the 
interaction term, and was repeated for: the recorded incidence of any anxiety code, symptom and 
diagnosis codes; the prevalence of prescriptions of any anxiolytic, and each drug class; and the 
incidence of prescriptions of any anxiolytic, and each drug class. Given this multiple testing (34 tests 
of interaction), there is an increased likelihood of finding evidence against the null hypothesis (of no 
interaction) that is due to chance, and therefore incorrectly rejecting the null hypothesis (a Type I 
error). Therefore, it is important to interpret the evidence of an interaction between year and 
gender/age with caution as some of the differences identified may be due to chance. Moreover, the 
large size of the dataset means that it is possible to identify small differences that may not be 
meaningful. This was particularly apparent in terms of the interaction parameters related to year 
and gender as previously discussed (section 5.3.3 and 5.3.6).   
In the quantitative studies, whilst the potential influence of age and gender on findings was 
examined, no adjustment was made for level of deprivation when investigating trends in recording 
of anxiety or anxiolytic prescriptions. Previous research in this area has indicated that adjustment for 
deprivation does not materially affect the reported trends in coding of anxiety (Walters et al., 2012),  
and evidence for the relationship between deprivation and prescribing of antidepressants is mixed 
(Spence et al., 2014). 
Finally, the quantitative analyses in this thesis were of CPRD Gold data. It is possible that if another 
primary care database had been used, such as THIN or QResearch, then differing trends may have 
been identified. CPRD Gold, THIN and QResearch differ in terms of the practice software they are 
derived from (discussed in Chapter 4, section 4.2.1), with only a 60% overlap in the practices 
providing data to both CPRD Gold and THIN databases (Carbonari et al., 2015). When comparing 
some of the results reported in Chapter 4 to existing research (section 4.4.3), incidence rates of 
coding were higher than rates found in previous similar studies which used the THIN database 
(Walters et al., 2012). Therefore, it is possible that the incidence and prevalence rates reported in 
the present studies may not be generalisable to THIN, or other primary care databases, due to the 
differences in the populations of the contributing practices. Nonetheless, the CPRD Gold database is 
considered to be representative of the UK population (Walley & Mantgani, 1997). In addition, it is 
possible that variation in the READ codes used may also account for differences between the results 





6.4 Implications of findings 
This study found that patients value being given a diagnosis of anxiety in primary care, and that 
doing so can create an opportunity to educate patients about this specific condition. The Royal 
College of General Practitioners (RCGP) GP undergraduate training syllabus explicitly refers to 
anxiety, and states that “there is an increasing recognition of the need to have more focus 
on…improving people's understanding of mental health” (page 206) (Royal College of General 
Practitioners, 2019). Patients’ accounts support this statement. Patients highlighted that the 
diagnosis itself is important, as it improved their understanding of their mental health and could lead 
to them accepting anxiety as a medical condition. For these reasons, diagnosis was an important 
step towards patients being ready to engage with treatment. The qualitative data also indicated that 
it can be important for patients that GPs discuss anxiety as a distinct disorder, alongside depression. 
Patients want anxiety and depression to be considered separately because of the greater impact 
anxiety has on their daily lives, and because it can be a cause of, or at least precede, depression. 
However, GPs often do not distinguish between anxiety and depression when discussing mental 
health with patients and tend to focus more on the management of the symptoms than the 
diagnosis itself. GPs gave valid reasons for why they may not diagnose an anxiety disorder, including 
short appointments and a lack of continuity of care which mean they have limited information on 
which to make a decision. Therefore, continuity of care and follow-up appointments should be 
encouraged for patients presenting with poor mental health. Additionally, despite GPs concerns that 
an anxiety disorder ‘label’ may feel stigmatising, a diagnosis is important for many patients. GPs 
need to be aware that using diagnostic codes in specific way can be helpful for patients’ 
understanding of their mental health. At a wider societal level, patients reported less ‘caring’ 
treatment toward anxiety by other people, compared with depression, with anxiety viewed as ‘just 
worry’. It seems important for both GPs and researchers to consider the discussion of anxiety as a 
distinct disorder from depression. This in turn may help to reduce stigma around anxiety and 
increase understanding of this condition.  
There has been a clear increase in anxiety – in symptoms and diagnoses - in recent years in the UK, 
that was driven by a rise in younger adults. Whilst this may indicate that this group appears to be 
seeking help from GPs, we also need interventions to reduce the risk of developing anxiety, and 
reduce severity of symptoms, that are acceptable and effective for young adults. The need is for 
interventions that are an alternative to pharmacological treatment. Whilst interviews with GPs 
suggested that they think patients often prefer to take medication, this was at odds with patients’ 





anxiolytic medication had increased, particularly prescriptions of antidepressants. The long-term 
effects of taking these drugs are not known, and it can be difficult for patients to discontinue 
treatment, despite the drugs being considered ‘non-addictive’ (Rogers et al., 2007). Additionally, 
some of the prescribing is not based on robust evidence of effectiveness, or is contrary to clinical 
guidelines, and may even be harmful. There is no NICE clinical guidance for the use of beta-blockers 
in anxiety, and a recently published report has highlighted a potential under-recognised risk of harm 
in the use of propranolol for patients with depression or anxiety (Healthcare Safety Investigation 
Branch, 2020). Considering this thesis found evidence for increasing incident beta-blocker 
prescribing in recent years, it is important that the BNF and NICE guidance in relation to anxiety is 
reviewed and updated accordingly. Incident prescriptions for antipsychotics also increased, and this 
is not in line with NICE clinical guidelines, in which the 2011 update specified that antipsychotics 
should no longer be prescribed for GAD (NICE, 2011b). There may be a need for greater awareness 
of this recommendation among GPs, or to understand why this drug has continued to be prescribed 
for anxiety. Furthermore, a rise in benzodiazepine prescribing in young adults, along with lengthy 
duration of prescriptions, is at odds with the NICE clinical guidelines for the management of anxiety 
(NICE, 2011b). It could be important for GPs to reflect on when they are prescribing this drug in 
young adults, and for how long. Future work that could be conducted to investigate this is discussed 
below.  
 
6.5 Future work 
The overall aim of this thesis was to gain an understanding of how anxiety is being diagnosed and 
managed within UK primary care. Whilst this aim has been achieved, further work is needed to 
understand and address some of the findings and the related gaps in our knowledge.  
Research is needed to understand why there has been a rise in anxiety amongst young adults in 
recent years. Whilst we have data on why practitioners think there has been an increase, we need to 
understand why this is happening from young adults themselves. A limitation of this thesis, and 
specifically the qualitative study, is that only five of those interviewed were under the age of 35 and 
clearly this is the age group in which anxiety has risen most notably. Whilst there is previous 
research on help-seeking for mental distress in young adults in the form of interviews (16-24years) 
(Biddle et al., 2006), and survey data (18-25 years) (Salaheddin & Mason, 2016), there is a lack of 
such data in more recent years, particularly with a focus on anxiety. Future qualitative research 
could also explore the views and experiences of anxiety in young adults in terms of causes and 





groups or charities. The latter may enable recruitment of individuals who have not yet sought help 
for their symptoms. In addition, a longitudinal cohort study investigating the impact of the use of the 
internet and social media (referred to by practitioners as possible causes of the rise in anxiety), may 
aid understanding of the role of such factors in the aetiology of anxiety in young adults. Whilst there 
have been previous studies on the relationship between mental health and social media use, a 
recent systematic review concluded that much of the research has methodological limitations, and 
that a longitudinal study, along with qualitative data, is needed (Keles et al., 2020). Such findings 
may help inform the development of interventions for patients with anxiety, particularly for young 
adults, as we know patients are most at risk of anxiety at this age. The Millennium Cohort Study, 
which is an ongoing UK prospective cohort study, has followed a cohort of young people since their 
birth in 2000/2002 (UCL, 2020b). Data has been collected most recently in 2018, at age 17, with 
measures of anxiety and depression, and of social media use (UCL, 2020b), and it may be possible to 
utilise data collected to undertake secondary analyses to answer this question within this or similar 
cohorts..  
In addition, as discussed in the previous section (section 6.4), it is important to understand why 
young adults are being prescribed benzodiazepines. Previous qualitative research has been 
undertaken with GPs to understand when they prescribe benzodiazepines, but it was conducted 
with GPs in America around 2006, and was in relation to prescribing in elderly patients (Cook et al., 
2007b). Other qualitative research has been synthesised to understand GPs’ experiences of 
prescribing this drug, but this was in relation to prescribing in patients of all ages (Sirdifield et al., 
2013). Clearly there is a need for more recent research, particularly in the case of the former study 
which was conducted over ten years ago, as prescribing habits and attitudes may have changed in 
recent years (Mehdi, 2012). It is currently unclear at what point benzodiazepines are being 
prescribed for anxiety in younger adults in terms of severity and chronicity, and how long they are 
being prescribed for. In addition, as discussed previously, it may also be important to understand 
when GPs are prescribing antipsychotics for anxiety. Qualitative research, perhaps in the form of 
semi-structured interviews using vignettes, may help to answer this. Vignettes have been shown to 
be useful in studying attitudes and perceptions, particularly for potentially sensitive topics (Hughes 
& Huby, 2002). It would be important to interview GPs from practices that varied in terms of the 
socio-demographic characteristics of their patient populations, and particularly from practices where 
the rate of benzodiazepine prescribing for anxiety has remained steady over time, rather than 
decreased. 
Finally, it is important to acknowledge the current global pandemic that has been ongoing during the 





substantial mental health impact on many individuals. Some of the causes of anxiety identified by 
practitioners and patients in the interviews will have intensified. These include social isolation, 
increased use of the internet and social media, increase in pressure on young adults in terms of their 
future, and a general sense of uncertainty. Therefore, these factors may have contributed to 
increasing levels of anxiety that have been reported since the start of the pandemic (March 2020), 
particularly in young people (Kwong et al., 2020). The pandemic has also indicated the importance 
of, for example, socialising with other people, and highlighted the number of individuals who are 
living on their own. Any future work will need to take this period of uncertainty into account, and 
research should be undertaken to understand if there has been a lasting impact of COVID-19 on 
levels of anxiety, or on prescribing of treatments for anxiety.  
 
6.6 Closing remarks  
It is clear that the incidence of anxiety symptoms, and anxiety diagnoses, is increasing in UK primary 
care. This was particularly notable in young adults and tackling this is a major public health 
challenge. There has also been a corresponding increase in the number of new patients prescribed 
anxiolytic medication, despite patients reporting a reluctance to take it. Importantly, there is a lack 
of evidence for some of the anxiolytics being prescribed for anxiety, some of this prescribing practice 
is contrary to clinical guidelines, and some may even cause patients harm.  
The key focus for future research is in understanding the rise in anxiety and prescribing in young 
adults. There are effective psychological interventions for the treatment of anxiety but there is a 









A.1 GP interview topic guide 
Topic Guide - GP 
Read through consent form including agreement to audio recording. Reassure confidentiality 
We are interested in your views on how anxiety, both alongside depression and alone, is diagnosed 
and discussed with patients, and managed in primary care. Thinking here in terms of patients with 
general anxiety, and those with more formal anxiety disorders. There are no right or wrong answers. 
I just want to know what you think and what your clinical experiences have been. 
Just so you know something about the structure of the interview, first I am going to ask some 
questions covering anxiety labels, followed by some questions on treatment, and then focus on 
comparing depression and anxiety. 
Anxiety Labels and Patients with Anxiety 
1. Thinking about anxiety, what do you think the causes are? 
A. Do patients present with anxiety, or do they present with another condition or problem? 
B. When they present with anxiety, how do you respond? What do you say, what do you 
do?  
i. What about when they present with another problem? 
C. What labels do you use? 
D. How do you record anxiety in their medical notes? Do you use free text, or codes? 
i. If codes, what codes do you use? 
ii. Do these codes differ from the labels you use with patients? If so, why? 
iii. What factors influence your choice of codes/text to record? 
 
2. Do you think there is a distinction between ‘anxiety’ and ‘anxiety disorder’, and if so, in what 
way is this this reflected in what you say, record and do? (Prompt – how do you define an 
anxiety disorder; do you use generalised anxiety disorder/phobia/panic disorder or just anxiety 
disorder). 
A. Do you differentiate between the sub-types of anxiety? 
B. Do you think within society in general, anxiety is normalised or over-medicalised? 






3. How often do you see patients with anxiety or anxiety disorders?  
A. Who do you think is most at risk of anxiety?   
B. Who tends to consult about it? 
C. When seeing such patients, how often do you diagnose anxiety disorders? 
i. And when do you make a diagnosis? So, thinking here in terms of symptoms, 
duration, and knowledge of patient. 
ii. Having made a diagnosis, do you then communicate this to the patient? If so, 
when; if not, why not. (Prompts – patient opinion, value of doing so, stigma, any 
other factors) 
 
4. How do patients react to being given a label/diagnosis? 
A. What do you think is the value of giving a diagnosis? (Prompt – is recognition 
important?)   
B. Are there any negative implications to giving a label/diagnosis? 
Anxiety Treatment [if not already covered in above questions] 
5. Thinking about treatment, how do you normally manage patients with anxiety?  
A. How often do you prescribe, and what would trigger a prescription? E.g. Severity? 
Chronicity? Patient preference? Comorbidity with depression?  
B. What medication do you usually prescribe?  
i. Has that always been the case? 
ii. When do you use benzodiazepines? (Prompt – acute crisis, start SSRIs, second 
line treatment) 
C. Do you currently refer patients with anxiety to IAPT services? 
i. What do you think the role of IAPT is? 
ii. What are your reasons for referring/not referring patients to IAPT? 
D. What do you think the role of secondary care is? (Prompt – sub-types) 
i. What are your reasons for referring/not referring patients to secondary care? 
Comparing Anxiety and Depression 
6. So, in what ways do you think depression and anxiety are similar or different, in terms of causes, 
symptoms, chronicity and how they play out in terms of the patient’s life?  
7. And how do you think they are similar or different in terms of management? 






B. [If not already covered] And how do you think they are similar or different in terms of 
therapy accessed through IAPT? (or other support or therapies accessed) 
 
Comorbid Anxiety and Depression 
8. Thinking about patients that present with both anxiety and depression, are you more likely to 
diagnose one before the other? If yes, why?  (Prompt - It is more common, more easily 
diagnosed, more important to manage) 
A. How do you manage these patients? Do you treat them separately? 
B. What labels do you use with these patients?  (is depression used a label for both? Is it a 
more acceptable term?) 
C. What codes and notes do you record in their medical notes? 
D. Do you distinguish anxiety from depression?  If so, do you explain this comorbidity to the 
patient? 
i. How do you do that? 
ii. Why/Why not? (Prompt – value in distinguishing) 
iii. Do you prioritise treating one over the other?   
iv. What treatment, support and advice to you offer? 
E. Evidence shows that patients with a comorbid diagnosis of anxiety and depression have 
a worse prognosis than those with a single mood disorder. Why do you think that is? 
 
9. Do you have any other points you would like to mention about managing patients with anxiety 
disorders or comorbid anxiety and depression? 
 

















Patients’ and Practitioners’ views on detecting, diagnosing and 
managing Anxiety Disorders in Primary Care 
Patient Information Sheet 
We would like to invite you to take part in a research study. Before you decide whether to take part, 
it is important you understand why the research is being done and what it would involve for you. 
Please take the time to read the following information carefully. Please ask us if there is anything 
that is not clear or if you would like more information. 
What is the purpose of the study?  
Researchers at the University of Bristol are interested in the views and experiences of patients who 
have symptoms of anxiety, or have been diagnosed with an anxiety disorder. Research has shown 
that less people are being diagnosed with anxiety over time, despite reports of more people 
experiencing anxiety in the general population.  
Studies have suggested that people with anxiety may be reluctant to seek help for their symptoms, 
they may find it difficult to talk about their mental health with their GP, or they may view their 
anxiety as just a normal part of life. To date, there has been very little research on how patients 
think about anxiety, why patients may or may not seek help, and how this may impact on whether 
they are given a diagnosis. In addition, very little is known about what treatments or support they 
find most helpful for managing their symptoms.  
As part of this study we are asking patients to take part in an interview to explore their views and 
experiences of anxiety. We hope to interview 20 patients in total.  
Why have I been contacted? 
Having discussed symptoms of anxiety during a recent consultation with your GP, you will have been 
given an information leaflet about this study by your GP or been posted an invitation letter and 
information about the study from your GP surgery. Your GP practice has not and will not pass on 
your details to the research team without your permission.  
What is involved? 
If you agree to take part in the study, you will be asked to take part in an interview with a member of 
the research team. First, the researcher would telephone you to discuss the study and answer any 
questions you may have. If you are willing to be interviewed, the researcher will agree a time and 
place to interview you. You can choose to be interviewed over the telephone, at your own home, or 
in a private room at your GP practice. The interview will last about 30-40minutes. Just before the 
interview, the researcher will answer any further questions you may have and ask you sign a consent 





interview you would be asked about your views and experiences of seeking help for anxiety, 
treatments for anxiety, and how you view anxiety compared with depression. After the interview 
you will be asked to complete some short questions about yourself and your mental health.  
What do I need to do if I want to take part? 
If you are interested in taking part, please ask your GP to refer you to the study. They will then pass 
your contact details to the study team. 
If you have received the study invitation in the post, please complete the reply form enclosed with 
the invitation, and return this to the research team in the prepaid envelope provided. The 
researcher will then contact you (as described above).   
We hope to interview people from a range of backgrounds. Therefore, we may not contact everyone 
who is willing to be interviewed. 
Do I have to take part? 
You do not have to take part in this research study. If you do decide to take part, you can withdraw 
from the interview at any stage or chose not to answer specific questions.   
What are the possible benefits of taking part? 
You may enjoy talking to a researcher about your views and experiences, and the information you 
provide will help inform patient care for people with anxiety. Those who take part in an interview 
will be given a £10 shopping voucher to thank them for their time.  
What are the possible disadvantages to taking part? 
Some people may find it difficult to talk about their experiences. However, the researcher will do 
their best to make you feel comfortable. If you experience any distress during the interview, this will 
be handled sensitively, and, if required, we will be able to contact a study clinician to offer support if 
necessary. Your participation is voluntary, and you do not have to answer any question if you do not 
want to. Also, you can stop the interview at any time, without giving a reason and without your 
medical care being affected. 
What will happen to the information that I provide?  
Any information that you give us will be treated as confidential, and audio recordings of the 
interviewed will be deleted as soon as possible after the interview, once they been typed up. In 
addition, once the interview is typed up, any names mentioned will be removed so that the written 
record is anonymous. When reporting the findings of the study, we may use direct quotes from you. 
If we do this, we will give you a false name so that your identity is protected. Anonymised transcripts 
will be archived for use in future research studies in the area of mental health. 
If we have concerns about your safety or the safety of others, we may have to inform your GP. 
Wherever possible we would consult you before doing this. We would only pass information to your 
GP without first consulting you, if we had immediate concerns for your welfare (for example, if you 
told us that you were having thoughts of harming yourself) or the welfare of others. 
We will keep your contact details for up to 7 years (in line with University of Bristol archiving 
policies); we will then destroy this information securely. We will keep anonymised, electronic 





What will happen to the results of the interviews? 
The results will be published in medical journals and presented at conferences to health care 
professionals and researchers. We will also send a summary of the findings to everyone who has 
taken part in an interview.  
Who is organising and funding the study?  
The study is being funded by the NIHR School for Primary Care Research as part of a PhD at the 
University of Bristol. The University of Bristol is the study’s sponsor and is responsible for the 
research. Further information on the School can be found through this link - www.spcr.nihr.ac.uk. 
Who has reviewed the study?  
Ethical approval has been obtained from South West – Frenchay Research Ethics Committee. 
Complaints 
If you have a concern about any aspect of this study you can contact the researcher 
(charlotte.archer@bristol.ac.uk or 0117 331 0146), or one of the senior members of the research 
team based at the University of Bristol (nicola.wiles@bristol.ac.uk or 0117 331 3358). 
You can also contact the Bristol Clinical Commissioning group (CCG) Patient Advice and Liaison 
Service (PALS) (bnssg.pals@nhs.net or 0117 947 4477). The PALS service is independent to the 
research project and will be able to help with any complaints or problems you may wish to report. 
Contact for further information 
If you have any questions about the study or require further information, please contact Charlotte 
Archer by writing to the Centre for Academic Mental Health, University of Bristol, Oakfield House, 
Oakfield Road, Bristol, BS8 2BN, telephoning her on 01173310146, or emailing her on 
charlotte.archer@bristol.ac.uk.  
 















A.3 Patient interview topic guide 
Patient Topic Guide  
Read through consent form including agreement to audio recording. Reassure confidentiality.  
We are interested in your views on how anxiety disorders, both alongside depression and alone, are 
diagnosed and talked about. There are no right or wrong answers. I just want to know what you 
think and what your experience has been. 
Just so you know something about the structure of the interview, first I am going to ask some 
questions about yourself and your mental health, followed by some questions on labels and 
treatment of anxiety, and then compare anxiety with depression.  
The individual  
1. So just to give me some context, please can you tell me a bit about yourself, for example, your 
age, who you live with, and what you do? 
A. Can you now tell me a bit about your mental health? What has it been like for you, what 
symptoms do you experience and how long have you had them? 
B. How has it impacted on you and your life? How frequent or severe are your symptoms? 
C. Would you say you are someone who tend to be anxious a lot of the time? If so, what in 
particular made you seek help? 
D. What do you think is the cause of your symptoms/mental health/anxiety? (use patients 
descriptive) 
Help seeking and Diagnosis 
2. In the past you have discussed symptoms of anxiety with your GP, do you remember who 
brought it up? Was it yourself or your GP? 
A. [If GP] What did you think to that? Did you find it helpful? 
B. [If self] When did you first seek help for your symptoms/mental health/anxiety from 
your GP and why did you seek it then? (use patients descriptive) 
i. Why had you not sought help earlier?  Were there any factors that made you 
reluctant to seek help?  
ii. And when you brought it up with your GP, how did they respond to you? 
C. How do you feel talking to your GP about how your symptoms/mental health/anxiety? 
How easy or difficult is it to discuss with your GP? Prompt – duration, training, continuity 







3. Has your GP discussed with you any diagnoses or labels for your symptoms? 
A. [If have label/diagnosis] How long after seeking help from your GP/your GP brought up 
your symptoms of anxiety did s/he give you a diagnosis or label? 
i. How easy was it to understand and accept the diagnosis or label? 
ii. Was having a diagnosis or label for your symptoms important to you? 
iii. In what way did receiving a diagnosis or label change or affect you, if at all? 
Treatment 
4. Have you ever received any treatment for your symptoms/anxiety/mental health? (use patients 
descriptive) 
A. Thinking about when you were first given a label or explanation for your symptoms, can 
you remember what treatment or support options your GP discussed with you? Which 
did you choose, if any? Why or why didn’t you choose those options? Prompt - 
medication, talking therapy, other 
B. [If chose medication], What medication were you prescribed? Did you find this the 
medication helpful? If yes, why? If not, why not? 
i.How long did you take this medication for, or are you still taking it? If you stopped 
taking it, why have you stopped? 
ii.Did you experience any side effects? 
C. [If chose therapy or other support] What therapy/support did you receive? Who 
provided it? 
i. Did you find this therapy/support helpful? If yes, why? If not, why not? 
ii. How long did you receive this therapy for?  
 
5. Since then, what other treatments or support have you had for your mental 
health/symptoms/anxiety? (use patients descriptive) Prompt - medication, talking therapy, other 
A. What do you or did you find helpful?  
B. What do you or did you find less helpful?  
C. [If taking medication] How long did you take this medication for, or are you still taking 
it? If you stopped taking it, why have you stopped? 
i. Did you experience any side effects? 
D.  [If receiving therapy or other support] Who provides this therapy/support? How long 






6. Do you think anxiety is ‘treated’ or ‘managed’? 
A. What do you want from your GP in terms of support? 
B. What do you want from a treatment? 
C. What do you think about the support and treatment you have been given? 
 
7. Thinking more generally, is there anything else you have found helpful or unhelpful in terms of 
treatment or management of your mental health/symptoms/anxiety? (use patients descriptive).  
Comparing anxiety to depression 
8. So now thinking about depression, have you ever had, or do you currently have, depression?  
A. Thinking about anxiety and depression as separate diagnoses, what do you think the 
differences are between them, in terms of causes, symptoms, and the impact they can have 
on people’s lives? 
B. Do you think there is more, or less, awareness and understanding of anxiety compared 
with depression? 
C. Sometimes depression can be seen as an illness, do you see anxiety in the same way, or as 
a normal part of life? 
D. [For patients that mention co-morbid depression] Having been diagnosed with depression 
and anxiety, do you find one easier to manage or talk about than the other? 
E. [For patients that mention co-morbid depression] In terms of the 
medication/therapy/support that you have tried, did the GP/therapist explain they were 
treating just the anxiety or just the depression, or treating both together? Prompt – helpful, 
appropriate 
9. Is there anything you want to talk about in relation to the diagnosis and management of anxiety 
disorders? 
  















IAPT Therapist Consent Form 
Patients’ and Practitioners’ views on detecting, diagnosing and managing 
Anxiety Disorders in Primary Care 
Participant Study ID:  ___________________ Please initial 
the box 
1.  I have read and understood the information sheet dated 14/05/2018 
(version 2.0) for the above study, and been given a copy to keep. 
 
 
2.  I have had the opportunity to consider the information and ask any 
questions. I have had satisfactory answers to all of my questions. 
 
 
3.  I understand that my participation is voluntary and that I am free to 
stop the interview at any time, without giving any reason, and without 
my legal rights being affected. 
 
 
4.  I understand I will be asked to complete a short questionnaire about my 
background and professional experience. 
 
 
5.  I understand that all the information I give will be treated as 
confidential by the study team, unless there are concerns for my safety 
or the safety of others. 
 
 
6.  I understand that the interview will be audio taped and the recording 
will be stored on a secure computer at the University 
 
 
7.  I understand that the interview will be typed up and that parts of what I 




8.  I agree that all the information collected can be stored and analysed by 
the research team 
 
 
9.  I understand that all the information collected (including the transcript 
of my interview) will be stored for use in future studies in the area of 


















Name of Therapist  
(BLOCK CAPITALS)  
Date Signature 



















Name of Researcher 
(BLOCK CAPITALS)  
Date Signature 
2 copies of form to be completed: 1 for therapist to keep; 1 for researcher site file. If verbal consent 














A.5 Therapist interview topic guide 
 
10.  I understand that relevant sections of the data collected during the 
study may be looked at by individuals from the University of Bristol, 
from regulatory authorities, or from the NHS Trust, where it is relevant 
to my taking part in this research. I give permission for these individuals 
to have access to my records. 
 
 







Topic Guide – IAPT Therapist 
Read through consent form and agree to audio recording. Reassure confidentiality 
We are interested in your views on how anxiety, both alongside depression and alone, is managed 
within IAPT services. Thinking in terms of patients with general anxiety, and those with more formal 
disorders. There are no right or wrong answers. I just want to know what you think and what your 
clinical experiences have been. 
Just so you know something about the structure of the interview, first I am going to ask some 
questions covering patients with anxiety, followed by some questions on treatment approaches, and 
then focus on comorbid anxiety and depression.  
Anxiety Labels and Patients with Anxiety, and links with GP 
2. Just starting off, please could you give me a little bit of information on your professional 
background, so how long you have worked in IAPT, the types of therapy you deliver, and the 
types of patient you see.  
3. Thinking about anxiety, what do you think the causes are? 
E. What symptoms do patients with anxiety discuss with you or present to you?  
F. How do you respond and discuss that with them? 
G. What labels do you use? 
i. [If use anxiety label] How do patients respond to being labelled with anxiety? 
H. How do you record anxiety in their IAPTUS notes? Do you use free text, or codes? 
iv. If codes, what codes do you use? 
v. Do these codes differ from the labels you use with patients? If so, why? 
vi. What factors influence your choice of codes/text to record? 
 
10. Do you think there is a distinction between ‘anxiety’ and ‘anxiety disorder’, and if so, in what 
way is this reflected in the therapies offered within IAPT services? (Prompt – how do you define 
an anxiety disorder; do you use generalised anxiety disorder/phobia/panic disorder or just 
anxiety disorder). 
A. What do you think comes under the umbrella of anxiety disorder, in terms of sub-types? 
B. Do you differentiate between the sub-types of anxiety? If yes, when do you? 
C. Do you think within society in general, anxiety is normalised or over medicalised? 
D. Do you think within IAPT anxiety is normalised or over medicalised? 
 
11. How often do you see patients with just anxiety or anxiety disorders? How does this compare to 
how many people you see with mixed anxiety and depression?  
D. Who do you think is most at risk of anxiety?   





F. Who tends to self-refer, rather than be referred by their GP? 
G. What do you think is the value of patients being given a diagnosis? (Prompt – Is 
recognition important?)  
i. Does having a diagnosis or label prior to IAPT therapy impact on engagement 
with treatment? (Prompt: from a GP or other professional) 
ii. What codes do GPs tend to use when referring patients to you? 
iii. Do you think GPs are able to appropriately diagnose and manage anxiety?  
 
Treatment and the IAPT service 
12. At what point during the patient’s engagement with the IAPT service is their problem identified, 
and how is this done?  
A. What screening questionnaires do you use? 
B. Once the problem has been identified as anxiety, how do you usually manage these 
patients in terms of treatment? How do you go about deciding what the patient wants 
to work on? 
i. Is this different from their original hopes or ideas for therapy? 
 
13. Where within IAPT’s stepped care model is treatment for patients with anxiety provided?  
A. Why here?  What do you think of this in terms of appropriateness?  
B. Do you think IAPT therapists are able to appropriately diagnose and manage anxiety? 
C. Who mainly works with these patients? (Probe - High intensity workers vs. low intensity 
workers).  
 
Comparing Anxiety and Depression 
14. So, in what ways do you think depression and anxiety are similar or different, in terms of causes, 
symptoms, chronicity and how they play out in terms of the patient’s life?  
 
15. And how do you think they are similar or different in terms of management? 
A. [If not already covered] How do you think they are similar or different in terms of 
therapy accessed through and management in IAPT? (Prompt: aims, focus, content, 
structure, order).   
B. [If not already covered] And how do you think they are similar or different in terms of 





C. How do you think anxiety and depression be managed, and where? 
 
Comorbid Anxiety and Depression 
16. Thinking about patients that present with both anxiety and depression, how do you manage 
these patients?  
A. Is the depression and anxiety treated together or separately? How important is it to 
treat together/separately? 
i. If treated together, do you distinguish anxiety from depression when talking to 
the patient? 
ii. How do you do that? 
iii. Why/Why not? (Prompt – value in distinguishing) 
B. Do these patients tend to choose to deal with their anxiety or depression first? 
C. i. Does this treatment tend to improve symptoms of both diagnoses? 
ii. If not, do patients tend to return for therapy for the un-treated disorder? What labels 
do you use with these patients?   
D. What codes and notes do you record in their IAPTUS notes? 
i. How do these codes influence the treatment pathway? 
E. Evidence shows that patients with a comorbid diagnosis of anxiety and depression have 
a worse prognosis than those with a single mood disorder. Why do you think that is? 
 
17. Do you have any other points you would like to mention about managing patients with anxiety in 
IAPT services? 
















A.7 List of read codes  
Anxiety codes 
1B13.11 Anxiousness symptom 
1B12.11 Nerves 
1B12.12 Tension - nervous 
1B13.00 Anxiousness 
1Bk.00 Worried 
1B12.00 Nerves - nervousness 
1B13.12 - Anxious 
2258.00 O/E - anxious 
225J.00 O/E panic attack 
E200.00 Anxiety states [parent] 
E200000 Anxiety state unspecified 
E200100 Panic disorder 
E200111 Panic attack 
E200200 Generalised anxiety disorder 
E200300 Anxiety with depression 
E200400 Chronic anxiety 
E200500 Recurrent anxiety 
E200z00 Anxiety state NOS 
E202100 Agoraphobia with panic attacks 
E202.11 Social phobic disorders 
E202200 Agoraphobia without mention of panic attacks 
Eu34114 [X] Persistent anxiety depression 
Eu40000 [X] Agoraphobia 
Eu40011 [X] Agoraphobia without history of panic disorder 
Eu40012 [X] Panic disorder with agoraphobia 
Eu40100 [X] Social phobias 
Eu40112 [X] Social neurosis 
Eu41.00 [X] Other anxiety disorders 
Eu41000 [X] Panic disorder [episodic paroxysmal anxiety] 
Eu41011 [X] Panic attack 
Eu41012 [X] Panic state 





Eu41111 [X] Anxiety neurosis 
Eu41113 [X] Anxiety state 
Eu41200 [X] Mixed anxiety and depressive disorder 
Eu41211 [X] Mild anxiety depression 
Eu41300 [X] Other mixed anxiety disorders 
Eu41y00 [X] Other specified anxiety disorders 
Eu41z00 [X] Anxiety disorder, unspecified 






A.8 Incidence rate ratios for GP recorded anxiety - diagnosis and symptom codes, accounting for clustering by general practice 
Table 31 Incidence rate ratios for GP recorded anxiety - diagnosis and symptom codes, accounting for clustering by general practice 
Variable  Any anxiety code Diagnosis Symptom 
Multivariable IRR* (95%CI) P value Multivariable IRR* (95%CI) P value Multivariable IRR* (95%CI) P value 
Year 2003 1.00  <0.001 1.00  <0.001 1.00  <0.001 
2004 1.03 (1.00-1.07) 0.96 (0.92-1.00) 1.20 (1.08-1.33) 
2005 1.04 (0.99-1.10) 0.93 (0.88-0.99) 1.25 (1.12-1.41) 
2006 1.04 (0.98-1.10) 0.89 (0.82-0.96) 1.34 (1.20-1.50) 
2007 1.05 (0.98-1.13) 0.84 (0.76-0.93) 1.47 (1.29-1.67) 
2008 1.04 (0.97-1.12) 0.78 (0.70-0.86) 1.56 (1.35-1.79) 
2009 1.12 (1.04-1.20) 0.83 (0.74-0.92) 1.65 (1.43-1.90) 
2010 1.10 (1.01-1.19) 0.79 (0.70-0.89) 1.67 (1.43-1.95) 
2011 1.14 (1.06-1.24) 0.80 (0.71-0.90) 1.77 (1.53-2.06) 
2012 1.21 (1.11-1.31) 0.84 (0.74-0.94) 1.89 (1.60-2.23) 
2013 1.24 (1.14-1.34) 0.84 (0.75-0.95) 1.96 (1.69-2.27) 
2014 1.27 (1.17-1.38) 0.87 (0.77-0.98) 2.01 (1.72-2.35) 
2015 1.36 (1.26-1.48) 0.93 (0.83-1.05) 2.12 (1.81-2.49) 
2016 1.51 (1.39-1.64) 1.08 (0.95-1.22) 2.28 (1.92-2.69) 
2017 1.58 (1.45-1.72) 1.12 (0.99-1.27) 2.38 (1.99-2.83) 
2018 1.65 (1.52-1.81) 1.20 (1.06-1.36) 2.41 (2.02-2.88) 
Gender Male 1.00  <0.001 1.00  <0.001 1.00  <0.001 
Female 2.13 (2.09-2.16) 2.07 (2.03-2.11) 2.12 (2.06-2.17) 
Age Band 
(years) 
18-24 1.00  <0.001 1.00  <0.001 1.00  <0.001 
25-34 1.08 (1.05-1.12) 1.08 (1.05-1.12) 1.07 (1.04-1.11) 
35-44 1.05 (1.01-1.09) 1.06 (1.02-1.10) 1.00 (0.95-1.04) 
44-54 0.97 (0.93-1.02) 0.96 (0.92-1.00) 0.93 (0.88-0.99) 
55-64 0.84 (0.80-0.88) 0.80 (0.76-0.84) 0.83 (0.78-0.89) 
65-74 0.72 (0.68-0.76) 0.64 (0.60-0.67) 0.78 (0.72-0.84) 
75-84 0.73 (0.69-0.78) 0.62 (0.58-0.66) 0.83 (0.76-0.92) 
85+ 0.58 (0.53-0.64) 0.48 (0.44-0.52) 0.67 (0.59-0.76) 





A.9 Incidence rates for GP recorded any anxiety code between 2003 and 2018 by gender 































Variable Any anxiety code 
Gender Year N of events PYAR Incidence 
(1000PYAR) 
(95%CI) 
Male 2003 6304 543552.7 11.6 (11.3-11.9) 
2004 6560 545658.2 12.0 (11.7-12.3) 
2005 6535 544270.4 12.0 (11.7-12.3) 
2006 6539 546649.9 12.0 (11.7-12.3) 
2007 6545 548228.9 11.9 (11.7-12.2) 
2008 6515 552185.9 11.8 (11.5-12.1) 
2009 7066 553369.5 12.8 (12.5-13.1) 
2010 6899 555542.8 12.4 (12.1-12.7) 
2011 7236 555648.8 13.0 (12.7-13.3) 
2012 7778 558733.4 13.9 (13.6-14.2) 
2013 7860 558795.8 14.1 (13.8-14.4) 
2014 8029 562217.3 14.3 (14.0-14.6) 
2015 8591 565304.3 15.2 (14.9-15.5) 
2016 9756 569055.1 17.1 (16.8-19.5) 
2017 10035 570041.4 17.6 (17.3-18.0) 
2018 10581 571285.7 18.5 (18.2-18.9) 
Female 2003 13349 561287.3 23.8 (23.4-24.2) 
2004 13614 555435.5 24.5 (24.1-24.9) 
2005 13604 546254.9 24.9 (24.5-25.3) 
2006 13430 542955.5 24.7 (24.3-25.2) 
2007 13620 539418.2 25.3 (24.8-25.7) 
2008 13494 539335.4 25.0 (24.6-25.5) 
2009 14257 536586.6 26.6 (26.1-27.0) 
2010 14107 536094.4 26.3 (25.9-26.8) 
2011 14572 535672.9 27.2 (26.8-27.7) 
2012 15336 537700.5 28.5 (28.1-29.0) 
2013 15785 537306.6 29.4 (28.9-29.8) 
2014 16291 537438.6 30.3 (29.9-30.8) 
2015 17497 537874.8 32.5 (32.1-33.0) 
2016 19196 538701.5 35.6 (35.1-36.1) 
2017 20217 536615.3 37.7 (37.2-38.2) 






A.10 Incidence rates for GP recorded anxiety –anxiety diagnoses and anxiety symptoms – 
between 2003 and 2018 by gender 
Table 33 Incidence rates for GP recorded anxiety –anxiety diagnoses and anxiety symptoms – 
between 2003 and 2018 by gender 
Variable Diagnoses Symptoms 









Male 2003 4635 544350.3 8.5 (8.3-8.8) 2221 545599.9 4.1 (3.9-4.2) 
2004 4499 548188.7 8.2 (8.0-8.5) 2671 551347.3 4.8 (4.7-5.0) 
2005 4358 548466.8 8.0 (7.7-8.2) 2761 552893.2 5.0 (4.8-5.2) 
2006 4135 552412.6 7.5 (7.3-7.7) 3054 557670.6 5.5 (5.3-5.7) 
2007 3900 555506.7 7.0 (6.8-7.2) 3304 561012.4 5.9 (5.7-6.1) 
2008 3670 561067.7 6.5 (6.3-6.8) 3505 566396.5 6.2 (6.0-6.4) 
2009 3938 563874.4 7.0 (6.8-7.2) 3829 568816.7 6.7 (6.5-7.0) 
2010 3834 567609.2 6.8 (6.5-7.0) 3787 572203.5 6.6 (6.4-6.8) 
2011 3942 569122.8 6.9 (6.7-7.2) 4011 573363.1 7.0 (6.8-7.2) 
2012 4200 573727 7.3 (7.1-7.6) 4414 577532.3 7.6 (7.4-7.9) 
2013 4251 575153.7 7.4 (7.2-7.6) 4435 578626.9 7.7 (7.4-7.9) 
2014 4358 579977.6 7.5 (7.3-7.7) 4606 582997.1 7.9 (7.7-8.1) 
2015 4648 584412.9 8.0 (7.7-8.2) 4881 587058.3 8.3 (8.1-8.6) 
2016 5476 589574.6 9.3 (9.0-9.5) 5400 592054.6 9.1 (8.9-9.4) 
2017 5730 591884.4 9.7 (9.4-9.9) 5424 594415.2 9.1 (8.9-9.4) 
2018 6169 594429.1 10.4 (10.1-10.6) 5559 597261.7 9.3 (9.1-9.6) 
Female 2003 9925 562974.3 17.6 (17.3-18.0) 4684 565671.2 8.3 (8.0-8.5) 
2004 9458 560647.1 16.9 (16.5-17.2) 5624 567469.7 9.9 (9.7-10.2) 
2005 9118 554856.7 16.4 (16.1-16.8) 5907 564257.5 10.5 (10.2-10.7) 
2006 8673 554631.6 15.6 (15.3-16.0) 6247 565530.9 11.1 (10.8-11.3) 
2007 8272 553988.2 14.9 (14.6-15.3) 6911 565566.6 12.2 (11.9-12.5) 
2008 7654 556878.8 13.7 (13.4-14.1) 7379 568120.3 13.0 (12.7-13.3) 
2009 8098 557063.6 14.5 (14.2-14.9) 7696 567679.7 13.6 (13.3-13.9) 
2010 7748 559247.4 13.9 (13.6-14.2) 7936 569284.6 13.9 (13.6-14.3) 
2011 7743 561546.1 13.8 (13.5-14.1) 8454 570493.4 14.8 (14.5-15.1) 
2012 8118 566365.2 14.3 (14.0-14.7) 8958 574077 15.6 (15.3-15.9) 
2013 8205 568338.9 14.4 (14.1-14.8) 9411 575007.1 16.4 (16.0-16.7) 
2014 8552 571015.8 15.0 (14.7-15.3) 9644 576475.4 16.7 (16.4-17.1) 
2015 9259 573988.8 16.1 (15.8-16.5) 10256 578389.1 17.7 (17.4-18.1) 
2016 10661 577522.2 18.5 (18.1-18.8) 10905 581342.2 18.8 (18.4-19.1) 
2017 11105 577582.9 19.2 (18.9-19.6) 11607 581258.9 20.0 (19.6-20.3) 





A.11 Incidence rates for GP recorded anxiety – any anxiety code, anxiety diagnoses and anxiety symptoms – between 2003 and 2018 by age 
Table 34 Incidence rates for GP recorded anxiety – any anxiety code, anxiety diagnoses and anxiety symptoms – between 2003 and 2018 by age 
Variable Any anxiety code Diagnosis Symptom 
Age 
band 













<25 2003 1582 107319.9 14.7 (14.0-15.5) 1225 107503.1 11.4 (10.8-12.1) 492 107868.6 4.6 (4.2-5.0) 
2004 1618 107411.1 15.1 (14.3-15.8) 1147 107910 10.6 (10.0-11.3) 616 108747.7 5.7 (5.2-6.1) 
2005 1662 106761.4 15.6 (14.8-16.3) 1131 107586.6 10.5 (9.9-11.1) 690 108521.4 6.4 (5.9-6.9) 
2006 1647 107927.9 15.3 (14.5-16.0) 1067 109003.2 9.8 (9.2-10.4) 729 109943.8 6.6 (6.2-7.1) 
2007 1696 109077.5 15.6 (14.8-16.3) 1042 110390.8 9.4 (8.9-10.0) 807 111189 7.3 (6.8-7.8) 
2008 1791 111442.7 16.1 (15.3-16.8) 1045 112921.7 9.3 (8.7-9.8) 897 113614.5 7.9 (7.4-8.4) 
2009 1887 112236.1 16.8 (16.1-17.6) 1123 113917.3 9.9 (9.3-10.5) 955 114465.8 8.3 (7.8-8.9) 
2010 1992 113160.3 17.6 (16.8-18.4) 1134 114968 9.9 (9.3-10.5) 1084 115355.6 9.4 (8.9-10.0) 
2011 2150 113537.3 18.9 (18.1-19.8) 1251 115496.5 10.8 (10.2-11.5) 1116 115742.8 9.6 (9.1-10.2) 
2012 2294 114650.5 20.0 (19.2-20.8) 1269 116750.3 10.9 (10.3-11.5) 1313 116930.6 11.2 (10.6-11.9) 
2013 2585 114512 22.6 (21.7-23.5) 1381 116756.8 11.8 (11.2-12.5) 1474 116807.2 12.6 (12.0-13.3) 
2014 2899 114271.1 25.4 (24.5-26.3) 1615 116761.2 13.8 (13.2-14.5) 1629 116769.2 14.0 (13.3-14.6) 
2015 3436 113289.3 30.3 (29.3-31.4) 1868 116072.3 16.1 (15.4-16.8) 1929 116027 16.6 (15.9-17.4) 
2016 4058 111990.4 36.2 (35.1-37.4) 2253 115250.3 19.6 (18.8-20.4) 2292 115144.9 19.9 (19.1-20.7) 
2017 4274 110473.8 38.7 (37.5-39.9) 2393 114138.8 21.0 (20.1-21.8) 2371 114009.7 20.8 (20.0-21.7) 
2018 4712 109112.6 43.2 (42.0-44.4) 2755 113059.8 24.4 (23.5-25.3) 2506 113089.2 22.2 (21.3-23.0) 
25-
34 
2003 3347 187876.1 17.8 (17.2-18.4) 2563 188252.3 13.6 (13.1-14.2) 1080 189013.5 5.7 (5.4-6.1) 
2004 3362 184527.9 18.2 (17.6-18.9) 2387 185668.2 12.9 (12.4-13.4) 1293 187532.8 6.9 (6.5-7.3) 
2005 3228 181083.1 17.8 (17.2-18.5) 2222 182896.2 12.2 (11.7-12.7) 1312 185423.1 7.1 (6.7-7.5) 





2007 3368 177331.2 19.0 (18.4-19.7) 2148 180297.2 11.9 (11.4-12.4) 1606 183253 8.8 (8.3-9.2) 
2008 3381 176953.3 19.1 (18.5-19.8) 2020 180548.2 11.2 (10.7-11.7) 1751 183384.1 9.6 (9.1-10.0) 
2009 3684 177128.9 20.8 (20.1-21.5) 2178 181362.3 12.0 (11.5-12.5) 1904 183963.5 10.4 (9.9-10.8) 
2010 3591 178077.8 20.2 (19.5-20.8) 2074 182940.6 11.3 (10.9-11.8) 1920 185365.4 10.4 (9.9-10.8) 
2011 3907 179423.6 21.8 (21.1-22.5) 2143 184977.2 11.6 (11.1-12.1) 2188 187020.8 11.7 (11.2-12.2) 
2012 4427 181854.2 24.3 (23.6-25.1) 2414 188128.3 12.8 (12.3-13.4) 2516 189826.7 13.3 (12.7-13.8) 
2013 4567 182407.8 25.0 (24.3-25.8) 2480 189373.4 13.1 (12.6-13.6) 2646 190728 13.9 (13.4-14.4) 
2014 5036 182770 27.6 (26.8-28.3) 2816 190384.7 14.8 (14.3-15.4) 2871 191311.7 15.0 (14.5-15.6) 
2015 5664 183326.6 30.9 (30.1-31.7) 3102 191652.1 16.2 (15.6-16.8) 3274 192182.2 17.0 (16.5-17.6) 
2016 6337 183383 34.6 (33.7-35.4) 3630 192478.9 18.9 (18.3-19.5) 3582 192851.5 18.6 (18.0-19.2) 
2017 6970 182359.7 38.2 (37.3-39.1) 3999 192097.7 20.8 (20.2-21.5) 3933 192518.5 20.4 (19.8-21.1) 
2018 7427 181263.3 41.0 (40.1-41.9) 4346 191706.6 22.7 (22.0-23.4) 4072 192145.1 21.2 (20.6-21.9) 
35-
44 
2003 4459 224848.8 19.8 (19.3-20.4) 3476 225313.2 15.4 (14.9-16.0) 1416 226414.2 6.3 (5.9-6.6) 
2004 4486 224455.6 20.0 (19.4-20.6) 3261 226015.3 14.4 (13.9-14.9) 1701 228721.8 7.4 (7.1-7.8) 
2005 4458 221398.7 20.1 (19.6-20.7) 3154 223923.4 14.1 (13.6-14.6) 1780 227765.9 7.8 (7.5-8.2) 
2006 4371 219522.7 19.9 (19.3-20.5) 2947 222966.7 13.2 (12.7-13.7) 1909 227477.6 8.4 (8.0-8.8) 
2007 4317 216356.2 20.0 (19.4-20.6) 2724 220654.4 12.4 (11.9-12.8) 2103 225412.5 9.3 (8.9-9.7) 
2008 4169 213051.6 19.6 (9.0-20.2) 2497 218118.9 11.5 (11.0-11.9) 2154 222769.3 9.7 (9.3-10.1) 
2009 4546 207588.5 21.9 (21.3-22.6) 2735 213412.3 12.8 (12.3-13.3) 2291 217764.5 10.5 (10.1-11.0) 
2010 4344 202138.5 21.5 (20.9-22.1) 2544 208598.2 12.2 (11.7-12.7) 2279 212774 10.7 (10.3-11.2) 
2011 4320 196676.1 22.0 (21.3-22.6) 2419 203698.8 11.9 (11.4-12.4) 2395 207543.8 11.5 (11.1-12.0) 
2012 4514 191800.1 23.5 (22.9-24.2) 2573 199494.3 12.9 (12.4-13.4) 2450 202750 12.1 (11.6-12.6) 
2013 4542 187467.1 24.2 (23.5-24.9) 2492 195692.1 12.7 (12.2-13.2) 2586 198469.3 13.0 (12.5-13.5) 
2014 4706 185154.5 25.4 (24.7-26.2) 2580 193971.5 13.3 (12.8-13.8) 2645 196288.1 13.5 (13.0-14.0) 
2015 4956 184271.4 26.9 (26.2-27.7) 2717 193674.4 14.0 (13.5-14.6) 2813 195608.3 14.4 (13.9-14.9) 





2017 5786 181743.5 31.8 (31.0-32.7) 3294 192247.3 17.1 (16.6-17.7) 3212 193685.9 16.6 (16.0-17.2) 
2018 6059 180598.8 33.6 (32.7-34.4) 3503 191689.7 18.3 (17.7-18.9) 3275 193061.2 17.0 (16.4-17.6) 
45-
54 
2003 3592 188212.3 19.1 (18.5-19.7) 2694 188657.4 14.3 (13.8-14.8) 1218 189413.4 6.4 (6.1-6.8) 
2004 3791 187401 20.2 (19.6-20.9) 2671 188791.6 14.2 (13.6-14.7) 1539 190802.7 8.1 (7.7-8.5) 
2005 3681 186911.9 19.7 (19.1-20.3) 2533 189263.5 13.4 (12.9-13.9) 1515 192187.6 7.9 (7.5-8.3) 
2006 3680 188372.4 19.5 (18.9-20.2) 2435 191568.9 12.7 (12.2-13.2) 1629 195232.4 8.3 (7.9-8.8) 
2007 3754 190363.3 19.7 (19.1-20.4) 2258 194490.5 11.6 (11.1-12.1) 1911 198486 9.6 (9.2-10.1) 
2008 3834 193353.2 19.8 (19.2-20.5) 2214 198496.9 11.2 (10.7-11.6) 2033 202558.2 10.0 (9.6-10.5) 
2009 4056 196082.1 20.7 (20.1-21.3) 2315 202236.6 11.5 (11.0-11.9) 2163 206346.3 10.5 (10.1-10.9) 
2010 4130 199206.5 20.7 (20.1-21.4) 2323 206293.4 11.3 (10.8-11.7) 2233 210465 10.6 (10.2-11.1) 
2011 4306 200340.4 21.5 (20.9-22.2) 2320 208379.5 11.1 (10.7-11.6) 2438 212442.6 11.5 (11.0-11.9) 
2012 4555 202124.8 22.5 (21.9-23.2) 2501 211177.4 11.8 (11.4-12.3) 2569 214961.7 12.0 (11.5-12.4) 
2013 4569 202494.1 22.6 (21.9-23.2) 2476 212253.8 11.7 (11.2-12.1) 2593 216051.8 12.0 (11.5-12.5) 
2014 4447 203392.2 21.9 (21.2-22.5) 2413 213979 11.3 (10.8-11.7) 2563 217424.8 11.8 (11.3-12.2) 
2015 4756 203127.2 23.4 (22.8-24.1) 2617 214428.1 12.2 (11.7-12.7) 2671 217626.2 12.3 (11.8-12.8) 
2016 5239 203234.6 25.8 (25.1-26.5) 3027 215230.6 14.1 (13.6-14.6) 2830 218387 13.0 (12.5-13.5) 
2017 5327 200620.6 26.6 (25.8-27.3) 3031 213048 14.2 (13.7-14.7) 2882 216245.1 13.3 (12.9-13.8) 
2018 5444 197390.5 27.6 (26.9-28.3) 3065 210318.4 14.6 (14.1-15.1) 2924 213424.7 13.7 (13.2-14.2) 
55-
64 
2003 3023 167206.2 18.1 (17.4-18.7) 2207 167608.7 13.2 (12.6-13.7) 1088 168182.3 6.5 (6.1-6.9) 
2004 3078 168682.9 18.3 (17.6-18.9) 2096 169945.3 12.3 (11.8-12.9) 1288 171508.4 7.5 (7.1-7.9) 
2005 3119 168982.9 18.5 (17.8-19.1) 2092 171112.3 12.2 (11.7-12.8) 1346 173320.8 7.8 (7.4-8.2) 
2006 3141 169883.5 18.5 (17.9-19.2) 1959 172875.9 11.3 (10.8-11.8) 1514 175516.4 8.6 (8.2-9.1) 
2007 3199 169210.3 18.9 (18.3-19.6) 1923 172989.8 11.1 (10.6-11.6) 1594 175952.9 9.1 (8.6-9.5) 
2008 3029 169214.5 17.9 (17.3-18.6) 1630 173790.1 9.4 (8.9-9.9) 1727 176773.2 9.8 (9.3-10.2) 
2009 3182 167312.8 19.0 (18.4-19.7) 1715 172674.9 9.9 (9.5-10.4) 1786 175539.4 10.2 (9.7-10.7) 





2011 2953 165133.8 17.9 (17.2-18.5) 1583 171914.2 9.2 (8.8-9.7) 1666 174448.9 9.6 (9.1-10.0) 
2012 3163 162635 19.5 (18.8-20.1) 1635 169937.6 9.6 (9.2-10.1) 1832 172350.6 10.6 (10.2-11.1) 
2013 3152 161855 19.5 (18.8-20.2) 1619 169828 9.5 (9.1-10.0) 1859 171968.4 10.8 (10.3-11.3) 
2014 3041 162643.7 18.7 (18.0-19.4) 1555 171187.9 9.1 (8.6-9.6) 1800 173294.9 10.4 (9.9-10.9) 
2015 3159 164643.3 19.2 (18.5-19.9) 1624 173811.1 9.3 (8.9-9.8) 1874 175813.3 10.7 (10.2-11.2) 
2016 3470 167386 20.7 (20.1-21.4) 1926 177224.2 10.9 (10.4-11.4) 1925 179319.1 10.7 (10.3-11.2) 
2017 3560 170152.8 20.9 (20.2-21.6) 1935 180733.7 10.7 (10.2-11.2) 2004 182819.1 11.0 (10.5-11.5) 
2018 3710 173340.6 21.4 (20.7-22.1) 2088 184636.1 11.3 (10.8-11.8) 2046 186835.5 11.0 (10.5-11.4) 
65-
74 
2003 1936 120073.2 16.1 (15.4-16.9) 1299 120390.3 10.8 (10.2-11.4) 828 120632.4 6.9 (6.4-7.4) 
2004 1967 119994.3 16.4 (15.7-17.1) 1252 120957 10.4 (9.8-10.9) 929 121560.8 7.6 (7.2-8.2) 
2005 2008 118020.5 17.0 (16.3-17.8) 1233 119555.6 10.3 (9.8-10.9) 969 120460.4 8.0 (7.6-8.6) 
2006 2023 117357.3 17.2 (16.5-18.0) 1185 119469.3 9.9 (9.4-10.5) 1063 120500.3 8.8 (8.3-9.4) 
2007 1995 117646.3 17.0 (16.2-17.7) 1128 120298 9.4 (8.8-9.9) 1085 121440.1 8.9 (8.4-9.5) 
2008 1941 119312.3 16.3 (15.6-17.0) 992 122599.3 8.1 (7.6-8.6) 1172 123679.9 9.5 (8.9-10.0) 
2009 2060 121128.9 17.0 (16.3-17.8) 1074 124995.4 8.6 (8.1-9.1) 1223 126096.8 9.7 (9.2-10.3) 
2010 2060 121956.3 16.9 (16.2-17.6) 981 126458.2 7.8 (7.3-8.3) 1305 127446.2 10.2 (9.7-10.8) 
2011 2217 125257.5 17.7 (17.0-18.5) 1106 130375.3 8.5 (8.0-9.0) 1364 131294.7 10.4 (9.8-11.0) 
2012 2216 130685.8 17.0 (16.3-17.7) 1054 136522.1 7.7 (7.3-8.2) 1408 137414.1 10.3 (9.7-10.8) 
2013 2290 133466.9 17.2 (16.5-17.9) 1070 139939.1 7.7 (7.2-8.1) 1440 140719.8 10.2 (9.7-10.8) 
2014 2301 135829.1 16.9 (16.3-17.7) 1062 142925 7.4 (7.0-7.9) 1504 143551 10.5 (10.0-11.0) 
2015 2230 138268.7 16.1 (15.5-16.8) 1106 145967.9 7.6 (7.1-8.0) 1386 146471.6 9.5 (9.0-10.0) 
2016 2434 141041.4 17.3 (16.6-18.0) 1216 149242.7 8.2 (7.7-8.6) 1469 149634.1 9.8 (9.3-10.3) 
2017 2368 141881.6 16.7 (16.0-17.4) 1215 150517.5 8.1 (7.6-8.5) 1413 150884.3 9.4 (8.9-9.9) 
2018 2337 142668.8 16.4 (15.7-17.0) 1228 151638.7 8.1 (7.7-8.6) 1356 152157 8.9 (8.4-9.4) 
75-
84 
2003 1356 81430.34 16.7 (15.8-17.6) 861 81670.02 10.5 (9.9-11.3) 636 81774.7 7.8 (7.2-8.4) 





2005 1479 78819.3 18.8 (17.8-19.8) 844 80030.16 10.6 (9.9-11.3) 775 80402.41 9.6 (9.0-10.3) 
2006 1394 77794.72 17.9 (17.0-18.9) 796 79398.55 10.0 (9.3-10.8) 768 79821.07 9.6 (9.0-10.3) 
2007 1355 77446.36 17.5 (16.6-18.5) 714 79413.96 9.0 (8.3-9.7) 808 79803.81 10.1 (9.4-10.9) 
2008 1364 77326.82 17.6 (16.7-18.6) 680 79684.17 8.5 (7.9-9.2) 849 79925.85 10.6 (9.9-11.4) 
2009 1424 77362.89 18.4 (17.5-19.4) 678 80130.29 8.5 (7.8-9.1) 898 80163.8 11.2 (10.5-12.0) 
2010 1315 77737.17 16.9 (16.0-17.9) 606 80858.78 7.5 (6.9-8.1) 862 80727.87 10.7 (10.0-11.4) 
2011 1446 78323.32 18.5 (17.5-19.4) 642 81822.65 7.9 (7.3-8.5) 969 81561.76 11.9 (11.1-12.7) 
2012 1405 79603.21 17.7 (16.7-18.6) 629 83441.21 7.5 (7.0-8.2) 925 83060.86 11.1 (10.4-11.9) 
2013 1438 80492.91 17.9 (17.0-18.8) 712 84551.17 8.4 (7.8-9.1) 927 84192.29 11.0 (10.3-11.7) 
2014 1363 81553.54 16.7 (15.8-17.6) 630 85899.45 7.3 (6.8-7.9) 887 85430.37 10.4 (9.7-11.1) 
2015 1415 81743.02 17.3 (16.4-18.2) 647 86352.49 7.5 (6.9-8.1) 900 85743.17 10.5 (9.8-11.2) 
2016 1415 82163.47 17.2 (16.3-18.1) 690 87070.82 7.9 (7.3-8.5) 885 86371.06 10.3 (9.6-10.9) 
2017 1440 83575.17 17.2 (16.4-18.1) 718 88674.82 8.1 (7.5-8.7) 877 88039.27 10.0 (9.3-10.6) 
2018 1426 85670.39 16.7 (15.8-17.5) 742 91110.94 8.1 (7.6-8.8) 834 90402.99 9.2 (8.6-9.9) 
85+ 2003 358 27873.18 12.8 (11.6-14.3) 235 27929.67 8.4 (7.4-9.6) 147 27971.99 5.3 (4.4-6.2) 
2004 427 27735.88 15.4 (14.0-16.9) 249 27944.32 8.9 (7.8-10.1) 212 28050.12 7.6 (6.6-8.7) 
2005 504 28547.61 17.7 (16.2-19.3) 267 28955.7 9.2 (8.2-10.4) 281 29069.08 9.7 (8.6-10.9) 
2006 462 29728.66 15.5 (14.2-17.0) 259 30298.23 8.6 (7.5-9.7) 253 30420.54 8.3 (7.3-9.4) 
2007 481 30215.97 15.9 (14.5-17.4) 235 30960.21 7.6 (6.7-8.6) 301 31041.59 9.7 (8.6-10.9) 
2008 500 30866.85 16.2 (14.8-17.7) 246 31787.23 7.7 (6.8-8.8) 301 31811.69 9.5 (8.4-10.6) 
2009 484 31115.84 15.6 (14.2-17.0) 218 32209 6.8 (5.9-7.7) 305 32156.38 9.5 (8.5-10.6) 
2010 476 31945.97 14.9 (13.6-16.3) 221 33191.33 6.7 (5.8-7.6) 310 33077.92 9.4 (8.4-10.5) 
2011 509 32629.64 15.6 (14.3-17.0) 221 34004.71 6.5 (5.7-7.4) 329 33801.21 9.7 (8.7-10.8) 
2012 540 33080.46 16.3 (15.0-17.8) 243 34640.97 7.0 (6.2-8.0) 359 34314.68 10.5 (9.4-11.6) 
2013 502 33406.57 15.0 (13.7-16.4) 226 35098.21 6.4 (5.6-7.3) 321 34697.13 9.3 (8.3-10.3) 





2015 472 34509.73 13.7 (12.5-15.0) 226 36443.28 6.2 (5.4-7.1) 290 35975.87 8.1 (7.2-9.0) 
2016 529 35170.29 15.0 (13.8-16.4) 239 37228.24 6.4 (5.6-7.3) 338 36731.64 9.2 (8.3-10.2) 
2017 527 35849.45 14.7 (13.5-16.0) 250 38009.54 6.6 (5.8-7.5) 339 37472.1 9.1 (8.1-10.1) 





A.12 List of BNF codes  
2.4: Beta-Adrenoceptor Blocking Drugs – propranolol 
4.1.1: Hypnotics 
4.1.2: Anxiolytics 
4.2.1: Antipsychotic Drugs – quetiapine, risperidone, olanzapine, aripiprazole 
4.3: Antidepressant Drugs 
      4.3.1: Tricyclic & Related Antidepressant Drugs 
      4.3.2: Monoamine-Oxidase Inhibitors (MAOIs) 
      4.3.3: Selective Serotonin Re-Uptake Inhibitors 
      4.3.4: Other Antidepressant Drugs 
4.7.3: Neuropathic Pain – gabapentin 








A.13 Best fitting join point model of prevalence of all antidepressant prescriptions per 1000 person-years 






A.14 Best fitting join point model of prevalence of SSRI & ‘other’ antidepressant prescriptions per 1000 person-years 





A.15 Prevalence rate ratio for prescriptions of SSRI & ‘other’ antidepressants 
Table 35 Prevalence rate ratios for prescriptions of SSRI & ‘other’ antidepressants 
SSRI & ‘other’ antidepressants 






(95%CI) P value 
Year 2003 1.00  <0.001 1.00  <0.001 
2004 1.03 (1.01-1.05) 1.03 (1.01-1.06) 
2005 1.01 (0.99-1.03) 1.01 (0.99-1.03) 
2006 1.03 (1.01-1.05) 1.04 (1.02-1.06) 
2007 1.07 (1.05-1.10) 1.09 (1.06-1.11) 
2008 1.06 (1.04-1.08) 1.08 (1.05-1.10) 
2009 1.13 (1.11-1.15) 1.14 (1.12-1.17) 
2010 1.20 (1.18-1.22) 1.22 (1.20-1.25) 
2011 1.28 (1.25-1.30) 1.30 (1.27-1.32) 
2012 1.36 (1.34-1.39) 1.39 (1.36-1.42) 
2013 1.42 (1.39-1.45) 1.45 (1.43-1.48) 
2014 1.51 (1.48-1.54) 1.55 (1.52-1.58) 
2015 1.65 (1.62-1.68) 1.70 (1.67-1.73) 
2016 1.85 (1.82-1.89) 1.91 (1.88-1.94) 
2017 1.98 (1.95-2.02) 2.05 (2.02-2.09) 
2018 2.11 (2.07-2.15) 2.19 (2.15-2.23) 
Gender Male 1.00  <0.001 1.00  <0.001 
Female 2.16 (2.14-2.17) 2.22 (2.2-2.23) 
Age Band 
(years) 
18-24 1.00  <0.001 1.00  <0.001 
25-34 1.30 (1.29-1.32) 1.29 (1.28-1.31) 
35-44 1.25 (1.24-1.27) 1.28 (1.26-1.29) 
44-54 1.14 (1.13-1.15) 1.13 (1.12-1.15) 
55-64 0.91 (0.90-0.92) 0.90 (0.89-0.92) 
65-74 0.70 (0.69-0.71) 0.67 (0.66-0.68) 
75-84 0.70 (0.69-0.71) 0.65 (0.64-0.67) 
85+ 0.63 (0.61-0.64) 0.54 (0.52-0.55) 





A.16 Prevalence rate ratio for prescriptions of antipsychotics 
Table 36 Prevalence rate ratios for prescriptions of antipsychotics 
 Antipsychotic 








Year 2003 1.00  <0.001 
 
1.00  <0.001 
2004 1.06 (0.97-1.16) 1.06 (0.97-1.16) 
2005 1.09 (1.00-1.19) 1.10 (1.00-1.19) 
2006 1.14 (1.04-1.24) 1.14 (1.05-1.24) 
2007 1.15 (1.05-1.25) 1.15 (1.05-1.25) 
2008 1.21 (1.11-1.32) 1.21 (1.12-1.32) 
2009 1.30 (1.20-1.41) 1.31 (1.20-1.42) 
2010 1.45 (1.34-1.57) 1.46 (1.34-1.58) 
2011 1.58 (1.46-1.71) 1.59 (1.47-1.72) 
2012 1.71 (1.58-1.84) 1.72 (1.59-1.86) 
2013 1.78 (1.64-1.92) 1.79 (1.66-1.94) 
2014 1.84 (1.70-1.98) 1.86 (1.72-2.00) 
2015 1.93 (1.79-2.08) 1.95 (1.81-2.11) 
2016 2.20 (2.04-2.37) 2.23 (2.07-2.40) 
2017 2.39 (2.22-2.58) 2.43 (2.25-2.61) 
2018 2.49 (2.31-2.68) 2.53 (2.35-2.72) 
Gender Male 1.00  <0.001 
 
1.00  <0.001 
Female 1.44 (1.41-1.48) 1.46 (1.42-1.49) 
Age Band 
(years) 
18-24 1.00  <0.001 
 
1.00  <0.001 
25-34 1.41 (1.34-1.48) 1.40 (1.33-1.47) 
35-44 1.41 (1.34-1.48) 1.43 (1.36-1.51) 
44-54 1.42 (1.35-1.49) 1.40 (1.33-1.47) 
55-64 1.11 (1.05-1.17) 1.10 (1.04-1.16) 
65-74 0.82 (0.77-0.87) 0.79 (0.75-0.84) 
75-84 1.03 (0.96-1.10) 0.99 (0.93-1.05) 
85+ 1.19 (1.10-1.30) 1.09 (1.00-1.18) 





A.17 Prevalence rate ratios for prescriptions of anticonvulsants 
Table 37 Prevalence rate ratios for prescriptions of anticonvulsants 
 Anticonvulsant 








Year 2003 1.00  <0.001 1.00  <0.001 
2004 1.23 (1.04-1.46) 1.23 (1.04-1.46) 
2005 1.59 (1.35-1.87) 1.59 (1.35-1.87) 
2006 2.19 (1.88-2.55) 2.19 (1.88-2.55) 
2007 2.63 (2.26-3.05) 2.63 (2.26-3.05) 
2008 3.25 (2.81-3.76) 3.25 (2.81-3.76) 
2009 4.42 (3.84-5.09) 4.42 (3.84-5.09) 
2010 5.61 (4.89-6.44) 5.61 (4.89-6.44) 
2011 6.69 (5.84-7.67) 6.69 (5.84-7.67) 
2012 7.68 (6.71-8.80) 7.70 (6.72-8.81) 
2013 8.98 (7.86-10.27) 9.00 (7.87-10.29) 
2014 10.35 (9.06-11.82) 10.37 (9.07-11.85) 
2015 11.84 (10.37-13.52) 11.86 (10.39-13.55) 
2016 13.61 (11.93-15.53) 13.62 (11.94-15.54) 
2017 14.57 (12.77-16.62) 14.58 (12.79-16.64) 
2018 14.61 (12.81-16.66) 14.62 (12.82-16.68) 
Gender Male 1.00  <0.001 1.00  <0.001 
Female 2.18 (2.13-2.24) 2.19 (2.14-2.25) 
Age Band 
(years) 
18-24 1.00  <0.001 1.00  <0.001 
25-34 2.40 (2.23-2.58) 2.37 (2.20-2.54) 
35-44 3.18 (2.96-3.41) 3.32 (3.10-3.56) 
44-54 3.92 (3.66-4.20) 3.80 (3.55-4.07) 
55-64 3.56 (3.32-3.82) 3.50 (3.26-3.75) 
65-74 3.16 (2.94-3.40) 2.93 (2.72-3.15) 
75-84 3.24 (3.00-3.50) 3.01 (2.79-3.25) 
85+ 2.49 (2.26-2.75) 2.08 (1.89-2.30) 





A.18 Prevalence ratios for prescriptions of any anxiolytic, all antidepressants, and benzodiazepines between 2003 and 2013 - accounting for 
clustering  
Table 38 Prevalence rate ratios for prescriptions of any anxiolytic, all antidepressants, and benzodiazepines between 2003 and 2018 – account for clustering 
 Any anxiolytic All antidepressants Benzodiazepines 
Variable  Multivariable PRR* (95%CI) P value Multivariable PRR* (95%CI) P value Multivariable PRR* (95%CI) P value 
Year 2003 1.00  <0.001 1.00  <0.001 1.00  <0.001 
2004 1.03 (1.00-1.06) 1.02 (0.99-1.06) 1.04 (1.01-1.07) 
2005 1.03 (0.99-1.07) 1.00 (0.96-1.04) 1.07 (1.02-1.11) 
2006 1.04 (0.99-1.09) 1.01 (0.96-1.07) 1.08 (1.02-1.14) 
2007 1.06 (1.00-1.13) 1.04 (0.97-1.11) 1.10 (1.03-1.17) 
2008 1.05 (0.98-1.12) 1.03 (0.96-1.11) 1.06 (1.00-1.14) 
2009 1.10 (1.03-1.18) 1.09 (1.01-1.17) 1.10 (1.02-1.18) 
2010 1.14 (1.06-1.23) 1.15 (1.06-1.24) 1.09 (1.01-1.18) 
2011 1.19 (1.11-1.28) 1.21 (1.12-1.31) 1.11 (1.03-1.20) 
2012 1.26 (1.17-1.35) 1.28 (1.19-1.39) 1.12 (1.04-1.21) 
2013 1.30 (1.21-1.40) 1.33 (1.23-1.44) 1.11 (1.03-1.20) 
2014 1.36 (1.26-1.47) 1.41 (1.30-1.53) 1.12 (1.03-1.21) 
2015 1.47 (1.36-1.58) 1.53 (1.41-1.66) 1.11 (1.02-1.21) 
2016 1.62 (1.50-1.75) 1.71 (1.57-1.86) 1.16 (1.06-1.26) 
2017 1.72 (1.59-1.86) 1.82 (1.68-1.99) 1.13 (1.03-1.23) 
2018 1.81 (1.66-1.96) 1.94 (1.77-2.11) 1.10 (1.00-1.20) 
Gender Male 1.00  <0.001 1.00  <0.001 1.00  <0.001 
Female 2.23 (2.19-2.28) 2.26 (2.21-2.30) 2.22 (2.16-2.27) 
Age Band 
(years) 
18-24 1.00  <0.001 1.00  <0.001 1.00  <0.001 
25-34 1.28 (1.24-1.32) 1.31 (1.26-1.36) 1.72 (1.65-1.79) 
35-44 1.28 (1.23-1.33) 1.33 (1.27-1.39) 1.98 (1.88-2.08) 
44-54 1.18 (1.13-1.25) 1.22 (1.15-1.29) 2.04 (1.93-2.16) 
55-64 1.01 (0.96-1.07) 1.01 (0.95-1.08) 1.95 (1.83-2.08) 
65-74 0.84 (0.79-0.90) 0.79 (0.74-0.84) 2.01 (1.85-2.17) 
75-84 0.85 (0.79-0.92) 0.78 (0.73-0.84) 2.19 (1.99-2.41) 
85+ 0.71 (0.64-0.78) 0.63 (0.58-0.69) 1.91 (1.70-2.16) 





A.19 Prevalence rate ratios for prescriptions of beta-blockers, anticonvulsants and antipsychotics between 2003 and 2018 - accounting for 
clustering  
 Table 39 Prevalence rate ratios for prescriptions of beta-blockers, anticonvulsants, and antipsychotics between 2003 and 2013 - accounting for clustering  
 Beta-blockers (propranolol) Anticonvulsants Antipsychotics 
Variable  Multivariable PRR* (95%CI) P value Multivariable PRR* (95%CI) P value Multivariable PRR* (95%CI) P value 
Year 2003 1.00  <0.001 1.00  <0.001 1.00  <0.001 
2004 1.07 (1.02-1.13) 1.23 (1.08-1.40) 1.06 (0.98-1.15) 
2005 1.07 (1.00-1.15) 1.59 (1.36-1.87) 1.10 (1.00-1.20) 
2006 1.08 (1.01-1.17) 2.19 (1.85-2.59) 1.14 (1.03-1.26) 
2007 1.08 (0.99-1.17) 2.63 (2.21-3.12) 1.15 (1.03-1.28) 
2008 1.11 (1.02-1.21) 3.25 (2.74-3.87) 1.21 (1.09-1.36) 
2009 1.21 (1.10-1.33) 4.42 (3.74-5.22) 1.31 (1.16-1.48) 
2010 1.30 (1.18-1.43) 5.61 (4.77-6.60) 1.46 (1.29-1.64) 
2011 1.40 (1.27-1.55) 6.69 (5.73-7.82) 1.59 (1.40-1.80) 
2012 1.56 (1.42-1.72) 7.70 (6.60-8.98) 1.72 (1.52-1.94) 
2013 1.71 (1.55-1.89) 9.00 (7.68-10.55) 1.79 (1.59-2.02) 
2014 1.87 (1.69-2.08) 10.37 (8.84-12.16) 1.86 (1.62-2.13) 
2015 2.02 (1.83-2.24) 11.86 (10.05-14.00) 1.95 (1.73-2.20) 
2016 2.23 (2.00-2.48) 13.62 (11.42-16.24) 2.23 (1.98-2.51) 
2017 2.42 (2.17-2.71) 14.58 (12.30-17.29) 2.43 (2.13-2.77) 
2018 2.61 (2.34-2.90) 14.62 (12.30-17.38) 2.53 (2.21-2.88) 
Gender Male 1.00  <0.001 1.00  <0.001 1.00  <0.001 
Female 2.33 (2.26-2.4) 2.19 (2.10-2.28) 1.46 (1.39-1.53) 
Age Band 
(years) 
18-24 1.00  <0.001 1.00  <0.001 1.00  <0.001 
25-34 1.12 (1.08-1.17) 2.37 (2.11-2.65) 1.40 (1.32-1.56) 
35-44 1.00 (0.95-1.05) 3.32 (2.91-3.78) 1.43 (1.28-1.52) 
44-54 0.82 (0.78-0.87) 3.80 (3.30-4.39) 1.40 (0.99-1.22) 
55-64 0.57 (0.54-0.61) 3.50 (3.03-4.03) 1.10 (0.71-0.88) 
65-74 0.34 (0.32-0.38) 2.93 (2.51-3.41) 0.79 (0.87-1.12) 
75-84 0.23 (0.21-0.26) 3.01 (2.57-3.53) 0.99 (0.92-1.29) 
85+ 0.11 (0.09-0.13) 2.08 (1.75-2.48) 1.09 (1.31-1.50) 





A.20 Prevalence rate of anxiolytic prescriptions - any anxiolytics, all antidepressants, and SSRIs and ‘other’ antidepressants – per 1000 person years 
by gender 
Table 40 Prevalence rate of anxiolytic prescriptions - any anxiolytics, all antidepressants, and SSRIs and ‘other’ antidepressants – per 1000 person years by 
gender 
Variable Any anxiolytic All antidepressants SSRIs and ‘other’ antidepressants 
Gender Year N* PYAR Prevalence 
(1000PYAR) 
(95%CI) N* PYAR Prevalence 
(1000PYAR) 
(95%CI) N* PYAR Prevalence 
(1000PYAR) 
(95%CI) 
Male 2003 8499 539948.5 15.7 (15.4-16.1) 6715 541088 12.4 (12.1-12.7) 5704 541764 10.5 (10.3-10.8) 
2004 8690 544370.9 16.0 (15.6-16.3) 6836 546508.5 12.5 (12.2-12.8) 5872 547656.6 10.7 (10.5-11.0) 
2005 8545 544415.8 15.7 (15.4-16.0) 6593 547386.2 12.0 (11.8-12.3) 5677 548823.9 10.3 (10.1-10.6) 
2006 8685 547927.9 15.9 (15.5-16.2) 6685 551687.3 12.1 (11.8-12.4) 5820 553379.8 10.5 (10.3-10.8) 
2007 8859 550394.8 16.1 (15.8-16.4) 6906 554803.8 12.5 (12.2-12.7) 6137 556661 11.0 (10.8-11.3) 
2008 8773 555196.9 15.8 (15.5-16.1) 6838 560186.6 12.2 (11.9-12.5) 6082 562172.5 10.8 (10.6-11.1) 
2009 9436 557164.8 16.9 (16.6-17.3) 7387 562676.2 13.1 (12.8-13.4) 6631 564792.7 11.7 (11.5-12.0) 
2010 9879 559924.1 17.6 (17.3-18.0) 7948 565978.4 14.0 (13.7-14.4) 7233 568201.9 12.7 (12.4-13.0) 
2011 10359 560450.8 18.5 (18.1-18.8) 8359 566942.8 14.7 (14.4-15.0) 7657 569221.5 13.5 (13.2-13.8) 
2012 11023 563974.6 19.6 (19.2-19.9) 8961 570882.9 15.7 (15.4-16.0) 8281 573196.6 14.5 (14.1-14.8) 
2013 11354 564409.9 20.1 (19.8-20.5) 9260 571665.9 16.2 (15.9-16.5) 8631 574014.2 15.0 (14.7-15.4) 
2014 11804 568154.3 20.8 (20.4-21.2) 9782 575765.4 17.0 (16.7-17.3) 9105 578159.2 15.8 (15.4-16.1) 
2015 12920 571441.6 22.6 (22.2-23.0) 10772 579350.8 18.6 (18.2-19.0) 10170 581762 17.5 (17.1-17.8) 
2016 14300 575257.4 24.9 (24.5-25.3) 12111 583488.6 20.8 (20.4-21.1) 11490 585929.8 19.6 (19.3-12.0) 
2017 15061 576383.7 26.1 (25.7-26.6) 12894 584934.3 22.0 (21.7-22.4) 12275 587387.8 20.9 (20.5-21.3) 
2018 15958 577774.9 27.6 (27.2-28.1) 13744 586570.2 23.4 (23.0-23.8) 13162 589024.9 22.4 (22.0-22.7) 
Female 2003 18760 554313.1 33.8 (33.4-34.3) 14999 556838.8 26.9 (26.5-27.4) 12512 558629.5 22.4 (22.0-22.8) 
2004 19324 551609.9 35.0 (34.5-35.5) 15417 556139.4 27.7 (27.3-28.2) 13021 558995 23.3 (22.9-23.7) 
2005 19210 545048.5 35.2 (34.8-35.8) 15052 551307.2 27.3 (26.9-27.7) 12732 554882.1 23.0 (22.6-23.4) 
2006 19316 543927.7 35.5 (35.0-36.0) 15248 551654.9 27.6 (27.2-28.1) 13146 555725.7 23.7 (23.3-24.0) 
2007 19712 541957.3 36.4 (35.9-36.9) 15659 550910.7 28.4 (28.0-28.9) 13645 555366.2 24.6 (24.2-25.0) 
2008 19531 543288.6 36.0 (35.5-36.5) 15535 553342.3 28.1 (27.6-28.5) 13613 558099.4 24.4 (24.0-24.8) 
2009 20255 541853 37.4 (36.9-37.9) 16226 552887.2 29.4 (28.9-29.8) 14333 557888.2 25.7 (25.3-26.1) 
2010 20865 542248.2 38.5 (38.0-39.0) 17029 554136 30.7 (30.3-31.2) 15182 559382.5 27.1 (26.7-27.6) 





2012 23019 545243.2 42.2 (41.7-42.8) 19156 558484 34.3 (33.8-34.8) 17345 564049.8 30.8 (30.3-31.2) 
2013 23851 545273.5 43.7 (43.2-44.3) 19877 559053.5 35.6 (35.1-36.1) 18121 564702.9 32.1 (31.6-32.6) 
2014 25100 545835.7 46.0 (45.4-46.6) 21129 560203.1 37.7 (37.2-38.2) 19440 565931.6 34.4 (33.9-34.8) 
2015 26953 546502.4 49.3 (48.7-49.9) 22883 561426.6 40.8 (40.2-41.3) 21256 567159.1 37.5 (37.0-38.0) 
2016 29823 547379.6 54.5 (53.9-55.1) 25556 562956.4 45.4 (44.8-46.0) 23927 568722.6 42.1 (41.5-42.6) 
2017 31554 545392.5 57.9 (57.2-58.5) 27226 561400.1 48.5 (47.9-49.1) 25653 567168.8 45.2 (44.7-45.8) 
2018 32959 544422.1 60.5 (59.9-61.2) 28737 560777.7 51.2 (50.7-51.8) 27178 566566.5 48.0 (47.4-48.5) 





A.21 Prevalence rate of benzodiazepines and beta-blockers (propranolol) prescriptions per 
1000 person years by gender 
Table 41 Prevalence rate of benzodiazepines and beta-blocker prescriptions per 1000 person years by 
gender 
 
Variable Benzodiazepines Beta-blockers (propranolol) 
Gender Year N* PYAR Prevalence 
(1000PYAR) 
(95%CI) N* PYAR Prevalence 
(1000PYAR) 
(95%CI) 
Male 2003 3505 543279.9 6.5 (6.2-6.7) 1269 544587.6 2.3 (2.2-2.5) 
2004 3621 550364.7 6.6 (6.4-6.8) 1278 553051.7 2.3 (2.2-2.4) 
2005 3760 552291 6.8 (6.6-7.0) 1248 556078.5 2.2 (2.1-2.4) 
2006 3866 557447.9 6.9 (6.7-7.2) 1284 562341.2 2.3 (2.2-2.4) 
2007 3875 561415.7 6.9 (6.7-7.1) 1283 567223 2.3 (2.1-2.4) 
2008 3736 567636.7 6.6 (6.4-6.8) 1398 574227.3 2.4 (2.3-2.6) 
2009 3996 571042.2 7.0 (6.8-7.2) 1541 578231.4 2.7 (2.5-2.8) 
2010 4067 575319.7 7.1 (6.9-7.3) 1645 583133.6 2.8 (2.7-3.0) 
2011 4190 577319 7.3 (7.0-7.5) 1756 585693.6 3.0 (2.9-3.1) 
2012 4307 582470.4 7.4 (7.2-7.6) 1973 591353.5 3.3 (3.2-3.5) 
2013 4192 584534.1 7.2 (7.0-7.4) 2126 593679.1 3.6 (3.4-3.7) 
2014 4294 589943.7 7.3 (7.1-7.5) 2325 599273.3 3.9 (3.7-4.0) 
2015 4311 595070 7.2 (7.0-7.5) 2541 604475.9 4.2 (4.0-4.4) 
2016 4549 601229.4 7.6 (7.4-7.8) 2799 610720.6 4.6 (4.4-4.8) 
2017 4495 604817.9 7.4 (7.2-7.7) 2970 614250.9 4.8 (4.7-5.0) 
2018 4390 608911.1 7.2 (7.0-7.4) 3199 618156.7 5.2 (5.0-5.4) 
Female 2003 8102 561676.9 14.4 (14.1-14.7) 2598 565080.2 4.6 (4.4-4.8) 
2004 8534 564378.7 15.1 (14.8-15.5) 2913 571064.4 5.1 (4.9-5.3) 
2005 8666 561701.9 15.4 (15.1-15.8) 2949 570855 5.2 (5.0-5.4) 
2006 8764 563755.3 15.6 (15.2-15.9) 2981 575043.7 5.2 (5.0-5.4) 
2007 9035 564742.5 16.0 (15.7-16.3) 2979 578042.9 5.2 (5.0-5.3) 
2008 8881 568687.9 15.6 (15.3-15.9) 3019 583819.8 5.2 (5.0-5.4) 
2009 9079 569776.8 15.9 (15.6-16.3) 3297 586464.6 5.6 (5.4-5.8) 
2010 8941 572806.8 15.6 (15.3-15.9) 3572 590822.4 6.1 (5.9-6.3) 
2011 9156 575752.6 15.9 (15.6-16.2) 3911 594681.7 6.6 (6.4-6.8) 
2012 9285 581312.5 16.0 (15.7-16.3) 4368 600973.4 7.3 (7.1-7.5) 
2013 9306 584136.8 15.9 (15.6-16.3) 4836 604121.9 8.0 (7.8-8.2) 
2014 9415 587604.2 16.0 (15.7-16.4) 5332 607846.6 8.8 (8.5-9.0) 
2015 9422 591608.2 15.9 (15.6-16.3) 5755 611845.6 9.4 (9.2-9.7) 
2016 9893 596861.8 16.6 (16.3-16.9) 6408 616966.1 10.4 (10.1-10.6) 
2017 9650 599153.7 16.1 (15.8-16.4) 7025 618696 11.4 (11.1-11.6) 
2018 9460 602744.1 15.7 (15.4-16.0) 7568 621377 12.2 (11.9-12.5) 





A.22 Prevalence rate of antipsychotic and anticonvulsant prescriptions per 1000 person 
years by gender 








Variable Antipsychotics Anticonvulsants 
Gender Year N* PYAR Prevalence 
(1000PYAR) 
(95%CI) N* PYAR Prevalence 
(1000PYAR) 
(95%CI) 
Male 2003 372 545114 0.7 (0.6-0.8) 93 545275.6 0.2 (0.1-0.2) 
2004 414 554247.4 0.8 (0.7-0.8) 84 554604.7 0.2 (0.1-0.2) 
2005 436 557861.6 0.8 (0.7-0.9) 111 558346.3 0.2 (0.2-0.2) 
2006 464 564627.5 0.8 (0.8-0.9) 177 565223.4 0.3 (0.3-0.4) 
2007 479 569962.4 0.8 (0.8-0.9) 207 570620.5 0.4 (0.3-0.4) 
2008 491 577468.6 0.9 (0.8-0.9) 264 578171.1 0.5 (0.4-0.5) 
2009 547 582030.4 0.9 (0.9-1.0) 370 582684 0.6 (0.6-0.7) 
2010 593 587522.1 1.0 (0.9-1.1) 444 588160.5 0.8 (0.7-0.8) 
2011 636 590652.3 1.1 (1.0-1.2) 523 591237.6 0.9 (0.8-1.0) 
2012 690 596906.4 1.2 (1.1-1.3) 626 597445.8 1.1 (1.0-1.1) 
2013 789 599834 1.3 (1.2-1.4) 712 600304.8 1.2 (1.1-1.3) 
2014 832 606149.1 1.4 (1.3-1.5) 816 606537.8 1.4 (1.3-1.4) 
2015 837 612128.9 1.4 (1.3-1.5) 963 612385.1 1.6 (1.5-1.7) 
2016 984 619206.6 1.6 (1.5-1.7) 1062 619322.3 1.7 (1.6-1.8) 
2017 1056 623537.4 1.7 (1.6-1.8) 1193 623537.1 1.9 (1.8-2.0) 
2018 1079 628340.7 1.7 (1.6-1.8) 1177 628218 1.9 (1.8-2.0) 
Female 2003 594 566232.5 1.1 (1.0-1.1) 142 566530.8 0.3 (0.2-0.3) 
2004 626 573873.9 1.1 (1.0-1.2) 210 574386.9 0.4 (0.3-0.4) 
2005 642 575239.4 1.1 (1.0-1.2) 271 575866.2 0.5 (0.4-0.5) 
2006 669 580854.4 1.2 91.1-1.2) 354 581536.6 0.6 (0.6-0.7) 
2007 671 585120.9 1.2 (1.1-1.2) 435 585816.6 0.7 (0.7-0.8) 
2008 740 592117.5 1.3 (1.2-1.3) 541 592758.1 0.9 (0.8-1.0) 
2009 786 595962.6 1.3 (1.2-1.4) 731 596524.5 1.2 (1.1-1.3) 
2010 906 601621.1 1.5 (1.4-1.6) 967 602004.8 1.6 (1.5-1.7) 
2011 1006 606889.5 1.7 (1.6-1.8) 1171 606963.5 1.9 (1.8-2.0) 
2012 1106 614753.8 1.8 (1.7-1.9) 1342 614510.8 2.2 (2.1-2.3) 
2013 1094 619435.7 1.8 (1.7-1.9) 1603 618801 2.6 (2.5-2.7) 
2014 1132 624911.2 1.8 (1.7-1.9) 1875 623788.4 3.0 (2.9-3.2) 
2015 1246 630791.2 2.0 (1.9-2.1) 2145 629122.1 3.4 (3.3-3.6) 
2016 1417 638036 2.2 (2.1-2.3) 2548 635746.4 4.0 (3.9-4.2) 
2017 1576 641892.7 2.5 (2.3-2.6) 2695 638996.9 4.2 (4.1-4.4) 
2018 1677 646797.3 2.6 (2.5-2.7) 2749 643357.9 4.3 (4.1-4.4) 





A.23 Prevalence rate ratios for prescriptions for any anxiolytic between 2003 and 2018 - test 
for interaction between year and gender 
Table 43 Prevalence rate ratios for prescriptions for any anxiolytic between 2003 and 2018 - test for 
interaction between year and gender 
Variable  Multivariable PRR* (95%CI) P value 
Year 2003 1.00  <0.001 
2004 1.01 (0.99-1.05) 
2005 1.00 (0.97-1.03) 
2006 1.01 (0.98-1.04) 
2007 1.03 (1.00-1.06) 
2008 1.01 (0.98-1.04) 
2009 1.08 (1.05-1.11) 
2010 1.13 (1.10-1.16) 
2011 1.18 (1.15-1.22) 
2012 1.26 (1.22-1.29) 
2013 1.29 (1.26-1.33) 
2014 1.34 (1.30-1.38) 
2015 1.46 (1.42-1.50) 
2016 1.61 (1.56-1.65) 
2017 1.69 (1.65-1.74) 
2018 1.79 (1.74-1.84) 
Gender Male 1.00  <0.001 
Female 2.19 (2.13-2.25) 
Year X 
Gender 
2003 1.00   
2004 1.02 (0.98-1.06) 0.270 
2005 1.04 (1.01-1.08) 0.019 
2006 1.04 (1.00-1.08) 0.027 
2007 1.05 (1.01-1.09) 0.007 
2008 1.06 (1.02-1.10) 0.003 
2009 1.02 (0.99-1.06) 0.172 
2010 1.01 (0.98-1.05) 0.498 
2011 1.01 (0.97-1.04) 0.686 
2012 1.00 (0.97-1.04) 0.944 
2013 1.01 (0.97-1.04) 0.685 
2014 1.02 (0.99-1.06) 0.152 
2015 1.01 (0.98-1.04) 0.562 
2016 1.01 (0.98-1.05) 0.389 
2017 1.02 (0.99-1.06) 0.137 




18-24 1.00  <0.001 
25-34 1.28 (1.27-1.29) 
35-44 1.28 (1.26-1.29) 
44-54 1.18 (1.17-1.20) 
55-64 1.01 (1.00-1.02) 
65-74 0.84 (0.83-0.85) 
75-84 0.85 (0.84-0.87) 






A.24 Prevalence rates, absolute differences, and prevalence rate ratios for prescriptions for 
any anxiolytic between 2003 and 2018 by gender - test for interaction between year 
and gender 
Table 44 Prevalence rates, absolute differences, and prevalence rate ratios for prescriptions for any 
anxiolytic between 2003 and 2018 by gender - test for interaction between year and gender 
 Male Female Interaction 
parameter 
P value for 
interaction 
parameter 









Year 2003 15.7 - 1.00 33.8 - 1.00 1.00  
2004 16.0 0.3 1.01 35.0 1.2 1.04 1.02 0.270 
2005 15.7 0 1.00 35.2 1.4 1.04 1.04 0.019 
2006 15.9 0.2 1.01 35.5 1.7 1.05 1.04 0.027 
2007 16.1 0.4 1.00 36.4 2.6 1.05 1.05 0.007 
2008 15.8 0.1 1.00 36.0 2.2 1.06 1.06 0.003 
2009 16.9 1.2 1.08 37.4 3.6 1.10 1.02 0.172 
2010 17.6 1.9 1.12 38.5 4.7 1.14 1.01 0.498 
2011 18.5 2.8 1.17 40.1 6.3 1.19 1.01 0.686 
2012 19.6 3.9 1.24 42.2 8.4 1.25 1.00 0.944 
2013 20.1 4.4 1.28 43.7 9.9 1.29 1.01 0.685 
2014 20.8 5.1 1.32 46.0 12.2 1.36 1.02 0.152 
2015 22.6 6.9 1.44 49.3 15.5 1.46 1.01 0.562 
2016 24.9 9.2 1.58 54.5 20.7 1.61 1.01 0.389 
2017 26.1 10.4 1.66 57.9 24.1 1.71 1.02 0.137 





A.25 Prevalence rate of anxiolytic prescriptions - any anxiolytic, all antidepressants, and SSRIs and ‘other’ antidepressants – per 1000 person 
years by age  
Table 45 Prevalence rate of anxiolytic prescriptions - any anxiolytic, all antidepressants, and SSRIs and ‘other’ antidepressants – per 1000 person years by 
age 
Variable Any anxiolytic All antidepressants SSRIs and ‘other’ antidepressants 
Age 
band 
Year N* PYAR Prevalence 
(1000PYAR) 
(95%CI) N* PYAR Prevalence 
(1000PYAR) 
(95%CI) N* PYAR Prevalence 
(1000PYAR) 
(95%CI) 
<25 2003 1841 106772.9 17.2 (16.5-18.0) 1492 106990.3 13.9 (13.2-14.7) 1385 107057 12.9 (12.3-13.6) 
2004 1895 107419.6 17.6 (16.9-18.5) 1474 107836.5 13.7 (13.0-14.4) 1363 107943.9 12.6 (12.0-13.3) 
2005 1835 107126.9 17.1 (16.4-17.9) 1365 107722 12.7 (12-13.4) 1260 107852.2 11.7 (11.0-12.3) 
2006 1802 108536.8 16.6 (15.8-17.4) 1333 109285.1 12.2 (11.6-12.9) 1257 109425.6 11.5 (10.9-12.1) 
2007 1913 109838.3 17.4 (16.6-18.2) 1458 110661.8 13.2 (12.5-13.9) 1388 110803.5 12.5 (11.9-13.2) 
2008 1979 112299.6 17.6 (16.9-18.4) 1467 113188.6 13.0 (12.3-13.6) 1415 113313.4 12.5 (11.8-13.2) 
2009 2101 113244.4 18.6 (17.8-19.4) 1623 114155.8 14.2 (13.5-14.9) 1561 114262.9 13.7 (13.0-14.4) 
2010 2354 114144.4 20.6 (19.8-21.5) 1872 115080.4 16.3 (15.5-17.0) 1793 115192.3 15.6 (14.9-16.3) 
2011 2581 114471.1 22.5 (21.7-23.4) 2075 115406.4 18.0 (17.2-18.8) 1996 115522.6 17.3 (16.5-18.1) 
2012 2880 115494.4 24.9 (24.0-25.9) 2325 116444.9 20.0 (19.2-20.8) 2248 116562.6 19.3 (18.5-20.1) 
2013 3251 115260.2 28.2 (27.2-29.2) 2639 116228.9 22.7 (21.8-23.6) 2541 116368 21.8 (21.0-22.7) 
2014 3638 115082.1 31.6 (30.6-32.7) 2965 116109.2 25.5 (24.6-26.5) 2864 116248.4 24.6 (23.7-25.6) 
2015 4405 114065.8 38.6 (37.5-39.8) 3628 115199.1 31.5 (30.5-32.5) 3518 115337.3 30.5 (29.5-31.5) 
2016 5345 112721.1 47.4 (46.2-48.7) 4467 114001.4 39.2 (38.0-40.3) 4360 114149.7 38.2 (37.1-39.3) 
2017 5757 111231.5 51.8 (50.4-53.1) 4892 112626 43.4 (42.2-44.7) 4770 112776.9 42.3 (41.1-43.5) 
2018 6488 109764 59.1 (57.7-60.6) 5577 111192.9 50.2 (48.8-51.5) 5466 111349.2 49.1 (47.8-50.4) 
25-
34 
2003 4690 186164 25.2 (24.5-25.9) 3884 186677.2 20.8 (20.2-21.5) 3528 186918.1 18.9 (18.3-19.5) 
2004 4579 183649.1 24.9 (24.2-25.7) 3755 184614.9 20.3 (19.7-21.0) 3450 184987.5 18.6 (18.0-19.3) 
2005 4468 180776.3 24.7 (24.0-25.5) 3587 182124.5 19.7 (19.1-20.4) 3306 182544.6 18.1 (17.5-18.7) 
2006 4438 179157.5 24.8 (24.0-25.5) 3596 180827.1 19.9 (19.2-20.5) 3347 181269.2 18.5 (17.8-19.1) 
2007 4599 177860.8 25.9 (25.1-26.6) 3742 179758.2 20.8 (20.2-21.5) 3501 180201.6 19.4 (18.8-20.1) 
2008 4698 177850.1 26.4 (25.7-27.2) 3802 180003 21.1 (20.5-21.8) 3567 180458.3 19.8 (19.1-20.4) 





2010 5325 179426.3 29.7 (28.9-30.5) 4399 182039.7 24.2 (23.5-24.9) 4168 182542.2 22.8 (22.1-23.5) 
2011 5706 180931.4 31.5 (30.7-32.4) 4760 183756.5 25.9 (25.2-26.7) 4499 184281.3 24.4 (23.7-25.1) 
2012 6312 183549.4 34.4 (33.5-35.2) 5238 186609.6 28.1 (27.3-28.8) 4991 187135.1 26.7 (25.9-27.4) 
2013 6803 184221.9 36.9 (36.1-37.8) 5654 187487 30.2 (29.4-31.0) 5403 188015.9 28.7 (28.0-29.5) 
2014 7589 184512.9 41.1 (40.2-42.1) 6371 187923.2 33.9 (33.1-34.7) 6092 188479 32.3 (31.5-33.1) 
2015 8603 184988 46.5 (45.5-47.5) 7303 188546.1 38.7 (37.8-39.6) 7022 189123.4 37.1 (36.3-38.0) 
2016 9898 184858.3 53.5 (52.5-54.6) 8506 188593 45.1 (44.1-46.1) 8192 189198.3 43.3 (42.4-44.2) 
2017 10819 183646.5 58.9 (57.8-60.0) 9309 187502.4 49.6 (48.6-50.7) 9006 188103.2 47.9 (46.9-48.9) 
2018 11577 182462.8 63.4 (62.3-64.6) 10059 186418.5 54.0 (52.9-55.0) 9756 186996.2 52.2 (51.1-53.2) 
35-
44 
2003 6338 222439.9 28.5 (27.8-29.2) 5317 223118.6 23.8 (23.2-24.5) 4679 223573.5 20.9 (20.3-21.5) 
2004 6434 223114.8 28.8 (28.1-29.6) 5345 224374.2 23.8 (23.2-24.5) 4741 225085 21.1 (20.5-21.7) 
2005 6306 220913.5 28.5 (27.8-29.3) 5151 222687.4 23.1 (22.5-23.8) 4573 223564.9 20.5 (19.9-21.1) 
2006 6246 219733.4 28.4 (27.7-29.1) 5101 221940.9 23.0 (22.4-23.6) 4588 222908.6 20.6 (20.0-21.2) 
2007 6253 216981.5 28.8 (28.1-29.5) 5199 219528.1 23.7 (23.0-24.3) 4747 220528.2 21.5 (20.9-22.1) 
2008 6071 214050.1 28.4 (27.7-29.1) 4998 216830.3 23.1 (22.4-23.7) 4553 217833.2 20.9 (20.3-21.5) 
2009 6414 208927.7 30.7 (30.0-31.5) 5308 211964.6 25.0 (24.4-25.7) 4873 212986.8 22.9 (22.2-23.5) 
2010 6515 203759.8 32.0 (31.2-32.8) 5483 206943.7 26.5 (25.8-27.2) 5081 207945.8 24.4 (23.8-25.1) 
2011 6675 198474.6 33.6 (32.8-34.4) 5602 201759.9 27.8 (27.0-28.5) 5211 202727.4 25.7 (25.0-26.4) 
2012 6889 193700.2 35.6 (34.7-36.4) 5843 197061.6 29.7 (28.9-30.4) 5466 198034.5 27.6 (26.9-28.3) 
2013 7041 189423.8 37.2 (36.3-38.0) 5971 192888.3 31.0 (30.2-31.8) 5622 193818.5 29.0 (28.3-29.8) 
2014 7453 187142.2 39.8 (38.9-40.7) 6407 190737.2 33.6 (32.8-34.4) 6046 191637.3 31.5 (30.8-32.4) 
2015 7881 186226 42.3 (41.4-43.3) 6863 189921.6 36.1 (35.3-37.0) 6529 190806.6 34.2 (33.4-35.1) 
2016 8609 185294.8 46.5 (45.5-47.5) 7469 189065.4 39.5 (38.6-40.4) 7105 189920.8 37.4 (36.5-38.3) 
2017 9159 183668.4 49.9 (48.9-50.9) 8007 187542.8 42.7 (41.8-43.6) 7683 188396.2 40.8 (39.9-41.7) 
2018 9636 182455.9 52.8 (51.8-53.9) 8452 186475.6 45.3 (44.4-46.3) 8133 187321.9 43.4 (42.5-44.4) 
45-
54 
2003 5102 186180.5 27.4 (26.7-28.2) 4158 186788.1 22.3 (21.6-22.9) 3440 187296.8 18.4 (17.8-19.0) 
2004 5278 186345 28.3 (27.6-29.1) 4355 187465 23.2 (22.5-23.9) 3694 188268.2 19.6 (19.0-20.3) 
2005 5331 186594.5 28.6 (27.8-29.3) 4252 188165.1 22.6 (21.9-23.3) 3634 189148.9 19.2 (18.6-19.8) 
2006 5349 188685.6 28.3 (27.6-29.1) 4337 190706.3 22.7 (22.1-23.4) 3778 191830.4 19.7 (19.1-20.3) 
2007 5554 191135.6 29.1 (28.3-29.8) 4513 193568.5 23.3 (22.6-24.0) 3982 194826.3 20.4 (19.8-21.1) 
2008 5566 194596.7 28.6 (27.9-29.4) 4542 197357.5 23.0 (22.3-23.7) 4035 198707.3 20.3 (19.7-20.9) 





2010 6214 201033.7 30.9 (30.1-31.7) 5183 204521.9 25.3 (24.7-26.0) 4665 206042.4 22.6 (22.0-23.3) 
2011 6640 202430.1 32.8 (32.0-33.6) 5580 206241.8 27.1 (26.4-27.8) 5070 207795.7 24.4 (23.7-25.1) 
2012 7020 204457 34.3 (33.5-35.1) 5951 208486.9 28.5 (27.8-29.3) 5431 210076.2 25.9 (25.2-26.5) 
2013 7074 205003.8 34.5 (33.7-35.3) 5982 209168.1 28.6 (27.9-29.3) 5493 210776.8 26.1 (25.4-26.8) 
2014 7110 206076.6 34.5 (33.7-35.3) 6136 210448.9 29.2 (28.4-29.9) 5650 212047.4 26.6 (26.0-27.3) 
2015 7550 205895.4 36.7 (35.8-37.5) 6518 210401.1 31.0 (30.2-31.7) 6072 211978 28.6 (27.9-29.4) 
2016 8205 206042.6 39.8 (39.0-40.7) 7185 210720.9 34.1 (33.3-34.9) 6710 212318.6 31.6 (30.9-32.4) 
2017 8474 203493.7 41.6 (40.8-42.5) 7475 208203.9 35.9 (35.1-36.7) 7016 209757.4 33.4 (32.7-34.2) 
2018 8677 200388.9 43.3 (42.4-44.2) 7663 205112.8 37.4 (36.5-38.2) 7236 206666.9 35.0 (34.2-35.8) 
55-
64 
2003 4203 165478.4 25.4 (24.6-26.2) 3253 166112.3 19.6 (18.9-20.3) 2555 166621.2 15.3 (14.7-15.9) 
2004 4419 167806.5 26.3 (25.6-27.1) 3418 168995.1 20.2 (19.6-20.9) 2735 169812.8 16.1 (15.5-16.7) 
2005 4360 168744.8 25.8 (25.1-26.6) 3389 170353.7 19.9 (19.2-20.6) 2739 171404.1 16.0 (15.4-16.6) 
2006 4622 170202.4 27.2 (26.4-28.0) 3637 172153.1 21.1 (20.4-21.8) 2952 173412 17.0 (16.4-17.6) 
2007 4632 170003.1 27.2 (26.5-28.0) 3630 172276.1 21.1 (20.4-21.8) 3018 173678 17.4 (16.8-18.0) 
2008 4426 170390.7 26.0 (25.2-26.8) 3498 172969.4 20.2 (19.6-20.9) 2925 174468.5 16.8 (16.2-17.4) 
2009 4567 168913 27.0 (26.3-27.8) 3579 171737 20.8 (20.2-21.5) 3064 173299.3 17.7 (17.1-18.3) 
2010 4556 169334.9 26.9 (26.1-27.7) 3705 172364.1 21.5 (20.8-22.2) 3179 173989.6 18.3 (17.6-18.9) 
2011 4538 167283.5 27.1 (26.3-27.9) 3720 170451 21.8 (21.1-22.5) 3254 172115 18.9 (18.3-19.6) 
2012 4776 164920.7 29.0 (28.1-29.8) 4034 168225.1 24.0 (23.2-24.7) 3540 169883.7 20.8 (20.2-21.5) 
2013 4804 164317.4 29.2 (28.4-30.1) 4021 167749 24.0 (23.2-24.7) 3592 169383.8 21.2 (20.5-21.9) 
2014 4818 165205.9 29.2 (28.3-30.0) 4069 168790.3 24.1 (23.4-24.9) 3657 170443.2 21.5 (20.8-22.2) 
2015 4989 167369.6 29.8 (29.0-30.6) 4239 171111.9 24.8 (24.0-25.5) 3848 172760.3 22.3 (21.6-23.0) 
2016 5396 170247.9 31.7 (30.9-32.6) 4667 174173.8 26.8 (26.0-27.6) 4306 175836.6 24.5 (23.8-25.2) 
2017 5690 173099.4 32.9 (32.0-33.7) 4976 177225.1 28.1 (27.3-28.9) 4573 178931.3 25.6 (24.8-26.3) 
2018 5939 176429 33.7 (32.8-34.5) 5220 180713.2 28.9 (28.1-29.7) 4813 182449.9 26.4 (25.6-27.1) 
65-
74 
2003 2655 118952.8 22.3 (21.5-23.2) 1910 119458.7 16.0 (15.3-16.7) 1408 119822 11.8 (11.1-12.4) 
2004 2777 119531.1 23.2 (22.4-24.1) 2052 120391.1 17.0 (16.3-17.8) 1527 121019.3 12.6 (12.0-13.3) 
2005 2754 117960.2 23.3 (22.5-24.2) 2028 119138.7 17.0 (16.3-17.8) 1492 119937.6 12.4 (11.8-13.1) 
2006 2868 117642 24.4 (23.5-25.3) 2038 119112.3 17.1 (16.4-17.9) 1592 120048.8 13.3 (12.6-13.9) 
2007 2872 118234.2 24.3 (23.4-25.2) 2060 119947.7 17.2 (16.4-17.9) 1626 121003.8 13.4 (12.8-14.1) 
2008 2866 120195.9 23.8 (23.0-24.7) 2128 122175 17.4 (16.7-18.2) 1692 123352.1 13.7 (13.1-14.4) 





2010 3027 123391.9 24.5 (23.7-25.4) 2316 125836.4 18.4 (17.7-19.2) 1873 127258.3 14.7 (14.1-15.4) 
2011 3220 126901.7 25.4 (24.5-26.3) 2506 129530.6 19.3 (18.6-20.1) 2073 131036.1 15.8 (15.1-16.5) 
2012 3301 132578.6 24.9 (24.1-25.8) 2577 135462.7 19.0 (18.3-19.8) 2163 137064.6 15.8 (15.1-16.5) 
2013 3364 135592.3 24.8 (24.0-25.7) 2633 138677.1 19.0 (18.3-19.7) 2224 140339.7 15.8 (15.2-16.5) 
2014 3418 138232.3 24.7 (23.9-25.6) 2726 141443 19.3 (18.6-20.0) 2335 143188.9 16.3 (15.7-17.0) 
2015 3502 140904.8 24.9 (24.0-25.7) 2824 144206.6 19.6 (18.9-20.3) 2475 145997.6 17.0 (16.3-17.6) 
2016 3629 143824.2 25.2 (24.4-26.1) 2943 147243.5 20.0 (19.3-20.7) 2602 149031.7 17.5 (16.8-18.1) 
2017 3632 144801.7 25.1 (24.3-25.9) 3035 148286.1 20.5 (19.7-21.2) 2736 150044.2 18.2 (17.6-18.9) 
2018 3582 145700.4 24.6 (23.8-25.4) 3041 149243.8 20.4 (19.7-21.1) 2739 150999.7 18.1 (17.5-18.8) 
75-
84 
2003 1911 80630.53 23.7 (22.6-24.8) 1358 81011.65 16.8 (15.9-17.7) 967 81276.66 11.9 (11.2-12.7) 
2004 2016 80480.54 25.0 (24.0-26.2) 1451 81110.63 17.9 (17.0-18.8) 1068 81572.3 13.1 (12.3-13.9) 
2005 2002 78780.58 25.4 (24.3-26.6) 1411 79620.91 17.7 (16.8-18.7) 1044 80217.28 13.0 (12.2-13.8) 
2006 1953 78078.39 25.0 (23.9-26.1) 1394 79096.85 17.6 (16.7-18.6) 1072 79780.05 13.4 (12.6-14.3) 
2007 1983 77927.77 25.4 (24.3-26.6) 1421 79123.87 18.0 (17.0-18.9) 1101 79880.75 13.8 (13.0-14.6) 
2008 1968 77970.24 25.2 (24.1-26.4) 1403 79356.49 17.7 (16.8-18.6) 1085 80190.4 13.5 (12.7-14.4) 
2009 2007 78223.24 25.7 (24.5-26.8) 1492 79741.96 18.7 (17.8-19.7) 1186 80631.59 14.7 (13.9-15.6) 
2010 2027 78748.9 25.7 (24.6-26.9) 1503 80358.31 18.7 (17.8-19.7) 1224 81267.05 15.1 (14.2-15.9) 
2011 2049 79470 25.8 (24.7-26.9) 1553 81219.58 19.1 (18.2-20.1) 1291 82197.94 15.7 (14.9-16.6) 
2012 2072 80921.14 25.6 (24.5-26.7) 1567 82729.27 18.9 (18.0-19.9) 1297 83749.21 15.5 (14.7-16.4) 
2013 2103 81899.96 25.7 (24.6-26.8) 1640 83778.24 19.6 (18.6-20.5) 1385 84845.86 16.3 (15.5-17.2) 
2014 2067 83103.55 24.9 (23.8-26.0) 1614 85077.6 19.0 (18.1-19.9) 1369 86162.95 15.9 (15.1-16.8) 
2015 2152 83363.85 25.8 (24.7-26.9) 1656 85415.9 19.4 (18.5-20.3) 1435 86481.47 16.6 (15.7-17.5) 
2016 2184 83803.19 26.1 (25.0-27.2) 1757 85923.48 20.4 (19.5-21.4) 1546 86998.92 17.8 (16.9-18.7) 
2017 2228 85307.35 26.1 (25.0-27.2) 1756 87470.28 20.1 (19.1-21.0) 1558 88609.74 17.6 (16.7-18.5) 
2018 2228 87539.92 25.5 (24.4-26.5) 1835 89778.81 20.4 (19.5-21.4) 1630 90946.91 17.9 (17.1-18.8) 
85+ 2003 519 27642.65 18.8 (17.2-20.5) 342 27770 12.3 (11.0-13.7) 254 27828.2 9.1 (8.0-10.3) 
2004 616 27634.3 22.3 (20.6-24.1) 403 27860.59 14.5 (13.1-15.9) 315 27962.68 11.3 (10.1-12.6) 
2005 699 28567.51 24.5 (22.7-26.4) 462 28881.21 16.0 (14.6-17.5) 361 29036.36 12.4 (11.2-13.8) 
2006 723 29819.43 24.2 (22.5-26.1) 497 30220.67 16.4 (15.0-18.0) 380 30430.9 12.5 (11.3-13.8) 
2007 765 30370.79 25.2 (23.4-27.0) 542 30850.46 17.6 (16.1-19.1) 419 31105.15 13.5 (12.2-14.8) 
2008 730 31131.98 23.4 (21.8-25.2) 535 31648.62 16.9 (15.5-18.4) 423 31948.52 13.2 (12.0-14.6) 




















2010 726 32332.3 22.5 (20.9-24.1) 516 32969.78 15.7 (14.3-17.1) 432 33346.67 13.0 (11.8-14.2) 
2011 727 33057.76 22.0 (20.4-23.7) 542 33731.52 16.1 (14.7-17.5) 461 34112.43 13.5 (12.3-14.8) 
2012 792 33596.35 23.6 (22.0-25.3) 582 34346.73 16.9 (15.6-18.4) 490 34740.45 14.1 (12.9-15.4) 
2013 765 33964.14 22.5 (21.0-24.2) 597 34742.75 17.2 (15.8-18.6) 492 35168.58 14.0 (12.8-15.3) 
2014 811 34634.47 23.4 (21.8-25.1) 623 35439.16 17.6 (16.2-19.0) 532 35883.68 14.8 (13.6-16.1) 
2015 791 35130.62 22.5 (21.0-24.1) 624 35975.09 17.3 (16.0-18.8) 527 36436.5 14.5 (13.3-15.8) 
2016 857 35845.06 23.9 (22.3-25.6) 673 36723.46 18.3 (17.0-19.8) 596 37197.75 16.0 (14.8-17.4) 
2017 856 36527.53 23.4 (21.9-25.1) 670 37477.82 17.9 (16.5-19.3) 586 37937.77 15.4 (14.2-16.7) 
2018 790 37456.15 21.1 (19.6-22.6) 634 38412.4 16.5 (15.2-17.8) 567 38860.82 14.6 (13.4-15.8) 





A.26 Prevalence rate of benzodiazepine and beta-blocker prescriptions – per 1000 person 
years by age 
Table 46 Prevalence rate of benzodiazepine and beta-blocker (propranolol) prescriptions – per 1000 
person years by age 
Variable Benzodiazepines Beta-blockers (propranolol) 
Age 
band 
Year N* PYAR Prevalence 
(1000PYAR) 
(95%CI) N* PYAR Prevalence 
(1000PYAR) 
(95%CI) 
<25 2003 532 107592.5 4.9 (4.5-5.4) 337 107677.1 3.1 (2.8-3.5) 
2004 539 108825.2 5.0 (4.5-5.4) 383 109004.3 3.5 (3.2-3.9) 
2005 559 108830.6 5.1 (4.7-5.6) 398 109013.2 3.7 (3.3-4.0) 
2006 552 110470.3 5.0 (4.6-5.4) 419 110626.1 3.8 (3.4-4.2) 
2007 604 111892.1 5.4 (5.0-5.8) 417 112073.1 3.7 (3.4-4.1) 
2008 578 114464.8 5.0 (4.6-5.5) 454 114630.7 4.0 (3.6-4.3) 
2009 573 115548.8 5.0 (4.6-5.4) 477 115670.9 4.1 (3.8-4.5) 
2010 631 116610.2 5.4 (5.0-5.9) 574 116663 4.9 (4.5-5.3) 
2011 679 117123.8 5.8 (5.4-6.3) 616 117142.3 5.3 (4.9-5.7) 
2012 747 118417.3 6.3 (5.9-6.8) 718 118408 6.1 (5.6-6.5) 
2013 730 118512 6.2 (5.7-6.6) 906 118371.6 7.7 (7.2-8.2) 
2014 794 118711.4 6.7 (6.2-7.2) 1035 118433.6 8.7 (8.2-9.3) 
2015 843 118300.6 7.1 (6.7-7.6) 1226 117788.2 10.4 (9.8-11.0) 
2016 942 117950.4 8.0 (7.5-8.5) 1453 117195.3 12.4 (11.8-13.1) 
2017 898 117326.9 7.7 (7.2-8.2) 1530 116304.1 13.2 (12.5-13.8) 
2018 902 116813.5 7.7 (7.2-8.2) 1755 115530.6 15.2 (14.5-15.9) 
25-
34 
2003 1571 188209.4 8.3 (7.9-8.8) 831 188640.4 4.4 (4.1-4.7) 
2004 1536 187212.8 8.2 (7.8-8.6) 827 188047.4 4.4 (4.1-4.7) 
2005 1572 185346.9 8.5 (8.1-8.9) 862 186396.4 4.6 (4.3-4.9) 
2006 1602 184466.9 8.7 (8.3-9.1) 825 185753.5 4.4 (4.1-4.8) 
2007 1646 183798.2 9.0 (8.5-9.4) 844 185223.2 4.6 (4.3-4.9) 
2008 1654 184413.2 9.0 (8.5-9.4) 891 185959.6 4.8 (4.5-5.1) 
2009 1800 185456.6 9.7 (9.3-10.2) 1032 187128.3 5.5 (5.2-5.9) 
2010 1809 187300.3 9.7 (9.2-10.1) 1098 189072.1 5.8 (5.5-6.2) 
2011 1945 189499.8 10.3 (9.8-10.7) 1284 191284.3 6.7 (6.4-7.1) 
2012 2030 192995.5 10.5 (10.1-11.0) 1464 194654.3 7.5 (7.1-7.9) 
2013 2080 194551.3 10.7 (10.2-11.2) 1749 195938.6 8.9 (8.5-9.4) 
2014 2271 195793.5 11.6 (11.1-12.1) 1931 196929.7 9.8 (9.4-10.3) 
2015 2430 197350.3 12.3 (11.8-12.8) 2214 198237.8 11.2 (10.7-11.6) 
2016 2701 198738.4 13.6 (13.1-14.1) 2489 199355.1 12.5 (12.0-13.0) 
2017 2627 199242.6 13.2 (12.7-13.7) 2781 199409.1 13.9 (13.4-14.5) 
2018 2695 199815.3 13.5 (13.0-14.0) 2987 199493.1 15.0 (14.4-15.5) 
35-
44 
2003 2353 225164.1 10.5 (10.0-10.9) 1024 225940.4 4.5 (4.3-4.8) 
2004 2421 227918.4 10.6 (10.2-11.1) 1130 229543.7 4.9 (4.6-5.2) 
2005 2481 227161.3 10.9 (10.5-11.4) 1097 229356.6 4.8 (4.5-5.1) 
2006 2490 227143.2 11.0 (10.5-11.4) 1103 229860.9 4.8 (4.5-5.1) 
2007 2491 225433.9 11.0 (10.6-11.5) 1112 228585.3 4.9 (4.6-5.2) 
2008 2437 223219.9 10.9 (10.5-11.4) 1068 226738.3 4.7 (4.4-5.0) 
2009 2563 218765.7 11.7 (11.3-12.2) 1175 222443.6 5.3 (5.0-5.6) 





2011 2591 209467.7 12.4 (11.9-12.9) 1348 213319 6.3 (6.0-6.7) 
2012 2525 205235.4 12.3 (11.8-12.8) 1490 209110 7.1 (6.8-7.5) 
2013 2524 201502.2 12.5 (12.0-13.0) 1539 205301.7 7.5 (7.1-7.9) 
2014 2618 199799.4 13.1 (12.6-13.6) 1705 203578.9 8.4 (8-8.8) 
2015 2558 199754.8 12.8 (12.3-13.3) 1771 203313.7 8.7 (8.3-9.1) 
2016 2766 199697.9 13.9 (13.3-14.4) 2029 203092.5 10.0 (9.6-10.4) 
2017 2658 199097.1 13.4 (12.8-13.9) 2193 202249.7 10.8 (10.4-11.3) 
2018 2702 199226.5 13.6 (13.1-14.1) 2384 201935.9 11.8 (11.3-12.3) 
45-
54 
2003 2085 188262.4 11.1 (10.6-11.6) 769 189076.6 4.1 (3.8-4.4) 
2004 2233 190037.5 11.8 (11.3-12.2) 836 191673.4 4.4 (4.1-4.7) 
2005 2315 191530.3 12.1 (11.6-12.6) 878 193858.6 4.5 (4.2-4.8) 
2006 2298 194720.5 11.8 (11.3-12.3) 902 197660.6 4.6 (4.3-4.9) 
2007 2446 198268.2 12.3 (11.9-12.8) 894 201793.1 4.4 (4.1-4.7) 
2008 2447 202810.2 12.1 (11.6-12.6) 954 206863.9 4.6 (4.3-4.9) 
2009 2592 207012.3 12.5 (12.0-13.0) 1051 211645.5 5.0 (4.7-5.3) 
2010 2567 211466 12.1 (11.7-12.6) 1123 216645.9 5.2 (4.9-5.5) 
2011 2760 213953.3 12.9 (12.4-13.4) 1201 219542.9 5.5 (5.2-5.8) 
2012 2892 217064.8 13.3 (12.8-13.8) 1324 223058.4 5.9 (5.6-6.3) 
2013 2842 218572 13.0 (12.5-13.5) 1378 224838.2 6.1 (5.8-6.5) 
2014 2725 220599.2 12.4 (11.9-12.8) 1502 226955.7 6.6 (6.3-7.0) 
2015 2736 221359.9 12.4 (11.9-12.8) 1584 227832.6 7.0 (6.6-7.3) 
2016 2823 222727.6 12.7 (12.2-13.2) 1685 229131.6 7.4 (7.0-7.7) 
2017 2779 221140.7 12.6 (12.1-13.0) 1820 227349.6 8.0 (7.6-8.4) 
2018 2635 219055.2 12.0 (11.6-12.5) 1860 224924.5 8.3 (7.9-8.7) 
55-
64 
2003 2010 167059 12.0 (11.5-12.6) 535 167961.7 3.2 (2.9-3.5) 
2004 2116 170590.6 12.4 (11.9-12.9) 621 172423.6 3.6 (3.3-3.9) 
2005 2181 172452.4 12.6 (12.1-13.2) 575 175080.2 3.3 (3.0-3.6) 
2006 2282 174797 13.1 (12.5-13.6) 618 178129.6 3.5 (3.2-3.8) 
2007 2287 175446.2 13.0 (12.5-13.6) 600 179368.2 3.3 (3.1-3.6) 
2008 2155 176590.1 12.2 (11.7-12.7) 629 181073.8 3.5 (3.2-3.8) 
2009 2224 175769.5 12.7 (12.1-13.2) 655 180673.5 3.6 (3.4-3.9) 
2010 2136 176958.3 12.1 (11.6-12.6) 682 182237 3.7 (3.5-4.0) 
2011 2049 175566.1 11.7 (11.2-12.2) 688 181042.7 3.8 (3.5-4.1) 
2012 2079 173844.4 12.0 (11.5-12.5) 749 179458.1 4.2 (3.9-4.5) 
2013 2027 173975.6 11.7 (11.1-12.2) 769 179768.4 4.3 (4.0-4.6) 
2014 1987 175681.6 11.3 (10.8-11.8) 827 181719.4 4.6 (4.2-4.9) 
2015 1908 178586.5 10.7 (10.2-11.2) 844 184830.1 4.6 (4.3-4.9) 
2016 2004 182484.9 11.0 (10.5-11.5) 892 188988.2 4.7 (4.4-5.0) 
2017 2043 186493.6 11.0 (10.5-11.4) 966 193214.5 5.0 (4.7-5.3) 
2018 2028 190931.1 10.6 (10.2-11.1) 1055 197897.6 5.3 (5.0-5.7) 
65-
74 
2003 1555 119755.9 13.0 (12.3-13.6) 239 120585.5 2.0 (1.7-2.2) 
2004 1647 120879.9 13.6 (13.0-14.3) 254 122479.8 2.1 (1.8-2.3) 
2005 1620 119776.1 13.5 (12.9-14.2) 248 121986.1 2.0 (1.8-2.3) 
2006 1724 119848 14.4 (13.7-15.1) 256 122645.7 2.1 (1.8-2.4) 
2007 1702 120858.5 14.1 (13.4-14.8) 253 124213.7 2.0 (1.8-2.3) 
2008 1661 123302.4 13.5 (12.8-14.1) 266 127170.9 2.1 (1.8-2.4) 
2009 1655 125903.9 13.1 (12.5-13.8) 288 130264.1 2.2 (2.0-2.5) 
2010 1711 127508.7 13.4 (12.8-14.1) 314 132292.3 2.4 (2.1-2.7) 





2012 1701 138080.4 12.3 (11.7-12.9) 407 143801.8 2.8 (2.6-3.1) 
2013 1734 141702.9 12.2 (11.7-12.8) 407 147765.9 2.8 (2.5-3.0) 
2014 1710 144937.5 11.8 (11.2-12.4) 448 151212 3.0 (2.7-3.3) 
2015 1684 148260 11.4 (10.8-11.9) 450 154775.2 2.9 (2.6-3.2) 
2016 1685 151871.1 11.1 (10.6-11.6) 430 158481.8 2.7 (2.5-3.0) 
2017 1598 153466.5 10.4 (9.9-10.9) 463 160164.1 2.9 (2.6-3.2) 
2018 1452 155073.8 9.4 (8.9-9.9) 493 161771.8 3.0 (2.8-3.3) 
75-
84 
2003 1160 81148.47 14.3 (13.5-15.1) 110 81814.38 1.3 (1.1-1.6) 
2004 1232 81426.26 15.1 (14.3-16.0) 121 82670.05 1.5 (1.2-1.7) 
2005 1247 79997.58 15.6 (14.7-16.5) 121 81707.28 1.5 (1.2-1.8) 
2006 1221 79508.2 15.4 (14.5-16.2) 112 81620.93 1.4 (1.1-1.7) 
2007 1240 79568.16 15.6 (14.7-16.5) 110 82090.68 1.3 (1.1-1.6) 
2008 1223 79788.5 15.3 (14.5-16.2) 134 82694.66 1.6 (1.4-1.9) 
2009 1199 80222.25 14.9 (14.1-15.8) 129 83414.55 1.5 (1.3-1.8) 
2010 1199 80966.55 14.8 (14.0-15.7) 128 84418.78 1.5 (1.3-1.8) 
2011 1143 81936.99 13.9 (13.2-14.8) 145 85703.29 1.7 (1.4-2.0) 
2012 1170 83561.96 14.0 (13.2-14.8) 152 87615.97 1.7 (1.5-2.0) 
2013 1143 84800.82 13.5 (12.7-14.3) 182 89030.88 2.0 (1.8-2.4) 
2014 1146 86175.33 13.3 (12.5-14.1) 178 90590.56 2.0 (1.7-2.3) 
2015 1134 86638.37 13.1 (12.3-13.9) 179 91164.26 2.0 (1.7-2.3) 
2016 1084 87387.09 12.4 (11.7-13.2) 186 92163.87 2.0 (1.7-2.3) 
2017 1107 89198.1 12.4 (11.7-13.2) 195 94099.08 2.1 (1.8-2.4) 
2018 1037 91797.15 11.3 (10.6-12.0) 193 96842.39 2.0 (1.7-2.3) 
85+ 2003 341 27765.07 12.3 (11.0-13.7) 22 27971.65 0.8 (0.5-1.2) 
2004 431 27852.72 15.5 (14.0-17.0) 19 28273.82 0.7 (0.4-1.0) 
2005 451 28897.63 15.6 (14.2-17.1) 18 29535.13 0.6 (0.4-1.0) 
2006 461 30249.06 15.2 (13.9-16.7) 30 31087.38 1.0 (0.7-1.4) 
2007 494 30892.96 16.0 (14.6-17.5) 32 31918.72 1.0 (0.7-1.4) 
2008 462 31735.51 14.6 (13.3-15.9) 21 32915.3 0.6 (0.4-1.0) 
2009 469 32139.85 14.6 (13.3-16.0) 31 33455.55 0.9 (0.6-1.3) 
2010 451 33100.44 13.6 (12.4-14.9) 39 34584.21 1.1 (0.8-1.5) 
2011 441 33922.3 13.0 (11.8-14.3) 24 35490.44 0.7 (0.4-1.0) 
2012 448 34583.22 13.0 (11.8-14.2) 37 36220.16 1.0 (0.7-1.4) 
2013 418 35053.93 11.9 (10.8-13.1) 32 36785.7 0.9 (0.6-1.2) 
2014 458 35849.9 12.8 (11.6-14.0) 31 37700.1 0.8 (0.6-1.2) 
2015 440 36427.84 12.1 (11.0-13.3) 28 38379.55 0.7 (0.5-1.1) 
2016 437 37233.78 11.7 (10.7-12.9) 43 39278.32 1.1 (0.8-1.5) 
2017 435 38006.1 11.4 (10.4-12.6) 47 40156.7 1.2 (0.9-1.6) 
2018 399 38942.5 10.2 (9.3-11.3) 40 41137.75 1.0 (0.7-1.3) 





A.27 Prevalence rate of antipsychotic and anticonvulsant prescriptions – per 1000 person 
years by age 
Table 47 Prevalence rate of antipsychotic and anticonvulsant prescriptions – per 1000 person years 
by age 
Variable Antipsychotics Anticonvulsants 
Age 
band 
Year N * PYAR Prevalence 
(1000PYAR) 
(95%CI) N* PYAR Prevalence 
(1000PYAR) 
(95%CI) 
<25 2003 56 107840.4 0.5 (0.4-0.7) 4 107869.6 0.0 (0.0-0.1) 
2004 81 109343.1 0.7 (0.6-0.9) 7 109410.8 0.1 (0.0-0.1) 
2005 76 109521.1 0.7 (0.5-0.9) 5 109604.7 0.0 (0.0-0.1) 
2006 66 111262.8 0.6 (0.5-0.8) 4 111363.6 0.0 (0.0-0.1) 
2007 58 112795.4 0.5 (0.4-0.7) 11 112893.7 0.1 (0.0-0.2) 
2008 68 115440.2 0.6 (0.5-0.7) 14 115539.3 0.1 (0.1-0.2) 
2009 86 116505.2 0.7 (0.6-0.9) 14 116613.1 0.1 (0.1-0.2) 
2010 103 117576.3 0.9 (0.7-1.1) 26 117691.1 0.2 (0.1-0.3) 
2011 117 118135.6 1.0 (0.8-1.2) 43 118241 0.4 (0.3-0.5) 
2012 115 119500.5 1.0 (0.8-1.2) 41 119604.9 0.3 (0.2-0.5) 
2013 137 119579.7 1.1 (1.0-1.4) 65 119684 0.5 (0.4-0.7) 
2014 162 119817.1 1.4 (1.2-1.6) 90 119934 0.8 (0.6-0.9) 
2015 186 119433.7 1.6 (1.3-1.8) 133 119546.4 1.1 (0.9-1.3) 
2016 231 119144.6 1.9 (1.7-2.2) 157 119264.8 1.3 (1.1-1.5) 
2017 277 118517.2 2.3 (2.1-2.6) 162 118647.4 1.4 (1.2-1.6) 
2018 289 117983.6 2.4 (2.2-2.7) 144 118153.6 1.2 (1.0-1.4) 
25-
34 
2003 171 188998.7 0.9 (0.8-1.1) 17 189091.9 0.1 (0.1-0.1) 
2004 170 188903.1 0.9 (0.8-1.0) 25 189075.9 0.1 (0.1-0.2) 
2005 181 187687.4 1.0 (0.8-1.1) 25 187922.4 0.1 (0.1-0.2) 
2006 186 187387.4 1.0 (0.9-1.1) 41 187676.1 0.2 (0.2-0.3) 





2008 204 188199.9 1.1 (0.9-1.2) 64 188545.8 0.3 (0.3-0.4) 
2009 226 189673.2 1.2 (1.0-1.4) 85 190026.7 0.4 (0.4-0.6) 
2010 262 191950.8 1.4 (1.2-1.5) 137 192333.4 0.7 (0.6-0.8) 
2011 299 194555.6 1.5 (1.4-1.7) 177 194929.2 0.9 (0.8-1.1) 
2012 321 198410.2 1.6 (1.4-1.8) 229 198790.2 1.2 (1.0-1.3) 
2013 349 200246.1 1.7 (1.6-1.9) 305 200591.4 1.5 (1.4-1.7) 
2014 369 201741.5 1.8 (1.6-2.0) 369 202037.3 1.8 (1.6-2.0) 
2015 437 203632.9 2.1 (1.9-2.4) 459 203860.7 2.3 (2.1-2.5) 
2016 492 205443.5 2.4 (2.2-2.6) 570 205587.9 2.8 (2.5-3.0) 
2017 565 206228 2.7 (2.5-3.0) 593 206347 2.9 (2.6-3.1) 
2018 600 206978.1 2.9 (2.7-3.1) 591 207107.3 2.9 (2.6-3.1) 
35-
44 
2003 188 226410.6 0.8 (0.7-1.0) 52 226497.1 0.2 (0.2-0.3) 
2004 216 230687.6 0.9 (0.8-1.1) 46 230874.9 0.2 (0.1-0.3) 
2005 229 231079.3 1.0 (0.9-1.1) 66 231328.8 0.3 (0.2-0.4) 
2006 222 232115.8 1.0 (0.8-1.1) 104 232398.1 0.4 (0.4-0.5) 
2007 239 231274.8 1.0 (0.9-1.2) 116 231607.2 0.5 (0.4-0.6) 
2008 276 229761.1 1.2 (1.1-1.4) 159 230106.3 0.7 (0.6-0.8) 
2009 297 225893.2 1.3 (1.2-1.5) 215 226204.2 1.0 (0.8-1.1) 
2010 326 221829.9 1.5 (1.3-1.6) 260 222126.2 1.2 (1.0-1.3) 
2011 352 217467.3 1.6 (1.5-1.8) 312 217706 1.4 (1.3-1.6) 
2012 381 213625.2 1.8 (1.6-2.0) 370 213832.8 1.7 (1.6-1.9) 
2013 409 210076.1 1.9 (1.8-2.1) 419 210255.3 2.0 (1.8-2.2) 
2014 385 208801.7 1.8 (1.7-2.0) 537 208881.8 2.6 (2.4-2.8) 
2015 433 209026.9 2.1 (1.9-2.3) 570 209028.4 2.7 (2.5-3.0) 
2016 553 209303.4 2.6 (2.4-2.9) 695 209232.1 3.3 (3.1-3.6) 





2018 573 209472.4 2.7 (2.5-3.0) 810 209110.5 3.9 (3.6-4.1) 
45-
54 
2003 141 189452.7 0.7 (0.6-0.9) 45 189510.2 0.2 (0.2-0.3) 
2004 162 192528.7 0.8 (0.7-1.0) 67 192653.1 0.3 (0.3-0.4) 
2005 199 195196.3 1.0 (0.9-1.2) 85 195373.5 0.4 (0.3-0.5) 
2006 231 199441.4 1.2 (1.0-1.3) 120 199663.7 0.6 (0.5-0.7) 
2007 248 203986.7 1.2 (1.1-1.4) 154 204235.7 0.8 (0.6-0.9) 
2008 255 209560.8 1.2 (1.1-1.4) 206 209789.1 1.0 (0.9-1.1) 
2009 291 214771.1 1.4 (1.2-1.5) 267 215033.4 1.2 (1.1-1.4) 
2010 335 220303.8 1.5 (1.4-1.7) 352 220541.9 1.6 (1.4-1.8) 
2011 377 223698 1.7 (1.5-1.9) 418 223865.6 1.9 (1.7-2.1) 
2012 430 227723.6 1.9 (1.7-2.1) 502 227766.3 2.2 (2.0-2.4) 
2013 450 230059.9 2.0 (1.8-2.1) 559 229989.5 2.4 (2.2-2.6) 
2014 456 232720.8 2.0 (1.8-2.1) 612 232529.9 2.6 (2.4-2.8) 
2015 442 234131.4 1.9 (1.7-2.1) 746 233733.5 3.2 (3.0-3.4) 
2016 495 236049.3 2.1 (1.9-2.3) 845 235441.9 3.6 (3.4-3.8) 
2017 544 234735.9 2.3 (2.1-2.5) 871 234022.7 3.7 (3.5-4.0) 
2018 549 232794.6 2.4 (2.2-2.6) 917 231920.4 4.0 (3.7-4.2) 
55-
64 
2003 139 168198.3 0.8 (0.7-1.0) 51 168260.3 0.3 (0.2-0.4) 
2004 139 173030.7 0.8 (0.7-0.9) 63 173129.6 0.4 (0.3-0.5) 
2005 160 175979.1 0.9 (0.8-1.1) 88 176109.3 0.5 (0.4-0.6) 
2006 192 179340.1 1.1 (0.9-1.2) 123 179479.5 0.7 (0.6-0.8) 
2007 181 180873.2 1.0 (0.9-1.2) 148 181007.7 0.8 (0.7-1.0) 
2008 187 182840.7 1.0 (0.9-1.2) 163 182985 0.9 (0.8-1.0) 
2009 192 182777.2 1.1 (0.9-1.2) 241 182839.6 1.3 (1.2-1.5) 
2010 215 184653.6 1.2 (1.0-1.3) 283 184643.8 1.5 (1.4-1.7) 





2012 261 182510 1.4 (1.3-1.6) 367 182364.3 2.0 (1.8-2.2) 
2013 262 183095 1.4 (1.3-1.6) 412 182869.1 2.3 (2.0-2.5) 
2014 281 185416.6 1.5 (1.3-1.7) 453 185087.2 2.4 (2.2-2.7) 
2015 270 188935.9 1.4 (1.3-1.6) 479 188498.1 2.5 (2.3-2.8) 
2016 310 193524 1.6 (1.4-1.8) 611 192913.6 3.2 (2.9-3.4) 
2017 331 198256.6 1.7 (1.5-1.9) 684 197422.2 3.5 (3.2-3.7) 
2018 385 203421.7 1.9 (1.7-2.1) 701 202408.3 3.5 (3.2-3.7) 
65-
74 
2003 115 120668.2 1.0 (0.8-1.1) 36 120718.6 0.3 (0.2-0.4) 
2004 110 122668.1 0.9 (0.7-1.1) 42 122756.3 0.3 (0.2-0.5) 
2005 90 122313.3 0.7 (0.6-0.9) 51 122411.3 0.4 (0.3-0.5) 
2006 112 123092.5 0.9 (0.7-1.1) 63 123208.5 0.5 (0.4-0.7) 
2007 103 124793.3 0.8 (0.7-1.0) 73 124903.2 0.6 (0.5-0.7) 
2008 120 127913.6 0.9 (0.8-1.1) 99 127995.3 0.8 (0.6-0.9) 
2009 105 131159.5 0.8 (0.7-1.0) 156 131201.9 1.2 (1.0-1.4) 
2010 111 133394.6 0.8 (0.7-1.0) 206 133378.4 1.5 (1.3-1.8) 
2011 139 138190 1.0 (0.8-1.2) 246 138094.5 1.8 (1.6-2.0) 
2012 140 145406 1.0 (0.8-1.1) 250 145228.2 1.7 (1.5-1.9) 
2013 146 149632.5 1.0 (0.8-1.1) 303 149364.8 2.0 (1.8-2.3) 
2014 163 153370.4 1.1 (0.9-1.2) 344 153001.2 2.2 (2.0-2.5) 
2015 159 157208.4 1.0 (0.9-1.2) 405 156709 2.6 (2.3-2.8) 
2016 144 161224.5 0.9 (0.8-1.1) 398 160580.2 2.5 (2.2-2.7) 
2017 167 163155 1.0 (0.9-1.2) 425 162368.8 2.6 (2.4-2.9) 
2018 173 165060.5 1.0 (0.9-1.2) 412 164150.1 2.5 (2.3-2.8) 
75-
84 
2003 103 81824.52 1.3 (1.0-1.5) 26 81873.04 0.3 (0.2-0.5) 
2004 108 82715.41 1.3 (1.1-1.6) 37 82795.4 0.4 (0.3-0.6) 





2006 77 81769.36 0.9 (0.7-1.2) 62 81833.18 0.8 (0.6-1.0) 
2007 97 82285.06 1.2 (1.0-1.4) 68 82341.2 0.8 (0.6-1.0) 
2008 89 82942.09 1.1 (0.9-1.3) 67 83008.74 0.8 (0.6-1.0) 
2009 93 83724.48 1.1 (0.9-1.4) 97 83779.66 1.2 (0.9-1.4) 
2010 104 84796.55 1.2 (1.0-1.5) 115 84794.29 1.4 (1.1-1.6) 
2011 99 86156.17 1.1 (0.9-1.4) 143 86094.9 1.7 (1.4-2.0) 
2012 107 88144.55 1.2 (1.0-1.5) 157 88031.85 1.8 (1.5-2.1) 
2013 90 89643.08 1.0 (0.8-1.2) 195 89456.77 2.2 (1.9-2.5) 
2014 98 91317.46 1.1 (0.9-1.3) 219 91045.53 2.4 (2.1-2.7) 
2015 100 91975.53 1.1 (0.9-1.3) 245 91643.41 2.7 (2.3-3.0) 
2016 117 93063.08 1.3 (1.0-1.5) 248 92667.79 2.7 (2.4-3.0) 
2017 123 95111.62 1.3 (1.1-1.5) 253 94660.24 2.7 (2.4-3.0) 
2018 121 98014.67 1.2 (1.0-1.5) 256 97479.38 2.6 (2.3-3.0) 
85+ 2003 53 27953.13 1.9 (1.4-2.5) 4 27985.6 0.1 (0.0-0.4) 
2004 54 28244.59 1.9 (1.4-2.5) 7 28295.62 0.2 (0.1-0.5) 
2005 38 29516.32 1.3 (0.9-1.8) 11 29569.49 0.4 (0.2-0.7) 
2006 47 31072.57 1.5 (1.1-2.0) 14 31137.37 0.4 (0.2-0.8) 
2007 34 31917.01 1.1 (0.7-1.5) 27 31971.38 0.8 (0.6-1.2) 
2008 32 32927.7 1.0 (0.7-1.4) 33 32959.66 1.0 (0.7-1.4) 
2009 43 33489.2 1.3 (0.9-1.7) 26 33510.02 0.8 (0.5-1.1) 
2010 43 34637.53 1.2 (0.9-1.7) 32 34656.28 0.9 (0.6-1.3) 
2011 35 35565.47 1.0 (0.7-1.4) 22 35582.48 0.6 (0.4-0.9) 
2012 41 36340.19 1.1 (0.8-1.5) 52 36337.99 1.4 (1.1-1.9) 
2013 40 36937.49 1.1 (0.8-1.5) 57 36894.79 1.5 (1.2-2.0) 
2014 50 37874.79 1.3 (1.0-1.7) 67 37809.46 1.8 (1.4-2.3) 
































2016 59 39490 1.5 (1.1-1.9) 86 39380.25 2.2 (1.7-2.7) 
2017 64 40410.48 1.6 (1.2-2.0) 83 40283.75 2.1 (1.6-2.6) 
2018 66 41412.41 1.6 (1.2-2.0) 95 41246.21 2.3 (1.9-2.8) 





A.28 Prevalence of anxiolytic prescriptions (any anxiolytic, all antidepressants, and 
benzodiazepines) per 1000 person years between 2003 and 2018 - restricted time 
frame sensitivity analysis 
Figure 62 Prevalence of anxiolytic prescriptions (any anxiolytic, all antidepressants, and 





























A.29 Prevalence of anxiolytic prescriptions (any anxiolytic and all antidepressants) per 1000 
person years between 2003 and 2018 – excluded low dose amitriptyline sensitivity 
analysis 
Figure 63 Prevalence of anxiolytic prescriptions (any anxiolytic and all antidepressants) per 1000 






A.30 Best fitting join point model of the incidence of prescriptions of all antidepressants per 1000 person-years 























A.31 Best fitting join point model of the incidence of prescriptions of SSRIs & ‘other’ antidepressant per 1000 person-years 





A.32 Incidence rate ratios for prescriptions of SSRI & ‘other’ antidepressant 
Table 48 incidence rate ratios for prescriptions of SSRI & ‘other’ antidepressant 
 SSRI & ‘other’ antidepressant 








Year 2003 1.00  <0.001 1.00  <0.001 
2004 0.94 (0.91-0.97) 0.94 (0.92-0.97) 
2005 0.81 (0.78-0.83) 0.81 (0.79-0.84) 
2006 0.80 (0.78-0.82) 0.81 (0.78-0.83) 
2007 0.81 (0.79-0.83) 0.82 (0.79-0.84) 
2008 0.76 (0.74-0.78) 0.77 (0.74-0.79) 
2009 0.81 (0.79-0.83) 0.82 (0.80-0.84) 
2010 0.83 (0.80-0.85) 0.84 (0.81-0.86) 
2011 0.87 (0.84-0.89) 0.88 (0.86-0.91) 
2012 0.88 (0.86-0.91) 0.90 (0.87-0.93) 
2013 0.90 (0.87-0.92) 0.91 (0.89-0.94) 
2014 0.96 (0.93-0.98) 0.98 (0.95-1.01) 
2015 1.05 (1.03-1.08) 1.08 (1.05-1.11) 
2016 1.18 (1.14-1.21) 1.21 (1.18-1.24) 
2017 1.22 (1.19-1.25) 1.26 (1.22-1.29) 
2018 1.26 (1.23-1.30) 1.31 (1.27-1.34) 
Gender Male 1.00  <0.001 1.00  <0.001 




18-24 1.00  <0.001 1.00  <0.001 
25-34 1.00 (0.98-1.02) 0.99 (0.97-1.01) 
35-44 0.92 (0.91-0.94) 0.93 (0.91-0.95) 
44-54 0.82 (0.81-0.84) 0.82 (0.80-0.83) 
55-64 0.67 (0.66-0.68) 0.66 (0.65-0.68) 
65-74 0.53 (0.52-0.54) 0.51 (0.50-0.52) 
75-84 0.58 (0.56-0.59) 0.54 (0.53-0.56) 
85+ 0.50 (0.48-0.52) 0.44 (0.42-0.46) 














A.33 Incidence rate ratios for prescriptions of antipsychotics 
Table 49 incidence rate ratios for prescriptions of antipsychotics 
 Antipsychotic 








Year 2003 1.00  <0.001 1.00  <0.001 
2004 0.95 (0.84-1.07) 1.12 (0.84-1.08) 
2005 0.88 (0.78-1.00) 1.10 (0.78-1.00) 
2006 0.91 (0.80-1.03) 1.04 (0.81-1.03) 
2007 0.83 (0.73-0.94) 0.80 (0.73-0.94) 
2008 0.91 (0.81-1.03) 0.65 (0.81-1.03) 
2009 0.95 (0.85-1.07) 0.88 (0.85-1.08) 
2010 1.04 (0.92-1.16) 0.95 (0.93-1.17) 
2011 1.07 (0.96-1.20) 1.12 (0.96-1.21) 
2012 1.14 (1.02-1.28) 1.10 (1.03-1.29) 
2013 1.13 (1.01-1.27) 1.04 (1.02-1.28) 
2014 1.25 (1.12-1.40) 0.80 (1.13-1.41) 
2015 1.23 (1.10-1.38) 0.65 (1.12-1.39) 
2016 1.41 (1.26-1.57) 0.88 (1.28-1.59) 
2017 1.59 (1.43-1.77) 0.95 (1.45-1.79) 
2018 1.51 (1.36-1.68) 1.12 (1.38-1.71) 
Gender Male 1.00  <0.001 1.00  <0.001 




18-24 1.00  <0.001 1.00  <0.001 
25-34 1.13 (1.05-1.22) 1.12 (1.04-1.21) 
35-44 1.09 (1.01-1.17) 1.10 (1.02-1.18) 
44-54 1.05 (0.98-1.13) 1.04 (0.97-1.12) 
55-64 0.81 (0.75-0.88) 0.80 (0.74-0.87) 
65-74 0.67 (0.61-0.74) 0.65 (0.60-0.72) 
75-84 0.91 (0.83-1.01) 0.88 (0.80-0.97) 
85+ 1.03 (0.91-1.16) 0.95 (0.83-1.07) 





A.34 Incidence rate ratios for prescriptions of anticonvulsants 
Table 50 incidence rate ratios for prescriptions of anticonvulsants 
 Anticonvulsant 






(95%CI) P value 
Year 2003 1.00  <0.001 1.00  <0.001 
2004 1.21 (0.98-1.49) 1.21 (0.98-1.49) 
2005 1.53 (1.25-1.87) 1.53 (1.25-1.87) 
2006 2.21 (1.83-2.67) 2.21 (1.83-2.67) 
2007 2.24 (1.85-2.70) 2.24 (1.85-2.70) 
2008 3.10 (2.59-3.71) 3.10 (2.60-3.71) 
2009 3.98 (3.34-4.74) 3.98 (3.34-4.74) 
2010 5.11 (4.31-6.06) 5.11 (4.31-6.06) 
2011 5.58 (4.71-6.61) 5.58 (4.71-6.61) 
2012 6.27 (5.30-7.42) 6.28 (5.31-7.43) 
2013 7.13 (6.04-8.43) 7.13 (6.04-8.43) 
2014 7.87 (6.67-9.28) 7.87 (6.67-9.29) 
2015 8.74 (7.41-10.31) 8.74 (7.41-10.31) 
2016 9.89 (8.39-11.65) 9.88 (8.39-11.64) 
2017 9.73 (8.26-11.46) 9.72 (8.25-11.45) 
2018 9.37 (7.95-11.04) 9.35 (7.94-11.02) 
Gender Male 1.00  <0.001 1.00  <0.001 
Female 2.21 (2.13-2.29) 2.21 (2.14-2.29) 
Age Band 
(years) 
18-24 1.00  <0.001 1.00  <0.001 
25-34 2.04 (1.86-2.25) 2.02 (1.83-2.22) 
35-44 2.69 (2.45-2.95) 2.79 (2.55-3.06) 
44-54 3.32 (3.03-3.63) 3.23 (2.95-3.53) 
55-64 3.04 (2.77-3.34) 3.00 (2.73-3.29) 
65-74 2.89 (2.62-3.18) 2.70 (2.45-2.97) 
75-84 3.01 (2.72-3.33) 2.81 (2.54-3.11) 
85+ 2.26 (1.98-2.59) 1.91 (1.67-2.18) 





A.35 Incidence rate ratio for prescriptions of any anxiolytics, all antidepressants, and benzodiazepines - model accounting for clustering  
Table 51 Incidence rate ratio for prescriptions of any anxiolytic, all antidepressants, and benzodiazepines - model accounting for clustering 
 Any anxiolytic All antidepressants Benzodiazepines 
Variable  Multivariable IRR* (95%CI) P value Multivariable IRR* (95%CI) P value Multivariable IRR* (95%CI) P value 
Year 2003 1.00  <0.001 1.00  <0.001 1.00  <0.001 
2004 0.94 (0.90-0.97) 0.93 (0.89-0.98) 0.95 (0.91-0.99) 
2005 0.83 (0.79-0.86) 0.80 (0.76-0.84) 0.89 (0.85-0.94) 
2006 0.79 (0.74-0.84) 0.78 (0.72-0.83) 0.85 (0.79-0.90) 
2007 0.78 (0.73-0.84) 0.78 (0.72-0.84) 0.84 (0.78-0.91) 
2008 0.74 (0.68-0.80) 0.73 (0.67-0.80) 0.78 (0.71-0.85) 
2009 0.77 (0.71-0.83) 0.77 (0.71-0.84) 0.82 (0.75-0.89) 
2010 0.76 (0.70-0.83) 0.79 (0.72-0.86) 0.77 (0.70-0.84) 
2011 0.78 (0.72-0.85) 0.81 (0.75-0.89) 0.77 (0.71-0.84) 
2012 0.79 (0.73-0.86) 0.83 (0.76-0.91) 0.75 (0.69-0.82) 
2013 0.80 (0.74-0.87) 0.84 (0.77-0.91) 0.74 (0.68-0.81) 
2014 0.84 (0.78-0.91) 0.90 (0.83-0.98) 0.76 (0.69-0.84) 
2015 0.92 (0.85-1.00) 0.98 (0.90-1.07) 0.75 (0.69-0.83) 
2016 1.01 (0.93-1.09) 1.10 (1.00-1.20) 0.78 (0.71-0.86) 
2017 1.04 (0.95-1.13) 1.13 (1.04-1.24) 0.75 (0.68-0.83) 
2018 1.06 (0.97-1.16) 1.18 (1.07-1.29) 0.72 (0.66-0.79) 
Gender Male 1.00  <0.001 1.00  <0.001 1.00  <0.001 
Female 2.02 (1.99-2.05) 2.04 (2.00-2.07) 2.06 (2.01-2.10) 
Age Band 
(years) 
18-24 1.00  <0.001 1.00  <0.001 1.00  <0.001 
25-34 0.94 (0.91-0.97) 0.99 (0.96-1.03) 1.37 (1.30-1.43) 
35-44 0.88 (0.85-0.92) 0.94 (0.91-0.98) 1.48 (1.40-1.56) 
44-54 0.80 (0.77-0.83) 0.85 (0.81-0.89) 1.44 (1.36-1.52) 
55-64 0.68 (0.66-0.71) 0.71 (0.68-0.74) 1.36 (1.28-1.44) 
65-74 0.57 (0.55-0.60) 0.57 (0.54-0.60) 1.33 (1.24-1.43) 
75-84 0.60 (0.57-0.63) 0.60 (0.57-0.64) 1.42 (1.32-1.53) 
85+ 0.49 (0.45-0.53) 0.48 (0.45-0.52) 1.16 (1.06-1.28) 






A.36 Incidence rate ratio for prescriptions of all beta-blockers, anticonvulsants, and antipsychotics - model accounting for clustering  
Table 52 Incidence rate ratio for prescriptions of all beta-blockers, anticonvulsants, and antipsychotics – model accounting for clustering 
 Beta-blockers (propranolol) Anticonvulsants Antipsychotics 
Variable  Multivariable IRR* (95%CI) P value Multivariable IRR* (95%CI) P value Multivariable IRR* (95%CI) P value 
Year 2003 1.00  <0.001 1.00  <0.001 1.00  <0.001 
2004 1.05 (0.98-1.12) 1.21 (0.98-1.48) 0.95 (0.83-1.10) 
2005 0.98 (0.91-1.06) 1.53 (1.26-1.87) 0.88 (0.77-1.01) 
2006 0.93 (0.85-1.01) 2.21 (1.80-2.72) 0.91 (0.78-1.06) 
2007 0.91 (0.83-0.99) 2.24 (1.82-2.75) 0.83 (0.70-0.98) 
2008 0.90 (0.81-0.99) 3.10 (2.51-3.84) 0.91 (0.79-1.06) 
2009 1.00 (0.90-1.11) 3.98 (3.29-4.81) 0.96 (0.81-1.12) 
2010 1.03 (0.92-1.15) 5.11 (4.20-6.22) 1.04 (0.90-1.21) 
2011 1.10 (0.99-1.23) 5.58 (4.59-6.78) 1.08 (0.93-1.26) 
2012 1.19 (1.08-1.32) 6.28 (5.21-7.56) 1.15 (0.99-1.34) 
2013 1.29 (1.15-1.44) 7.13 (5.91-8.62) 1.14 (0.97-1.34) 
2014 1.40 (1.26-1.56) 7.87 (6.50-9.52) 1.26 (1.06-1.50) 
2015 1.52 (1.36-1.69) 8.74 (7.18-10.64) 1.25 (1.08-1.44) 
2016 1.67 (1.50-1.87) 9.88 (8.03-12.14) 1.42 (1.23-1.64) 
2017 1.77 (1.57-1.99) 9.72 (7.96-11.86) 1.62 (1.38-1.89) 
2018 1.88 (1.68-2.10) 9.35 (7.63-11.47) 1.54 (1.33-1.78) 
Gender Male 1.00  <0.001 1.00  <0.001 1.00  <0.001 
Female 2.29 (2.23-2.35) 2.21 (2.13-2.30) 1.44 (1.38-1.51) 
Age Band 
(years) 
18-24 1.00  <0.001 1.00  <0.001 1.00  <0.001 
25-34 0.93 (0.89-0.97) 2.02 (1.81-2.24) 1.12 (1.04-1.21) 
35-44 0.80 (0.75-0.84) 2.79 (2.48-3.15) 1.10 (1.00-1.21) 
44-54 0.63 (0.60-0.67) 3.23 (2.85-3.65) 1.04 (0.95-1.14) 
55-64 0.43 (0.41-0.46) 3.00 (2.64-3.41) 0.80 (0.72-0.89) 
65-74 0.25 (0.23-0.28) 2.70 (2.36-3.09) 0.65 (0.58-0.73) 
75-84 0.18 (0.16-0.20) 2.81 (2.42-3.27) 0.88 (0.77-1.01) 
85+ 0.08 (0.07-0.10) 1.91 (1.59-2.28) 0.95 (0.80-1.13) 






A.37 Incidence rate for prescriptions of any anxiolytic, all antidepressants, and SSRIs and ‘other’ antidepressants between 2003 and 2018, by gender 
Table 53  Incidence rate for prescriptions of any anxiolytic, all antidepressants, and SSRIs and ‘other’ antidepressants between 2003 and 2018, by gender 
Variable Any anxiolytic All antidepressants SSRIs and ‘other’ antidepressants 
Gender Year N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) 
Male 2003 4474 542784.8 8.2 (8.0-8.5) 3558 543285.9 6.5 (6.3-6.8) 3113 543534.9 5.7 (5.5-5.9) 
2004 4143 547443 7.6 (7.3-7.8) 3272 548896.4 6.0 (5.8-6.2) 2928 549582.5 5.3 (5.1-5.5) 
2005 3712 547407.9 6.8 (6.6-7.0) 2852 549714.6 5.2 (5.0-5.4) 2575 550696.1 4.7 (4.5-4.9) 
2006 3609 550840.8 6.6 (6.3-6.8) 2842 553950.9 5.1 (4.9-5.3) 2594 555201.7 4.7 (4.5-4.9) 
2007 3563 553213.4 6.4 (6.2-6.7) 2839 556988.4 5.1 (4.9-5.3) 2640 558421.1 4.7 (4.5-4.9) 
2008 3334 557922.1 6.0 (5.8-6.2) 2635 562299 4.7 (4.5-4.9) 2443 563873.4 4.3 (4.2-4.5) 
2009 3735 559785.9 6.7 (6.5-6.9) 2978 564711.9 5.3 (5.1-5.5) 2762 566430.9 4.9 (4.7-5.1) 
2010 3652 562478 6.5 (6.3-6.7) 3035 567957.9 5.3 (5.2-5.5) 2876 569792 5.0 (4.9-5.2) 
2011 3781 562926.9 6.7 (6.5-6.9) 3145 568861.1 5.5 (5.3-5.7) 3026 570766.4 5.3 (5.1-5.5) 
2012 3970 566381.6 7.0 (6.8-7.2) 3331 572745.3 5.8 (5.6-6.0) 3180 574696.5 5.5 (5.3-5.7) 
2013 3914 566724.1 6.9 (6.7-7.1) 3275 573456.6 5.7 (5.5-5.9) 3191 575458.3 5.5 (5.4-5.7) 
2014 4072 570401.7 7.1 (6.9-7.4) 3522 577505 6.1 (5.9-6.3) 3383 579565.3 5.8 (5.6-6.0) 
2015 4518 573604.2 7.9 (7.6-8.1) 3906 581031.7 6.7 (6.5-6.9) 3781 583123.3 6.5 (6.3-6.7) 
2016 5040 577343 8.7 (8.5-9.0) 4447 585114.1 7.6 (7.4-7.8) 4336 587246.3 7.4 (7.2-7.6) 
2017 5099 578392.4 8.8 (8.6-9.1) 4507 586500 7.7 (7.5-7.9) 4398 588653.4 7.5 (7.3-7.7) 
2018 5265 579697.1 9.1 (8.8-9.3) 4737 588072.3 8.1 (7.8-8.3) 4658 590242.6 7.9 (7.7-8.1) 
Female 2003 9616 561165.4 17.1 (16.8-17.5) 7747 562206 13.8 (13.5-14.1) 6813 562761.7 12.1 (11.8-12.4) 
2004 9031 559146.1 16.2 (15.8-16.5) 7298 562065.9 13.0 (12.7-13.3) 6464 563562.5 11.5 (11.2-11.8) 
2005 7819 552457.7 14.2 (13.8-14.5) 6141 557111 11.0 (10.7-11.3) 5466 559358.2 9.8 (9.5-10.0) 
2006 7436 551190.1 13.5 (13.2-13.8) 5916 557340.1 10.6 (10.3-10.9) 5410 560126.1 9.7 (9.4-9.9) 
2007 7300 549048.9 13.3 (13.0-13.6) 5929 556467.5 10.7 (10.4-10.9) 5481 559666 9.8 (9.5-10.1) 
2008 6981 550176.7 12.7 (12.4-13.0) 5653 558752.2 10.1 (9.9-10.4) 5229 562280.8 9.3 (9.0-9.6) 
2009 7037 548524.2 12.8 (12.5-13.1) 5805 558121.1 10.4 (10.1-10.7) 5433 561937.9 9.7 (9.4-9.9) 
2010 7009 548729.1 12.8 (12.5-13.1) 5903 559239.4 10.6 (10.3-10.8) 5528 563338.2 9.8 (9.6-10.1) 
2011 7148 548855.7 13.0 (12.7-13.3) 6118 560116.9 10.9 (10.7-11.2) 5799 564423.3 10.3 (10.0-10.5) 





2013 7326 551188.3 13.3 (13.0-13.6) 6265 563730.8 11.1 (10.8-11.4) 6002 568352.8 10.6 (10.3-10.8) 
2014 7761 551562.5 14.1 (13.8-14.4) 6750 564731.9 12.0 (11.7-12.2) 6484 569470.4 11.4 (11.1-11.7) 
2015 8421 552035.3 15.3 (14.9-15.6) 7356 565811.7 13.0 (12.7-13.3) 7139 570592.8 12.5 (12.2-12.8) 
2016 9138 552747.5 16.5 (16.2-16.9) 8146 567215.5 14.4 (14.1-14.7) 7891 572072.9 13.8 (13.5-14.1) 
2017 9455 550555.3 17.2 (16.8-17.5) 8479 565495.9 15.0 (14.7-15.3) 8279 570406.2 14.5 (14.2-14.8) 
2018 9551 549433.9 17.4 (17.0-17.7) 8705 564762.4 15.4 (15.1-15.7) 8497 569723.3 14.9 (14.6-15.2) 





A.38 Incidence rates for prescriptions of benzodiazepines and beta-blockers between 2003 
and 2018, by gender 
Table 54 Incidence rates for prescriptions of benzodiazepines and beta-blockers between 2003 and 
2018, by gender 
Variable Benzodiazepines Beta-blockers (propranolol) 
Gender Year N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) 
Male 2003 2203 544135.8 4.0 (3.9-4.2) 815 544864.4 1.5 (1.4-1.6) 
2004 2075 551290.9 3.8 (3.6-3.9) 814 553355.5 1.5 (1.4-1.6) 
2005 2016 553184.3 3.6 (3.5-3.8) 742 556372.5 1.3 (1.2-1.4) 
2006 1934 558313.8 3.5 (3.3-3.6) 716 562629 1.3 (1.2-1.4) 
2007 1898 562248.5 3.4 (3.2-3.5) 718 567503.8 1.3 (1.2-1.4) 
2008 1730 568436.8 3.0 (2.9-3.2) 766 574502.1 1.3 (1.2-1.4) 
2009 1928 571811.1 3.4 (3.2-3.5) 845 578500.5 1.5 (1.4-1.6) 
2010 1887 576064.5 3.3 (3.1-3.4) 849 583395.8 1.5 (1.4-1.6) 
2011 1895 578031.8 3.3 (3.1-3.4) 929 585948.2 1.6 (1.5-1.7) 
2012 1919 583161 3.3 (3.1-3.4) 1022 591600.6 1.7 (1.6-1.8) 
2013 1806 585190.4 3.1 (2.9-3.2) 1096 593917.3 1.8 (1.7-2.0) 
2014 1902 590575.6 3.2 (3.1-3.4) 1202 599505.4 2.0 (1.9-2.1) 
2015 1896 595673.2 3.2 (3.0-3.3) 1280 604697.2 2.1 (2.0-2.2) 
2016 1999 601808.4 3.3 (3.2-3.5) 1418 610932.5 2.3 (2.2-2.4) 
2017 1994 605370.6 3.3 (3.2-3.4) 1490 614460 2.4 (2.3-2.6) 
2018 1904 609436.3 3.1 (3.0-3.3) 1551 618356.1 2.5 (2.4-2.6) 
Female 2003 4899 563994.6 8.7 (8.4-8.9) 1748 565659.9 3.1 (2.9-3.2) 
2004 4737 566934.3 8.4 (8.1-8.6) 1898 571729.1 3.3 (3.2-3.5) 
2005 4349 564184.3 7.7 (7.5-7.9) 1795 571512.1 3.1 (3.0-3.3) 
2006 4134 566156.3 7.3 (7.1-7.5) 1697 575694.5 2.9 (2.8-3.1) 
2007 4167 567048.8 7.3 (7.1-7.6) 1657 578682 2.9 (2.7-3.0) 
2008 3912 570895.7 6.9 (6.6-7.1) 1609 584446.7 2.8 (2.6-2.9) 
2009 4001 571900.3 7.0 (6.8-7.2) 1806 587074.3 3.1 (2.9-3.2) 
2010 3719 574836.8 6.5 (6.3-6.7) 1894 591418.4 3.2 (3.1-3.4) 
2011 3777 577676.2 6.5 (6.3-6.8) 2023 595271.5 3.4 (3.3-3.5) 
2012 3649 583166.7 6.3 (6.1-6.5) 2186 601548.9 3.6 (3.5-3.8) 
2013 3687 585911.9 6.3 (6.1-6.5) 2373 604681.8 3.9 (3.8-4.1) 
2014 3800 589311.2 6.4 (6.2-6.7) 2579 608388.5 4.2 (4.1-4.4) 
2015 3777 593245.1 6.4 (6.2-6.6) 2838 612367.6 4.6 (4.5-4.8) 
2016 3942 598437.4 6.6 (6.4-6.8) 3146 617470.4 5.1 (4.9-5.3) 
2017 3756 600645.5 6.3 (6.1-6.5) 3346 619186 5.4 (5.2-5.6) 
2018 3635 604173.5 6.0 (5.8-6.2) 3573 621857.5 5.7 (5.6-5.9) 





A.39 Incidence rates for prescriptions of antipsychotics and anticonvulsants between 2003 
and 2018, by gender 
Table 55 Incidence rates for prescriptions of antipsychotics and anticonvulsants between 2003 and 
2018, by gender 
Variable Antipsychotics Anticonvulsants 
Gender Year N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) 
Male 2003 214 545211.8 0.4 (0.3-0.4) 63 545296.2 0.1 (0.1-0.1) 
2004 212 554347.5 0.4 (0.3-0.4) 46 554626.2 0.1 (0.1-0.1) 
2005 198 557954.3 0.4 (0.3-0.4) 75 558369.2 0.1 (0.1-0.2) 
2006 213 564716.6 0.4 (0.3-0.4) 117 565246.4 0.2 (0.2-0.2) 
2007 180 570046.6 0.3 (0.3-0.4) 120 570643.3 0.2 (0.2-0.3) 
2008 190 577549.2 0.3 (0.3-0.4) 168 578193.2 0.3 (0.2-0.3) 
2009 221 582107.5 0.4 (0.3-0.4) 218 582705.3 0.4 (0.3-0.4) 
2010 239 587595.8 0.4 (0.4-0.5) 258 588181.1 0.4 (0.4-0.5) 
2011 240 590723.4 0.4 (0.4-0.5) 279 591257.7 0.5 (0.4-0.5) 
2012 265 596977.1 0.4 (0.4-0.5) 344 597466.8 0.6 (0.5-0.6) 
2013 298 599902.3 0.5 (0.4-0.6) 361 600324.1 0.6 (0.5-0.7) 
2014 304 606214.1 0.5 (0.4-0.6) 424 606555.8 0.7 (0.6-0.8) 
2015 305 612189 0.5 (0.4-0.6) 458 612401.6 0.7 (0.7-0.8) 
2016 364 619263.8 0.6 (0.5-0.7) 509 619337.3 0.8 (0.8-0.9) 
2017 378 623594.3 0.6 (0.5-0.7) 527 623552 0.8 (0.8-0.9) 
2018 365 628395 0.6 (0.5-0.6) 489 628232.3 0.8 (0.7-0.9) 
Female 2003 323 566430.6 0.6 (0.5-0.6) 93 566566.6 0.2 (0.1-0.2) 
2004 307 574071.4 0.5 (0.5-0.6) 145 574425.6 0.3 (0.2-0.3) 
2005 284 575426.3 0.5 (0.4-0.6) 169 575903.2 0.3 (0.3-0.3) 
2006 290 581030.1 0.5 (0.4-0.6) 239 581571.1 0.4 (0.4-0.5) 
2007 282 585286.8 0.5 (0.4-0.5) 243 585850.4 0.4 (0.4-0.5) 
2008 324 592273.3 0.5 (0.5-0.6) 342 592791.5 0.6 (0.5-0.6) 
2009 321 596114.4 0.5 (0.5-0.6) 440 596557.6 0.7 (0.7-0.8) 
2010 356 601767.7 0.6 (0.5-0.7) 595 602036 1.0 (0.9-1.1) 
2011 381 607028.2 0.6 (0.6-0.7) 659 606992.2 1.1 (1.0-1.2) 
2012 405 614885 0.7 (0.6-0.7) 723 614538.9 1.2 (1.1-1.3) 
2013 370 619564.1 0.6 (0.5-0.7) 859 618828.3 1.4 (1.3-1.5) 
2014 439 625032.8 0.7 (0.6-0.8) 934 623815.4 1.5 (1.4-1.6) 
2015 436 630906.9 0.7 (0.6-0.8) 1065 629149 1.7 (1.6-1.8) 
2016 490 638148.9 0.8 (0.7-0.8) 1232 635772.4 1.9 (1.8-2.0) 
2017 596 641999.1 0.9 (0.9-1.0) 1196 639020.5 1.9 (1.8-2.0) 
2018 568 646898.8 0.9 (0.8-1.0) 1182 643381.7 1.8 (1.7-1.9) 











A.40 Incidence rate ratios for prescriptions for any anxiolytic between 2003 and 2018 - test 
for interaction between year and gender 
Table 56 Incidence rate ratios for prescriptions for any anxiolytic between 2003 and 2018 - test for 
interaction between year and gender 
Variable  Multivariable IRR (95%CI) P value 
Year 2003 1.00  <0.001 
2004 0.92 (0.88-0.96) 
2005 0.82 (0.79-0.86) 
2006 0.80 (0.76-0.83) 
2007 0.78 (0.75-0.82) 
2008 0.73 (0.70-0.76) 
2009 0.81 (0.78-0.85) 
2010 0.79 (0.76-0.83) 
2011 0.82 (0.79-0.86) 
2012 0.86 (0.82-0.90) 
2013 0.85 (0.81-0.89) 
2014 0.88 (0.84-0.92) 
2015 0.97 (0.93-1.01) 
2016 1.08 (1.03-1.12) 
2017 1.10 (1.05-1.13) 
2018 1.13 (1.08-1.17) 
Gender Male 1.00  <0.001 
Female 2.12 (2.05-2.20) 
Year X 
Gender 
2003 1.00   
2004 1.03 (0.98-1.08) 0.320 
2005 1.00 (0.95-1.06) 0.899 
2006 0.99 (0.94-1.04) 0.700 
2007 0.99 (0.94-1.04) 0.757 
2008 1.02 (0.97-1.08) 0.492 
2009 0.92 (0.87-0.97) 0.003 
2010 0.94 (0.89-1.00) 0.032 
2011 0.93 (0.88-0.98) 0.007 
2012 0.88 (0.83-0.93) 0.000 
2013 0.92 (0.87-0.97) 0.002 
2014 0.94 (0.89-0.99) 0.025 
2015 0.93 (0.88-0.97) 0.003 
2016 0.90 (0.86-0.95) 0.000 
2017 0.93 (0.89-0.98) 0.004 




18-24 1.00  <0.001 
25-34 0.94 (0.92-0.95) 
35-44 0.88 (0.87-0.90) 
44-54 0.80 (0.79-0.81) 
55-64 0.68 (0.67-0.70) 
65-74 0.57 (0.56-0.58) 
75-84 0.60 (0.58-0.61) 






A.41 Incidence rates, absolute differences, and incidence rate ratios for prescriptions for any 
anxiolytic between 2003 and 2018 by gender - test for interaction between year and 
gender 
Table 57 Incidence rates, absolute differences, and incidence rate ratios for prescriptions for any 
anxiolytic between 2003 and 2018 by gender - test for interaction between year and gender 
 Male Female Interaction 
parameter 
P value for 
interaction 
parameter 









Year 2003 8.2 - 1.00 17.1 - 1.00 1.00  
2004 7.6 -0.6 0.92 16.2 -0.9 0.94 1.03 0.320 
2005 6.8 -1.4 0.82 14.2 -2.9 0.83 1.00 0.899 
2006 6.6 -1.6 0.80 13.5 -3.6 0.79 0.99 0.700 
2007 6.4 -1.8 0.74 13.3 -3.8 0.73 0.99 0.757 
2008 6.0 -2.2 0.73 12.7 -4.4 0.74 1.02 0.492 
2009 6.7 -1.5 0.81 12.8 -4.3 0.75 0.92 0.003 
2010 6.5 -1.7 0.79 12.8 -4.3 0.75 0.94 0.032 
2011 6.7 -1.5 0.82 13.0 -4.1 0.76 0.93 0.007 
2012 7.0 -1.2 0.86 12.9 -4.2 0.76 0.88 0.000 
2013 6.9 -1.3 0.85 13.3 -3.8 0.78 0.92 0.002 
2014 7.1 -1.1 0.88 14.1 -3.0 0.83 0.94 0.025 
2015 7.9 -0.3 0.97 15.3 -1.8 0.90 0.93 0.003 
2016 8.7 0.5 1.08 16.5 -0.6 0.97 0.90 0.000 
2017 8.8 0.6 1.09 17.2 0.1 1.01 0.93 0.004 






A.42 Incidence rates for prescriptions of any anxiolytics, all antidepressants, and SSRIs and ‘other’ antidepressants between 2003 and 2018, by 
age 
Table 58  Incidence rates for prescriptions of any anxiolytic, all antidepressants, and SSRIs and ‘other’ antidepressants between 2003 and 2018, by age 
Variable Any anxiolytic All antidepressants SSRIs and ‘other’ antidepressants 
Age 
band 
Year N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) 
<25 2003 1041 107177.3 9.7 (9.1-10.3) 826 107323 7.7 (7.2-8.2) 785 107351.4 7.3 (6.8-7.8) 
2004 1003 107748.6 9.3 (8.7-9.9) 754 108110.7 7.0 (6.5-7.5) 702 108183.3 6.5 (6.0-7.0) 
2005 923 107356.6 8.6 (8.1-9.2) 652 107911.8 6.0 (5.6-6.5) 602 108022 5.6 (5.1-6.0) 
2006 915 108688.2 8.4 (7.9-9.0) 643 109411.7 5.9 (5.4-6.3) 614 109539.4 5.6 (5.2-6.1) 
2007 983 109924.1 8.9 (8.4-9.5) 747 110735.3 6.7 (6.3-7.2) 722 110868.6 6.5 (6.0-7.0) 
2008 1031 112333.2 9.2 (8.6-9.8) 738 113217.2 6.5 (6.1-7.0) 713 113339 6.3 (5.8-6.8) 
2009 1048 113244.4 9.3 (8.7-9.8) 808 114155.8 7.1 (6.6-7.6) 787 114262.9 6.9 (6.4-7.4) 
2010 1187 114144.4 10.4 (9.8-11) 933 115080.4 8.1 (7.6-8.6) 895 115192.3 7.8 (7.3-8.3) 
2011 1287 114471.1 11.2 (10.6-11.9) 1027 115406.4 8.9 (8.4-9.5) 996 115522.6 8.6 (8.1-9.2) 
2012 1363 115494.4 11.8 (11.2-12.4) 1095 116444.9 9.4 (8.9-10) 1066 116562.6 9.1 (8.6-9.7) 
2013 1572 115260.2 13.6 (13.0-14.3) 1267 116228.9 10.9 (10.3-11.5) 1222 116368 10.5 (9.9-11.1) 
2014 1760 115082.1 15.3 (14.6-16.0) 1433 116109.2 12.3 (11.7-13.0) 1407 116248.4 12.1 (11.5-12.8) 
2015 2192 114065.8 19.2 (18.4-20.0) 1801 115199.1 15.6 (14.9-16.4) 1755 115337.3 15.2 (14.5-15.9) 
2016 2541 112721.1 22.5 (21.7-23.4) 2112 114001.4 18.5 (17.7-19.3) 2074 114149.7 18.2 (17.4-19.0) 
2017 2682 111231.5 24.1 (23.2-25.0) 2292 112626 20.4 (19.5-21.2) 2246 112776.9 19.9 (19.1-20.8) 
2018 2884 109764 26.3 (25.3-27.3) 2507 111192.9 22.5 (21.7-23.4) 2475 111349.2 22.2 (21.4-23.1) 
25-34 2003 2304 187675 12.3 (11.8-12.8) 1910 187921.7 10.2 (9.7-10.6) 1790 187996.9 9.5 (9.1-10.0) 
2004 2152 185169.4 11.6 (11.1-12.1) 1735 185853 9.3 (8.9-9.8) 1633 186080.9 8.8 (8.4-9.2) 
2005 1851 182127.9 10.2 (9.7-10.6) 1465 183214.1 8.0 (7.6-8.4) 1387 183510.4 7.6 (7.2-8.0) 
2006 1754 180358.4 9.7 (9.3-10.2) 1441 181785.3 7.9 (7.5-8.3) 1381 182124.1 7.6 (7.2-8.0) 
2007 1771 178910.7 9.9 (9.4-10.4) 1453 180598 8.0 (7.6-8.5) 1402 180955.4 7.7 (7.3-8.2) 
2008 1718 178735.1 9.6 (9.2-10.1) 1405 180710 7.8 (7.4-8.2) 1362 181092.3 7.5 (7.1-7.9) 
2009 1854 179034.7 10.4 (9.9-10.8) 1548 181256 8.5 (8.1-9.0) 1496 181665.3 8.2 (7.8-8.7) 





2011 1994 181433.5 11.0 (10.5-11.5) 1714 184159.3 9.3 (8.9-9.8) 1660 184634.1 9.0 (8.6-9.4) 
2012 2213 183945.6 12.0 (11.5-12.5) 1865 186931 10.0 (9.5-10.4) 1821 187412.5 9.7 (9.3-10.2) 
2013 2277 184540.4 12.3 (11.8-12.9) 1917 187742.1 10.2 (9.8-10.7) 1863 188234.8 9.9 (9.5-10.4) 
2014 2623 184746.7 14.2 (13.7-14.8) 2288 188110.7 12.2 (11.7-12.7) 2215 188639.3 11.7 (11.3-12.2) 
2015 2939 185151.2 15.9 (15.3-16.5) 2567 188679.4 13.6 (13.1-14.1) 2514 189239.8 13.3 (12.8-13.8) 
2016 3334 184965.9 18.0 (17.4-18.6) 2983 188681.6 15.8 (15.2-16.4) 2925 189275.9 15.5 (14.9-16.0) 
2017 3536 183710 19.2 (18.6-19.9) 3170 187555.9 16.9 (16.3-17.5) 3129 188150.7 16.6 (16.1-17.2) 
2018 3582 182487.8 19.6 (19.0-20.3) 3252 186440.5 17.4 (16.8-18.1) 3215 187016.2 17.2 (16.6-17.8) 
35-44 2003 3360 224626.8 15.0 (14.5-15.5) 2835 224935.2 12.6 (12.1-13.1) 2586 225097.4 11.5 (11.0-11.9) 
2004 2948 225538 13.1 (12.6-13.6) 2444 226388.9 10.8 (10.4-11.2) 2244 226776.7 9.9 (9.5-10.3) 
2005 2575 223264.3 11.5 (11.1-12.0) 2096 224640.5 9.3 (8.9-9.7) 1944 225201.2 8.6 (8.3-9.0) 
2006 2437 222014 11.0 (10.5-11.4) 1992 223823.5 8.9 (8.5-9.3) 1901 224508.8 8.5 (8.1-8.9) 
2007 2296 219141.1 10.5 (10.1-10.9) 1935 221296.7 8.7 (8.4-9.1) 1841 222042.6 8.3 (7.9-8.7) 
2008 2155 216089.6 10.0 (9.6-10.4) 1786 218513.1 8.2 (7.8-8.6) 1683 219283.1 7.7 (7.3-8.1) 
2009 2306 210799.7 10.9 (10.5-11.4) 1917 213500.4 9.0 (8.6-9.4) 1823 214315.2 8.5 (8.1-8.9) 
2010 2163 205471.2 10.5 (10.1-11.0) 1872 208340.7 9.0 (8.6-9.4) 1806 209154.6 8.6 (8.2-9.0) 
2011 2164 200026.4 10.8 (10.4-11.3) 1874 203021.4 9.2 (8.8-9.7) 1802 203826.7 8.8 (8.4-9.3) 
2012 2162 195105.1 11.1 (10.6-11.6) 1889 198196 9.5 (9.1-10.0) 1832 199031.1 9.2 (8.8-9.6) 
2013 2171 190651.2 11.4 (10.9-11.9) 1862 193874.5 9.6 (9.2-10.1) 1817 194692.5 9.3 (8.9-9.8) 
2014 2286 188236 12.1 (11.7-12.7) 2025 191620.5 10.6 (10.1-11.0) 1955 192427.3 10.2 (9.7-10.6) 
2015 2362 187202.4 12.6 (12.1-13.1) 2142 190707.1 11.2 (10.8-11.7) 2091 191511.9 10.9 (10.5-11.4) 
2016 2490 186161.2 13.4 (12.9-13.9) 2247 189755.8 11.8 (11.4-12.3) 2178 190541.5 11.4 (11.0-11.9) 
2017 2651 184433.4 14.4 (13.8-14.9) 2402 188151.6 12.8 (12.3-13.3) 2396 188944.7 12.7 (12.2-13.2) 
2018 2705 183106 14.8 (14.2-15.3) 2486 186990.2 13.3 (12.8-13.8) 2442 187783.2 13.0 (12.5-13.5) 
45-54 2003 2617 188110.1 13.9 (13.4-14.5) 2147 188350.2 11.4 (10.9-11.9) 1881 188502.9 10.0 (9.5-10.4) 
2004 2476 188528.5 13.1 (12.6-13.7) 2092 189238.1 11.1 (10.6-11.5) 1878 189654.1 9.9 (9.5-10.4) 
2005 2148 188818.6 11.4 (10.9-11.9) 1707 189969.1 9.0 (8.6-9.4) 1550 190574.1 8.1 (7.7-8.5) 
2006 1977 190903.5 10.4 (9.9-10.8) 1601 192521.6 8.3 (7.9-8.7) 1466 193266.4 7.6 (7.2-8.0) 
2007 2046 193375.5 10.6 (10.1-11.0) 1697 195420 8.7 (8.3-9.1) 1581 196297.1 8.1 (7.7-8.5) 
2008 1990 196866 10.1 (9.7-10.6) 1620 199232 8.1 (7.7-8.5) 1504 200205.4 7.5 (7.1-7.9) 
2009 2035 199960.6 10.2 (9.7-10.6) 1700 202704.7 8.4 (8.0-8.8) 1593 203766.5 7.8 (7.4-8.2) 





2011 2122 204703.3 10.4 (9.9-10.8) 1818 208135.4 8.7 (8.3-9.1) 1759 209352.6 8.4 (8.0-8.8) 
2012 2080 206701.3 10.1 (9.6-10.5) 1858 210352.3 8.8 (8.4-9.2) 1765 211622.1 8.3 (8.0-8.7) 
2013 1992 207152.4 9.6 (9.2-10.0) 1737 210950.4 8.2 (7.9-8.6) 1687 212259.7 7.9 (7.6-8.3) 
2014 2008 208164.3 9.6 (9.2-10.1) 1796 212182.4 8.5 (8.1-8.9) 1720 213498.6 8.1 (7.7-8.4) 
2015 2206 207882.5 10.6 (10.2-11.1) 1940 212044.8 9.1 (8.7-9.6) 1877 213358.7 8.8 (8.4-9.2) 
2016 2400 207941.1 11.5 (11.1-12.0) 2218 212285.2 10.4 (10-10.9) 2126 213650.5 10.0 (9.5-10.4) 
2017 2322 205256.8 11.3 (10.9-11.8) 2134 209645.8 10.2 (9.8-10.6) 2063 210989.8 9.8 (9.4-10.2) 
2018 2417 202046.4 12.0 (11.5-12.4) 2231 206480.2 10.8 (10.4-11.3) 2158 207847.5 10.4 (9.9-10.8) 
55-64 2003 2190 167103.9 13.1 (12.6-13.7) 1690 167359.6 10.1 (9.6-10.6) 1400 167530.6 8.4 (7.9-8.8) 
2004 2039 169692.1 12.0 (11.5-12.5) 1595 170444.6 9.4 (8.9-9.8) 1361 170877 8.0 (7.5-8.4) 
2005 1783 170696.8 10.4 (10.0-10.9) 1401 171866.8 8.2 (7.7-8.6) 1223 172519.7 7.1 (6.7-7.5) 
2006 1801 172208.3 10.5 (10.0-11.0) 1474 173705.9 8.5 (8.1-8.9) 1281 174574.1 7.3 (6.9-7.8) 
2007 1695 172026.1 9.9 (9.4-10.3) 1346 173841.3 7.7 (7.3-8.2) 1202 174859.5 6.9 (6.5-7.3) 
2008 1490 172393.6 8.6 (8.2-9.1) 1212 174524.5 6.9 (6.6-7.3) 1104 175645.9 6.3 (5.9-6.7) 
2009 1600 170923.2 9.4 (8.9-9.8) 1268 173299.4 7.3 (6.9-7.7) 1159 174479.2 6.6 (6.3-7.0) 
2010 1481 171307.3 8.6 (8.2-9.1) 1255 173912.2 7.2 (6.8-7.6) 1153 175174 6.6 (6.2-7.0) 
2011 1460 169241.6 8.6 (8.2-9.1) 1214 172005.6 7.1 (6.7-7.5) 1143 173310.3 6.6 (6.2-7.0) 
2012 1423 166828 8.5 (8.1-9.0) 1262 169751.7 7.4 (7.0-7.9) 1174 171062 6.9 (6.5-7.3) 
2013 1374 166227.5 8.3 (7.8-8.7) 1186 169292 7.0 (6.6-7.4) 1147 170584.4 6.7 (6.3-7.1) 
2014 1342 167096.2 8.0 (7.6-8.5) 1183 170321.4 6.9 (6.6-7.4) 1127 171648.5 6.6 (6.2-7.0) 
2015 1388 169268.8 8.2 (7.8-8.6) 1211 172653.3 7.0 (6.6-7.4) 1170 173984.2 6.7 (6.3-7.1) 
2016 1525 172124.5 8.9 (8.4-9.3) 1385 175716.3 7.9 (7.5-8.3) 1343 177059.4 7.6 (7.2-8.0) 
2017 1524 174978.2 8.7 (8.3-9.2) 1378 178781.9 7.7 (7.3-8.1) 1314 180174.1 7.3 (6.9-7.7) 
2018 1562 178306.4 8.8 (8.3-9.2) 1425 182266.1 7.8 (7.4-8.2) 1383 183699.2 7.5 (7.1-7.9) 
65-74 2003 1354 120020.2 11.3 (10.7-11.9) 1002 120198.2 8.3 (7.8-8.9) 792 120315.6 6.6 (6.1-7.1) 
2004 1328 120721.3 11.0 (10.4-11.6) 1011 121242.3 8.3 (7.8-8.9) 800 121585.8 6.6 (6.1-7.1) 
2005 1167 119159.7 9.8 (9.2-10.4) 857 120002.6 7.1 (6.7-7.6) 679 120524.7 5.6 (5.2-6.1) 
2006 1126 118863 9.5 (8.9-10.0) 839 120005.8 7.0 (6.5-7.5) 716 120656.7 5.9 (5.5-6.4) 
2007 1069 119490.1 8.9 (8.4-9.5) 797 120870.9 6.6 (6.1-7.1) 706 121624.2 5.8 (5.4-6.2) 
2008 989 121509.7 8.1 (7.6-8.7) 787 123155.6 6.4 (6.0-6.9) 691 124018.6 5.6 (5.2-6.0) 
2009 1000 123630.4 8.1 (7.6-8.6) 771 125485 6.1 (5.7-6.6) 652 126477.5 5.2 (4.8-5.6) 





2011 995 128318 7.8 (7.3-8.3) 846 130597 6.5 (6.0-6.9) 775 131797.5 5.9 (5.5-6.3) 
2012 978 134084.5 7.3 (6.8-7.8) 796 136600.3 5.8 (5.4-6.2) 725 137887.8 5.3 (4.9-5.7) 
2013 983 137148 7.2 (6.7-7.6) 820 139859 5.9 (5.5-6.3) 759 141198.5 5.4 (5.0-5.8) 
2014 971 139809.8 6.9 (6.5-7.4) 837 142638.3 5.9 (5.5-6.3) 773 144061.5 5.4 (5.0-5.8) 
2015 956 142480.9 6.7 (6.3-7.1) 826 145419.8 5.7 (5.3-6.1) 782 146887.2 5.3 (5.0-5.7) 
2016 1004 145422.4 6.9 (6.5-7.3) 856 148475 5.8 (5.4-6.2) 821 149952.9 5.5 (5.1-5.9) 
2017 982 146386.7 6.7 (6.3-7.1) 885 149507.3 5.9 (5.5-6.3) 837 150970.1 5.5 (5.2-5.9) 
2018 891 147264.9 6.1 (5.7-6.5) 811 150450.9 5.4 (5.0-5.8) 769 151923.5 5.1 (4.7-5.4) 
75-84 2003 988 81382.27 12.1 (11.4-12.9) 723 81515.27 8.9 (8.2-9.5) 563 81590.26 6.9 (6.3-7.5) 
2004 948 81317.42 11.7 (10.9-12.4) 737 81688.17 9.0 (8.4-9.7) 597 81930.23 7.3 (6.7-7.9) 
2005 830 79605.97 10.4 (9.7-11.2) 627 80183.17 7.8 (7.2-8.5) 500 80559.01 6.2 (5.7-6.8) 
2006 783 78898.41 9.9 (9.2-10.6) 587 79661.18 7.4 (6.8-8.0) 500 80122.25 6.2 (5.7-6.8) 
2007 728 78759.03 9.2 (8.6-9.9) 573 79693.26 7.2 (6.6-7.8) 486 80235.13 6.1 (5.5-6.6) 
2008 688 78784.05 8.7 (8.1-9.4) 533 79895.96 6.7 (6.1-7.3) 438 80519.68 5.4 (4.9-6.0) 
2009 677 79014.34 8.6 (7.9-9.2) 580 80267.15 7.2 (6.6-7.8) 513 80956.66 6.3 (5.8-6.9) 
2010 658 79533.11 8.3 (7.7-8.9) 512 80891.24 6.3 (5.8-6.9) 474 81595.2 5.8 (5.3-6.4) 
2011 675 80253.78 8.4 (7.8-9.1) 573 81756.39 7.0 (6.4-7.6) 512 82529.33 6.2 (5.7-6.8) 
2012 616 81717.39 7.5 (7.0-8.2) 535 83273.28 6.4 (5.9-7.0) 479 84094.91 5.7 (5.2-6.2) 
2013 645 82685.79 7.8 (7.2-8.4) 553 84323.39 6.6 (6.0-7.1) 515 85197.18 6.0 (5.5-6.6) 
2014 582 83899.34 6.9 (6.4-7.5) 501 85632.39 5.9 (5.3-6.4) 470 86516.66 5.4 (5.0-5.9) 
2015 666 84172.19 7.9 (7.3-8.5) 577 85986.68 6.7 (6.2-7.3) 549 86853.58 6.3 (5.8-6.9) 
2016 624 84627.6 7.4 (6.8-8.0) 569 86508.83 6.6 (6.0-7.1) 543 87385.4 6.2 (5.7-6.8) 
2017 626 86143.62 7.3 (6.7-7.9) 524 88074.55 5.9 (5.5-6.5) 499 89013.07 5.6 (5.1-6.1) 
2018 573 88414.97 6.5 (6.0-7.0) 542 90427.07 6.0 (5.5-6.5) 528 91384.58 5.8 (5.3-6.3) 
85+ 2003 236 27854.61 8.5 (7.4-9.6) 172 27888.53 6.2 (5.3-7.2) 129 27911.55 4.6 (3.9-5.5) 
2004 280 27873.62 10.0 (8.9-11.3) 202 27996.49 7.2 (6.3-8.3) 177 28057.02 6.3 (5.4-7.3) 
2005 254 28835.83 8.8 (7.8-10) 188 29037.44 6.5 (5.6-7.5) 156 29143.33 5.4 (4.5-6.3) 
2006 252 30097.11 8.4 (7.4-9.5) 181 30376.11 6.0 (5.1-6.9) 145 30536.11 4.7 (4.0-5.6) 
2007 275 30635.61 9.0 (7.9-10.1) 220 31000.42 7.1 (6.2-8.1) 181 31204.67 5.8 (5.0-6.7) 
2008 254 31387.46 8.1 (7.1-9.2) 207 31802.9 6.5 (5.7-7.5) 177 32050.28 5.5 (4.7-6.4) 
2009 252 31702.8 7.9 (7.0-9.0) 191 32164.59 5.9 (5.1-6.8) 172 32445.64 5.3 (4.5-6.2) 



















2011 232 33334.92 7.0 (6.1-7.9) 197 33896.59 5.8 (5.0-6.7) 178 34216.65 5.2 (4.5-6.0) 
2012 274 33863.49 8.1 (7.2-9.1) 212 34507.16 6.1 (5.3-7.0) 193 34837.96 5.5 (4.8-6.4) 
2013 226 34246.91 6.6 (5.8-7.5) 198 34917.02 5.7 (4.9-6.5) 183 35275.98 5.2 (4.5-6.0) 
2014 261 34929.75 7.5 (6.6-8.4) 209 35622 5.9 (5.1-6.7) 200 35995.42 5.6 (4.8-6.4) 
2015 230 35415.59 6.5 (5.7-7.4) 198 36153.09 5.5 (4.7-6.3) 182 36543.41 5.0 (4.3-5.8) 
2016 260 36126.73 7.2 (6.3-8.1) 223 36905.45 6.0 (5.3-6.9) 217 37303.91 5.8 (5.1-6.6) 
2017 231 36807.51 6.3 (5.5-7.1) 201 37652.82 5.3 (4.6-6.1) 193 38040.32 5.1 (4.4-5.8) 
2018 202 37740.44 5.4 (4.6-6.1) 188 38586.78 4.9 (4.2-5.6) 185 38962.49 4.7 (4.1-5.5) 





A.43 Incidence rates for prescriptions of benzodiazepines and beta-blockers between 2003 
and 2018, by age 
Table 59 Incidence rates for prescriptions of benzodiazepines and beta-blockers between 2003 and 
2018, by age 
Variable Benzodiazepines Beta-blockers (propranolol) 
Age 
band 
Year N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) 
<25 2003 374 107653.3 3.5 (3.1-3.8) 231 107725.6 2.1 (1.9-2.4) 
2004 338 108876.6 3.1 (2.8-3.5) 280 109038.3 2.6 (2.3-2.9) 
2005 344 108861.8 3.2 (2.8-3.5) 277 109037.2 2.5 (2.3-2.9) 
2006 351 110491.6 3.2 (2.9-3.5) 300 110644.8 2.7 (2.4-3.0) 
2007 373 111904.1 3.3 (3.0-3.7) 278 112081.1 2.5 (2.2-2.8) 
2008 361 114467.8 3.2 (2.8-3.5) 316 114633.7 2.8 (2.5-3.1) 
2009 360 115548.8 3.1 (2.8-3.5) 309 115670.9 2.7 (2.4-3.0) 
2010 398 116610.2 3.4 (3.1-3.8) 392 116663 3.4 (3.0-3.7) 
2011 423 117123.8 3.6 (3.3-4.0) 397 117142.3 3.4 (3.1-3.7) 
2012 438 118417.3 3.7 (3.4-4.1) 460 118408 3.9 (3.5-4.3) 
2013 446 118512 3.8 (3.4-4.1) 574 118371.6 4.8 (4.5-5.3) 
2014 477 118711.4 4.0 (3.7-4.4) 657 118433.6 5.5 (5.1-6.0) 
2015 518 118300.6 4.4 (4.0-4.8) 782 117788.2 6.6 (6.2-7.1) 
2016 578 117950.4 4.9 (4.5-5.3) 907 117195.3 7.7 (7.2-8.3) 
2017 528 117326.9 4.5 (4.1-4.9) 928 116304.1 8.0 (7.5-8.5) 
2018 543 116813.5 4.6 (4.3-5.1) 1050 115530.6 9.1 (8.5-9.7) 
25-34 2003 966 188533.5 5.1 (4.8-5.5) 558 188784.5 3.0 (2.7-3.2) 
2004 910 187538.6 4.9 (4.5-5.2) 549 188204.4 2.9 (2.7-3.2) 
2005 849 185625.7 4.6 (4.3-4.9) 528 186536.3 2.8 (2.6-3.1) 
2006 815 184710.4 4.4 (4.1-4.7) 479 185883 2.6 (2.4-2.8) 
2007 837 183993.7 4.5 (4.2-4.9) 490 185338.8 2.6 (2.4-2.9) 
2008 770 184568.7 4.2 (3.9-4.5) 485 186061.6 2.6 (2.4-2.8) 
2009 898 185581.7 4.8 (4.5-5.2) 578 187216.5 3.1 (2.8-3.3) 
2010 843 187402.2 4.5 (4.2-4.8) 570 189142.7 3.0 (2.8-3.3) 
2011 897 189584.5 4.7 (4.4-5.1) 701 191339.9 3.7 (3.4-3.9) 
2012 947 193065.9 4.9 (4.6-5.2) 814 194700 4.2 (3.9-4.5) 
2013 964 194605.8 5.0 (4.6-5.3) 896 195976.5 4.6 (4.3-4.9) 
2014 1091 195829.8 5.6 (5.2-5.9) 984 196954.7 5.0 (4.7-5.3) 
2015 1176 197371.2 6.0 (5.6-6.3) 1130 198252.6 5.7 (5.4-6.0) 
2016 1268 198754.4 6.4 (6.0-6.7) 1229 199366.2 6.2 (5.8-6.5) 
2017 1226 199251.6 6.2 (5.8-6.5) 1371 199414.1 6.9 (6.5-7.2) 
2018 1238 199818.3 6.2 (5.9-6.6) 1436 199494.1 7.2 (6.8-7.6) 
35-44 2003 1543 225683.7 6.8 (6.5-7.2) 700 226153.8 3.1 (2.9-3.3) 
2004 1386 228498.9 6.1 (5.8-6.4) 734 229792 3.2 (3.0-3.4) 
2005 1332 227714.9 5.8 (5.5-6.2) 651 229597.4 2.8 (2.6-3.1) 
2006 1267 227666.4 5.6 (5.3-5.9) 613 230091.3 2.7 (2.5-2.9) 
2007 1204 225932.1 5.3 (5-5.6) 607 228798.6 2.7 (2.4-2.9) 
2008 1131 223682.6 5.1 (4.8-5.4) 559 226939.9 2.5 (2.3-2.7) 
2009 1195 219191.1 5.5 (5.1-5.8) 667 222628 3.0 (2.8-3.2) 
2010 1104 214598.2 5.1 (4.8-5.5) 647 218218.2 3.0 (2.7-3.2) 





2012 1045 205539.4 5.1 (4.8-5.4) 700 209250.7 3.3 (3.1-3.6) 
2013 1089 201772.8 5.4 (5.1-5.7) 771 205428.6 3.8 (3.5-4.0) 
2014 1127 200032.1 5.6 (5.3-6.0) 818 203693.6 4.0 (3.7-4.3) 
2015 1076 199962.7 5.4 (5.1-5.7) 841 203420.3 4.1 (3.9-4.4) 
2016 1161 199884.6 5.8 (5.5-6.2) 955 203188.4 4.7 (4.4-5.0) 
2017 1093 199257.4 5.5 (5.2-5.8) 1022 202336.6 5.1 (4.7-5.4) 
2018 1113 199358.5 5.6 (5.3-5.9) 1080 202012.4 5.3 (5.0-5.7) 
45-54 2003 1261 188873.9 6.7 (6.3-7.1) 497 189267.5 2.6 (2.4-2.9) 
2004 1271 190709.9 6.7 (6.3-7.0) 534 191884.2 2.8 (2.6-3.0) 
2005 1173 192197.9 6.1 (5.8-6.5) 526 194072.3 2.7 (2.5-3.0) 
2006 1059 195351.1 5.4 (5.1-5.8) 495 197869.3 2.5 (2.3-2.7) 
2007 1142 198875.1 5.7 (5.4-6.1) 485 202010.1 2.4 (2.2-2.6) 
2008 1103 203415.8 5.4 (5.1-5.8) 513 207085.6 2.5 (2.3-2.7) 
2009 1169 207602.8 5.6 (5.3-6) 538 211866.9 2.5 (2.3-2.8) 
2010 1105 212061 5.2 (4.9-5.5) 555 216871.9 2.6 (2.4-2.8) 
2011 1164 214528.9 5.4 (5.1-5.7) 585 219767.5 2.7 (2.5-2.9) 
2012 1144 217601.4 5.3 (5.0-5.6) 610 223286.2 2.7 (2.5-3.0) 
2013 1081 219061 4.9 (4.6-5.2) 616 225051.2 2.7 (2.5-3.0) 
2014 1090 221075.7 4.9 (4.6-5.2) 645 227166.4 2.8 (2.6-3.1) 
2015 1051 221813.1 4.7 (4.5-5.0) 697 228033.2 3.1 (2.8-3.3) 
2016 1093 223149.5 4.9 (4.6-5.2) 802 229316.3 3.5 (3.3-3.7) 
2017 1081 221532.5 4.9 (4.6-5.2) 807 227517.9 3.5 (3.3-3.8) 
2018 986 219424.1 4.5 (4.2-4.8) 796 225083 3.5 (3.3-3.8) 
55-64 2003 1222 167668.5 7.3 (6.9-7.7) 344 168106.1 2.0 (1.8-2.3) 
2004 1189 171291.7 6.9 (6.6-7.3) 375 172609.4 2.2 (2.0-2.4) 
2005 1115 173151 6.4 (6.1-6.8) 319 175268.7 1.8 (1.6-2.0) 
2006 1061 175503.3 6.0 (5.7-6.4) 318 178332.6 1.8 (1.6-2.0) 
2007 1033 176131.3 5.9 (5.5-6.2) 312 179574.8 1.7 (1.5-1.9) 
2008 923 177253.8 5.2 (4.9-5.6) 302 181273.1 1.7 (1.5-1.9) 
2009 983 176416.4 5.6 (5.2-5.9) 336 180877.9 1.9 (1.7-2.1) 
2010 879 177566.8 5.0 (4.6-5.3) 344 182431.5 1.9 (1.7-2.1) 
2011 832 176160.9 4.7 (4.4-5.1) 334 181234.9 1.8 (1.7-2.1) 
2012 776 174421.9 4.4 (4.1-4.8) 338 179649.6 1.9 (1.7-2.1) 
2013 740 174541 4.2 (3.9-4.6) 350 179959.3 1.9 (1.7-2.2) 
2014 734 176219 4.2 (3.9-4.5) 382 181900.9 2.1 (1.9-2.3) 
2015 727 179117.2 4.1 (3.8-4.4) 393 185011.9 2.1 (1.9-2.3) 
2016 745 182989 4.1 (3.8-4.4) 390 189166.6 2.1 (1.9-2.3) 
2017 761 186972.4 4.1 (3.8-4.4) 395 193399.4 2.0 (1.8-2.3) 
2018 740 191394.9 3.9 (3.6-4.2) 449 198080.3 2.3 (2.1-2.5) 
65-74 2003 907 120274 7.5 (7.1-8.0) 151 120656.7 1.3 (1.1-1.5) 
2004 885 121450.2 7.3 (6.8-7.8) 156 122561.5 1.3 (1.1-1.5) 
2005 778 120335.7 6.5 (6.0-6.9) 148 122074.4 1.2 (1.0-1.4) 
2006 793 120403 6.6 (6.1-7.1) 140 122734.5 1.1 (1.0-1.3) 
2007 757 121420.4 6.2 (5.8-6.7) 130 124309.1 1.0 (0.9-1.2) 
2008 690 123853.6 5.6 (5.2-6.0) 119 127276 0.9 (0.8-1.1) 
2009 692 126455 5.5 (5.1-5.9) 146 130372.1 1.1 (0.9-1.3) 
2010 665 128060.6 5.2 (4.8-5.6) 153 132405.8 1.2 (1.0-1.4) 
2011 642 132135.5 4.9 (4.5-5.2) 164 136975.3 1.2 (1.0-1.4) 





2013 634 142250.9 4.5 (4.1-4.8) 172 147915.6 1.2 (1.0-1.4) 
2014 609 145489.3 4.2 (3.9-4.5) 200 151373.2 1.3 (1.1-1.5) 
2015 575 148787.2 3.9 (3.6-4.2) 178 154934.8 1.1 (1.0-1.3) 
2016 575 152397.7 3.8 (3.5-4.1) 181 158647.7 1.1 (1.0-1.3) 
2017 534 153972.7 3.5 (3.2-3.8) 197 160331.1 1.2 (1.1-1.4) 
2018 482 155559.4 3.1 (2.8-3.4) 208 161936.3 1.3 (1.1-1.5) 
75-84 2003 670 81542.39 8.2 (7.6-8.9) 69 81850 0.8 (0.7-1.1) 
2004 629 81851.29 7.7 (7.1-8.3) 76 82711.46 0.9 (0.7-1.2) 
2005 589 80420.62 7.3 (6.7-7.9) 78 81752.05 1.0 (0.8-1.2) 
2006 547 79923.76 6.8 (6.3-7.4) 52 81667.02 0.6 (0.5-0.8) 
2007 519 79987.86 6.5 (5.9-7.1) 58 82141.44 0.7 (0.5-0.9) 
2008 484 80205.42 6.0 (5.5-6.6) 71 82753.75 0.9 (0.7-1.1) 
2009 451 80625.67 5.6 (5.1-6.1) 60 83471.36 0.7 (0.5-0.9) 
2010 462 81352.86 5.7 (5.2-6.2) 64 84478.94 0.8 (0.6-1.0) 
2011 430 82314.3 5.2 (4.7-5.7) 69 85765.15 0.8 (0.6-1.0) 
2012 425 83939.69 5.1 (4.6-5.6) 79 87678.18 0.9 (0.7-1.1) 
2013 398 85166.87 4.7 (4.2-5.2) 77 89087.96 0.9 (0.7-1.1) 
2014 401 86534.1 4.6 (4.2-5.1) 82 90649.95 0.9 (0.7-1.1) 
2015 398 86994.67 4.6 (4.1-5.0) 85 91224.12 0.9 (0.7-1.2) 
2016 379 87744.23 4.3 (3.9-4.8) 79 92226.76 0.9 (0.7-1.1) 
2017 379 89554.02 4.2 (3.8-4.7) 95 94168.25 1.0 (0.8-1.2) 
2018 329 92148.89 3.6 (3.2-4.0) 86 96916.91 0.9 (0.7-1.1) 
85+ 2003 159 27901.02 5.7 (4.8-6.7) 13 27980.05 0.5 (0.2-0.8) 
2004 204 28008.02 7.3 (6.3-8.4) 8 28283.23 0.3 (0.1-0.6) 
2005 185 29061.06 6.4 (5.5-7.4) 10 29546.26 0.3 (0.2-0.6) 
2006 175 30420.59 5.8 (4.9-6.7) 16 31101.11 0.5 (0.3-0.8) 
2007 200 31052.72 6.4 (5.6-7.4) 15 31931.86 0.5 (0.3-0.8) 
2008 180 31884.8 5.6 (4.9-6.5) 10 32925.14 0.3 (0.1-0.6) 
2009 181 32290.07 5.6 (4.8-6.5) 17 33471.06 0.5 (0.3-0.8) 
2010 150 33249.37 4.5 (3.8-5.3) 18 34602.15 0.5 (0.3-0.8) 
2011 147 34062.41 4.3 (3.6-5.1) 12 35511.27 0.3 (0.2-0.6) 
2012 166 34716.74 4.8 (4.1-5.6) 19 36241.96 0.5 (0.3-0.8) 
2013 141 35191.99 4.0 (3.4-4.7) 13 36808.24 0.4 (0.2-0.6) 
2014 173 35995.39 4.8 (4.1-5.6) 13 37721.55 0.3 (0.2-0.6) 
2015 152 36571.43 4.2 (3.5-4.9) 12 38399.63 0.3 (0.2-0.5) 
2016 142 37375.85 3.8 (3.2-4.5) 21 39295.64 0.5 (0.3-0.8) 
2017 148 38148.65 3.9 (3.3-4.6) 21 40174.64 0.5 (0.3-0.8) 
2018 108 39092.3 2.8 (2.3-3.3) 19 41160.05 0.5 (0.3-0.7) 
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Table 60 Incidence rates for prescriptions of antipsychotics and anticonvulsants between 2003 and 
2018, by age 
Variable Antipsychotics Anticonvulsants 
Age 
band 
Year N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence (1000PYAR) (95%CI) 
<25 2003 29 107854.1 0.3 (0.2-0.4) 1 107870.2 0.0 (0.0-0.1) 
2004 48 109352.6 0.4 (0.3-0.6) 4 109410.8 0.0 (0.0-0.1) 
2005 35 109525.1 0.3 (0.2-0.4) 3 109604.7 0.0 (0.0-0.1) 
2006 32 111266.1 0.3 (0.2-0.4) 2 111363.6 0.0 (0.0-0.1) 
2007 29 112796.4 0.3 (0.2-0.4) 10 112893.7 0.1 (0.0-0.2) 
2008 32 115440.2 0.3 (0.2-0.4) 9 115539.3 0.1 (0.0-0.1) 
2009 46 116505.2 0.4 (0.3-0.5) 8 116613.1 0.1 (0.0-0.1) 
2010 57 117576.3 0.5 (0.4-0.6) 19 117691.1 0.2 (0.1-0.3) 
2011 60 118135.6 0.5 (0.4-0.7) 30 118241 0.3 (0.2-0.4) 
2012 54 119500.5 0.5 (0.3-0.6) 21 119604.9 0.2 (0.1-0.3) 
2013 76 119579.7 0.6 (0.5-0.8) 44 119684 0.4 (0.3-0.5) 
2014 78 119817.1 0.7 (0.5-0.8) 54 119934 0.5 (0.3-0.6) 
2015 92 119433.7 0.8 (0.6-0.9) 87 119546.4 0.7 (0.6-0.9) 
2016 96 119144.6 0.8 (0.7-1.0) 85 119264.8 0.7 (0.6-0.9) 
2017 126 118517.2 1.1 (0.9-1.3) 86 118647.4 0.7 (0.6-0.9) 
2018 141 117983.6 1.2 (1.0-1.4) 76 118153.6 0.6 (0.5-0.8) 
25-34 2003 87 189048.7 0.5 (0.4-0.6) 12 189095.5 0.1 (0.0-0.1) 
2004 77 188955.1 0.4 (0.3-0.5) 14 189078.9 0.1 (0.0-0.1) 
2005 82 187736.8 0.4 (0.3-0.5) 15 187923.4 0.1 (0.0-0.1) 
2006 79 187431 0.4 (0.3-0.5) 20 187677.1 0.1 (0.1-0.2) 
2007 64 187190.6 0.3 (0.3-0.4) 21 187478.6 0.1 (0.1-0.2) 





2009 97 189693.2 0.5 (0.4-0.6) 57 190027.7 0.3 (0.2-0.4) 
2010 105 191968 0.5 (0.4-0.7) 96 192334.4 0.5 (0.4-0.6) 
2011 103 194569.6 0.5 (0.4-0.6) 96 194930.2 0.5 (0.4-0.6) 
2012 127 198420.8 0.6 (0.5-0.8) 137 198790.2 0.7 (0.6-0.8) 
2013 131 200254.1 0.7 (0.5-0.8) 161 200591.4 0.8 (0.7-0.9) 
2014 151 201747.5 0.7 (0.6-0.9) 200 202037.3 1.0 (0.9-1.1) 
2015 165 203633.9 0.8 (0.7-0.9) 222 203860.7 1.1 (1.0-1.2) 
2016 184 205444.5 0.9 (0.8-1.0) 254 205587.9 1.2 (1.1-1.4) 
2017 226 206229 1.1 (1.0-1.2) 259 206347 1.3 (1.1-1.4) 
2018 202 206978.1 1.0 (0.8-1.1) 258 207107.3 1.2 (1.1-1.4) 
35-44 2003 104 226469.1 0.5 (0.4-0.6) 31 226513.1 0.1 (0.1-0.2) 
2004 109 230746.3 0.5 (0.4-0.6) 24 230891 0.1 (0.1-0.2) 
2005 100 231136.7 0.4 (0.4-0.5) 44 231347.8 0.2 (0.1-0.3) 
2006 104 232172.6 0.4 (0.4-0.5) 68 232414.3 0.3 (0.2-0.4) 
2007 101 231332.3 0.4 (0.4-0.5) 57 231622.2 0.2 (0.2-0.3) 
2008 107 229816.4 0.5 (0.4-0.6) 98 230117.5 0.4 (0.3-0.5) 
2009 118 225946.3 0.5 (0.4-0.6) 125 226215.1 0.6 (0.5-0.7) 
2010 114 221878 0.5 (0.4-0.6) 162 222133.2 0.7 (0.6-0.9) 
2011 134 217512.2 0.6 (0.5-0.7) 183 217713 0.8 (0.7-1.0) 
2012 140 213668.5 0.7 (0.6-0.8) 196 213837.8 0.9 (0.8-1.1) 
2013 141 210115.9 0.7 (0.6-0.8) 216 210259.3 1.0 (0.9-1.2) 
2014 133 208838.8 0.6 (0.5-0.8) 274 208885.8 1.3 (1.2-1.5) 
2015 172 209061 0.8 (0.7-1.0) 260 209030.4 1.2 (1.1-1.4) 
2016 186 209335.5 0.9 (0.8-1.0) 347 209234.1 1.7 (1.5-1.8) 
2017 194 209039.2 0.9 (0.8-1.1) 358 208784 1.7 (1.5-1.9) 





45-54 2003 85 189494.5 0.4 (0.4-0.6) 26 189523.6 0.1 (0.1-0.2) 
2004 79 192579.1 0.4 (0.3-0.5) 51 192666.2 0.3 (0.2-0.3) 
2005 86 195247.9 0.4 (0.4-0.5) 44 195384.6 0.2 (0.2-0.3) 
2006 102 199490.2 0.5 (0.4-0.6) 88 199676.6 0.4 (0.4-0.5) 
2007 89 204041.2 0.4 (0.4-0.5) 87 204248.7 0.4 (0.3-0.5) 
2008 114 209612.9 0.5 (0.4-0.7) 135 209803.2 0.6 (0.5-0.8) 
2009 102 214824.9 0.5 (0.4-0.6) 149 215046.3 0.7 (0.6-0.8) 
2010 139 220361.2 0.6 (0.5-0.7) 209 220557.9 0.9 (0.8-1.1) 
2011 130 223756.9 0.6 (0.5-0.7) 228 223880.3 1.0 (0.9-1.2) 
2012 146 227780.8 0.6 (0.5-0.8) 260 227782.3 1.1 (1.0-1.3) 
2013 123 230113.8 0.5 (0.4-0.6) 276 230004.1 1.2 (1.1-1.4) 
2014 157 232768.3 0.7 (0.6-0.8) 284 232542.9 1.2 (1.1-1.4) 
2015 136 234175.1 0.6 (0.5-0.7) 366 233747.4 1.6 (1.4-1.7) 
2016 176 236089.6 0.7 (0.6-0.9) 381 235454.9 1.6 (1.5-1.8) 
2017 191 234777 0.8 (0.7-0.9) 385 234033.7 1.6 (1.5-1.8) 
2018 181 232832.2 0.8 (0.7-0.9) 383 231929.2 1.7 (1.5-1.8) 
55-64 2003 77 168244.6 0.5 (0.4-0.6) 32 168274.4 0.2 (0.1-0.3) 
2004 74 173077.6 0.4 (0.3-0.5) 43 173145.7 0.2 (0.2-0.3) 
2005 70 176021.9 0.4 (0.3-0.5) 58 176126.1 0.3 (0.3-0.4) 
2006 83 179384.7 0.5 (0.4-0.6) 82 179495.2 0.5 (0.4-0.6) 
2007 76 180914.5 0.4 (0.3-0.5) 81 181021.7 0.4 (0.4-0.6) 
2008 70 182886.8 0.4 (0.3-0.5) 100 182999 0.5 (0.4-0.7) 
2009 70 182825.4 0.4 (0.3-0.5) 149 182855 0.8 (0.7-1.0) 
2010 79 184699.9 0.4 (0.3-0.5) 152 184655.6 0.8 (0.7-1.0) 
2011 78 183813.8 0.4 (0.3-0.5) 187 183699.4 1.0 (0.9-1.2) 





2013 87 183133.6 0.5 (0.4-0.6) 211 182880 1.2 (1.0-1.3) 
2014 95 185457.7 0.5 (0.4-0.6) 205 185096.1 1.1 (1.0-1.3) 
2015 69 188979.9 0.4 (0.3-0.5) 236 188508.1 1.3 (1.1-1.4) 
2016 96 193564.8 0.5 (0.4-0.6) 305 192923.7 1.6 (1.4-1.8) 
2017 105 198300.8 0.5 (0.4-0.6) 276 197433.2 1.4 (1.2-1.6) 
2018 112 203463.8 0.6 (0.5-0.7) 301 202418.7 1.5 (1.3-1.7) 
65-74 2003 70 120703.9 0.6 (0.5-0.7) 29 120723.8 0.2 (0.2-0.3) 
2004 55 122705.8 0.4 (0.3-0.6) 23 122763.3 0.2 (0.1-0.3) 
2005 44 122352.2 0.4 (0.3-0.5) 34 122416.9 0.3 (0.2-0.4) 
2006 47 123129.3 0.4 (0.3-0.5) 46 123214.2 0.4 (0.3-0.5) 
2007 40 124829.6 0.3 (0.2-0.4) 49 124910.2 0.4 (0.3-0.5) 
2008 52 127943 0.4 (0.3-0.5) 65 128004.5 0.5 (0.4-0.6) 
2009 46 131187.3 0.4 (0.3-0.5) 105 131209.7 0.8 (0.7-1.0) 
2010 37 133417.8 0.3 (0.2-0.4) 129 133388.4 1.0 (0.8-1.1) 
2011 60 138215.9 0.4 (0.3-0.6) 124 138102.6 0.9 (0.7-1.1) 
2012 56 145433.6 0.4 (0.3-0.5) 135 145239.2 0.9 (0.8-1.1) 
2013 64 149664 0.4 (0.3-0.5) 173 149376.8 1.2 (1.0-1.3) 
2014 55 153402.1 0.4 (0.3-0.5) 188 153013.8 1.2 (1.1-1.4) 
2015 44 157234.5 0.3 (0.2-0.4) 199 156720.6 1.3 (1.1-1.5) 
2016 48 161254.3 0.3 (0.2-0.4) 197 160590.2 1.2 (1.1-1.4) 
2017 57 163181 0.3 (0.3-0.5) 200 162378 1.2 (1.1-1.4) 
2018 63 165088.4 0.4 (0.3-0.5) 182 164162.1 1.1 (1.0-1.3) 
75-84 2003 56 81859.77 0.7 (0.5-0.9) 21 81876.5 0.3 (0.2-0.4) 
2004 50 82745.24 0.6 (0.4-0.8) 27 82800.2 0.3 (0.2-0.5) 
2005 46 81833.67 0.6 (0.4-0.7) 36 81898.36 0.4 (0.3-0.6) 





2007 53 82304.25 0.6 (0.5-0.8) 40 82345.03 0.5 (0.3-0.7) 
2008 36 82963.04 0.4 (0.3-0.6) 43 83011.75 0.5 (0.4-0.7) 
2009 41 83744.84 0.5 (0.4-0.7) 54 83784.65 0.6 (0.5-0.8) 
2010 47 84819.14 0.6 (0.4-0.7) 68 84798.29 0.8 (0.6-1.0) 
2011 40 86175.6 0.5 (0.3-0.6) 80 86098.9 0.9 (0.7-1.2) 
2012 40 88164.14 0.5 (0.3-0.6) 98 88035.86 1.1 (0.9-1.4) 
2013 32 89661.07 0.4 (0.2-0.5) 108 89460.77 1.2 (1.0-1.5) 
2014 50 91334.46 0.5 (0.4-0.7) 117 91051.52 1.3 (1.1-1.5) 
2015 43 91996.44 0.5 (0.3-0.6) 120 91647.41 1.3 (1.1-1.6) 
2016 50 93083.12 0.5 (0.4-0.7) 134 92672.74 1.4 (1.2-1.7) 
2017 52 95132.61 0.5 (0.4-0.7) 116 94664.62 1.2 (1.0-1.5) 
2018 40 98035.89 0.4 (0.3-0.6) 118 97483.38 1.2 (1.0-1.4) 
85+ 2003 29 27967.61 1.0 (0.7-1.5) 4 27985.6 0.1 (0.0-0.4) 
2004 27 28257.16 1.0 (0.6-1.4) 5 28295.62 0.2 (0.1-0.4) 
2005 19 29526.32 0.6 (0.4-1.0) 10 29570.49 0.3 (0.2-0.6) 
2006 22 31080.69 0.7 (0.4-1.1) 10 31138.37 0.3 (0.2-0.6) 
2007 10 31924.47 0.3 (0.2-0.6) 18 31973.38 0.6 (0.3-0.9) 
2008 15 32932.6 0.5 (0.3-0.8) 21 32961.66 0.6 (0.4-1.0) 
2009 22 33494.81 0.7 (0.4-1.0) 11 33511.22 0.3 (0.2-0.6) 
2010 17 34643.17 0.5 (0.3-0.8) 18 34658.27 0.5 (0.3-0.8) 
2011 16 35572 0.4 (0.3-0.7) 10 35584.48 0.3 (0.1-0.5) 
2012 21 36345.23 0.6 (0.4-0.9) 33 36339.99 0.9 (0.6-1.3) 
2013 14 36944.12 0.4 (0.2-0.6) 31 36895.93 0.8 (0.6-1.2) 
2014 24 37880.94 0.6 (0.4-0.9) 36 37809.84 1.0 (0.7-1.3) 
2015 20 38581.25 0.5 (0.3-0.8) 33 38489.58 0.9 (0.6-1.2) 

















2017 23 40416.59 0.6 (0.4-0.9) 43 40284.75 1.1 (0.8-1.4) 
2018 21 41418.4 0.5 (0.3-0.8) 45 41247.21 1.1 (0.8-1.5) 





A.45 Incidence of anxiolytic prescriptions (any anxiolytic, all antidepressants, and 
benzodiazepines) per 1000 person years between 2003 and 2018 – restricted time 
frame sensitivity analysis 
 
Figure 66 Incidence of anxiolytic prescriptions (any anxiolytic, all antidepressants, and 
















A.46 Incidence of anxiolytic prescriptions (any anxiolytic and all antidepressants) per 1000 
person years between 2003 and 2018 – excluding low dose amitriptyline sensitivity 
analysis 
Figure 67 Incidence of anxiolytic prescriptions (any anxiolytic and all antidepressants) per 1000 






A.47 Incidence rates for prescriptions of any combination therapy, and SSRIs & ‘other’ antidepressants with a benzodiazepine, and for SSRIs & 
‘other’ antidepressants with a beta-blocker (propranolol), between 2003 and 2018 
Table 61 Incidence rates for prescriptions of any combination therapy, and SSRIs & ‘other’ antidepressants with a benzodiazepine, and for SSRIs & ‘other’ 
antidepressants with a beta-blocker between 2003 and 2018 
 
Variable Combination therapy – any combination of 
anxiolytics 
Combination therapy – SSRI & ‘other’ 
antidepressant with benzodiazepine 
Combination therapy – SSRI & ‘other’ antidepressant 
with a beta-blocker (propranolol) 
N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) N* PYAR Incidence 
(1000PYAR) 
(95%CI) 
Year 2003 1252 1111328 1.1 (1.1-1.2) 760 1111570 0.7 (0.6-0.7) 128 1111871 0.1 (0.1-0.1) 
2004 1214 1128673 1.1 (1.0-1.1) 742 1128921 0.7 (0.6-0.7) 140 1129221 0.1 (0.1-0.2) 
2005 1090 1134194 1.0 (0.9-1.0) 623 1134434 0.6 (0.5-0.6) 123 1134665 0.1 (0.1-0.1) 
2006 1055 1147014 0.9 (0.9-1.0) 629 1147221 0.6 (0.5-0.6) 124 1147486 0.1 (0.1-0.1) 
2007 985 1157048 0.9 (0.8-0.9) 599 1157239 0.5 (0.5-0.6) 106 1157501 0.1 (0.1-0.1) 
2008 944 1171977 0.8 (0.8-0.9) 550 1172180 0.5 (0.4-0.5) 113 1172377 0.1 (0.1-0.1) 
2009 1042 1180713 0.9 (0.8-0.9) 625 1180913 0.5 (0.5-0.6) 115 1181161 0.1 (0.1-0.1) 
2010 1010 1192350 0.9 (0.8-0.9) 574 1192567 0.5 (0.4-0.5) 125 1192785 0.1 (0.1-0.1) 
2011 1096 1201149 0.9 (0.9-1.0) 602 1201388 0.5 (0.5-0.5) 153 1201600 0.1 (0.1-0.2) 
2012 1132 1215730 0.9 (0.9-1.0) 559 1216008 0.5 (0.4-0.5) 175 1216224 0.1 (0.1-0.2) 
2013 1200 1223821 1.0 (0.9-1.0) 625 1224110 0.5 (0.5-0.6) 187 1224315 0.1 (0.1-0.2) 
2014 1306 1236030 1.1 (1.0-1.1) 640 1236365 0.5 (0.5-0.6) 236 1236560 0.2 (0.2-0.2) 
2015 1438 1248347 1.2 (1.1-1.2) 694 1248697 0.6 (0.5-0.6) 313 1248882 0.3 (0.2-0.3) 
2016 1592 1263215 1.3 (1.2-1.3) 722 1263636 0.6 (0.5-0.6) 358 1263813 0.3 (0.3-0.3) 
2017 1620 1272066 1.3 (1.2-1.3) 686 1272533 0.5 (0.5-0.6) 435 1272654 0.3 (0.3-0.4) 
2018 1643 1282381 1.3 (1.2-1.3) 697 1282850 0.5 (0.5-0.6) 464 1282977 0.4 (0.3-0.4) 
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